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Summary
Human cutaneous malignant melanoma
progresses through well-defined stages, culminating 
in metastatic melanoma. The underlying genetic 
changes have not b e n  identified. The aim of
this work was to identify activated transforming 
genes in human melanoma samples.
Transfection assays have been used to
identify potential transforming genes in melanoma
samples, and transmissable transforming activity 
was demonstrated in several cases. A secondary
transfectant obtained following transfection of DNA 
from the cell line NKI4 retained a single 
human repeat sequence-containing EcoRI fragment of 
approximately 16 kb. This fragment was molecularly 
cloned and analysis revealed the presence of 
human sequences corresponding to a novel human 
gene, which was designated MEL. Homologous sequences 
were also present in mouse DNA. The MEL gene 
was expressed in human melanoma cell lines and NIH 
3T3 mouse fibroblasts, and cDNA clones were
isolated from a normal human fibroblast cDNA library. 
The human MEL gene was localised to a region of
chromosome 19 (pl3.2) implicated in some human
malignancies. However the clone isolated from the 
secondary transfectant lacked transforming activity, 
and was not retained in either tertiary transformants
or additional primary transformants. A related 
sequence was isolated from the cell line NKI4, 
which was capable of transforming NIH 3T3 cells. 
This sequence also detected a restriction fragment 
length polymorphism in human melanoma cell lines.
To conclusively identify the transforming 
gene in NKI4, transfectant DNA was "tagged" 
with a selectable marker, G418 resistance (neo). The 
sequences adjacent to the "tag" on one side were 
cloned and analysed, from which it was deduced that 
the transforming gene must lie on the other side of the 
"tag".
Melanoma cell lines and tumour biopsies were 
analysed for the presence of activated RAS genes, 
using a combination of biological (transfection) and 
biochemical (restriction enzyme polymorphisms, PCR 
and sequence specific oligonucleotide
hybridisation) assays. Mutations were detected in all 
three RAS genes (K12, H12, N61) , at all stages of
melanoma development, including benign naevi.
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Chapter 1 Introduction
Chapter 1 Introduction
Section I (i) Cancer as a genetic disease
The proliferation and differentiation of 
somatic cells in higher organisms is regulated by 
multiple factors; thus a single cell must evolve via 
several steps to acquire a fully malignant phenotype, 
and form a tumour in the host. Concomitant with this 
process, some if not all the daughter cells must 
inherit the information for maintenance of 
transformation, in the form of stable genetic changes. 
Support for a genetic component in tumour development 
has come from a variety of sources which can 
outlined as follows; tumours frequently display 
karyotypic abnormalities, which increase in number 
with progression; some tumours display an inherited 
component in the form of susceptibility; known 
carcinogens also display mutagenic activity; and 
most convincingly, transforming genes have been 
isolated from acutely oncogenic retroviruses 
which have counterparts in the normal cell, and in some 
cases these cellular oncogenes are activated in the 
absence of the virus.
(ii) Tumour development
The concept of tumour progression was
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first expounded by Foulds (1954,1958) with the
description of several unit characteristics, 
combinations of which constitute the neoplastic
phenotype. Thus the endpoint can be reached by
several alternative, although not neccessarily 
mutually exclusive pathways (Foulds, 1958). Foulds' 
phenotypic traits included hormone dependence, growth 
rate, invasiveness, and the ability to metastasise; 
each step could conceivably represent a single 
genetic change. Evidence for a stepwise development 
comes from the statistical analyses of age-incidence 
curves (Cook et al. 1969; Knudson, 1973; Farber and
Cameron, 1980); with three to four successive steps 
predicted for leukaemias, and six to seven for 
carcinomas. As only rate-limiting steps will be detected 
by such methods, these figures must be considered a 
minimum. Histologic analyses have identified precursor 
lesions in most if not all cellular systems. However, 
in many cases where large numbers of precursors are 
observed prior to the development of cancer, progression 
must be considered uncommon or exceedingly rare.
(iii) Familial Cancers
In 1820 the Scottish surgeon Sir William 
Norris reported the occurence of cutaneous malignant 
melanoma (CMM) in a father and son (Norris, 1820),
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raising the possibility of a familial element in 
the aetiology of this disease. Further support for 
this hypothesis was provided by the observation of a 
family with a high proportion of members who developed 
breast or liver cancer (Broca, 1866). Subsequent 
studies have identified aggregations of some tumours 
in families, suggesting a genetic determinant in the 
aetiology of these neoplasms (Wartin,1914; Lynch,1974; 
Lynch and Krush, 1967; Lynch et al. 1977; Li, 1977), 
hence the term "cancer family". There is evidence for 
hereditary involvement in 50 human cancers, although 
this figure must be an underestimate (Knudson, 1985). 
Well known examples of hereditary cancer include 
Familial polyposis coli which carries an increased risk 
of colon carcinoma, the multiple endocrine neoplasia 
syndrome Type 2 (MEN2), which predisposes to 
pheochromocytoma and medullary cancer of the thyroid 
and the Dysplastic Naevus syndrome with an increased 
risk of CMM. The frequently used term "hereditary 
cancer" is a misnomer in that what is inherited 
is a predisposition to cancer. This genetic 
susceptibility to cancer frequently behaves as an 
autosomal dominant Mendelian trait. Typically 50% 
of the offspring of affected persons would be 
similarly affected; however many display incomplete 
penetrance, reinforcing the suggestion that other 
factors, both genetic and i environmental have a 
contribution.
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Inherent in the proposal that neoplasia 
has a hereditary component, is the presence of 
the susceptibility in all the somatic cells of the 
affected person. These individuals would thus be 
expected to display an increased incidence of multiple 
primary tumours at distinct sites. Indeed this is the 
case, with over 30,000 such cases reported (Moertel,
1977). Examination of tissues from patients treated for 
primary epithelial carcinoma (Moertel, 1977) 
revealed a striking example of multicentric 
neoplasia? between 20 and 93% of all cases displayed 
multiple primary epithelial cancer of shared epithelial 
surfaces e.g. lips and skin; kidney, ureter, urethra, 
and stomach (Schell et al. 1954)? colon (Moertel 
et al. 1958); liver (Moertel, 1977)? and breast (Dunn et 
al. 1988) . In the majority of situations the 
susceptibility to malignancy is to a specific 
cancer or cell type. In contrast there are examples of 
diseases which manifest as a predisposition to a range 
of cancers. The Li-Fraumeni syndrome was first 
described as a susceptibility to soft tissue 
sarcoma, breast cancer and other neoplasms with a 
pattern of autosomal dominant inheritance in 4 families 
(Li and Fraumeni, 1969) . This has been noted in 45 
kindreds to date and the features of this disease are as 
follows: an autosomal dominant pattern of diverse
neoplasms with a predominance of soft tissue
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sarcomas, osteosarcoma, and breast cancer; an excess 
of brain tumours, leukaemia, and adrenocortical 
carcinoma? and occurrence of the component
neoplasms as multiple primary neoplasms in young family 
members (Li et al. 1988). It has also been observed that 
individuals with genetic diseases that increase 
chromosomal instability are at increased risk of 
developing cancer. In Xeroderma Pigmentosum (XP) the 
genes involved in the pathway for excision repair 
contain an inherited defect (Cleaver and Bootsma, 1975? 
Friedberg et al. 1979)? XP patients are extremely 
sensitive to UV light, and suffer an age-specific 
incidence of skin cancer that is several thousand 
times higher than normal.
An oft-quoted model for inherited cancer 
is the childhood ocular cancer, retinoblastoma, one 
of a group of childhood tumours to which 
predisposition can be inherited as an autosomal dominant 
trait (Sparkes et al. 1983? Strong et al. 1981). The 
disease presents in two forms? an inherited form 
generally present in both eyes, and a sporadic form in 
only a single eye. The high cure rate for this disease 
revealed that not only did a percentage of survivors 
of the bilateral form produce affected offspring, but 
that survivors frequently developed second primary 
tumours, predominantly osteosarcomas (Kitchen and 
Ellsworth,1974? Abramson et al. 1984). Furthermore, 
most survivors of non-inherited, unilateral
retinoblastoma neither developed a second malignancy nor 
produced affected offspring. Knudson hypothesised that 
a single gene was responsible for the suceptibility, 
but that a further somatic event was required 
for malignant transformation (Knudson, 1971,
1978) . Furthermore it was suggested that not only 
were the same genes affected in the sporadic 
disease, but that the two events involved the two copies 
of the same gene. The study of retinoblastoma and 
similar malignancies led to the proposition of a 
class of genes, varyingly termed "suppressor genes" or 
"anti-oncogenes" that have to be functionally 
incapacitated before a tumour can arise (Benedict et 
al. 1983; Cavanee et al. 1983? Knudson, 1983; 
Murphree and Benedict, 1984).
(iv) Karyotype abnormalities in human
tumours
Cytogenetic analyses of cancer cells 
have indicated that 90% of human malignancies 
carry clonal cytogenetic changes (Yunis, 1983). The 
majority of human haemopoietic neoplasms carry 
specific chromosomal alterations (Rowley, 1983) 
which suggests that such defects contribute to the 
aetiology of human malignancies. Attempts to 
identify consistent abnormalities in human solid tumours 
have been largely unsuccessful; however in the
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childhood cancers Wilms' tumour and Retinoblastoma, 
both of which display familial inheritance,
alterations of llpl3 and 13ql4 respectively have 
been reported (Riccardi et al. 1978? Knudson et al. 
1976). Such abnormalities are consistent with the view 
that alterations to specific genes, which result 
in either activation or inactivation, are crucial to 
neoplastic development. The majority of patients with 
Chronic Myelogenous Leukaemia (CML) display a specific 
abnormality, the Philadelphia chromosome (Nowell and 
Hungerford, 1960), as a result of a translocation 
between chromosomes 9 and 22, t(9?22)(q24?qll) (Rowley, 
1983).
(v) Carcinogens as mutagens
Much research into cancer is based 
on the legitimate premise that insight into human 
malignancy can be gained from the study of 
carcinogenesis in animals. The agents chosen are 
frequently those shown to damage DNA? indeed the 
carcinogenic potency of such physical or chemical 
agents is fairly well correlated with their ability 
to cause point mutations (Meselson and Russell, 1977? 
Ames and Hooper, 1978? Bartsch, 1980).
(vi) Retroviral Oncogenes
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Study of retroviruses capable of
inducing tumours in experimental animals has led 
to identification of genes specifically responsible
for transformation. Retroviruses are RNA-containing 
viruses that replicate through a DNA proviral 
intermediate integrated into cellular DNA. They can be 
divided loosely into acute and latent transforming
viruses on the basis of the time viral infection and
development of malignancy. Over 20 acutely oncogenic 
retroviruses isolated from species as diverse as
chickens, turkeys, mice, rats, cats and monkeys have 
been characterised. They induce a variety of 
malignancies in their hosts from leukaemias to solid 
tumours including carcinomas and sarcomas, and are 
also capable of transforming primary and established 
cells in culture. The transforming sequences are
independent of the genes required for viral 
replication, and specify a variety of biochemical 
functions (Table 1:1). The archetypal acute oncogenic 
retrovirus, the Rous Sarcoma Virus (RSV), includes 
a single transforming sequence ( v-src), encoding a 
60,000-dalton phosphoprotein (pp60src) with a tyrosine 
specific protein kinase activity (Brugge and Erikson, 
1977? Collett and Erikson, 1978; Collett et al. 
1980) . The significant fact in the progress of 
oncogene research was the discovery of a counterpart of 
the viral src gene in the normal genome of many
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Table 1:1
Retroviral oncogenes
Gene Location Function Comments
v-src cytoplasmic tyrosine kinase
v-fgr i i i i
v-abl i i i i
v-fes/fps i i i i
v-yes i i i i
v-erbB membrane bound " EGFR
v-fms i i 11 CSF1R
v-kit i i " receptor like
v-sea i i 11 receptor like
v-ros i i " Homology 
INSR
to
v-mil/raf cytoplasm serine/threonine kinase
v-mos n i i
v-Ha-ras cytoplasm G protein, signal 
transduction
v-Ki-ras i i i i
v-erbA i i Steroid T3 receptor 
receptor
v-rel i i 7
v-sis secreted,
cytoplasm?
growth factor PDGFB
v-fos nucleus transcription APlcomplex
v-jun n « "
v-myc " 11 ?
v-ski " ?
v-cbl " transcription GNC4 homology
v-myb 11 ?
v-ets 1 ?
v-akt 7 7 7
species (Bishop, 1981). Cellular homologues of all the 
retroviral oncogenes have been identified and 
their importance to normal cellular activity is 
emphasised by the conservation of these sequences 
across many species. These cellular genes were 
probably acquired by the retrovirus following 
integration of the provirus into the host DNA, and
the subsequent transduction of adjacent sequences. 
Several models have been proposed for this process. 
Transformation is thought to be as a consequence of both 
overexpression of the oncogene due to the viral LTR, 
which functions as a powerful promoter, and the 
accumulation of point mutations and deletion of coding 
sequences, following passage in animal hosts.
The substitution of viral gag, pol
or env genes for cellular sequences (or in the 
case of RSV, in addition to the viral genes) usually 
renders the virus replication defective. The v-src gene 
is a paradigm for a number of viral oncogenes that 
encode tyrosine kinases that include v-abl. v-fes/fps 
and v-fgr. A significant advance was the discovery 
that the v-sis oncogene of the Simian Sarcoma Virus 
(SSV) , encoded the B subunit of PDGF (Doolittle et al. 
1983? Waterfield et al. 1983; Chiu et al. 1984? Johnson 
et al. 1984). Subsequently the product of v-erbB 
was demonstrated to be a truncated version of the 
receptor for epidermal growth factor (EGF), (Downward et 
al. 1984? Ullrich et al. 1984), and v-erbA was
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identified as a thyroid hormone receptor (Sap et al. 
1986; Weinberger et al. 1986). Two other v-erbB
related oncogenes have been identified, v-fms
which encodes the receptor for the haemopoietic
growth factor CSF-1/M-CSF (Sherr et al. 1985) and v- 
kit which is a receptor for an as yet unidentified 
ligand (Besmer et al. 1986). Recently the cellular 
equivalent of the oncogene of avian sarcoma virus 17, 
v-iun (Maki et al. 1987), has been identified as a 
component of the transcription factor AP-1 (Vogt et 
al. 1987; Bohman et al. 1987; Angel et al. 1988), and 
shown to complex with the cellular homologue of another 
viral oncogene, v-fos (Rauscher et al. 1988; Chiu et al. 
1988; Sassone-Corsi et al. 1988). Two related genes
were separately identified in retroviruses 
isolated from independent mouse tumours which had been 
passaged through rats, namely the Harvey and 
Kirsten strains of murine sarcoma virus (Ha-MuSV and Ki- 
MuSV) (Harvey, 1964; Kirsten and Mayer, 1967). These 
genes designated v-Ha-ras and v-Ki-ras respectively, 
encode 21 kd cytoplasmic proteins that are unrelated to 
any of the other viral oncogenes. These will be 
discussed in greater detail later. However v-Ha-ras has 
been identified in a number of retroviruses to date 
including the BALB-Murine Sarcoma Virus (BALB-MSV), 
(Anderson et al. 1981), murine leukaemia viruses 
(Fredrickson et al. 1987), and Malignant
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Histiocytosis Sarcoma Virus (MHSV), (Franz et al, 
1985).
Acute oncogenic retroviruses
seemingly belie the observation of multistep 
carcinogenisis; however the difference in kinetics 
between oncogenesis by acute oncogenic viruses 
(single hit) and oncogenesis by other carcinogenic 
agents (multi hit) is apparent rather than real. They 
are instead pseudo-single hit, due to the 
accumulation of several genetic changes during the 
evolution of a highly oncogenic retrovirus (Temin, 
1988) . A model has been proposed for v-src 
(Swanstrom et al. 1983) and v-fms (Woolford et al. 1988) 
in which the primary activating mutation (a C- 
terminal truncation) occurred during retroviral 
transduction, but the acquisition of point mutations 
(which in some cases activate transformation alone) 
occurred during passage of the retrovirus. In the 
case of v-fms. C-terminal truncation stimulates 
colony formation in soft agar only in the presence of 
CSF-1, which would be sufficient for tumour formation in 
the host, whereas point mutations at 301 in human FMS 
and both 301 and 374 in feline fms transform cells in 
the absence of ligand (Roussel et al. 1988; 
Woolford et al. 1988). The individual contributions 
of coding and non-coding sequences to the in vitro 
and in vivo properties of HaMuSV have been assessed 
(Cichutek and Duesberg, 1989; Velu et al. 1989). HaMuSV
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variants with one or both the v-Ha-ras missense 
mutations were more transforming than the corresponding 
proto-oncogene. Rather than the characteristic 
fibrosarcomas and erythroleukaemias, the HaMuSV 
variant possessing the proto-oncogene induced 
lymphoid leukaemias. Deletion of the 3' VL30 derived 
sequence, which has an enhancer activity, from wild 
type HaMuSV, results in a reduction in expression 
of p21 and in vitro transforming activity, and 
induction of lymphoid leukaemias in vivo. In 
contrast to the presence of multiple mutations within 
a single gene, three avian leukaemia viruses that 
specifically transform cells of the myeloid and 
erythroid lineage, have been shown to each possess 
two oncogenes (Graf, 1988). The avian
erythroblastosis virus (AEV) strain ES4 
induces acute erythroleukaemia as well as sarcomas 
in newborn chicks and contains the v-erbA and v- 
erbB oncogenes. The v-erbA gene itself is not oncogenic 
but modulates the in vivo and in vitro transforming 
properties of the v-erbB gene. The MH2 leukaemia 
virus induces predominantly monocytic leukaemia and 
contains the v-mil fv-raf) and v-mvc oncogenes. The 
E2 6 virus induces a mixed
erythroblastosis/myeloblastosis and contains the v-mvb 
and v-ets oncogenes. The acquisition of multiple 
mutations within a single gene or a second cellular
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oncogene during viral evolution probably reflects 
the selective pressure for highly oncogenic variants 
at the time of isolation (Graf and Beug, 1978; Graf and 
Stehlin, 1982? Graf et al. 1986? Temin et al. 1988).
(vii) Transformation by latent oncogenic
viruses
The majority of replication-competent 
transforming retroviruses do not possess oncogenic 
sequences, but rather induce tumours after a long 
latency period, probably by the integration at 
critical genetic loci and activation of cellular 
oncogenes. Proviral integration at preferred sites is 
associated with induction of a particular neoplasm 
(Nusse, 1986; Nusse and Berns, 1988); the clonal nature 
of such integrations is evidence for the importance 
this phenomenon. In MoMuLV-induced T-lymphomas the 
PIM1, MYC and NMYC genes are frequently activated by 
proviral insertion (Cuypers et al. 1984? Selten et 
al. 1984, 1985? van Lohuizen et al. 1989), whereas 
in FMuLV-induced myeloid leukaemias, three sites 
of integration have been identified, namely fim-1, 
fim-2, which is equivalent to the FMS/CSF-1 
receptor gene (Gisselbrecht et al. 1987), and fim-3 
(Bordereaux et al. 1987) which is equivalent to the evi- 
1 locus (Mucenski et al. 1988). MMTV commonly 
integrates and activates at four unrelated loci? int-
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l,int-2 which is a member of the fibroblast growth
factor family of genes, int-3 and int-4 (Nusse
and Varmus, 1982; Peters et al. 1983? Dickson et al. 
1984? Dickson and Peters, 1987? Galahan et al. 1987). 
Homologs of many of these sequences have been noted
in the human genome, and may conceivably be
involved in human neoplasia.
(viii) Cellular Oncogenes
Although acute oncogenic retroviruses 
induce neoplasia in susceptible animals, there is no 
evidence that analogous viruses are responsible for 
human malignancy. Nonetheless they provide a useful
model for human neoplasia. The discovery that the
transforming sequences in acute oncogenic
retroviruses were present in normal genomes led to 
the suggestion that such cellular genes could be
involved in non-virally induced cancer. Furthermore, 
latent oncogenic viruses are thought to act via the
integration of the proviral form into critical 
loci. Transfection of integrated RSV DNA was first 
demonstrated by Hill and Hillova in 1971, thus raising 
the possibility that activated cellular genes could 
be similarly detected. Early attempts to induce 
transformation of normal cells by transfection of DNA 
from malignant cells were either not reproducible
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(Karpas and Tuckenan, 1974) or yielded negative 
results (Nicolson et al, 1978). Improvements in 
the efficiency of transfection (Graham and van Der Eb, 
1973) and the use of an immortal mouse fibroblast cell 
line, NIH 3T3 (Jainchill et al. 1969) as recipient cells 
has led to the development of reliable transfection 
assays (Weinberg, 1981? Cooper, 1982).
Transforming activity is usually demonstrated by 
the ability of DNA to induce foci of morpho­
logically transformed cells on a monolayer of 
nontransformed NIH3T3 cells (Shih et al. 1979), but
transformation can be confirmed by assaying for
growth in semisolid medium (Cooper et al. 1980) or 
tumour formation in nude mice (Blair et al. 1982).
(ix) Oncogenes and chromosome translocations
The majority of human malignancies 
display clonal karyotypic abnormalities, indicative of 
DNA damage (Yunis, 1983), which are presumed to identify 
important genetic regions which, if altered, can 
contribute to the malignant phenotype (Croce, 1986). 
The chromosomal locations of many of the
known proto-oncogenes have been identified (Table 1:2). 
A paradigm for oncogene activation as a consequence of 
chromosomal translocation is the case of Burkitt's 
lymphoma, an aggressive B-cell neoplasm, predominantly 
affecting children. A characteristic marker
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Table 1:2
Proto-oncogene (and related gene) locations
Chromosome Localisation Oncogene
1 lp36.2-p36.1 FGR
Ip35-p32 LCK
lp32 BLYM
lp32—p31 JUN
lp32 MYCL
lp22 and/or lpl3 NRAS
lq21.l-q24 SKI
Iq24-q25 ABLL
2 2 LCO
2p24 MYCN
2pl3-cen REL
3 3p25 RAF1
3p22-p21.3 THR
4 4pl6.1 RAF1P1
4qll-q22 KIT
4q21 FGF5
5 5q33-q34 CSF1R/FMS
6 6p21 PIM
6pl2-pll KRASIP
6q21 SYR
6q21-q22 ROS1
6q22-q23 MYB
6q24-q27 MAS1
6 SYN
7 7p22-pl5 RAL
7pl4-q21 ARAF2
7pl3-pl2 EGFR
7q31-q32 MET
7q31-q32 INT1L1
8 8qll or 8q21-q23 MOS
8ql3-qter LYN
8q24 MYC
8q24 PVT1
9 9q34 ABL
9p NRASLI
10 10qll-ql2 PTC
11 llpl5.5 HRAS1
llql3 HST/KFGF
llql3 INT2
llql3.3 BCL1
llql3 SEA
llq23.3 ETS1
12 12pl2.1 KRAS 2
12pl3 FGF6
12ql3 INTI
12ql3-ql4.3 GLI
14 14q24.3-q31 FOS
14q32 AKT1
15 15q25-qter FES
17 17pl3 P53
17qll.2-q22 ERBA1
17qll-ql2 ERBB2
17q25 ERBA2L
18 18q21.3 YES1
18q21.3 BCL2
19 19pl3.2 MEL
19 RRAS
20 20ql2-ql3 SRC
21 21q22.3 ETS2
21 ERG
22 22 NRASL2
22qll.2 YESP
22ql2.3-ql3.1 PDGFB
X Xq26.3-q27.2 MCF2/DBL
Xpter-q2 6 HRAS2P
Xpll.4-cen ARAF1
chromosome consists of the translocation of the distal 
portion of chromosome 8 to the distal portion of 
chromosome 14 (Zech et al. 1976). A minority of 
Burkitt's lymphomas carry variant translocations, in 
which the same segment of chromosome 8
translocates to either chromosome 2 or 22 (van Den 
Berghe et al. 1976; Lenoir et al. 1982). Because the 
involved regions on chromosomes 2,14 and 22 correspond 
to immunoglobulin loci, it was speculated that human 
immunoglobulin genes might play a part in the 
generation of chromosome rearrangements (Erikson et 
al. 1981). The breakpoint on chromosome 14 splits the 
heavy chain locus, such that the genes for the variable 
region translocate to chromosome 8 while the constant 
region genes are retained on chromosome 14 (Erikson
et al. 1982). Similarly, in the case of the variant 
translocations, the light chains on chromosome 2 and 
22 are disrupted (Croce et al. 1983; Erikson et 
al. 1983). The breakpoint on chromosome 8 is invariably 
at band q2 4, in both the common and variant 
translocations. The human homolog (MYC) of the v-mvc 
oncogene resides on chromosome 8 at band q24, and is 
translocated to the heavy chain locus on the 14q+ 
chromosome in Burkitt's lymphomas with the t(8;14)
translocation (Dalla-Favera et al. 1982). Whilst
the normal MYC gene on chromosome 8 is
transcriptionally silent, the juxtaposition of
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immunoglobulin sequences results in constitutive 
expression of the translocated MYC gene (Dalla Favera 
et al. 1982; Erikson et al. 1983? Nishikura et 
al.1983). Alterations in the first exon (Taub et al. 
1984; Pelicci et al. 1986? Zajac-Kaye et al.1988) or 
separation from exons 2 and 3 (Hamlyn and Rabbits, 
1983? Gelmann et al. 1983) have also been proposed to 
activate the MYC oncogene. The relative contributions 
of these mechanisms to the oncogenic activity of the 
MYC gene remains controversial.
Chronic myelogenous leukaemia (CML) is 
characterised by the presence of a specific 
karyotypic abnormality, the Philadelphia chromosome 
(Nowell and Hungerford, 1960)? indeed greater than 90% 
of CML patients possess the Philadelphia chromosome 
(Nowell and Hungerford, 1960? Rowley, 1973). In the 
majority of cases the Ph chromosome arises from a 
reciprocal translocation between chromosome 9 and 22 
(Rowley, 1973) , with the juxtaposition of the ABL 
proto-oncogene at 9q34 and a specific 5.8 kb site at 
chromosome 22qll known as the breakpoint cluster 
region (bcr), (Groffen et al. 1984). The bcr region 
corresponds to the 3' portion of the BCR gene 
(Groffen et al. 1984; de Klein et al. 1986), whereas 
the breakpoints in the ABL gene are scattered over a 
large area, which may vary from 14 kb (Heisterkamp et 
al.1983) up to more than 100 kb (Grosveld et al. 1986) 
of the v-abl homologous sequences. This region
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corresponds to the first intron of the ABL gene which is 
at least 200 kb long (Bernards et al. 1987). The
ABL sequences are arranged in a head-to-tail fashion 
to the 5' bcr sequences, and as a consequence a
chimaeric BCR/ABL mRNA is generated (Gale and Canaani, 
1984; Grosveld et al.1984). This hybrid mRNA encodes a 
novel P210 bcr-ABL fusion protein, with enhanced 
in vitro tyrosine kinase activity compared with the 
normal ABL protein (Konopka and Witte, 1985; Shtivelman 
et al. 1987; Kurzrock et al. 1987a). This activation of 
the ABL gene is thought to contribute to the
pathogenesis of CML (Konopka et al. 1984) . Such is
the primacy of this particular lesion that in 
cases of CML with cytogenetic variants of the Ph 
chromosome, a standard BCR-ABL fusion still occurs 
(Hagemeijer et al. 1984,1985; Bartram et al. 1985a; De 
Braekeleer, 1987). Ph-negative CML patients generally 
display different clinical and haematologic features 
(Pugh et al.1985) although a few present with
features that are indistinguishable from Ph- 
positive CML patients (Fitzgerald et al. 1987). Such 
patients with either a normal karyotype or
abnormalities not involving chromosome 22, have 
nonetheless been demonstrated to possess breakpoints 
in the BCR gene and juxtaposition of BCR and 
ABL sequences (Bartram et al. 1985b; Kurzrock et al. 
1986; van der Plas et al. 1989). The Ph
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chromosome has also been identified in a subgroup of 
ALL with poor prognosis (Bloomfield et al. 1977), 
although heterogeneity is observed with regards to the 
position of the breakpoint in the BCR gene. 
Approximately half the cases involve bcr as with CML, 
whereas in the rest, the breakpoint lies 57 to the 
bcr, in the first BCR intron (Rodenhuis et al. 1985; 
Erikson et al. 1986? de Klein et al. 1986? Kurzrock 
et al. 1987b). The product of the more 5' breakpoint is 
a P190 BCR-ABL protein, which similarly has increased 
kinase activity (Kurzrock et al.1987c; Chan et al.
1987). It has been suggested that Ph+ bcr+ ALL may be a 
variant of CML, arising in a pluripotent stem cell
and presenting in lymphoid blast crisis following 
silent or undiagnosed chronic phase, and that Ph+
bcr- may alone represent a true de novo ALL originating 
in a committed lymphoid progenitor cell (de Klein et 
al. 1986? Kurzrock et al. 1987b,c) . It is more
likely that potential heterogeneity of the Ph+ target
cell may be more important in determining disease 
outcome than the precise location of the BCR
breakpoint (Secker-Walker et al. 1988).
Molecular analysis of the cytogenetic
abnormalities of Burkitt's lymphoma and Philadelphia 
positive CML and ALL has revealed an involvement of the 
MYC and ABL oncogenes, both of which have been
identified as the transforming components of acutely
transforming retroviruses. By analogy, a proportion
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of common cytogenetic abnormalities should lead to 
the activation of previously described or novel proto­
oncogenes. A number of potential oncogenes have been 
identified by the molecular cloning of chromosome 
breakpoints, particularly in lymphoid neoplasms. Bcl- 
1 was identified as the site of the breakpoint on 
chromosome 11 in CLL of the B-cell type carrying 
a t(11;14)(ql3?q32) translocation (Tsujimoto et al. 
1984,1985a). Bcl-2 has been identified at the 
breakpoint on chromosome 18 involved in the t(14;18) 
(q32?q21) translocation in follicular lymphoma 
(Tsujimoto et al. 1985b, Tsujimoto and Croce, 1986). 
Follicular lymphoma patients with breakpoints in 
the Bcl-2 gene have a poorer prognosis than those 
without such lesions (Yunis et al. 1989).
(x) Gene amplification
Increased expression of a gene product 
represents another means by which an oncogene can 
contribute to transformation, and one way this can be 
achieved is by genomic amplification. DNA
amplification and mRNA expression of the MYC family 
of genes (MYC, NMYC and LMYC) is a frequent phenomenon 
in small cell lung cancer (Little et al. 1983? Nau et 
al. 1985, 1986? Johnson et al. 1988) and in addition,
MYC amplification has been associated with shortened 
survival (Johnson et al. 1987). In neuroblastoma NMYC
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amplification has been linked with advanced stage 
disease and rapid tumour progression (Brodeur et 
al. 1984; Seeger et al. 1985). The EGF receptor-related 
gene, alternatively known as HER-2/NEU/ERBB2 is 
amplified in human mammary carcinomas, although the 
frequency differs between separate studies (Slamon et 
al. 1987; Ali et al. 1988). HER-2 amplification has 
been linked with both overall survival time and time 
to relapse in patients breast cancer (Slamon et al.
1987). Molecular techniques have been developed to 
identify amplified sequences in genomic DNA, wherein 
amplified sequences preferentially reassociate 
following repeated cycles of denaturation. Kinzler et 
al. (1987) have used this approach to identify and 
clone a gene (GLI) that was amplified and expressed in a 
malignant glioma. Fukumoto et al. (1988) screened 
16 cell lines derived from a variety of tumours for 
amplified sequences, but only found co-amplification of 
ERBA1 and HER-2 in the Calu-3 lung adenocarcinoma cell 
line.
(xi) Transforming activity detected by 
in vitro transformation assays
Transforming activity was first 
demostrated with DNA from chemically transformed mouse 
cell lines (Shih et al. 1979, Cooper et al. 1980), and
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virally induced chicken tumours (Cooper and Neiman,
1980). Subsequently human tumours and tumour cell lines 
were assayed for transforming activity 
(Krontiris and Cooper,1981? Perucho et al. 1981); 
transformation of NIH 3T3 cells was demonstrated with 
DNA from the bladder carcinoma cell lines EJ, J82 
(Krontiris and Cooper, 1981; Shih et al. 1981) and T24 
(Perucho et al. 1981), and cell lines derived 
from a neuroblastoma (SK-N-SH),lung carcinomas (Calu-1 
and SK-Lu-1), and a colon carcinoma (SK-CO-1), (Perucho 
et al. 1981) . That the transforming activity was 
due to the transfer of human sequences was demonstrated 
by the presence of the middle-repetitive Alu 
sequence (Jelinek et al. 1980? Rubin et al. 1980) 
in primary transformants (Perucho et al. 1981). When DNA 
from NIH 3T3 cells transformed by genomic DNA from 
the bladder carcinoma cell line EJ was analysed on 
Southern blots with viral oncogene probes, sequences 
homologous to the v-Ha-ras oncogene of HaMuSV were 
detected (Der et al. 1982? Parada et al. 1982? Santos 
et al. 1982) in addition to the expected
endogenous mouse c-Ha-ras sequences. Furthermore, the 
cloned human oncogene hybridised to the cloned viral 
oncogene (Parada et al. 1982? Santos et al. 1982). 
Foci generated from the lung and colon carcinoma 
cell lines Calu-1, SK-LU-1 and SK-CO-1, were found 
to possess the cellular homologue of the v-Ki-ras
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oncogene of Ki-MSV (Der et al. 1982; Pulciani et 
al. 1982a; McCoy et al. 1983). Although HRAS and KRAS 
encode related 21 kD transforming proteins, they 
represent separate genetic loci. Four genes 
homologous to the viral Ha- and Ki-ras oncogenes have 
been identified in the human genome, one coding and 
one pseudogene for both HRAS and KRAS (Chang et al. 
1982).
The RAS genes constitute a multigene 
family (Ellis et al. 1981) , of which a fifth 
member, NRAS was detected following transfection of 
DNA from a neuroblastoma cell line SK-N-SH 
(Perucho et al. 1981; Shimizu et al. 1983 a,b) and a 
fibrosarcoma cell line HT1080 (Hall et al. 1983). To 
date, NRAS has not been observed in an oncogenic 
retrovirus. The properties and functions of the members 
of the RAS gene family will be discussed in 
greater detail in the introduction to chapter 6.
There have been a number of reports 
of transforming activity in human cell lines, in the 
absence of an activated RAS gene, in some cases due to 
the activation of either novel genes or genes 
related to previously identified retroviral oncogenes. 
These will be discussed further in Chapter 3.
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(xii) Tumour Suppressor genes
In contrast to the activation of 
proto-oncogenes as a consequence of translocation, it 
is probable that the majority of cytogenetic 
abnormalities affect so-called "tumour suppressor" 
genes. Cell fusion studies have shown that the 
transformed phenotype is suppressed in hybrids of 
normal and malignant cells (Harris, 1986), and the 
reacquisition of the transformed phenotype was 
accompanied by specific chromosome loss. The 
paradigm in human cancer for such a phenomenon is the 
childhood disease, retinoblastoma, where as described 
earlier, Knudson's hypothesis was that transformation 
arises as a consequence of the loss of two alleles of a 
suppressor gene, by inheritance of a defective 
allele and somatic loss of function of the 
corresponding normal gene, or the concurrent somatic 
inactivation of both alleles (Knudson, 1971). A 
gene has been cloned with properties consistent with the 
predicted retinoblastoma gene and designated RB-1 
(Friend et al. 1986; Lee et al. 1987). Gross 
structural changes have been detected in the RB-1 gene 
in some retinoblastomas and osteosarcomas, with the 
concomitant absence of a transcript (Friend et al.
1986). The majority of retinoblastomas do not 
display gross deletion or rearrangement and express 
transcripts of normal size and abundance (Goddard et
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al. 1988), but subtle mutations have been detected with 
use of an RNAase cleavage technique (Dunn et al. 1988). 
Alterations in the RB-1 gene have been noted in 
tumours unrelated to retinoblastoma, including breast 
cancer (Lee et al. 1988a), SCLC (Harbour et al. 1988), 
and bladder cancer (Horowitz et al. 1989). Introduction 
of a cloned normal RB-1 gene into retinoblastoma or 
osteosarcoma cell lines results in suppression of 
the neoplastic phenotype (Huang et al. 1988).
Unexpectedly, the retinoblastoma gene may provide an 
explanation for the transforming activity of several DNA 
tumour viruses. The transforming genes of some of 
these viruses including SV40 large T antigen (De
Caprio et al. 1988), adenovirus E1A (Whyte et al.
1988), the large T antigens of polyoma virus, BK 
virus, and JC virus, and the HPV-16 E7 protein (Dyson et 
al. 1989) have all been shown to bind the 105 kD RB-1 
product.
The suppression of the transformed 
phenotype upon fusion of malignant and normal 
cells forms the basis of another approach to 
identify suppressor genes. Chromosome 11 has been 
implicated as the site for a putative suppressor gene 
with the observation that following fusion of HeLa 
cells and normal fibroblasts, loss of one copy of 
chromosomes 11 and 14 is associated with re- 
expression of the tumorigenic phenotype (Sager, 
1986; Stanbridge et al. 1981). In addition, the Wilms
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tumour locus has been mapped to chromosome 11 band pl3 
(Riccardi et al. 1978? Kaneko et al. 1981? Slater 
and de Kraker, 1982). Transfer of an intact chromosome 
11 is itself sufficient to reverse the transformed 
phenotype of HeLa cells and a Wilms tumour cell line 
(Saxon et al. 1986? Weissman et al. 1987) . 
Tumorigenicity is suppressed following fusion of 
normal human fibroblasts and tumorigenic RAS- 
transformed cells, although hybrids still express 
high levels of p21 (Geiser et al. 1986? Willecke et al.
1987). The presence of multiple loci capable of 
suppressing RAS transformation was suggested by 
Geiser et al. (1989), who fused pairs of tumour 
cell lines, each with activated RAS genes (H,K or 
N) . Hybrids involving HT1080 (activated NRAS) 
retained the tumorigenic phenotype although to 
different degrees, whereas in other hybrids (eg EJ 
[HRAS] x SW480 [KRAS]) tumorigenicity was suppressed, 
concurrent with continued expression of both mutant 
RAS genes. Noda et al. (1989) have isolated revertants 
of viral KRAS transformed NIH 3T3's following 
transfection of a normal fibroblast cDNA library. One 
cDNA clone with transformation suppressing activity 
(Krev-1) encodes a protein of 21kD, and surprisingly 
shares around 50% homology with RAS proteins (Kitayama 
et al. 1989). The predicted amino acid sequence 
for the Krev-1 protein is identical to rapl, a
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RAS-related gene that was isolated by screening a 
human cDNA library with a drosophila Dras 3 gene probe 
(Pizon et al. 1988), and also a low molecular weight 
GTP-binding protein smg-p21 (Kawata et al. 1988). 
Krev-1 displays identitiy with the RAS genes in the 
putative effector/GAP binding domain encompassing 
codons 30 to 40 (Kitayama et al. 1988) and would 
therefore be expected to interact with RAS-GAP. Ueda 
et al. (1989) have demonstrated two distinct GAP 
molecules (not RAS-GAP) in human platelets, capable of 
stimulating the GTPase activity of Krev-1/smg-p21 
but not p21-HRAS, It is unclear whether RAS-GAP 
interacts with Krev-1/smg-p21? in vitro RAS-GAP will 
stimulate the GTPase activity of RRAS, which shares 
identity with H, K, and NRAS, and Krev-1 between amino 
acids 30 and 40 (Garrett et al. 1989) . If Krev-1 
does indeed bind RAS-GAP then it may act 
antagonistically by binding GAP in preference to mutant 
p21 RAS.
A surprising candidate suppressor gene 
is the SV40 large T binding protein p53, originally 
proposed as an oncogene as a consequence of the ability 
of cloned p53 to immortalise primary rodent cells 
and cooperate with RAS for transformation (Eliyaha et 
al. 1984? Jenkins et al. 1984; Parada et al. 
1984) . Subsequently it has been shown that the p53 
clones used in such experiments were mutated and 
that wild type p53 fails to cooperate with RAS
27
to transform primary cells (Hinds et al. 1989) unless 
expressed at high levels (Tuck and Crawford, 1989).
Rearrangements of the p53 gene have been noted in
several mouse erythroleukaemia cell lines (Mowat et al. 
1985; Hicks and Mowat, 1988), and both p53 alleles have 
undergone major deletions in the human myeloid leukaemia 
cell line HL-60 (Wolf and Rotter, 1985). One patient 
with acute promyelocytic leukaemia showed 
rearrangement of one p53 allele and loss of the other 
(Prokocimer et al. 1986), and p53 gene arrangements
have been reported in osteosarcomas and Hodgkin's 
lymphoma (Masuda et al. 1987). The simultaneous loss 
of one p53 allele and missense mutation in the other 
alelle has been reported in 2 colorectal carcinomas 
(Baker et al. 1989) . DNA clones of the p53 proto­
oncogene inhibit the ability of oncogenic RAS in 
combination with either mutant p53 or E1A to transform 
primary rat embryo fibroblasts (Finlay et al. 1989).
Section II
(i) Human malignant melanoma
Malignant melanoma is a pigmented 
cutaneous lesion which arises from the 
proliferation of transformed melanocytes, the pigment 
containing cells of the skin. Melanoma accounts for 1-
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2% of all types of cancer and approximately 20% of all 
skin cancer (Romsdahl and Cox, 1976) although the 
worldwide incidence of melanoma is on the increase 
(Lee, 1982). The relative survival after diagnosis is 
85-90% at five years (Lemish et al. 1983)? however 
in Australia for example, melanoma ranks 10th among 
cancers as a cause of death (Giles et al. 1987). 
Several characteristics of melanoma render it suitable 
for study, both in an effort to understand this disease, 
and malignancy in general. The presence of pigment 
enables easy identification of early lesions, and the 
subsequent following of malignant development. This 
has led to the description of six clinically distinct 
steps of tumour progression (Clark et al. 1984). 
Aetiological studies have implicated several
enviromental and host factors in melanoma development, 
and some light has been shed on possible 
biochemical and genetic alterations that occur in CMM.
(ii) The Classification of Malignant
melanoma
The development of primary cutaneous 
human malignant melanoma can follow one of two basic 
patterns. In one, there is an antecedent spreading 
pigmentation, characterised histo-logically by 
intra-epidermal proliferation of melanocytes prior to 
the appearance of an invasive nodule. With the other,
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there is no antecedent area of spreading pigmentation; 
the tumour invades the dermis from the beginning. 
McGovern et al. (1973) classified primary CMM into 
three groups. Malignant melanoma, invasive, with 
adjacent intra-epidermal component of Hutchinson's 
melanotic freckle type arises in a pre-invasive lesion 
called Hutchinson's melanotic freckle, which displays a 
pattern of progression and regression as the lesion 
enlarges over the years. These lesions affect persons 
over 50 years of age and are usually quite 
large, irregularly pigmented, and occur virtually 
exclusively in sun-exposed areas. Microscopically, 
lentigo maligna melanoma is characterised by the 
presence of an increased number of melanocytes, 
which are larger, more hyperchromatic and thus more 
prominent than in normal skin. The melanocytes can form 
an almost continuous band at the basal layer, which can 
separate from the epidermis, with invasion of the 
dermis. The depth of invasion in these lesions is 
generally not very deep, and occurs late in the course 
of the disease. The prognosis for these lesions is by 
far the best of the three groups.
Malignant melanoma, invasive, with 
adjacent intra-epidermal component of superficial 
spreading type, or superficial spreading melanoma (SSM) 
as it is more commonly known develops as a spreading, 
pigmented, macular, or slightly palpable lesion, with
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an irregular border and shades of brown, black , bluish- 
red and white colouration. The white areas are 
ascribed to areas of depigmentation, which correspond 
to areas of regression microscopically, where 
lymhocyte infiltration is most pronounced. The 
melanocytes invade the epidermis in a manner 
similar to Pagetts disease prior to invasion of the 
dermis. The cells of the intra-epidermal portion of this 
type of melanoma tend to be fairly uniform in
size and shape. When they invade the dermis they may
resemble the tumour cells in the epidermis from which 
they arose, or they may appear as epitheloid 
cells, spindle cells, nevus-like cells, or a mixture of 
cell types.
Malignant melanoma, invasive, without 
adjacent intra-epidermal component, or nodular 
malignant melanoma (NMM) has no antecedent spreading 
pigmentation, and even when it arises in conjunction 
with a pre-existent junctional nevus, there is no
warning enlargement of the nevus prior to invasion of 
the dermis. Although in theory there should be an in 
situ intra-epidermal phase, in practice this is rarely 
seen. In most cases malignant melanocytes at the
dermo-epidermal junction invade the dermis from the 
beginning. As in the other forms of melanoma any cell 
type or mixture of cell types may be seen. The prognosis 
for this form of melanoma is far worse than the other 
two types, as a consequence of the rapidity of
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growth, depth of invasion and predilection for 
metastasis via the blood stream and/or lymphatic system.
(iii) Aetiological factors in melanoma
development
Large analytical studies of CMM have 
been undertaken, mainly in North America, Australia 
and Scandanavian countries (Klepp and Magnus, 1979; 
Elwood et al. 1984; Holman and Armstrong, 1984; 
Green et al. 1985a; Osterlind et al. 1988a, b, c, d) to 
assess the contribution of various factors to melanoma. 
In common with other types of skin cancer, a 
significantly increased risk of CMM is associated 
with sun exposure, specifically ultraviolet (UV) 
light, and particularly during recreational activities 
with more intense sun exposure. This has led to the 
hypothesis that intermittent sun exposure is an 
important risk factor for CMM (Elwood et al. 1985a; 
Holman et al. 1986). Several studies have reported 
elavated risks associated with a history of sunburning 
(MacKie and Aitchison, 1982; Lew et al. 1983; Elwood 
et al. 1986a; Green et al. 1985b; Osterlind et al, 
1988b) although others have failed to find evidence for 
such an association (Beral et al. 1983; Holman 
et al. 1986; Cristofilini et al. 1987). Continuous
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long-term occupational sun exposure is not a risk 
factor (Vagero et al. 1986? Osterlind et al. 1986) and 
may even be protective in males (Elwood et al. 
1986b? Osterlind et al. 1988a).
The age at which sunburn occurs may 
be important? a particularly strong association is 
seen with the frequency of painful sunburns in childhood 
and melanoma (Osterlind et al. 1988a), consistent 
with the hypothesis that the important time of exposure 
may be in early life (Holman et al. 1983).
The distribution of melanoma lesions 
is particularly pronounced for parts of the body 
which are normally protected with clothes and only 
occasionally exposed to sunlight. Beral et al. (1982) 
noted an association with exposure to fluorescent 
light at work, which subsequent studies have 
failed to corroborate (Sorahan and Grimley, 1985? 
English et al. 1985? Dubin et al. 1986? Elwood et al. 
1986? Osterlind et al. 1988b). No data is available 
on the risk associated with exposure to other sources 
of artificial UV light such as sun lamps and sun 
beds.
The observations that the incidence of 
CMM is higher in pre-menopausal women as
compared with men, and that hyperpigmentation 
may occur during pregnancy, or may be induced by 
topical oestrogens, oral contraceptives or 
menopausal replacement oestrogens (Snell et al.
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19 60) have implicated hormonal and reproductive 
factors. A few studies have reported a weak association 
between melanoma and oral contraceptives (Holly et al. 
1983? Beral et al. 1984); however many others have
failed to detect any significant association (Holman 
et al. 1984; Gallagher et al. 1985? Green and 
Bain, 1985? Osterlind et al. 1988c). A number of
reproductive factors were also examined in some 
studies, and an increased risk for CMM was noted with 
late age at first birth (Holly et al. 1983) and the 
number of live births (Gallagher et al. 1985) . No
increased risk was associated with early menarche or 
long duration of reproductive years (Holman et al. 
1984? Osterlind et al. 1988c). Osterlind et al. (1988c) 
failed to show any influence of pregnancy on 
melanoma risk.
Dietary factors have been investigated 
with regard to melanoma risk? poly-unsaturated fat
intake has been suggested as a risk factor for melanoma 
(Goldrick et al. 1976? Mackie et al. 1980), whereas 
retinoids and carotenes have been reported to be 
protective (Holman, 1983). Other potential risk ractors 
have been evaluated, including coffee,tea, and 
alcohol consumption, and tobacco smoking (Paffenbarger 
et al. 1978? Holman, 1983? Shaw and Milton, 1981; 
Williams and Horm, 1977? Osterlind et al. 1988d) with 
inconclusive or negative results. Hair dyes have
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been suggested as possible carcinogens (Holman and 
Armstrong, 1983), although Osterlind et al. (1988d) 
failed to find any evidence for such an association 
in Denmark. Increased susceptibility to UV-light 
exposure due to the removal of the upper layer of 
epidermis (stratum corneum) by frequent bathing with 
soaps and detergents has also been proposed as a 
possible aetiological factor (O'Rourke, 1980? Mackie,
1981), however in the most recent study in Denmark, 
Osterlind et al. (1988d) failed to detect any 
association between bathing habits and melanoma risk.
(iv) Host factors
Several constitutional characteristics 
are widely accepted as risk factors for CMM, including 
fair skin, red or blond hair, and blue or green eyes. A 
tendency to burn rather than tan on exposure to 
sunlight has been less consistently reported (Gellin et 
al. 1969? Beardmore, 1972? Beral et al. 1983? 
Holman and Armstrong, 1984? Elwood et al. 1984? 
Green et al. 1985), but melanoma has been associated 
with the degree of freckling (Klepp and Magnus, 1979? 
Beral et al. 1983? Elwood et al. 1984, 1986? Green et
al. 1985? Nordlund et al. 1985). Recent studies have 
also pointed to a strong and independent association 
between the presence of pigmented naevi and skin 
melanoma (Holman and Armstrong, 1984? Green et al.
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1985; Elwood et al. 1986; Rigel et al. 1989). An
apparent synergy between number of raised naevi and 
degree of freckling has been noted by Osterlind et al. 
(1988b), reflecting different interactions between 
susceptible individuals and sun exposure.
(v) The Dysplastic Naevus Syndrome
An inherited syndrome characterised by 
atypical moles and high risk for melanoma was 
identified in 1978 by two independent groups (Reimer et 
al. 1978; Lynch et al. 1978). Now widely known as 
Familial Dysplastic Naevus Syndrome (FDNS), this 
disease is transmitted in an autosomal dominant 
fashion (Greene et al. 1983), and family members 
who develop atypical moles have an approximately 100% 
cumulative lifetime risk for melanoma (Greene et al. 
1985b). Invasive melanoma has been observed in direct 
association with an adjacent dysplastic
naevus and histologically, remnants of a dysplastic 
melanotic precursor have been observed in 20 to 35% of 
primary melanomas (Elder et al. 1981; Clark et 
al. 1984; Rhodes et al. 1983). The evolution of
dysplastic naevi into invasive melanoma has been 
directly observed (Greene et al. 1985b).
Dysplastic naevi tend to be more 
numerous than common naevi, with reports of up to
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100 in an affected family member, although commonly only 
25 to 75 are observed (Clark et al. 1985a) . FDNS 
patients also possess ordinary moles, but dysplastic 
naevi are typically, but not invariably larger. 
Unlike common acquired naevi, dysplastic naevi often 
have irregular borders, a haphazard mixture of tan, 
brown, dark brown, and pink colours, and a margin 
that tends to be indistinct, fading into the 
adjacent normal skin. Although most numerous on the 
trunk, they also occur in locations on the skin that 
are unusual for common acquired naevi, such as the 
scalp, buttocks, and female breast.
A form of DNS has been identified in 
individuals who are not members of melanoma kindreds, 
and there is strong evidence to suggest that DN are 
markers of increased risk for melanoma outside the 
familial setting (Elder et al. 1980). In melanoma 
kindreds, 30% of those who develop one primary 
melanoma will subsequently develop a second primary 
melanoma (Greene et al. 1985b). Among patients with 
nonfamilial melanoma, approximately 5% will develop 
an additional primary (Mosely et al. 1979). The presence 
of DN is associated with an increased risk for multiple 
primary CMM in such patients (Titus-Ernstoff et al.
1988).
Dysplastic naevi have been classified 
into four types, with an assumed increase risk of 
melanoma from one type to the next (Kraemer et al, 1983;
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Rigel et al. 1989). Patients with Type A have 
nonfamilial dysplastic naevi, no personal history of 
melanoma, and no family history of either dysplastic 
naevi or melanoma. Patients with Type B are 
similar except that other members of the family have 
dysplastic naevi as well. Persons with Type C have a 
pesonal history of both dysplastic naevi and melanoma 
but a family history of neither. Patients with Type D 
have either one (Type Dl) or at least two (Type 
D2) family members with melanoma and dysplastic naevi.
(vi) Identification of persons at risk of 
developing CMM
Provided effective treatment is available for 
melanoma patients, early diagnosis would be effective 
in reducing morbidity from this disease. Mortality 
from melanoma increases with stage at diagnosis, which 
is indicated best by the thickness of the lesion 
(Lemish et al. 1983). Screening the whole population 
is not cost effective because most people do not 
develop melanoma; however the identification and 
surveillance of people within high risk groups could 
be cost effective. Several reports have suggested 
dysplastic naevi are markers for CMM (Titus-Ernstoff 
et al. 1988; Rigel et al. 1989). English and Armstrong 
(1988) identified a subgroup of the Australian
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population (16%), in whom about 54% of all cases of 
melanoma would be expected to develop. The criteria 
used were number of raised naevi on the arms, arrival 
in Australia before ten years of age, history of 
non-melanotic skin cancer, time spent outdoors in 
summer from the age of 10 to 24, and a family history 
of melanoma. The inclusion of age would substantially 
improve discrimiantion between those likely and not 
likely to develop melanoma, given that the highest 
rates of melanoma in Australia^occur among those aged 
40 or more (Giles et al. 1982). The additional 
inclusion of the presence or absence of dysplastic 
naevi would further delineate those at risk. English 
and Armstrong (1988) suggested that identification 
and surveillance of groups at high risk was 
potentially useful in reducing mortality from melanoma 
in Australia.
(vii) Multistage development of CMM
Like other human neoplasms, melanoma is 
considered to progress in a series of discrete steps. 
Studies of the age incidence of melanoma have 
suggested that only one step is required (Cook et al. 
1969), although this figure must be an underestimate, 
as such analyses will detect only rate-limiting 
steps. Clark et al. (1984) distinguished six 
clinically evident steps manifested by well-defined 
lesions in the progression from normal melanocytes to
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metastatic disease. The lesions of step 1 are the 
common acquired melanotic naevus (common mole) and the 
congenital naevus which are focal proliferations of 
structurally normal melanocytes. Steps 2 and 3, which 
usually appear together constitute the fully evolved 
dysplastic naevus with atypical hyperplasia, including 
random cytological atypia, but without persistent 
autonomous growth (Greene et al. 1985). Step 4, or 
primary melanoma in radial growth phase (RGP) is the 
first step of tumour progression showing clinical 
evidence of persistent autonomous growth (Elder et al.
1984). Histologically such melanomas show the 
contiguous growth of atypical cells that are invasive 
but apparently lack competence for metastasis (Elder 
et al.1984). Step 5, the vertical growth phase (VGP) 
of primary melanoma, is clinically and histologically 
characterised by the focal appearance of a population 
of cells within RGP having competence for metastasis. 
The VGP cells grow as an enlarged sphere forming a 
globoid nodule. Step 6 of tumour progression is 
metastasis, i.e. the maintenance of autonomous growth 
discontinuous from the primary site.
Normal melanocytes and melanocytes isolated 
from the stages of melanoma progression, exhibit a 
range of in vitro characteristics which correspond to 
the increased malignancy of such lesions in vitro 
(Table 1:3). Cultures of RGP and VGP primary melanoma 
and of metastatic lesions could be grown indefinitely,
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whereas cultures of normal melanocytes and nevi had a 
finite lifetime (Herlyn et al. 1985a). Melanocytes, 
naevus cells, RGP and a proportion of VGP melanoma 
cells display a bipolar spindle-shaped morphology, 
whereas cells from VGP and metastatic melanomas are 
frequently epithelioid in morphology (Herlyn et al.
1985). The efficiency of colony formation in soft agar 
is highest in cells from VGP (up to 19%) and 
metastatic (up to 31%) lesions, whereas normal 
melanocytes and cells from RGP melanoma, common 
acquired naevi and congenital naevi have a colony 
formation eficiency of 1% (Herlyn et al. 1985a). 
Melanoma cells from VGP and metastatic melanomas are 
tumorigenic when injected subcutaneously into athymic 
nude mice (Fogh et al. 1977? Herlyn et al. 1985a,b). 
Unlike melanocytes from normal skin, which require 
either phorbol ester or a growth factor to be 
maintained in culture (Eisinger and Marko, 1982; 
Wilkin et al. 1982), naevus cells, like melanoma 
cells, can be maintained in culture without these 
supplements (Herlyn et al. 1985b). Thus cells derived 
from the individual steps in melanoma development 
display the successive acquisition of a number of in 
vitro properties characteristic of malignant 
transformation.
(viii) Cytogenetics of human melanoma
Much effort has been made to identify common 
karyotypic abnormalities in human melanoma. Early
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studies in general concentrated on cells derived from 
far-advanced lesions, often metastases, which had 
frequently been in culture for long periods of time 
(Chen and Shaw, 1973? McCulloch et al. 1976? Kakati 
et al. 1977? Quinn et al. 1977? Muir and Gunz, 1979? 
Nayak et al. 1980? Atkin and Baker, 1981? Semple et 
al. 1982). Typically aneuploid karyotypes, with 
multiple rearrangements have been observed. A 
particularly frequent involvement of chromosomes 1 and 
7, as well as certain other chromosomes, have been 
noted in individual small series (Chen and Shaw, 
1973? McCulloch et al. 1976? Kakati et al. 1977? 
Quinn et al. 1977? Muir and Gunz, 1979? Nayak et al. 
1980? Atkin and Baker, 1981? Semple et al. 1982). As 
techniques have improved, it has been possible to 
obtain more detailed cytogenetic data on melanomas, by 
analysing direct preparations, early passage cultures 
and cell lines derived from melanotic lesions. 
Abnormalities of chromosomes 1, 6 and 7 have been 
most frequently noted (Becher et al. 1983? Balaban et 
al. 1984? Pedersen et al. 1986? Limon et al. 1988) and 
to a lesser extent chromosomes 2 and 9 (Pedersen et 
al. 1986? Limon et al. 1988). Parmiter et al. (1986) 
reported three cases of melanoma with a t(l:19) 
chromosome translocation. Naevi are karyotypically 
normal (Balaban et al. 1984? Herlyn et al. 1985a), 
whereas primary melanoma cell lines of RGP have only 
chromosome 6 abnormalities (Herlyn et al. 1985a). Only
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in VGP and metastatic melanoma are abnormalities of 
chromosomes 1,6 and 7 observed (Herlyn et al. 
1985a,b).
The majority of abnormalities of chromosome 1 
in human melanoma, either deletions or translocations 
involve the proximal segment Ipl2-lp22 (Balaban et al. 
1984; Limon et al. 1988). The oncogenes NRAS and SKI 
have both been localised to this portion of chromosome 
1, although they seem to- be unaffected by the 
translocations ((Pedersen et al. 1986). A linkage has 
been reported between FDNS/CMM and the Rhesus locus 
(Rh) (Greene et al. 1983) suggesting the presence of 
a gene for this autosomal dominant disorder on 
chromosome 1 (p36.2-p34). The DN and melanoma traits 
may represent pleiotropic effects of a single, highly 
penetrant gene (Bale et al. 1986), although this has 
been disputed (Pascoe, 1986); indeed familial and 
sporadic CMM may both involve abnormalities of the 
same locus. Recently the CMM-DNS susceptibility locus 
has been more precisely localised between an anonymous 
DNA marker (D1S47) and the gene locus for 
pronatrodilatin (Bale et al. 1989)
In an extensive survey of the karyotypes of 
human neoplasia, Mitelman and Levan (1981) noted that 
chromosome 6 was one of the chromosomes least 
frequently involved in marker formation. In contrast, 
chromosome 6 aberrations are frequent in melanomas 
(Becher et al. 1983; Balaban et al. 1984; Pedersen et
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al. 1986? Limon et al. 1988), such that Pathak et al. 
(1983) concluded that chromosome 6 anomalies are 
crucial in the transformation of malignant melanoma. 
Chromosome 6 breakpoints have been localised to 
6ql3-q24 (Pedersen et al. 1986), which correlates with 
the locations of the MYB (Harper et al. 1983), R0S1, 
SYR and MAS 1 genes. Trent et al. (1989) reported 
translocations between chromosomes 1 and 6 in five 
cases of melanoma, all involving 6qll-13, but no 
structural abnormalities of the MYB locus were 
detected by conventional Southern analysis. Bertrand 
et al. (1982) concluded that aberrations of chromosome 
7 were specifically related to tumorigenicity in human 
melanoma. Breakpoints on the Y chromosome have been 
most frequently found in three regions: p21, qll, and 
q22 (Pedersen et al. 1986). Within the vicinity of 
these breakpoints are to be found the EGF 
receptor/ERBB and RAL genes.
Melanomas are known to have a highly aneuploid 
karyotype (Pathak et al. 1983; Balaban et al. 1984) 
which may be reflected by RFLP loss at the molecular 
level. Dracopoli et al. (1985) demonstrated loss of 
heterozygosity at informative loci on 8 different 
chromosomes, most frequently chromosome 10.
(ix) Cell surface antigens of melanocytes and 
melanoma cells
A major question of tumour biology has been
44
what differentiates tumour cells of different types 
from each other and also normal progenitor cells. 
Specifically, the identification of cell surface 
antigens expressed only by tumour cells. A lot of 
attention has focused on antigens expressed on human 
malignant melanoma cells, which on the basis of 
immunological, biochemical and genetic analyses have 
been assigned a rudimentary classification. The only 
class of antigens defined as melanoma specific, are 
those termed class 1 unique antigens. Class 2 antigens 
are shared tumour antigens and are found on autologous 
as well as on certain allogeneic tumour cells; some 
class 2 antigens may also be found on a restricted 
range of normal cells and should therefore be 
classified as autoantigenic differentiation antigens 
(Watanabe et al. 1982). Class 3 antigens are found on 
a wide variety of normal and malignant cells of human 
and animal origin, and do not follow any 
differentiation-related or tumour restricted pattern.
Each of the class 1 unique antigens identified 
in human melanoma have the characteristics of 
glycoproteins. The prototype melanoma unique antigen 
(AU), has been characterised as a glycoprotein and has 
a molecular weight in the range of 25,000-40,000 Da 
(Carey et al. 1979). Somatic cell hybrids formed by 
fusing AU melanoma cells with Chinese hamster cells 
express AU antigen; as a result the gene encoding the 
AU antigen has been tentatively assigned to chromosome
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19 (Old, 1981). Serum from a melanoma patient (FD) 
contained antibodies that define another class 1 
antigen and also immunoprecipitate a specific glyco­
protein of 90 kDa (gp90) from radiolabeled autologous 
SK-MEL-131 melanoma extracts (Real et al. 1984; Mattes 
et al. 1988). Monoclonal antibodies generated against 
partially purified gp90 detect broad expression of 
this antigen in cultured cells, although only in a 
limited range of normal cell types in tissue sections? 
this contrasts with the highly restricted detection of 
gp90 by FD antisera (Real et al. 1988). It has been 
suggested that the mAbs recognise common epitopes on 
gp 90 molecules expressed on a wide variety of cells? 
whereas FD melanoma SK-MEL-131 carries two types of 
gp90 determinants: common determinants (detected by
mAbs) and a unique determinant (detected by autologous 
FD serum) (Real et al. 1988). The basis for the 
expression of different epitopes has not been 
resolved, although different glycosylation or protein 
determinants have been suggested. FD expression is not 
required however for maintenance of the transformed 
phenotype of SK-MEL-131 melanoma cells (Real et al.
1988) .
A number of class 1 antigens have now been 
molecularly cloned to assess the tissue specificity of 
expression. p97 (melanotransferrin) is expressed in 
most human melanomas and in certain foetal tissues, 
and as it s name suggests displays significant
46
homology to transferrin, with which it shares the 
property of iron binding (Rose et al. 1986). The 
melanoma- associated antigen ME491 is a marker for the 
early stages of tumour progression. It is not detected 
on normal tissue melanocytes, but is strongly 
expressed in dysplastic naevi and RGP of primary 
melanoma. However antigen expression is low or 
undetectable in the more advanced VGP or metastatic 
melanoma (Atkinson et al. 1984, 1985). ME491 antigen 
is also strongly expressed in adenocarcinomas of the 
colon and prostate (Atkinson et al. 1985). A large 
variation in the level of ME491 mRNA expression has 
been observed in melanoma cell lines, which is not 
associated with gene amplification or obvious gene 
rearrangement (Hotta et al. 1988) . The ME491 gene is 
conserved among different species but sequence 
analysis failed to reveal homology with any known 
proteins.
The melanoma-associated antigen P3.58, an 
89-kDa cell surface glycoprotein, is not detectable on 
quiescent melanocytes and is only occasionally found 
on naevi (Holzmann et al. 1985). On melanomas the 
frequency with which this antigen is found is 
proportional to tumour thickness (Holzmann et al. 
1985, 1987). Sequence analysis of cDNA clones encoding 
the P3.58 antigen from melanoma cells (Johnson et al.
1989), has revealed identity with the intracellular 
adhesion molecule 1 (ICAM-1), a cell adhesion molecule
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which mediates leukocyte adhesion through the 
lymphocyte function-associated molecule 1 (LFA-1)
(Makgoba et al. 1989). It is possible that the 
expression of ICAM-1 by melanomas leads to the 
heterotypic adhesion between melanomas and 
LFA-l-bearing leukocytes, thus contributing to 
dissemination of the cells from the primary tumour. 
This provides an explanation for the correlation 
between increasing thickness, which indicates 
progression and increased probability of metastatic 
disease, and the expression of this antigen by 
melanoma cells.
One of the factors determining the oncogenicity 
of tumour cells is the expression on the cell surface 
of class I major histocompatibiltiy complex (MHC) 
molecules, which function as restricting for 
recognition by T cells (Zinkernagal and Doherty, 
1979). In melanomas it has been shown that visceral 
metastases often have a lower class I HLA expression 
than primary tumours (Ruiter et al. 1984; Brocker et 
al. 1985), suggesting that reduction in the amount of 
class I HLA might be associated with increased 
malignancy of the tumour cell. Similarly class 1A 
antigens have been demonstrated on melanoma cells 
(Winchester et al. 1978), but not on normal 
melanocytes (Natali et al. 1981? Houghton et al. 
1982). It is possible that la antigens are expressed 
on an early, as yet unidentified cell in the normal
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melanocyte lineage and that la"1" melanomas arise from 
this Ia+ progenitor (Houghton et al. 1982). Thus la 
antigens would be classified as differentiation 
antigens in the melanocyte pathway, because they are 
expressed during an early stage of normal melanocyte 
differentiation. Alternatively, expression of la 
antigens may be a consequence of malignant 
transformation, and would not be expressed during 
normal melanocyte differentiation. Houghton et al. 
(1984) have shown that IFN-gamma can induce la antigen 
expression in a proportion of Ia“ melanomas. Because 
la antigens are strongly expressed on melanoma cells 
corresponding to early or intermediate stages of 
melanocyte differentiation, with weak or no expression 
to well-differentiated melanoma cells, la melanomas 
must correspond to progenitors at an earlier stage in 
the melanocyte lineage, whereas Ia“ melanomas 
correspond to a late stage.
A 120 kDa cell surface glycoprotein expressed 
by all cultured melanocytes but not melanomas has been 
identified as the adenosine deaminase binding protein 
(ADAbp) (Andy et al. 1984). ADAbp expression 
decreases at an early stage in the pathogenesis of 
melanoma and is extinguished upon transformation of 
melanocytes in vitro (Houghton et al. 1988).
Melanomas have a relatively high ganglioside 
composition when compared to other cell types, with 
GD3 and GM3 the most prominent gangliosides in
49
Table 1:3
Characteristics of melanocytes 
melanoma development
from stages of
Property
Source of Melanocvtic cells
Normal Dysplastic RGP VGP
Skin Naevus Melanoma Melanoma
Metastatic
Melanoma
Morphology Spindle Spindle
Indefinite 
growth in 
vitro
Al
NMTA
Karyotype
Abnormal­
ities
HLA Class 
I
No
No
No
No
No
No
+/-
Spindle Spindle Epithelioid
Epithelioid 
Yes Yes Yes
No
No
6
+
Yes Yes
Yes Yes
1,6&7 1,6,&7
+ +
Adenosine + - - -
Deaminase
ME491 — ++ ++ t/— t/—
P3.58/ - -/+ + + +
ICAM1
References
Herlyn et al. 1983, 1985a, 1985b; Holzman et al. 1987; Hotta et 
al. 1988; Houghton et al. 1988; Rose et al. 1986; Ruiter et al. 
1984;
cultured melanoma cells (Portoukalain et al. 1979) and 
GM2/ GD2 and alkali-labile ganglioside to a lesser 
extent (Tsuchida et al. 1987): gangliosides are glyco- 
sphingolipids containing sialic acids, and are 
expressed at high concentration in neural tissues. 
Human monoclonal antibodies against ganglioside GD2 
have been shown to have a strong cytotoxic effect on 
human melanoma cells both in vitro and in vivo (Irie 
and Morton, 1986).
(x) Growth factors in human melanoma
Normal human melanocytes do not propagate ■ in 
vitro, unless cultured in the presence of additional 
factors such as TPA (Eisinger and Marko, 1982); the 
mitogenic activity of TPA can be potentiated by 
cholera toxin (Eisinger and Marko, 1982) and 
isobutylmethylxanthine (Halaban and Alfano, 1984). In 
contrast, melanoma cells grow vigorously in vitro in 
the absence of TPA (Herlyn at al. 1983), suggesting 
that their independant growth might be associated with 
the production of melanocyte growth factor or factors. 
Melanocyte growth stimulating activity has been 
observed in extracts of metastatic melanoma (Eisinger 
et al. 1985), and other tissues including bovine 
brain (Wilkins et al. 1985), human placenta (Halaban 
et al. 1986), astrocytoma and fibroblast cell lines
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(Eisinger et al. 1985). Primary and metastatic 
melanoma cell lines from a single patient have been 
demonstrated to produce a PDGF-like activity, similar 
to the A chain homodimer form of PDGF, and express 
abundant PDGF A chain mRNA (Westermark et al. 1986). 
This is not a consistent feature of human melanoma 
cell lines. Melanoma cell lines have also been 
reported to produce transforming growth factors alpha 
and beta (DeLarco et al. 1985), interleukin 1 (IL-1) 
(Kock et al. 1989; Bennicelli et al. 1989), melanocyte 
growth-stimulatory activity (MGSA) (Richmond and 
Priest, 1987), and Mr 100,00 protein (Klein et al.
1987). Expression of MGSA cDNA in mammalian cells 
resulted in secretion of a peptide with mitogenic 
activity (Richmond et al. 1988). Sequence analysis of 
MGSA cDNA clones revealed identity with gro (Richmond 
et al. 1988) expression of which is transiently 
induced in normal fibroblasts following serum 
stimulation (Anisowicz et al. 1987). Melanoma cells in 
culture also produce bFGF (Lobb et al. 1986; 
Moscatelli et al. 1986), which in addition to 
stimulating angiogenisis (Folkman, 1985, 1986) may
also participate in transformation via an autocrine 
mechanism. The majority of purified growth factors 
including NGF, EGF, PDGF, TGF-beta, aFGF and ECGF 
fail to stimulate mitogenesis of normal human 
melanocytes (Eisinger et al. 1985; Halaban et al. 
1987; Halaban, 1988). Only bFGF has mitogenic activity
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for human melanocytes in vitro (Halaban et al. 1987)? 
support for a role of bFGF in autocrine transformation 
of melanocytes was provided by Halaban et al. (1988), 
who demonstrated expression of bFGF mRNA in melanoma 
cell lines, and inhibition of cell proliferation 
following addition of synthetic bFGF peptides that 
bind to the bFGF receptor and act as specific 
antagonists. Incubation of melanoma cells with 
anti-bFGF antibodies failed to inhibit DNA synthesis, 
whereas "injection" into melanoma cells by pinocytosis 
reduced DNA synthesis by up to 60% (Halaban et al.
1988). bFGF is probably not released into the culture 
medium, but instead binds to the intracellular matrix 
as a consequence of it s ability to bind heparin 
(Gospodarowicz et al. 1984).
TGF-alpha is frequently expressed in melanomas 
(Marquardt et al. 1983? Derynck et al. 1987; Ellem et 
al. 1988) and is inducible in melanocytes and melanoma 
cells in culture following UV irradiation (Ellem et 
al. 1988). A significant association has been noted 
between a TaqI RFLP at the TGF-alpha locus and CMM 
(Hayward et al. 1988) but it is unclear whether it 
localises within the TGF-alpha gene, or is instead 
evidence of linkage to a melanoma susceptibility 
gene.
(xi) Oncogene activation in human melanoma
Using the NIH 3T3 transformation assay,
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activated RAS oncogenes have been demonstrated in 
several human melanoma cell lines. Activated NRAS was 
identified in SK-MEL-93, SK-MEL-119, SK-MEL-147,
(Albino et al. 1984) and Mel Swift (Padua et al
1985), and HRAS in SK-MEL 146 (Albino et al. 1984) and
SK-2 (Sekiya et al. 1984). Raybaud et al. (1988) 
transfected genomic DNA from thirteen melanoma 
tumours, and identified an activated NRAS oncogene, 
mutated at codon 61, in one sample. It has been 
suggested that RAS gene activation is an infrequent
event in human melanoma (Albino et al. 1984; Raybaud 
et al. 1988). Interestingly, an activated NRAS gene 
(N61 Gln-His) was demonstrated in a melanoma isolated 
from a Xeroderma Pigmentosum (XP) patient (Keijzer et 
al. 1989). XP is a rare, autosomal recessive disorder, 
marked by extreme sensitivity of the skin to sun (UV) 
exposure and an increased risk of skin cancer (basal 
and squamous cell carcinomas, and melanomas) almost 
exclusively restricted to sun-exposed areas (Kraemer,
1987) . In most XP patients, DNA damage induced by UV
light cannot be eliminated effectively, due to
deficiency in the excision repair pathway (Cleaver, 
1968). An NRAS oncogene activated by a codon 61
mutation has also been detected in two independent 
squamous cell carcinomas from an XP individual (Suarez 
et al. 1989). Thus the most frequent site for RAS
mutation in human melanoma appears to be codon 61 of
NRAS, in common with that observed in other UV induced
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malignancies. Human melanocytes infected with either 
Ki-MSV or Ha-MSV acquire some characteristics of 
transformation, specifically expression of la 
antigens, a transformed morphology and ability to grow 
in soft agar and an increase cell surface expression 
of GD3 ganglioside (Albino et al. 1986). However other 
characteristics of transformed melanocytes, such as 
growth factor independence and loss of adenosine 
deaminase binding protein were not induced as a 
consequence of viral RAS gene expression (Albino et 
al. 1986), suggesting that RAS activation may be an 
early event in melanoma development, but is not itself 
sufficient to induce the full complement of the 
transformation phenotype.
The human HRAS gene displays a restriction 
fragment length polymorphism (RFLP), ascribed to a 
region of variable tandem repetition (VTR), situated 
3' to the coding sequences (Goldfarb et al. 1982? 
Krontiris et al. 1985). The disproportionate 
distribution of rare HRAS alleles amongst the genomes 
of cancer patients has led to the suggestion that they 
may be a predisposing marker for malignancy (Krontiris 
et al. 1985). Sutherland et al. (1986) and Gerhard et 
al. (1987) have analysed DNS/CMM kindreds and 
sporadic CMM patients for the distribution of HRAS 
rare alleles, but failed to demonstrate any 
association. Recently Radico et al. (1987) detected a 
significant correlation between rare HRAS alleles and
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CMM, with Taq I, which identifies additional
restriction sites within the VTR region itself 
(Pierotti et al. 1986).
Transforming activity has been detected in
melanomas in the absence of RAS mutations (Raybaud et 
al. 1988). An NIH 3T3 transformant obtained following 
transfection of genomic DNA from a metastatic melanoma 
was found to contain a human HST gene (Adelaide et 
al. 1988). HST and the human int.2 gene have been 
found co-amplified in a primary melanoma (Adelaide et 
al. 1988). HST and int.2 are located on chromosome 11 
at ql3 (Adelaide et al. 1988), separated by at most 40
kb of DNA (Nguyen et al.1988) and are both members of
the FGF family of growth factors (Delli Bovi et al. 
1987; Taira et al. 1987? Smith et al. 1988). The human 
homolog of the v-sea oncogene (Williams et al 1988), 
and the translocation breakpoint (Bcl-1) in some 
B-cell CLL's (Tsujimoto et al. 1984? Nguyen et 
al.1988) have both been localised to band ql3 of 
chromosome 11. Both bFGF and K-FGF/HST are capable 
of stimulating mitogenic activity in human melanocytes 
(Halaban et al. 1987,1988); thus increased expression 
of the K-FGF/HST gene as a consequence of genomic 
amplification could establish an autocrine loop. 
Genomic amplification of the K-FGF/HST gene is not 
however a common abnormality in human melanoma 
(Adelaide et al. 1988; Halaban et al.1988).
As mentioned previously, melanoma metastases
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frequently express lower levels of class I HLA antigen 
than primary tumours (Brocker et al. 1985), suggesting 
that reduced expression may contribute to increased 
malignancy. Patients with low class I HLA expression 
have a reportedly shorter survival than patients with 
a high class I HLA expression (van Duinen et al.
1988) . The adenovirus E1A oncogene is able to suppress 
class I MHC expression in adenovirus 12-transformed 
rodent and human cells (Schrier et al. 1983; Vaesen et 
al. 1986). In melanomas expression of the MYC 
oncogene, which shows functional (Land et al. 1983) 
and structural (Branton et al. 1983) homology to E1A, 
displays an inverse relationship with the expression 
of class I HLA (Versteeg et al. 1988). Introduction of 
the cloned MYC gene into melanoma cell lines results 
in the suppression of class I HLA and beta2 
microglobulin mRNA levels, but these can be restored 
following treatment with gamma-interferon which 
induces a transient decrease in MYC mRNA (Versteeg et 
al. 1988). Although abnormalities in the MYC gene, 
such as involvements in translocations, have not been 
reported in melanoma, it is possible that subtle 
alterations may increase MYC expression, thus 
contributing to malignant development.
Linnenebach et al. (1988) analysed 30 cell 
lines derived from primary or metastatic melanomas of 
28 patients for alterations in 28 different gene loci 
by Southern blotting techniques, and found
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alterations in the MYB gene in one primary melanoma 
in VGP cell line, which correlated with a 6q22 
abnormality. Homozygous deletion of at least one 
PKC-alpha exon was observed in another primary cell 
line, in the absence of cytogenetically detectable 
chromosome 17 abnormality.
A significant proportion of patients
successfully treated for the inherited form of
retinoblastoma, subsequently develop a second 
malignancy, usually osteosarcoma (Abramson et
al.1984). However, a small number of these individuals 
(6%) develop melanoma (Friend et al.1987). 
Abnormalities of the RB-1 gene have been noted in both 
retinoblastoma and osteosarcoma (Friend et 
al.1986,1987), and other tumours in patients where 
there is no evidence of a prediposition to 
retinoblastoma (Friend et al. 1987? Lee et al. 1988a; 
Harbour et al. 1988). In a study of tumours among 
patients having no previous evidence of retinoblastoma 
and no apparent disposition to retinoblastoma, Friend 
et al. (1987) failed to find evidence of homozygous 
deletion of the RB-1 gene in 17 melanoma samples. 
Nonetheless other abnormalities of the RB-1 gene may 
be present in sporadic CMM, such as interstitial 
deletions and point mutations, as shown in some 
retinoblastoma patients (Dunn et al. 1988) and the J82 
bladder carcinoma cell line (Horowitz et al. 1989).
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(xii) Tumour heterogeneity in human melanoma
The malignant cells within an individual tumour 
frequently display phenotypic variation, a phenomenon 
referred to as tumour heterogeneity. Such 
heterogeneity is manifest in human melanoma by 
variation in the degree of pigmentation, cell 
morphology, and growth rate (Albino et al. 1981). 
Antigenic markers corresponding to progressive stages 
of melanocyte differentiation, have been compared with 
other differentiation characteristics such as 
pigmentation, cell morphology and tyrosinase activity, 
enabling the assignment of the phenotype of melanoma 
cell lines to early, intermediate, or late stages of 
melanocyte differentiation (Houghton et al. 1982). 
Heterogeneity is observed within a single lesion as a 
consequence of the coexistence of populations of cells 
at different stages of differentiation, either early 
and intermediate, or intermediate and late (Houghton 
et al. 1987). Such cells are capable of 
differentiating when exposed to appropriate signals, 
such as phorbol esters, activators of cellular cAMP, 
and cAMP analogues (Houghton et al. 1987). The tissue 
microenviroment contributes to the phenotypic 
characteristics of melanoma metastases? for example 
the growth of liver-metastasising melanoma cells is 
stimulated by direct interaction with hepatocytes 
(Sargent et al. 1988).
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Six cell lines derived from anatomically 
distinct metastases occurring in a single patient 
showed marked pheno typic diversity, as indicated by 
characteristic differences in growth rate, morphology, 
pigmentation and the expression of surface antigens 
and glycoproteins. Four lines (DX-1, -3, -5 and -6) 
expressed HLA-DR products whereas two (DX-2 and -4) 
did not (Albino et al. 1981). Five of these lines 
expressed a clonotypic antigen, providing evidence for 
clonal derivation, although only one expressed at 
sufficient level to allow detection of autologous 
antibody reactivity (Albino et al. 1981). One cell 
line (DX-3) possessed an activated NRAS gene as 
detected by NIH 3T3 transfection, whereas the others 
failed to transform NIH 3T3 cells. (Albino et al. 
1984). In this patient, RAS activation has occurred as 
a relatively late event in malignant development, as a 
manifestation of tumour progression rather than 
contributing tumour initiation, maintenance or 
metastasis (Albino et al. 1984).
Section III
(i) Aims of thesis: The analysis of human
melanomas for the presence of activated 
oncogenes
The objective of this work was to identify 
specific genetic lesions in human melanoma, which 
result in the activation of dominantly transforming
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genes. To this end use was made of DNA-mediated gene 
transfer techniques and an assay designed to detect 
the ability of activated transforming genes to induce 
morphological transformation. A putative novel 
oncogene was identified following transfection of 
genomic DNA from a human melanoma cell line, and the 
aim of this work was to attempt to characterise, this 
previously undescribed human gene.
Activation of RAS genes represents the 
most frequent genetic lesion in human malignancy to date 
and there have been sporadic reports of RAS mutations in 
melanoma. Using a combination of biological and 
biochemical assays the frequency of RAS mutations 
in human melanoma cell lines and biopsies was 
assessed.
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Chapter 2 s Materials and Methods
Chapter 2 Materials and Methods
Section I: Biological Methods (Eukaryotic)
(i) Mammalian cell culture.
Cell lines were grown in Dulbeccos modification 
of Eagles Medium (DMEM) (Flow), supplemented with 
Penicillin and Streptomycin at 50 ug/ml and glutamine 
at 300 ug/ml. NIH 3T3 cells (obtained from R.A. 
Weinberg and given as a gift from D. Spandidos), were 
grown in medium with 10% heat inactivated foetal calf 
serum (Hyclone). Melanoma cell lines (provided by J. 
Embleton) and NIH 3T3 transformants were grown in 
medium with 5% heat inactivated calf serum (ACS) 
(Gibco-BRL Ltd). Cultures were maintained in plastic 
tissue culture flasks (Nunc) at 37°C in 10%C02. Medium 
was replaced every two to four days as required. For 
routine passaging of cells, culture medium was removed 
and the monolayer culture washed twice in phosphate 
bufferred saline (PBS), and the cells dissociated with 
trypsin-EDTA (Gibco-BRL) at room temperature or at 
37°C. The trypsin was neutralised by the addition of 
complete medium and the cells seeded, usually at a 1:10 
dilution, in growth medium in a fresh flask. Cell 
numbers were determined using an electronic cell 
counter (Coulter Electronics Ltd).
(ii) NIH 3T3 transformation assay 
Transfections were performed using calcium
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phosphate (Graham and van der Eb, 1973). NIH 3T3 mouse 
fibroblasts (passage 3) were plated at a density of 
3xl05 cells per 25 cm2 flask (F25, Nunc) in 5mls of 
DMEM containing 10% foetal calf serum (Hyclone). After 
24 hours, the medium was replaced with lOmls of DMEM 
containing 15% foetal calf serum (Hyclone) and lOug/ml 
of Gentamycin. The DNA to be transfected was ethanol 
precipitated and resuspended overnight in 0.1 X TE pH 
8.0 at a concentration of 20ug/0.45mls (20ug of DNA is 
transfected per 25cirr flask) . Transfection was 
performed within 4 hours of changing medium, each 
sample divided between 5 25cm2 flask. 2.5M CaCl2 was 
added to lOOug of DNA in 2.25 mis of O.lx TE and mixed. 
200ul aliqouts of this mixture were added sequentially 
to 2.5 mis of ice cold 2X HBS and vortexed. This was 
left at room temperature for 30 minutes for a medium 
coarse precipitate to form. 1ml of precpitated DNA was 
added to each F25 flask, and left at 37°C overnight. 
The following morning the medium was changed to 5mls of 
DMEM with 5% serum (Hyclone). Cultures were maintained 
in this medium until foci of transformed cells 
appeared. EJ foci were visible within 16 days, in 
contrast the melanoma samples tested produced foci up 
to 30 days post-transfection. Foci were counted under 
low power light microscopy. Contaminating normal cells 
were occasionally removed prior to foci being picked by 
replacing with DMEM containing 2% serum. Foci were 
picked by surrounding with a sterile cloning cylinder
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sealed with sterile silicon grease. Trypsin was added 
to loosen cells, then neutralised with fresh medium. 
Cell suspensions were transferred to fresh flasks of 
medium and cultured until enough cells were available 
for DNA analysis and for testing for anchorage 
independant growth.
(iii) Anchorage independence (soft agar) assay
To test for anchorage independent growth, cells
were plated at 5 x 104 and 1 xl05/ml in 0.3% agar.
4mls of molten bottom agar was added to each 5cm dish
(Nunc) and allowed to set. Meanwhile cells to be plated
were trypsinised, counted and diluted to 2x the final
concentration required. Cell suspensions were placed at
37°C until required. Top agar was melted and maintained
at 45°C until required. Equal volumes of top agar and
cell suspension were mixed and 2mls plated per 5cm
dish. Once set , cultures were transferred to 37°C and
fed weekly with top agar. Colonies were visible from
Ufa"
day 10 onwards, and were scored at day 20. Independent 
colonies were isolated using sterile glass pasteur 
pipettes and transferred to microtitre plates 
containing fresh medium. When cultures were confluent 
they were trypsinised and transferred to 25cm2 flasks
(iv) Cotransfection with pHSG272
The procedure for cotransfection of a selectable 
marker with genomic DNA was as described previously
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* The efficiency of plating in soft agar for NIH 3T3 cells 
was < 0.001% . Transfectants were considered positive for
anchorage independent growth when the efficiency of plating 
was > 2%.
(ii); lug of the vector pHSG272 (Brady et al. 1984) was 
added to 20ug genomic DNA, and ethanol precipitated and 
resuspended in 0.1XTE as before.
(v) G418 selection
Transfected cultures were split 2 days after 
transfection at a dilution of 1:4 into 75cm2 flasks 
(Nunc) of DMEM with 10%FCS and 800ug/ml Geneticin 
(G418, Gibco-BRL). The low density of plating was
essential to ensure efficient selection of cells 
expressing the drug resistance (Fasano et al. 1984). 
After 10-14 days selection without changing the
selective medium, resistant colonies were harvested by 
trypsinisation, pooled and counted .
(vi) Nude mouse tumorigenicity assay
Cells for injection were resuspended in
injection medium at a concentration of 107 cells/ml. 
106 cells were injected subcutaneously into the hind 
flanks of six week old athymic nude mice. Mice were 
examined for tumour formation every two days and 
tumours arising within 4-6 weeks were excised and
stored fozen at -70°C. Those tumours with a latency 
period of greater than 6 weeks were only occasionlly 
analysed further, and were assumed to be the result of 
spontaneous transformation.
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(vii) Growth curves
Cells were plated sparsely in DMEM/10% (v/v) 
FCS. The day after (day 0), cells from two dishes were 
counted. An appropriate number of cultures then 
received medium with reduced serum concentration (0.5%) 
or medium with the normal serum content (10%), in the 
presence or absence of suramin at 200 ug/ml. Duplicate 
dishes were counted every second day, and medium was 
changed on the remaining dishes.
Section II: Prokaryotic and nucleic acid biochemical 
methods
(i) Preparation of High Molecular Weight (HMW) DNA 
from cultured cells and tissue samples
Three protocols have been used through the 
course of this work to extract HMW DNA
(a) Cultured cells only
Harvested cells were washed twice in PBS, spinning 
between washes at 2000rpm for 5 minutes, room 
temperature. The cell pellet was resuspended in TSE, 
5mls/106 cells, and Proteinase K (Sigma) was added to 
a concentration of lOOug/ml. 20% SDS was then added to 
a final concentration of 0.5%, and incubated for 4 
hours-overnight at 37°C. Protein was extracted by 
phenol(1 x), phenol/chloroform (2 x), and chloroform
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(1 x). 1/10 vol 3M Sodium Acetate was added, then 2 
volumes of ethanol, mixed to precipitate the DNA, then 
pelleted by centifugation. The supernatant was removed 
and DNA pellet was rinsed in 70% ethanol, 
recentrifuged, again removing the supernatant, and the 
pellet allowed to air dry. DNA was resuspended in TE
(b) Cultured cells and tumours
Preparation of nuclei : All steps at 4°C, on ice in 
precooled solutions.
Frozen tissue was cut into small pieces, thawed for 5 
minutes in 0.3 M sucrose solution (lg of tissue/ lOmls) 
then homogenised in a Dounce homogeniser. The 
homogenate was filtererd through two layers of gauze 
(not applicable to cultured cells) then spun at 3k for5 
minutes at 4°C. The pellet was resuspended in lOmls of 
0.3 M sucrose solution (+0.1% Triton), homogenised (5x 
up and down), and centrifuged at 3k for 5 minutes, 4°C. 
The pellet was resuspended in 10 mis of 0.3 M sucrose 
solution (-triton), homogenised and spun as before. The 
pellet was resuspended in 0.3M sucrose solution, and 
spun at 3k, 5 minutes, 4°C. The pellet was resuspended 
in 7mls of 50mM Tris pH7.2, 2mM EDTA, proteinase K 
added to lOmg/ml, then 3 ml of 1% SDS in 50mM Tris, 
2mM EDTA, was added slowly, swirling to avoid 
clumping, then left at 37°C overnight, rotating 
gently. The lysate was extracted with phenol, 
phenol/chloroform, and chloroform. The DNA was 
precipitated by the addition of sodium acetate (pH 9)
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to a final concentration of 0.3M and 2.5 volumes of 
absolute ethanol, and resuspended over 1-2 days at room 
temperature in 1 x TE pH 8.0. The DNA was precipitated 
and resuspended a furhter two times.
(c) Cultured cells and tumours (suitable for cosmid 
cloning)
Cells (108-109) were resuspended and sliced frozen 
tissue homogenised in 5mls of lxSSC on ice. Then 5mls 
of lysis solution (lOOmM tris pH 7.5, lOOmM NaCl, lOmM 
EDTA, 1% Sarkosyl) was added, mixed for about 2-3 
minutes to lyse cells, then proteinase K added to 
lOOug/ml. The lysate was incubated at 55°C for 2 hours, 
extracted with phenol, phenol-chloroform (1:1 v/v) and 
chloroform. The sample was dialysed against 4 1 of 1 x 
TE plus lOOmM NaCl, 4°C, overnight, then repeated with 
fresh dialysis solution.
(ii) Isolation of total cytoplasmic mRNA
Cells were resuspended in guanidine thiocyanante 
(2 x 106 cells per ml) and passed 3X through a 21 
guauge needle. The lysate (6mls) was layered on a 6ml 
cushion (5.7M CsCl in 25mM sodium acetate pH 5.4) in a 
12 ml tube, and spun at 22K for 18 hours at 15°C. The 
supernatant was removed and the pellet rinsed with 
70% ethanol, and allowed to dry. The pellet was 
dissolved in 1ml of 1 X TE pH 7.5, 1.0% SDS, then 
precipitated with 1/10 volume of 2M sodium acetate pH
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5.4 and 2 volumes of absolute ethanol. RNA pellets were 
stored at -70°C.
(iii) Purification of poly A+ mRNA
Messenger affinity paper (Hybond-mAP: Amersham)
was cut to sufficient size to give required RNA 
capacity (weight of long-chain poly A+ mRNA which can 
be bound and released from paper: 14-20 ug/cm square),
and wetted in mAP high salt buffer. The RNA solution
was pippetted in small aliquots onto the mAP and 
allowed to dry between each application. The mAP was
washed in 3 x 5ml of 0.5M NaCl per 1cm for 10 minutes
each wash, placed in 70% ethanol for 2 minutes, then 
blotted dry on 3mm paper. The mAP with bound poly A+ 
mRNA was covered with a minimum volume of double 
distilled DEP treated H20 and incubated at 70°C, 5 
minutes. The mAP was removed and the poly A+ mRNA 
precipitatedwith 1/10 volume of 2M sodium acetate pH
5.4 and 2 volumes of absolute ethanol.
(iv) Southern analysis (DNA)
Southern analysis was performed essentially as 
described by Maniatis et al. (1984). DNA was digested 
with the required restriction enzyme in an appropriate 
volume (10-20 ug of genomic DNA in 50ul total reaction 
mixture, 10 x excess restriction endonuclease) for 4 
hours or overnight, 37°C. Complete digestion was 
confirmed by electrophoresing 1/2-lug of the sample on
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an agarose gel. Bromophenol blue dye (5ul) was added 
to the sample, loaded onto an agarose gel (usually 
0.8% in 1 x TAE) and run at 30V overnight. The gel was 
stained in ethidium bromide (5ug/ml in 1 x TAE, 30 
minutes) rinsed and photographed. The gel was trimmed 
accordingly, and denatured for 1 hour. The gel was 
rinsed with distilled H20 and neutralised for 1 hour. 
Nitrocellulose filters were presoaked in 2 x SSC. 
Transfer was carried out in 6 x SSC, overnight. 
Filters were rinsed filter in 2 x SSC and the DNA was 
fixed by baking at 80°C for 2 hours (nitrocellulose: 
Sartorius, Hybond-N: Amersham) or UV irradiation for 
2-5 minutes (Hybond-N).
Hybridisation (nitrocellulose)
The filter was prehybridised for 4-5 hours at 
42°C in nitrocellulose prehybridisation solution, which 
was then replaced with nitrocellulose hybridisation 
solution and the denatured radiolabelled probe (106 
cpm/ml), and incubated overnight at 42oC. The flter 
was washed twice in 2 x SSC for 5 minutes at room 
temperature, then for 30 minutes at 60°C in 2 x SSC, 
0.1% SDS. The conditions for low stringency washing 
were 0.6 x SSC, 0.1% SDS for 30 minutes at 60°C. The 
conditions for high stringency washing were 0.1 x SSC, 
0.1% SDS for 30 minutes at 60°C. The filter was then 
washed in 0.1 x SSC for 15 minutes at room temperature, 
and repeated twice. The filter was blotted dry, and
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autoradiographed at -70°C with intensifying screens.
Probe removal (nitrocellulose)
The filter was incubated at 70°C in probe wash 
solution for 1 hour, rinsed at room temperature in 2 x 
SSC, blotted dry and autoradiographed to confirm 
successful removal of probe.
Hybridisation (Hybond-N)
The filter was prehybridised for 4-5 hours at 
65°C in Hybond hybridisation solution, which was then 
replaced with fresh hybridisation solution and the 
denatured radiolabelled probe (106 cpm/ml), and 
incubated overnight at 65°C. The filter was washed 
twice in 2 x SSC at 65°C for 15 minutes, then in 2 x 
SSC, 0.1% SDS at 65°C for 30 minutes. The conditions 
for low stringency washing were 0.6 x SSC, 0.1% SDS,
for 30 minutes at 65°C. The conditions for high
stringency were 0.1 x SSC, 0.1% SDS, for 30 minutes at
65°C. The filter was blotted dry and autoradiographed
at -70°C with intensifying screens.
Probe removal (Hybond-N)
(i) The membrane was submerged in 0.1% SDS,
brought to the boil and left for 30-60 minutes,
allowing to cool to room temperature.
(ii) The membrane was incubated at 45°C for 30
minutes in 0.4M NaOH, then rinsed in 0.1 x SSC, 0.1%
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SDS, 0.2M Tris pH 7.5.
Reomval of the probe was confirmed by autoradiography 
at -70°C.
(v) Northern Analysis (mRNA)
Agarose (BRL) was melted (0.8-1.5%) in H20, 
cooled to 60°C, then northern gel buffer was added to 
give a 1 x concentration, and formaldehyde to 2.2 M. 
The RNA pellet was resuspended in H20, lyophilised, 
then resuspended in RNA sample buffer and heated at 
55°C for 15 minutes. RNA dye was added (5ul) and loaded 
onto the gel, and electrophoresesis was carried out 
overnight at 30 v. The gel was washed in 0.1 x SSC for 
1 hour, stained in lug/ml ethidium bromide in 0.1 x SSC 
for 30 minutes, then destained in 0.1 x SSC for 30 
minutes. The gel was photographed and transferred to 
a membrane as for Southern blotting.
(vi) P32 labelling of DNA Probes
Nick translation (Rigby et al. 1977)
Labelling of DNA by nick-translation was 
performed using a nick-translation kit (Amersham). The 
reaction mixture was composed of lOOng of DNA, lOul of 
Solution 1 (Nucleotide/buffer solution), 50-100 uCi of 
32P dCTP, 5ul of Solution 2 (Enzyme solution; DNA 
polymerase I/DNAase I) and H20 to a final volume of 
50ul, and incubated at 14°C for 2 hours.
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Random primer extension (Feinberg and Vogelstein,
1984)
Restricted DNA was electrophoresed in low 
gelling temperature agarose (BRL), and the reguired 
band was excised. H20 was added to the gel (1.5mls 
H20/g agarose) and placed at 95°C for 7 minutes to 
melt the agarose and denature the DNA. The DNA was 
stored at -20°C? for subsequent labellings the sample 
was placed at 95°C for 3 minutes. The DNA was placed at 
37°C for 10-60 minutes prior to initiating the 
labelling reaction. The labelling reaction consisted 
of 5ul of OLB buffer, lul of BSA (lOmg/ml stock), xul 
DNA (25ng) up to 6.25ul, 5-10ul of 32P alpha-dCTP
(lOuCi/ul), 0.5ul of Klenow (large fragment) DNA
polymerase I (BRL), and H20 to a total volume of 25ul. 
The reaction was incubated at room temperature for 5 
hours/overnight or at 37°C for 1-2 hours. The reaction 
was stopped by the addition of lOOuls of stop buffer.
Determination of percentage incorporation of labelled 
nucleotide.
0.5ul of reaction mix was added to 200ul of carrier DNA 
(calf thymus DNA, 150ug/ml), then 20ul was spotted onto 
a Whatman GF-C filter (count 1). 10% TCA (1ml) was
added, mixed and left on ice for 15 minutes. This was 
passed through a GF-C filter and fixed with absolute 
ethanol (count 2). The filters were dried at 80°C and
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counted in a liquid scintillation counter. The 
percentage incoporation = [(count 2) x 0.9/ (count 1) x 
10) x 100.
Separation of labelled DNA from unincorporated 
nucleotides
The reaction mixture was loaded onto a Sephadex G-50 
column, equilabrated with TE and and 0.5ml fractions 
were collected. Those fractions containing labelled DNA 
were pooled.
(vii) Polymerase chain reaction (Saiki et al. 1988)
The polymerase chain reaction was performed in 
lOOul of lOmM Tris pH 8.3, 50mM KC1, 2mM MgCl2, 0.1% 
gelatin, 80nM dNTP's, lOOpM of primers 1 and 2, and lug 
of DNA. The reaction mixture was overlaid with lOOul of 
mineral oil to prevent evaporation. Amplification was 
performed manually or with an automated thermal cycler 
(Perkin Elmer-Cetus) with cycles of denaturation (94°C, 
3 minutes), annealing of primers to DNA, (55°C, 3 
minutes) and extension (72°C, 3 minutes). After
amplification the mineral oil was removed by chloroform 
extraction.
For slot blotting the sample (5ul) was denatured in 
0.2M NaOH, 0.02M EDTA for 10 minutes, then applied to 
filter presoaked in 20 x SSC via a slot blot manifold 
(Schleiger and Schull) under vacuum.
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(viii) Preparation and use of end-labelled 
oligonucleotide probes
Sequence-specific oligonucleotides were
synthesised on an Applied Biosystems DNA synthesiser, 
model 381, and purified according instructions 
supplied. 30ng of oligonucleotide DNA was labelled by 
incubating in 10 ul of 50mM Tris pH7.6, lOmM MgCl2, 
5mM dithiothreitol, lOOnM spermidine, lOOnM EDTA, 32P 
gamma-ATP and 1 unit of T4 polynucleotide kinase 
(Amersham) at 37°C for 30 minutes. The reaction was 
stopped with the addition of 5ul of M13 dye and placed 
at 95°C for 3 minutes. The sample was
electrophoresed on a 10% polyacrylamide gel. The 
position of the labelled oligonucleotide was 
determined by autoradiography of the gel. The 
oligonucleotide was excised and eluted from the gel 
in ImM EDTA at room temperature overnight, and stored at 
-20°C.
For hybridisation of the oligonucleotide to slot blots, 
the filter was prehybridised for 30 minutes at 55°C in 
Temac hybridisation solution, then hybridised in fresh 
hybridisation solution with the 32P-labelled 
oligonucleotide (106cpm/ml) for at least 1 hour at 
55°C. The filter was washed twice in 2 x SSPE, 0.1% 
SDS, for 10 minutes at room temperature. Then the 
filter was washed in Temac wash solution at 55°C for 30 
minutes. Stringent washes were performed at the 
appropriate temperature in 5 x SSPE, 0.1% SDS for 10
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minutes. Autoradiography was caried out at -70°C with 
intensifying screens.
(ix) Preparation of competent bacterial cells 
and transformation.
HB101
50mls of L-broth was innoculated with 1ml of 
overnight culture and incubated at 37°C, with shaking, 
until the absorbance at 600nM = 0.4-0.6. The cells
were pelleted at 7K for 2 minutes at 4°C. The pellet 
was resuspended in 1/2 volume of ice cold 50mM CaCl2, 
placed on ice 30 minutes, then spun as before. The cell 
pellet was resuspended in 3mls of cold 50mM CaCl2.
JM101
40mls of 2 x YT medium was innoculated with 1ml 
of overnight culture and incubated at 37°C, with 
shaking until the absorbance at 550nM = 0.3. The cells 
were treated as for HB101.
DNA (1-100 ng) in 100 ul of 1 x TE was added to 
100-2OOul of competent cell suspension on ice, and left 
for 30 minutes. The cells were heat shocked for 90 
seconds at 42°C and placed on ice for two minutes. 1ml 
of L-broth was added and the cells were placed at 37°C 
(no shaking). Aliquots were plated on L-agar by 
spreading or top agar. For pUC based vectors, JM101 was 
used and plated on B-agar plates with B-top agar
75
containing x-gal and IPTG.
(x) Preparation of plasmid DNA
Small scale.
1 ml of TB or L-broth was inoculated with a 
bacterial colony, and incubated at 37°C, shaking, for 6 
hours/overnight. The cells were spun down in a 
microfuge for 1 minute, and the supernatant removed. 
The cell pellet was resuspended in 100 ul of plasmid 
lysis solution I (note without lysoszyme), and left on 
ice for 5 minutes. 200 ul of solution II was added, 
mixed and left on ice for 5 minutes. 150 ul of 
solution III was added mixed and left on ice for 5 
minutes. The lysate was spun down in a microfuge for 1 
minute, and the supernatant was transferred to a 
fresh tube, extracted once with phenol/chloroform, then 
the DNA was precipitated with either 2.5 volumes of 
absolute ethanol or 0.6 volumes of propanol. The DNA 
was pelleted and then rinsed in 70% ethanol. The DNA 
was resuspended in 50 ul of 1 x TE containing 10 ug/ml 
RNAase A.
Large scale.
400ml-ll of L-broth or TB was inoculated with 
10 ml of overnight culture and incubated at 37°C 
overnight, shaking. Cells were pelleted at 8K for 5 
minutes at 4°C. The cell pellet was resuspended in 
40mls of solution I, with lysozyme added to a
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concentration of 2mg/ml and left for 30 minutes on ice. 
80mls of solution II was added, mixed and left on ice 
for 5 minutes. 60mls of solution III was added, mixed 
and left on ice for 15 minutes. The lysate was spun at 
8k for 10 minutes at 4°C. The supernatant was poured 
through gauze, then 0.6 volumes of propanol was added 
to precipitate the DNA. The DNA was pelleted at 8k for 
10 minutes at 4°C. The pellet was resuspended in 8mls 
1 x TE, lOg of CsCl and 600ul of ethidium bromide, 
andspun at 10k for 10 minutes. The plasmid DNA was 
purified by centrifugation in sealed tubes in a 
vertical rotor (DuPont) at 63k for 4 hours. The
plasmid band was removed with a syringe and a needle.
Ethidium bromide was extracted with equal volumes of
propanol. To remove the CsCl the plasmid DNA was
dialysed against TE.
(xi) Purification of lambda DNA
Preparation of liquid lysate
Plating cells were prepared by pelleting 20 mis 
of an overnight culture at 10K for 10 minutes, and then 
resuspending in 5mls of lOmM MgS04. Phage were added
(0.1-0.2ml of phage lysate) and incubated at 37°C for 
10 minutes to allow adsorption of phage to cells.
Plating cells and phage were then added to 11 of CY
medium + 20mM MgS04, and incubated shaking overnight
at 37°C. Lysis was accompanied by clearing of the
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culture. Chloroform was added to the culture with 
continued shaking at 37°C for 10 minutes to complete 
lysis.
PEG precipitation of phage lysate
To 11 of liquid lysate, 20g of NaCL was added
and dissolved gently at room temperature. The lysate
was left at 4°C overnight or on ice for 1 hour, then
the bacterial debris was pelleted at 8K for 5 minutes
at 4°C. The lysate was transferred to a fresh flask, 
lOOg of crushed PEG 6000 was added, and left at 4°C 
overnight or on ice for 4 hours. The PEG precipitate 
was pelleted at 4K for 5 minutes at 4°C. The pellet 
was resusupended in the minimum of phage buffer on 
ice, and phage particles allowed to resuspend at 4°C 
overnight. PEG was precipitated by centrifugation at 
5K for 5 minutes at 4°C. The supernatant extracted 
with an equal volume of chloroform.
CsCl Block Gradient Purification of Phage.
2mls of 1.3g.cm“C CsCl in phage buffer was 
placed in a 12ml polyallomer tube and successively 
underlaid with 2mls of 1.5g.cm“3 and 1.7g.cm-3 CsCl in 
phage buffer. Resuspended phage were layered on top 
before centrifugation at 24K for 4 hours at 20°C. The 
phage band in the l.5g.cm~3 layer was removed with a 
hypodermic syringe and needle.
Preparation of phage DNA
CsCl was removed from the phage suspension by
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dialysis against 1 x TE pH 8.0 for 1 hour at 4°C. Any 
remaining RNA was digested with lOug/ml heat-treated 
RNAase A at room temperature, whilst continuing the 
dialysis against TE for 1 hour. Protein was digested 
with 50ug/ml proteinase K at 37°C whilst dialysing 
against pronase buffer for 1 hour. The remainder of 
the protein was removed by 2 extractions with phenol. 
Traces of phenol were removed by dialysis against TE, 
with 3 changes of buffer at 4°C.
(xii) Electroelution of DNA fragments onto DEAE 
cellulose.
Preparation of DEAE cellulose membrane.
Suitable sized strips of membrane were cut and 
soaked in 2.5M NaCl for 3 hours at room temperature, 
rinsed in 6 volumes of sterile H20 and stored at 4°C in 
ImM EDTA. Prior to use (at least 30 minutes) strips 
were soaked in electrophoresis buffer.
Gel Electrophoresis.
The sample was electrophoresed on an agarose gel 
and stained in ethidium bromide to visualise. A slit 
was cut in front of the fragment of interest and the 
membrane inserted. Electrophoresis was continued at 
high voltage e.g. 200V for 15 minutes, until the band 
could be seen on the membrane under UV illumination. 
Recovery of DNA.
The membrane was not allowed to dry to prevent 
irreversible binding. The membrane was washed with 4ml
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of sterile H20 (4 x), placed in 400ul of 20mM Tris pH 
7.5, lmM EDTA, 1.5M NaCl, vortexed for 1 minute and 
left at 37°C for 2 hours. The vortexing was repeated 
and the membrane removed. The DNA in solution was 
extract with water-saturated butanol (3-4 x) to remove 
ethidium bromide then with with phenol/chloroform (2 
x). The DNA was precipitated with the addition of 2.5 
volumes of absolute ethanol and incubation on dry ice 
for 5 minutes. The DNA was pelleted, rinsed in 70% 
ethanol, and resuspended in 1 x TE pH 8.0.
(xiii) Isolation of DNA fragments in LGT agarose.
Restricted DNA was electrophoresed in an LGT 
agarose (BRL) gel, and stained in ethidium bromide 
(0.5ug/ml). The fragment of interest was excised from 
the gel and sliced into small pieces. 5 volumes of H20 
was added, and the sample incubated at 65°C for 5-10 
minutes (or until gel was dissolved). The sample was 
extracted with an equal volume of ice-cold phenol and 
left on ice for 5 minutes. After centrifugation the 
upper layer was transferred to a fresh tube and the 
phenol extraction was repeated. The DNA was 
concentrated with Butan-2-ol prior to ethanol 
precipitation.
(xiv) Lambda cloning.
200,000 clones were screened on a single 22 x 22 
cm plate. As small an area as possible, corresponding
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to the positive hybridisation signal, was picked, 
replated on 150mm diameter plates and rescreened. 
Single plaques were picked and replated on 90mm 
diameter plates. This was repeated until a homogenous 
population of clones was obtained.
Preparation of lambda vector.
Vector DNA was digested with a twofold-threefold 
excess of restriction enzyme for 1 hour, then 
extracted with phenol/chloroform (2 x) and ethanol 
precipitated. The DNA was resuspended in 1 x TE, to a 
concentration of 150ug/ml? MgCl2 was added to lOmM and 
the DNA incubated at 42°C for 1 hour to allow cos ends 
of lambda to anneal. 60-70ug of DNA was loaded onto a 
38ml sucrose gradient (10%-40%) in a volume of 500ul or 
less and centrifugation was performed at 26k for 24 
hours at 15°C. Fractions (0.5ml) were collected from 
the bottom of the gradient. 15ul of every third 
fraction was diluted with 35ul of H20, 5ul of 
bromophenol blue dye was added and then heated at 68°C 
for 5 minutes, prior to electrophoresis through a 0.4% 
agarose gel. Fractions containing lambda arms were 
dialysed against 1 x TE pH 8.0 at 4°C. DNA was 
concentrated with Butanol, ethanol precipitated and 
resuspended in lOmM Tris pH 7.5 at a concentration of 
300-500ug/ml.
Preparation of insert DNA.
High molecular weight DNA (200-500ug) was 
either completely digested with the required
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restriction enzyme or partially digested with Sau3A 
under conditions optimised to yield fragments of 15-20 
kb, extracted gently with phenol/chloroform, and 
ethanol precipitated. The digested DNA was dissolved in 
500ul of 1 x TE, heated for 10 minutes at 68°C, cooled 
to 20°C and run on a 38ml 10-40% sucrose gradient (26k, 
24 hours, 20°C). Fractions (0.5ml) were collected from 
the bottom of the tube and every third fraction was 
analysed by electrophoresis through 0.4% agarose, and 
Southern blotting if required. Sucrose was removed by 
dialysis against 1 x TE. The DNA was concentrated with 
Butanol, ethanol precipitated and resuspended at 
300-500ug/ml.
Ligation and packaging.
Ligations were performed under conditions 
favouring concatamerisation of vector and insert? molar 
ratios of 2:1 and 3:1 of annealed arms to potential 
inserts were used to generate lambda genomic libraries. 
Each ligation contained a total of 2.0ug of DNA in a 
volume of lOul. Control samples containing only 1.5ug 
of arms were set up to estimate the background caused 
by contamination of the arms with stuffer fragment or 
intact lambda DNA. Ligations were performed in lOul's 
of 1 x ligation buffer with 1 unit of T4 DNA ligase 
(BRL), for 12-16 hours at 14°C. Ligated phage were 
packaged with an in vitro packaging kit (Amersham). 
Extracts A and B were removed from -70°C and allowed to 
thaw on ice. DNA (1 ug in no more than 4 ul) was added
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to extract A, to which transfer 15ul of extract B was 
transferred, mixed gently and spun to collect the 
contents at bottom of tube. The packaging reaction was 
incubated at room temperature for 2 hours. Packaging 
was stopped with the addition of 500ul of phage buffer 
and lOul of chloroform, and the reaction stored at 4°C. 
The packaging efficiency was approximately 5 x 108 
pfu/ug.
Preparation of plating cells
50mls of medium (CY,LB) containing 0.2% maltose 
was inoculated with 1ml of overnight culture, and 
incubated until the absorbance at 600nM = 0.4-0.6. The 
cells were pelleted by centrifugation at 10k for 10 
minutes at 4°C, resuspended in lOmls of lOmM MgS04 and 
stored at 4°C. Plating cells were incubated with phage 
lysate for 10 minutes at 37°C, mixed with top 
agar/agarose, and plated onto L-agar.
Plating and screening of lambda genomic libraries.
The titre of a phage library was determined by 
plating out serial dilutions of packaged phage. For a 
22 x 22 cm plate, 2 x 105 phage were added to 1.2ml of 
plating cells, incubated at 37°C for 10 minutes, mixed 
with molten (50°C) top agarose, and plated on agar. 
Agar plates were incubated at 37°C overnight, then 
placed at 4°C for at least 1 hour to allow top agarose 
to harden.
Lambda plaque lifts
The membrane (Pall) was placed on the agar
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surface, and both the membrane and petri dish marked 
for later orientation of colonies. After 1 minute the 
membrane was removed and placed, colony side up, on 
filter paper saturated with denaturing solution for 5 
minutes. The membrane was then placed on filter paper 
saturated with neutralising solution for 5 minutes. 
Duplicate filters were prepared as above, doubling the 
time of absorption of plaques onto membrane for each 
successive plaque lift. The membrane was allowed to air 
dry for 30 minutes and baked at 80°C for 1 hour to fix 
the DNA. Filters were hybridised as for nitrocellulose 
membranes.
Isolation of positive clones.
Clones were considered positive only if a signal 
was observed on independant filters. The 
autoradiograph was aligned to identify the position of 
positive clones on the plate. Plaques were isolated 
with sterile glass pasteur pippettes into 1ml of phage 
buffer, to which a few drops of chloroform were added 
and stored at 4°C.
(xv) Cosmid cloning
Preparation of vector DNA for cosmid library 
construction.
pJB8 (Ish-Horowicz and Burke, 1981)
pJB8 DNA (20ug) was digested with either 
Hindlll or Sail (lhour, 37°C, 2 x excess), then
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digestion was terminated by heating to 70°C for 10 
minutes. The DNA was extracted once with 
phenol/chloroform, ethanol precipitated and resuspended 
in 200 ul of lOmM Tris pH 8. Vector DNA was 
dephosphorylated with with calf intestinal
phosphatatase (Boehringer? O.lu) for 30 minutes at 
37°C, and the reaction terminated with the addition of 
lul of 0.5M EDTA, and phenol/chloroform extraction(2 
x). DNA was ethanol precipitated, resusupended in 50ul 
and both pJB8 (Sail) and pJB8 (Hindlll) were digested 
with BamHI (1 hour, 37°C, 2 x excess). The DNA was 
extracted with phenol/chloroform (2 x), ethanol 
precipitated (2 x), and resuspended at a concentration 
of 200ug/ml in lOmM Tris pH 7.5.
C2XB (Bates and Swift, 1983).
C2XB DNA (20ug) was digested with Smal and 
BamHI (1 hour, 37°C, 2 x excess), and the reaction was 
terminated by heating at 70°C for 10 minutes and 
extraction with phenol/chloroform (2 x). The vector 
DNA was ethanol precipitated (2 x) and resuspended at 
a concentration of 200ug/ml in lOmM Tris pH7.5. 
pHSG250 (Brady et al. 1985)
pHSG250 DNA was digested with HincII (directed 
packaging), or EcoRI or HincII (cosmid cloning), 
treated with CIP, then extracted with 
phenol/chloroform (2 x). The vector DNA was ethanol 
precipitated, resuspend in 1 x TE, then digested to 
completion with BamHI (HincII/BamHI or HincII/BamHI
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and EcoRI/BamHI). The reaction was extracted with 
phenol/chloroform (2 x), ethanol precipitated (2 x)
and resuspended at 200ug/ml in lOmM Tris pH7.5. 
Preparation of insert DNA.
High molecular weight DNA (200-500ug) was 
partially digested with Sau3A under conditions 
optimised to yield fragments of 40-50 kb, extracted 
gently with phenol/chloroform, and ethanol
precipitated. The DNA was dissolved in 500ul of 1 x 
TE, heated for 10 minutes at 68°C, cooled to 20°C and 
run on a 38ml 10-40% sucrose gradient (26k, 24 hours,
20°C). Fractions (0.5ml) were collected and every 
third fraction analysed by electrophoresis through 0.4% 
agarose. Fractions corresponding to 40-50 kb were 
pooled and dialysed against 1 x TE. The DNA was 
concentrated with Butanol, ethanol precipitated and 
resuspended at 300-500ug/ml in lOmM Tris pH 7.5. 
Ligation, Packaging and Transduction.
Cosmid and insert DNA were ligated at molar 
ratio of 2:1 of total vector to insert at 15°C 
overnight. Ligated molecules were packaged (Amersham 
lambda packaging kit) and the number of recombinants 
(pJB8 and C2XB only) was determined by incubating with 
1046 plating cells and plating on L-agar with 
appropriate antibiotic. For pHSG250, the packaged DNA 
was incubated with ED8767 plating cells and plate on 
L-agar with 15ug/ml kanamycin.
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Chapter 3: Transforming activity in melanomas and
characterisation of a putative novel oncogene
Section I: Introduction
The observation that genomic DNA from the human 
bladder carcinoma cell lines EJ and T24 contained 
sequences capable of conferring the phenotypic 
characteristics of transformation onto a non­
transformed cell, in this case NIH 3T3 mouse 
fibroblasts (Krontiris and Cooper, 1981? Shih et al. 
1981), revolutionised the search for cellular genes 
involved in neoplastic progression. The subsequent 
realisation that the gene responsible was homologous to 
the previously identified oncogene of the Harvey Murine 
Sarcoma Virus, (Der et al. 1982; Parada et al. 1982; 
Santos et al. 1982) suggested a possible relationship 
between retroviral and cellular oncogenes. Genomic DNA 
from a variety of human and animal malignancies has
been tested for the ability to transform rodent
fibroblast cell lines, (Cooper et al. 1980; Cooper and 
Neiman, 1980; Krontiris and Cooper, 1981; Perucho et 
al. 1981), and in the majority of cases where
transforming activity has been detected, subsequent 
analysis has revealed the presence of a mutated RAS 
gene (Bos, 1988). Other genes have been detected by 
such assays in a diverse series of neoplasms; these
are listed in table 3:1. Although all were identified
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Table 3:1
Transforming Genes detected by transfection assays
Gene
NEU
MET
MAS
RET
ROS
TRK
RAF-1
BRAF
KFGF
/HST
FGF5
Tumour Mechanism of 
Activation
Function Refere
NMU induced rat
neuroblatoma
MNNG-HOS
Epidermoid
Carcinoma
AML
Ovarian cancer 
T-cell lymphoma 
Sigmoid colon 
cancer
Human Mammary 
Carcinoma cell 
line (MCF-7)
Point mutation
Fusion of MET and 
TPR sequences
Transfection
rearrangement
Transfection
Recombination
Transfection 
Rearrangement 
(loss of extra­
cellular domain) 
colon carcinoma Somatic 
mammary carcinoma Transfection
Related [1,
to EGFR 2]
Related to [3]
Insulin 
receptor 
Angiotensin [4 
Receptor -7]
Tyrosine [8,9] 
kinase
homologous [10,11] 
to insulin 
receptor
[12,13]
cell line recombination
Human stomach, 
Rat hepatoma 
glioblastoma 
Fibroblasts 
(Li-Fraumeni 
syndrome) 
Ewing Sarcoma
Transfection 
Rearrangement 
5' substitution
Transfection 
Rearrangement 
5' substitution
Serine/
Threonine
kinase
[14-17]
[18]
Kaposi's sarcoma 
Stomach tumour 
Melanoma 
Hepatoma
Transfection FGF
rearrangement 
loss of regulatory 
sequences
Transfection FGF
Rearrangement 
juxtaposition 
of retroviral LTR
[19-22]
[23]
BLYM Chicken B-cell 
lymphoma,
Burkitts lymphoma
7 ? [24-27]
DBL Diffuse B-cell Transfection [28-31]
/mcf-2 lymphoma Rearrangement
mammary carcinoma 5' and 3' 
line MCF-7
LCA hepatoma ? [32]
TRE
PTC
VAV
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Ewing sarcoma
Thyroid
carcinoma
Oesophageal
carcinoma
Transfection 
recombination 
3 separate fragments
Transfection 
recombination with 
PSV2NEO
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on the basis of inducing a full malignant phenotype in 
NIH 3T3 cells, they display no consisistent functional 
similarities. Some show homology to previously 
described genes, such as the RAF gene family of
serine/threonine kinases related to the previously
described v-raf oncogene. Genes corresponding to many 
of the putative components of pathways for transmission 
of proliferative signals have been identified. The 
HST/k-FGF oncogene identified in transfectants of a 
human stomach cancer (Sakamoto et al. 1986) and a 
Kaposi's sarcoma (Delli Bovi and Basilico, 1987) is a 
member of the fibroblast growth factor family (Delli 
Bovi et al. 1987, 1988; Yoshida et al. 1987). The NEU 
oncogene which is frequently activated in 
carcinogen-induced rat neuroblastomas (Shih et al. 
1981; Padhy et al. 1982), alternatively known as ERBB-2 
or HER, is significantly homologous to the human 
epidermal growth factor receptor (King et al. 1985; 
Coussens et al. 1985; Yamamoto et al. 1986). The NEU 
gene product fails to bind EGF (Stern et al. 1986), and 
as yet no ligand capable of binding to this receptor 
has been identified. Other examples of receptor-like 
molecules include the insulin receptor related genes 
MET and ROS, detected after transfection of DNA from 
carcinogen treated human osteosarcoma cells, MNNG-HOS 
(Cooper et al. 1984a,b), and the human breast carcinoma
cell line MCF-7 (Matsushime et al. 1986). Cytoplasmic
kinases such as TRK (Martin-Zanca et al. 1986) and the
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RAF family (Fukui et al. 1985; Shimizu et al. 1985? 
Ishikawa et al. 1986,1987? Ikawa et al. 1988) have also 
been identified by transfection. Other genes of unknown 
function have been described such as DBL/mcf-2 (Fasano 
et al. 1984; Eva and Aaronson, 1985? Noguchi et al. 
1987? Ron et al. 1988) and BLYM (Goubin et al. 1983; 
Diamond et al. 1984).
No "nuclear" oncogenes have been identified by 
transfection assays, although viral equivalents of such 
genes, for example v-mvc and v-fos are capable of 
transforming immortal rodent fibroblasts (Bishop,
1985). This reinforces the suggestion that such
assays are limited to the detection of cellular
oncogenes which complement the "immortal" phenotype of 
NIH 3T3 cells and induce such transformation 
characteristics as loss of contact inhibition and
tumorigenicity in nude mice.
The majority of the non-RAS genes detected by 
transformation assays have been found infrequently in 
human and animal malignancies, and indeed some have 
been reported in only single cases. The RAS genes 
are activated by point mutations in coding sequences 
resulting in amino acid substitutions at critical
regions of p21. Other transforming genes display
diverse mechanisms of activation. The NEU gene is
rendered oncogenic by a point mutation within the 
predicted transmembrane region of the receptor, with 
substitution of glutamine for valine (Bargman et al.
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1986b). Replacement of valine by other amino acids does 
not activate NEU, indicating that transforming activity 
is a specific function of the presence of a glutamine 
residue (Bargman and Weinberg, 1988). The normal human 
homologue of the NEU gene is a potent oncogene when 
overexpressed in NIH 3T3 cells, even in the absence of 
an identifiable ligand and has been causally implicated 
in human mammary carcinogenesis (Hudziak et al. 1987; 
Di Fiore et al. 1987a? Slamon et al. 1987). However in 
one study, Kraus et al. (1984) failed to find any 
transforming genes in DNA extracted from 16 primary 
human breast tumours. Thus activating mutations in the 
NEU/HER gene are unlikely to occur in human mammary 
carcinomas.
Several protein kinase oncogenes have been 
identified by transfection assays and they can be 
divided into tyrosine specific and serine/threonine 
specific kinases. All of these, with the exception of 
the NEU oncogene, were activated by DNA rearrangement 
which resulted in the loss of amino terminal sequences. 
Such rearrangements are either somatic (TRK, 
Martin-Zanca et al. 1986? MET, Chan et al. 1987) or 
have occurred during transfection (RET, Takahashi and 
Cooper, 1987? ROS, Birchmeir et al. 1986, RAF, Ishikawa 
et al. 1986? Stanton and Cooper, 1987? Tahira et al. 
1987? TRK, Kozma et al. 1988). Transfection-induced 
rearrangements have also activated such disparate genes 
as HST/KFGF (Sakamoto et al. 1986), FGF-5 (Zhan et al.
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1987,1988), DBL/mcf-2 (Noguchi et al. 1988? Eva et al. 
1987). The TRE oncogene, identified by transfection of 
DNA from a Ewing sarcoma, arose as a consequence of the 
fusion of unrelated sequences from three discrete 
chromosomal locations (Nakamura et al. 1988; Huebner et 
al. 1988).
The neoplasm chosen for this particular study 
was human malignant melanoma, the reasons for which are 
stated in Chapter 1, but briefly recalled are as 
follows; comparison of age against incidence of 
melanoma suggests that the number of steps involved in 
neoplastic progression is small (Cook et al. 1969), 
therefore any genetic changes that have occurred are 
likely to be more dramatic. Such mutations would be 
readily detectable in an assay designed to identify 
single dominant transforming genes. Distinct steps of 
tumour progression have been identified in human 
melanoma, culminating in invasive and metastatic 
growth (Greene et al. 1985; Herlyn et al. 1983, 1985a,
1985b; Clarke et al. 1984). A large number of well 
characterised melanoma cell lines are available for 
study, many of which are highly tumorigenic upon 
injection into athymic nude mice (Fogh et al. 1977).
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Section II: Results
(i) Transfection of Melanoma DMA
High molecular weight DNA was extracted from 9 
melanoma cell lines and 7 tumour samples (table 3:2) 
and assayed for morphological transformation of NIH 3T3 
mouse fibroblasts following transfection by calcium 
phosphate coprecipitation (Graham and van der Eb, 1973; 
Wigler et al. 1979). Transformants were identified by
the focal proliferation of cells with an altered
morphology, against a background of a semi-confluent 
monolayer of normal cells. These results are 
summarised in Table 3:2. DNA from the human bladder
carcinoma cell line EJ, which contains an activated 
HRAS (Krontiris and Cooper, 1981; Der et al.1982 ; 
Parada et al. 1982; Santos et al. 1982) was included as 
a positive control, and NIH 3T3 DNA as a negative
control in every transfection. Transformation was
confirmed by assaying foci for growth in semi-solid 
medium, an in vitro characteristic which correlates 
well with tumorigenicity (Shin et al. 1975), and has 
been used to confirm transformation instead of (Cooper 
et al. 1980; Krontiris and Cooper, 1981), and in 
conjunction with focus formation (Sakamoto et al.
1986).
The isolation of anchorage independent colonies 
has the additional advantage of producing clonal
populations, free of untransformed cells. Of the
samples tested, 6 cell lines and 2 tumours registered
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positively for focus formation and anchorage
independent growth. Spontaneous foci arise at a low 
frequency in this assay, approximately 0.03 foci/ug 
DNA? this phenomenon has been observed following 
transfection of high molecular weight DNA from both 
neoplastic and normal cells (Cooper et al. 1980; 
Perucho et al. 1981) although spontaneous foci can 
arise in cultures of NIH 3T3 cells maintained at 
confluence or in low serum (Rubin and Xu, 1989). The 
frequency of transformation in the first round of 
transfection was equivalent to the background of
spontaneous focus formation observed with transfection 
of NIH 3T3 DNA (table 3:2). However these spontaneous 
foci are unable to grow in soft agar (table 3:2? Cooper 
et al 1980), and DNA from these foci will not transform 
above background levels on a second cycle of 
transfection (table 3:2? Perucho et al. 1981).
Foci and agar colonies were transferred to fresh 
flasks and expanded in culture. As the donor sequences 
were human in origin, foci were tested for the 
presence of human sequences with an Alu-repetitive 
sequence probe, BLUR 8 (Rubin et al, 1980). Genomic DNA 
was extracted and digested with Eco RI, and analysed by
Southern blotting and hybridisation for the presence of
human repetitive sequences. NIH 3T3 cells can stably 
incorporate up to 0.1-0.2% of the transfected genome 
(Robins et al. 1981)? primary transfectants contain a 
sizeable amount of human DNA as evident by the
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multiple copies of the Alu repetitive sequence present 
(Perucho et al. 1981, figures 3:1, 3:2). DNA from the 
cell lines MeWo, NKI4, Mel Swift, SKMEL-28, SKMEL-64 
and SKMEL6005, and the melanoma biopsy MT3 produced 
foci which were able to grow in soft agar. The cell 
lines SK-MEL-28, -64 and MeWo have previously been 
reported to lack transforming activity as defined by 
the NIH 3T3 assay (Albino et al. 1984). Multiple Alu 
bands were observed in transfectants so further rounds 
of transfection were performed (figures 3:1, 3:2).
DNA from primary transformants was transfected 
onto NIH 3T3 mouse fibroblasts and assayed for focus 
formation. Upon a second round of transfection the 
frequency of focus formation increased (table 3.1), a 
phenomenon which has been observed by others (Krontiris 
and Cooper,1981; Goldfarb et al. 1982) for which there 
are several possible explanations. The original donor 
cell lines may contain a heterogenous population of 
cells, not all of which possess the transforming gene. 
This reflects the situation in vivo, where melanomas 
are frequently heterogeneous, both with respect to the 
malignant population and the presence of contaminating 
normal cells (Albino et al. 1981? Albino et al. 1984; 
Dracapoli et al. 1985). Several groups have observed an 
increase in copy number of the transforming sequences 
in primary and secondary transformants (Winter and 
Perucho, 1986)? notably those transformed by NRAS 
(Raybaud et al. 1988) and KRAS (Sukumar et al. 1986,
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Figure 3:1 Presence of Human Alu-repetive sequences in 
primary transfectants. DNA samples (2 0ug) were digested 
with EcoRI, electrophoresed on 0.8% agarose, transferred to 
a nylon membrane and hybridised with BLUR 8. Lanes a,b, MeWo 
primary transformants; lanes c,d, MELT3 primary 
transformants; lanes e,f, NKI4 primary transformants; lane 
g, NIH 3T3; lane h, EJ secondary focus. DNA marker fragment 
sizes are indicated in kilobases (Kb). Multiple Alu bands 
were present in all transfectants.
a b  c d e  f g h
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Figure 3:2 Presence of Alu-repetitive sequences in NKI4 
transfectants. DNA samples (2 0ug) were digested with EcoRI, 
electrophoresed on 0.8% agarose, transferred to a nylon 
membrane and hybridised with BLUR 8. Lane a, NKI4 primary 
transfectant: lanes b-f, anchorage independant clones of an 
NKI4 secondary transfectant: lane g, NIH 3T3: lane h, EJ
secondary focus. DNA marker fragment sizes are indicated in 
kilobases (Kb).
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Eva and Trimmer, 1986). Thus a greater number of 
copies are subsequently transfected, so increasing the 
frequency of focus formation.
Secondary transfectants were tested for 
anchorage independent growth and the presence of human 
sequences. These transfectants were also screened for 
the presence of human RAS genes with the viral HRAS 
probe BS9 (Ellis et al. 1980), the viral KRAS probe 
HiHi3 (Ellis et al. 1981), and an EcoRI/SstI fragment 
from the NRAS genomic clone pAT8.8 (Hall et al. 1983). 
Human NRAS sequences were detectable in transfectants 
of the cell line Mel Swift (Padua et al 1985), whereas 
human HRAS sequences were detected in transfectants of 
SK-MEL 64 and SK6005 (see chapter 6). No human RAS 
sequences could be detected in transfectants of MeWo.
(ii) Unique Human sequences in NKI4 secondary focus
DNA from the cell line NKI4 gave rise to 
transformants in which only endogenous murine RAS 
sequences were detected by hybridisation with RAS 
specific probes. Upon hybridisation with BLUR 8, a 
single Alu positive Eco RI fragment was visible in the 
secondary transfectant NKI4-2-4 (figure 3:2). The 
assumption was that this fragment constituted some or 
all of the human sequences responsible for the 
transformation of NIH 3T3 cells by DNA from NKI4. 
Several transforming genes have been identified on the 
basis of retention of internal or flanking Alu
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sequences, and subsequently cloned by screening genomic 
libraries with either total human DNA or the BLUR 8 
probe (Murray et al. 1981; Perucho et al. 1981; Hall et 
al. 1983).
The BLUR 8 positive fragment in NKI4-2-4 was 
approximately 16 kb in size and was therefore amenable 
to cloning into a bacteriophage lambda vector. The 
vector chosen was lambda L.47 (Loenen and Brammar, 
1980) and the arms were prepared as described in 
Chapter 2. Genomic DNA was digested with Eco RI, and 
the region of interest was isolated from low melting 
point agarose following electrophoresis. A lambda 
library was constructed and screened with the BLUR 8
probe at low stringency. A single clone was plaque 
purified by successive rounds of plating and screening 
with BLUR 8. The identification and cloning of this 
fragment has been published (Padua et al. 1984)
(iii) Analysis of Cloned Sequence
DNA was purified from the phage and a
preliminary map was deduced (Padua et al 1984). The
cloned Eco RI fragment was 16 kb in size, as expected 
from BLUR 8 hybridisation to transfectant DNA, and was 
analysed for the presence of human and mouse repetitive 
sequences by hybridising with 32P labelled human 
placental, NIH 3T3 and BLUR 8 DNA. The original 
observation of human repetitive sequences in the Eco RI 
fragment in the transfectant, was confirmed by
96
hybridisation of human placental DNA and BLUR 8 probes 
to specific restriction fragments of the clone. Mouse 
sequences were detected, suggesting that the region or 
regions flanking the integration site of the 
transfected DNA had also been cloned. This is feasible, 
as it is unlikely that the particular restriction 
fragment chosen for cloning would also correspond to 
the boundaries of the human transforming sequence. The 
amount of human and mouse repetitive sequences present 
limited the use of the whole cloned fragment as a 
probe for hybridisation onto Southern blots of human 
and transfectant DNA's. By using a combination of 
restriction digests of the clone, and the subcloning 
and digestion of specific fragments, a more detailed 
restriction map was derived (figure 3:3) enabling the 
isolation of specific probes for hybridisation. 
Initially the mouse repetitive sequences were localised 
to the 5' and the human sequence to the 3' portion of 
the clone.
To assess whether any homology existed between 
the cloned sequences and previously identified 
oncogenes, a lOkb KpnI/EcoRI fragment (figure 3:3) was 
assayed for hybridisation to the following cloned 
oncogene probes: v-abl. v-erb. v-ets. v-fes/fps. v-fgr. 
v-fos. v-mos. v-mvb. v-mvc. v-raf. c-sis. v-ski. v-src 
and v-ves. Cross hybridisation due to common repetitive 
sequences was observed, but no specific hybridisation 
diagnostic of known oncogenes. It was originally
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thought that NK16 showed homology to the human RAS 
genes on the basis of this hybridisation data (Padua et 
al. 1984), but this was subsequently found by 
sequencing to be due to the presence of GC rich 
regions.
(iv) Derivation of Probes
Plasmid subclones were obtained corresponding to 
the majority of the cloned fragment, as shown in figure 
3:3, but these clones contained too high a proportion 
of repetitive sequence to be useful for hybridsation. 
Human sequences were present in clones NK/Pv/22, 
NK/Pv/8 and NK/Sph 4.0. A "shotgun" cloning of Sau 3A 
fragments from clone NK/Pv/22 was performed to isolate 
low repetitive sequences. One such clone (21) is shown 
in figure 3:4. From this clone two Ava I fragments, of 
100 bp and 600bp, were extracted for use as probes. To 
confirm that the clone NK16 represented the BLUR 8 
positive fragment in the transfectants, the 600 bp 
probe was hybridised at high stringency to a Southern 
blot of Eco RI digested DNA from NIH 3T3 mouse 
fibroblasts, anchorage-independent colonies of
NKI4-2-4, and human melanoma cell lines (figures 3:5, 
3:6). In addition to the 16 kb band in NKI4 
transfectants, this probe detected homologous sequences 
in both human and mouse genomes. The corresponding 
mouse and human sequences were contained within Eco RI 
fragments of 7.5 kb and 5.5 kb respectively. The 
observation of sequence conservation between species
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Figure 3:4 Restriction map of Cl.21. 
Arrows denote sequencing strategy.
Clone 21
Av
_ i _
Av■ AvEI* Hf Ac A v n s n  Av
(B)
—T—
Dd
io o  b p
Ac: AccI, Av: Aval, AvII: Avail, B: BamHI, Dd: Ddel, Hf:
Hinf I, SII: Sstll.
transfectants. DNA samples (2 0ug) were digested with EcoRI, 
and analysed by Southern blotting and hybridisation with a 
600bp Aval fragment of Clone 21. Lanes a,b, MeWo primary 
transfectants; lanes c-g anchorage independent clones of 
NKI4 secondary focus; lane h, NIH 3T3 ; lane i, NKI4 
secondary focus. DNA marker fragment sizes are indicated in 
kilobases (Kb). This probe detects a fragment of 7.5 kb in 
mouse DNA and 16 kb fragment in the NKI4 secondary 
transfectant and anchorage independent clones of this 
transfectant.
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Figure 3:6 Presence of MEL sequences in NIH 3T3 
transfectants and human melanoma cell lines. DNA samples 
(2 0ug) were digested with EcoRI, and analysed by Southern 
hybridisation with a 600bp Aval fragment of Cl 21. Lane A, 
NKI4 secondary NIH 3T3 transfectant: lane B-D, anchorage
independant clones of NKI4 secondary NIH 3T3 transfectant 
(NKI4-2-4) ; lane E, NKI4: lane F, MEL Swift: lane G, MeWo:
lane H, normal human leucocyte: lane I, SKMEL 64: lane J,
MEL 2a: lane K, RPMI 5966. DNA marker fragment sizes are
indicated in kilobases (Kb).This probe detects a fragments 
of 7.5 kb in mouse, and 5.5 kb in human DNA, and in 
addition a 16 kb fragment in NKI4 transfectants.
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was indicative of a gene of functional importance. The 
majority of genes so far described as oncogenic 
display conservation across a wide range of species 
(Marshall, 1985). Homologs of the RAS genes have been 
identified in such diverse organisms as yeasts, 
dictyostelium, and drosophila, as well as higher 
eukaryotes (Barbacid, 1987). It was therefore highly 
probable that the human sequences isolated from the 
transfectant were of significance and likely to be 
those responsible for transformation.
Further probes were derived from the human 
subclones of lambda NK16 and assessed for their 
effectiveness in hybridisation to DNA samples. A 
Southern blot of human, NIH 3T3 and transfectant DNA 
digested with Eco RI was hybridised with a Bam Hl/Sph I 
fragment of NK/Sph 4.0 (figure 3:7, probe A) and washed 
at high stringency. This probe detected sequences in 
mouse, human and transfectant DNA (figure 3:8). 
Hybridisation to the 16 kb fragment was readily visible 
in transfectants; the mouse and human bands were 6.6 kb 
and 8.5 kb respectively. This is in contrast to the 
fragment sizes observed with the 600bp Aval probe. From 
these findings it was clear that a rearrangement had 
occurred during transfection, either as the result of 
the deletion of a region containing an Eco RI site, 
which linked the two human probes, or the juxtaposition 
of two unrelated fragments. The subclone NK/Sph 4.0 
was further subdivided, and two probes were isolated
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Figure 3:7 Restriction map of pNK4.0. Fragments of this 
clone were used as hybridisation probes. The EcoRV and PstI 
fragments were human- and mouse-specific hybridisation 
probes respectively.
Probe B
HUMAN
SPECIFIC
Probe C
MOUSE
SPECIFIC
B
I
E
I
E
I
P
I
P
I
Probe A
B: BamHI, E: EcoRV, P: PstI, S: Sphl.
rxyujre nynriciisation of mouse and human DNA with pNK4.0 i
BamHI/SphI fragment. DNA samples (20ug) were digested with j 
EcoRI, and analysed by Southern blotting and hybridisation ! 
with a BamHI/SphI fragment of pNK4.0 (probe A). Lane A, j 
NKI4 secondary NIH 3T3 transfectant: lane B,C anchorage ;
independant clones of NKI4 secondary NIH 3T3 transfectant: 
lane D, NKI4: lane E, MEL Swift: lane F, MeWo: lane G,
normal human leucocyte: lane H, SKMEL 64: lane I, RPMI 5966: 
lane J, human placenta: lane K, NIH 3T3. DNA marker fragment 
sizes are indicated in kilobases (Kb). This probe detects 
fragments of 6.6 kb in mouse, and 8.5 kb in human DNA, and 
in addition a 16 kb fragment in NKI4 transfectants. A 16 kb 
. fragment was observed in lane b upon a longer exposure. j
A B C D E F G H I J K I
2 3.1-
4.4-
2.3-
2.0-
(figure 3:7). Firstly, a 500bp Eco RV fragment (figure 
3:7, probe B) was hybridised to NIH 3T3, human and 
transfectant DNA (figure 3:9). This probe was human 
specific, hybridising only to the 16 kb fragment in 
transfectants and the 8.5 kb fragment in human DNA. 
The blot was washed and rehybridised with a Pst I 
fragment (figure 3:7,probe C) which hybridised to the 
16 kb Eco RI fragment in transfectants and to a 6.6 kb 
EcoRI fragment in both NIH 3T3 and transfectant DNA but 
not to any human sequences (figure 3:10). On the basis 
of the hybridisation data, it was possible to 
rationalise the cloned sequences. The NK16 clone 
contains a central human region flanked by unrelated 
mouse sequences, the boundaries of which are the Kpn I 
site at the 5' end and between the Eco RV and Pst I 
.sites at the 3' end (figure 3:3). The clone NK16 
represents up to four different genomic regions, two 
derived from mouse and two from human DNA, which have 
recombined to generate this 16 kb Eco RI fragment. 
There is no evidence for any relationship between the 
different genomic fragments to explain their 
association in the transfectant. Three of the four 
defined regions yielded species specific probes. Only 
the sequences as defined by the 600bp Aval probe were 
conserved between mouse and human genomes, and as such 
were a likely candidate for the transforming gene of 
NKI4.
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Figure 3:9 Hybridisation of mouse and human DNA with pNK4.0 
probe &, DNA samples (2 0ug) were digested with EcoRI, and 
analysed by Southern blotting and hybridisation with an 
EcoRV fragment of pNK4.0 (probe B). Lane A, NKI4 secondary 
NIH 3T3 transfectant: lane B,C anchorage independant clones
of NKI4 secondary NIH 3T3 transfectant: lane D, NKI4: lane
E, MEL Swift: lane F, MeWo: lane G, normal human leucocyte: 
lane H, SKMEL 64: lane I, RPMI 5966: lane J, human placenta: 
lane K, NIH 3T3. DNA marker fragment sizes are indicated in 
kilobases (Kb). This probe detects fragments of 8.5 kb in 
human DNA and 16 kb in NKI4 transfectants.
A B C D E F G H I J K i
23 . 1-
9 . 4 -
6.6-
4 . 4 -
2 . 3 -  
2.0-
Figure 3:10 Hybridisation of mouse and human DNA with pNK4.0 
probeC . DNA samples (20ug) were digested with EcoRI, and 
analysed by Southern blotting and hybridisation with a 
Pstl/SphI fragment of pNK4.0 (probe c)  . Lane A, NKI4 
secondary NIH 3T3 transfectant: lanes B,C and D, anchorage 
independant clones of NKI4 secondary NIH 3T3 transfectant: 
lane E, NKI4: lane F, MEL Swift: lane G, MeWo: lane H,
normal human leucocyte: lane I, SKMEL 64: lane J, RPMI 5966: 
lane K, human placenta: lane L, NIH 3T3. DNA marker fragment 
sizes are indicated in kilobases (Kb). This probe detects a 
fragments of 6.6 kb in mouse DNA, and in addition a 16 kb 
fragment in NKI4 transfectants. A 16 kb fragment was 
observed in lane B upon longer exposure.
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(v) Tumorigenicity of NKI4 secondary focus
Many human tumour cell lines are able to form 
tumours upon injection into athymic nude mice (Fogh et 
al. 1977), a property shared with virally transformed 
rodent cells (Shin et al. 1975). NIH 3T3 cells 
transfected with proviral Molony murine sarcoma virus 
DNA or DNA from tumour-derived and
chemically-transformed human cell lines can also form 
tumours in nude mice (Blair et al. 1982). 
Tumorigenicity can be used to confirm the transformed
phenotype of an NIH 3T3 focus in conjunction with
previously described assays.
The secondary focus NKI4-2-4 was tested for 
tumorigenicity by subcutaneous injection of athymic 
nude mice as described in Material and Methods. Tumours 
appeared within 4 weeks in 5/8 sites of injection. 
Tumour DNA was digested with Eco RI and analysed for
retention of the 16 kb RI fragment, using the 600 bp
Aval and the Bam Hl/Sph I probes (figure 3:11). Both 
detected the 16 kb band in all the tumours tested. This 
further confirmed the transformed phenotype of the NKI4 
secondary transfectant. This also demonstrated that the 
transformed cells corresponded to those with the single 
Alu positive fragment, and not a previously undetected 
subpopulation.
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Figure 3:11 Presence of MEL sequences in nude mice tumours. 
NKI4 secondary transfectant cells were injected 
subcutaneously into the hind flanks of athymic nude mice, 
and DNA was extracted from the tumours generated. DNA 
samples (20ug each) were digested with EcoRI, and analysed 
by Southern hybridisation with a BamHI/SphI fragment of 
pNK4.0. Lanes a-c, tumours from nude mice injected with NKI4 
secondary transfectant; lane d, NKI4 secondary transfectant 
(NKI4-2-4) lane e, NIH 3T3; lane f, EJ secondary 
transfectant. lane e, NKI4 secondary transfectant. DNA
marker fragment sizes are indicated in kilobases (Kb). All 
tumours retained the 16 kb EcoRI fragment.
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(vi) Possible autocrine involvement in NKI4 
transformants
The possibility of an autocrine mechanism 
operating in the maintenance of the neoplastic 
phenotype has been advanced by a number of workers 
(Sporn and Todaro, 1980? Sporn and Roberts, 1985). 
Examples in vivo. include the production of 
bombesin-like peptides in small cell lung carcinomas 
(Moody et al., 1981; Erisman et al., 1982; Moody et 
al., 1983). When the v-sis oncogene and its cellular 
homolog SIS were identified as coding for the B-chain 
of the serum mitogen, platelet-derived growth factor 
(PDGF) (Doolittle et al. 1983? Waterfield et al.
1983), then a possible mechanism for transformation by 
v-sis became clear. Further evidence for neoplastic 
transformation arising as a result of autocrine 
stimulation was presented by Betsholtz et al. (1986) 
using the drug suramin. Suramin inhibits a large number 
of enzymatic functions in vitro (de Clerq. 1979? Basu 
and Modak. 1985? Agarwel et al. 1985; Taylor et al.
1984), but in this context its importance derives from 
the ability to prevent the binding of certain growth 
factors,such as PDGF, to their corresponding cell 
surface receptors (Williams et al. 1984). Human and rat 
fibroblasts transformed by v-sis and grown in the 
presence of suramin, displayed a less transformed 
phenotype and grew more slowly than their counterparts 
in the absence of suramin (Betsholtz et al. 1986).
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Treatment with suramin reverses the downregulation of 
the PDGF receptor observed in Simian sarcoma virus 
(SSV) transformed fibroblasts (Garrett et al 1984? 
Johnsson et al 1986). Cells transformed by viral 
(Ozanne et al. 1980) and activated cellular RAS genes 
(Marshall, 1985) synthesise TGF-alpha and grow in serum 
free medium. Whilst the production of growth factors by 
RAS-transformed cells is not neccessary for 
transformation, (Betsholz et al. 1986? McKay et al. 
1986), it is conceivable that such production could 
contribute to the transformed phenotype. The oncogene 
HST/K-FGF was recently identified by transfection of 
DNA from a human gastric cancer (Sakamoto et al. 1987) 
and a Kaposi's sarcoma (Delli Bovi and Basilico, 1987). 
Sequencing of these independent isolates revealed 
homology to basic Fibroblast Growth Factor (Taira et 
al. 1987: Yoshida et al. 1987: Delli Bovi et al. 1987). 
The mechanism of transformation by the oncogene is 
thought to be the constitutive overexpression of this 
growth factor (Delli Bovi et al. 1988).
To assess whether there was an autocrine 
mechanism operating in NKI4 transformants, an NKI4 
focus was grown in the presence of suramin. 
Untransformed NIH 3T3 mouse fibroblasts were included 
as a negative control? an EJ primary focus [activated 
HRAS] and a Mel Swift secondary focus [activated NRAS] 
(Padua et al. 1985) were included for comparison. For 
further details of the experimental conditions see
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Materials and Methods. For every sample, two dishes 
were counted every second day over a period of 10 days. 
Growth curves were constructed and compared for each 
sample (figures 3:12, 3:13). The growth of the NKI4
transformant in 10% serum showed no contact inhibition 
characteristic of untransformed NIH 3T3 cells, thus 
confirming the transformed phenotype (figure 3:12). 
Addition of suramin to the culture medium had dramatic 
effects on the growth of both transformed and 
nontransformed NIH 3T3 cells (figure 3:13). In the 
absence of suramin, the NKI4 transformant grew at a 
slower rate than the HRAS transformant, but slightly 
faster than the NRAS transformant. In the presence of 
suramin the NKI4 transformant displayed greater growth 
inhibition than the RAS foci. This data suggests that 
either NKI4 transformants have a greater reliance on 
serum growth factors than RAS-transformed cells, or 
that growth factor production contributes to the 
transformed phenotype in this particular instance, the 
MEL gene product itself perhaps coding for a growth 
factor.
(vii) Sequencing
The strategy used for sequencing clone 21 is 
summarised on figure 3:4. Fragments were sequenced 
according to the method of Maxam and Gilbert (1980). 
Analysis of the sequence of the 600 bp Ava I fragment
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I Figure 3:12 Growth of NIH 3T3 cells and NIH 3T3 
transformants.
NIH 3T3 cells and NIH 3T3 transformants [secondary foci of j 
EJ (HRAS), MEL SWIFT (NRAS) and NKI4] were grown in 10%
| serum and two dishes of each were counted every two days. 
The mean number of cells was plotted against time (days).
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transformants in the presence of Suramin
NIH 3T3 cells and NIH 3T3 transformants [secondary foci of 
EJ (HRAS) , MEL SWIFT (NRAS) and NKI4] were grown in 10% 
serum with suramin (200ug/ml), and two dishes of each were i 
counted every two days. The mean number of cells was plotted ; 
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revealed the existence of a Sau 3A site at position 
240. The method of isolation of clone 21 as described 
in section V was by Sau 3A digestion and cloning, 
suggesting that clone 21 consisted of two Sau 3A 
fragments from clone p2.2 that had ligated together 
during the cloning procedure. Figure 3:14 is a 
restriction map of the 600 bp Aval fragment, which was 
subsequently recloned into the Ava I site of pEMBL 8(+) 
and designated pEMBL 600. Computer analysis identified 
a possible open reading frame throughout the 600bp, 
interrupted only at the Sau3A site, whereupon the 
reading frame shifts by a single base. The full DNA 
sequence and possible translated sequence are shown in 
figure 3:15. This sequence was compared against those 
in the EMBL database and showed no significant 
homology to any known gene or protein sequence. The 
sequence underlined in figure 3:15 corresponds to an 
Alu-like repetitive sequence. Subsequent analyses 
utilised a 200 bp Sau 3a/Ava I fragment from pEMBL600 
as a probe, eliminating non-specific hybridisation due 
to the Alu-like repetitive sequence. As these sequences 
represented a novel gene, which was identified 
following transfection of melanoma DNA, the gene was 
designated MEL in keeping with acknowledged 
nomenclature.
(viii) Expression of MEL
A possible transcript was observed in mRNA from
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Figure 3:15 Nucleotide Sequence of Ava600 fragment and 
identification of possible open reading frame. Sequence 
underlined corresponds to Alu-like repetitive region.
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TCC
Ser
GGC
Gly
TCC
Ser
GCG
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TGC
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Ala
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GGG
Gly
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Gin
AGA
Arg
CAC
His
CCG
Pro
CCC
Pro
CAA
Gin
CTA
Leu
CTG
Leu
GCG
Ala
TGC
Cys
GCC
Ala
CTC
Leu
TGC
Cys
TGT
Cys
CGC
Arg
CTA
Leu
ACG
Thr
AAA
Lys
CTC
Leu
CGG
Arg
GCC
Ala
GGC
Gly
GCG
Ala
CAC
His
GCA
Ala
CCC
Pro
CAA
Gin
GCC
Ala
ACG
Pro
CCC
Thr
CGC
Pro
AAG
Arg
GCT
Lys
GCC
Ala
GGC
Ala
CGC
Gly
GGC
Arg
GGT
Gly
TGG
Gly
CGC
Trp
CGC CGC 
Arg Arg
TAC
Tyr
CCT
Pro
GCC
Ala
TTC
Phe
CCT
Pro
CCT
Leu
CTA
Leu
CAG
Gin
TGG
Trp
GGC
Gly
GGG GCC 
Gly Ala
GGG
Gly
CCG
Pro
CCT
Pro
presence of a Sau3A site suggests that two previously 
discontinuous fragments had ligated together durinq the 
subcloning. Hence the shift in a possible open reading frame 
following the Sau3A site.
human cells, following hybridisation with the 16 kb Eco 
RI insert from lambda NK16. However the high proportion 
of repetitive sequence present within the probe 
produced a high background. The identification of a 
possible open reading frame in the 600 bp Ava I 
fragment provided further evidence for the presence of 
a gene in the sequences isolated from the secondary 
transfectants.
(ix) Isolation and characterisation of MEL cDNA
clones
Following identification of an open reading 
frame in the 600 bp Aval MEL specific fragment, a 
normal human fibroblast cDNA library in the vector 
lambda GT10 (kindly provided by Dr. A. Hall) was 
screened with the 600 bp probe at high stringency. Two 
positive clones were identified in 400,000 phage 
screened. These were plaque purified and DNA was 
prepared. The inserts were isolated from the lambda 
clones C 2 - 1 - 1  and C 2 - 1 - 2  by digestion with Eco RI and 
recloned into pBR 3 3 2 .  When used as probes for 
hybridisation onto Eco RI digested human genomic DNA , 
the resulting smear was suggestive of repetitive 
sequence hybridisation.
The library filters were rescreened with the 
previously described 200bp Sau 3A/Ava I fragment from 
pEMBL 600, which lacked Alu repetitive sequences on 
the basis of the sequence data. A single positive
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signal was seen in 400,000 phage screened? the clone 
was plaque purified and DNA was extracted. This clone, 
designated lambda c2-2, contained an 850 bp Eco RI 
fragment. This fragment was subsequently recloned into 
the plasmid vector pEMBL8 (pc2-2) to enable isolation 
of a probe free of lambda sequences for rescreening the 
cDNA library. The library filters were washed and 
rehybridised with the pc2-2 Eco RI fragment at high 
stringency. Two positive signals were observed in 
400,000 phage screened, one of which corresponded to 
the previously identified clone lambda c2-2 , but the 
other had been undetected by the initial hybridisation 
with the 200 bp probe. This clone (lambda c2-3) was 
purified and DNA was extracted. Lambda c2-3 contained 
an Eco RI fragment of 1.1 kb, which was also subcloned 
into pEMBL 8 (pc2-3). The Eco RI fragments of pc2-2 and 
pc2-3 hybridised to human and mouse DNA in a manner 
analogous to other single copy genes (figures 3:16, 
3:17). A single mRNA of approximately 3.5 kb was 
detected upon hybridisation to a Northern blot of mRNA 
from NIH 3T3 cells and NKI4 secondary transfectants 
(figure 3:18). Human cells also expressed an mRNA of 
similar size to that observed in NIH 3T3 cells (figure 
3:19). A number of restriction sites were mapped and in 
conjunction with the results of cross hybridisation 
between the two clones, both a restriction map and the 
degree of overlap were determined (figure 3:20). 
Together the two clones represented approximately 1.5
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Figure 3:16 Presence of MEL sequences in human and mouse 
DNA. DNA samples (2 0ug) were digested with EcoRI, and 
analysed by Southern blotting and hybridisation with a MEL 
cDNA probe (pC2-2). Lanes A-D,I, nude mice tumours of NKI4 
secondary transformants; lane E, NKI4; lane F, MeWo; lane G, 
RPMI 5966 ; lane H, MEL Swift; lane J, NKI4 secondary 
transformant (NKI4); lane K, NIH 3T3. DNA marker fragment 
sizes are indicated in kilobases (Kb).
A B C D E F G H I J K B  
23.1 
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Figure 3:17 Presence of MEL sequences in human and mouse
DNA. DNA samples (20ug) were digested with EcoRI, and
analysed by Southern blotting and hybridisation with a MEL 
cDNA probe (pC2.3). Lane A, NKI4: lane B, MeWo: lane C, RPMI 
5966: lane D, MEL Swift: lanes E-J, nude mice tumours of
NKI4 secondary transformants: lane K, NKI4 secondary
transformant: lane L, NIH 3T3. DNA marker fragment sizes are 
indicated in kilobases (Kb).
A B C D E F G H I J K L
2 .3 -
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Figure 3:18 Expression of MEL. Poly A+ mRNA was 
electrophoresed on a 1% agarose/formaldehyde gel, 
transferred to a nitrocellulose membrane and hybridised with 
the MEL cDNA probe pC2.2 under stringent conditions. Lane a, 
NIH 3T3: lane b,c, NKI4 secondary transfectants. MEL is
expressed in both NIH 3T3 cells and NKI4 transfectants.
The reduced signal in lane a is due to less mRNA loaded, 
compared to lanes b and c, as demonstrated by hybridisation 
with an actin probe (data not shown).
a b e
28S
Figure 3:19 Expression of MEL. Poly A+ mRNA was 
electrophoresed on a 1% agarose/formaldehyde gel, 
transferred to a nitrocellulose membrane and hybridised with 
the MEL cDNA probe pC2.2 under stringent conditions. Lane a, 
EJ: lane b, MEL 57: lane c, MeWo: lane d, Mel Swift: lane e, 
SK-MEL 28: lane f, RPMI 5966: lane g, NKI4: lane h, MEL T6: 
lane i, MEL T7: lane j, MEL 57. All samples express a
transcript of 3.5 kb.
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Figure 
3:20 
Restriction 
maps 
of 
MEL 
cDNA 
clones.
kb or over 1/3 of the total messenger RNA. The cDNA 
library was then screened with probe A from pc2-3 and a 
single clone was identified in 400,00 phage screened. 
The Eco RI fragment in this clone (lambda c7-l) was 2.2 
kb and thus bigger than the previous two isolates. As 
before the Eco RI fragment of lambda c7.1 was recloned 
into pEMBL 8. The extent of the overlap was determined 
by comparison of the restriction map of pc7.1 with 
that already obtained for pc2-2 and pc2-3 (figure 
3:2o). Both pc2-2 and pc2-3 are contained within pc7-l. 
A 300bp Accl/Aval fragment (figure 3:15) was isolated 
from pEMBL600 and hybridised to So uthern blots of the 
cDNA clones digested with a number of restriction 
enzymes. Figure 3:21 illustrates the location of this 
probe on the cDNA. The presence of an Sstll site within 
pEMBL 600 was predicted on the basis of the sequence 
analysis (figure 3:15, 3:16) and this was confirmed by 
digestion of pEMBL600. This site was also present in 
the cDNA clones pc2-2 and pc7-l, and was mapped to the 
expected position relative to the AccI site (figure 
3:26?). However the clone pc2-3 does not digest with 
Sstll, contrary to what would be expected on the basis 
of the restriction map. pc2-3 may represent an 
alternative transcript from the MEL gene, although 
other restriction sites are conserved between the three 
cDNA clones. No other transcripts have been observed on 
hybridisation to Northern blots of mRNA from human 
cells. The exon present in such an alternative
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transcript would be expected to be relatively small 
(>100bp). Another possibility is that this represents a 
true allellic polymorphism, and that the individual 
from whom the cDNA library was consrueted was 
heterozygous for this polymorphism. Until the cDNA 
clone has been sequenced it will not be possible to 
assess whether the sequence difference changes the 
amino acid. A full length clone cDNA has not yet been 
isolated.
The pc2.2 probe detects several Eco RI 
fragments in both mouse and human DNA when hybridised 
at high stringency (figure 3:17), consistent with the 
observed conservation of the MEL gene. Altogether 6 
fragments were visible, ranging from 4 kb to >20 kb in 
size, but varying in intensity independently of 
fragment size. Variability in hybridisation could be 
due to differences in the amount of coding sequences in 
a particular fragment. Alternatively MEL related genes 
may be present in the mouse and human genomes, although 
there is no evidence to support this as yet. Assuming 
that all the fragments observed are within the MEL 
locus and given that two of the fragments possibly 
constitute the 5' and 3' limits of the gene then the 
minimum genomic size must be 14kb.
A restriction fragment length polymorphism 
(RFLP) defined by an Nco I site has been observed in 
the normal human population with the pC7.1 probe 
(Nimmo et al. 1987). Two alleles, corresponding to Ncol
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fragments of 4.0kb and 3.8 kb, have been observed at 
frequencies of 73.4% and 26.6% respectively. The cDNA 
probe pC7.1 also detects constant bands of 8kb, 4.3kb,
2.4 kb, 2.1kb and 1.95 kb. The human MEL sequences must 
therefore span at least 14 kb and possibly up to 50 kb 
of the genome.
(x) Expression of MEL in human melanoma cell lines
The patterns of proto-oncogene expression are 
multifarious? for example, all three RAS genes seem to 
be expressed in the majority of tissues so far analysed 
(Furth et al. 1987; Fiorucci and Hall, 1988) albeit at 
a low level, with variations between tissues (Furth et 
al. 1987; Leon et al. 1987) There is some dispute as to 
whether there is increased expression in neoplastic 
compared to normal tissue (Chesa et al. 1987). In 
contrast, the lymphocyte-specific tyrosine kinase LCK 
is only expressed in T-cells and some B-cells (Marth 
et al. 1985). In assessing the importance of the MEL 
gene, the specificity of expression is of considerable 
importance.
MEL expression was detected in the majority of 
the melanoma cell lines analysed with the pc2.2 probe 
(figure 3:19) No signal was visible in the cell line 
NKI4 due to insufficient mRNA loaded. Expression at a 
similar level was also detected in mRNA from EJ (figure 
3:19), arguing against tissue specific expression. The 
possibility still remained that expression was specific
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to transformed cells. It was therefore not possible to 
determine whether the human MEL sequences were 
expressed in the transformants.
(xi) Relationship between MEL genomic and cDNA 
sequences
The intron/exon organisation of the MEL gene was 
unknown, although Southern blot analysis of genomic DNA 
suggested that these sequences are spread over at least 
14 kb of the genome. As such, the clone NK16 is 
unlikely to contain the entire transcription unit. 
Comparison of the restriction maps for the homologous 
regions revealed no gross differences (figures 3:2, 
3:19). However the 5' Cla I and 37 Sst I sites 
observed in the cDNA clone pC7.1 are absent from the 
genomic clone lambda NK16. The MEL sequences in the 
secondary transfectant therefore lack the 5' and 3' 
exon sequences.
(xii) Chromosomal Localisation of human MEL
There are no reported consistent chromosomal 
abnormalities in human malignant melanoma analogous to, 
for example the Philadelphia chromosome in CML (Nowell 
and Hungerford, 1960) or the 8:14 translocation in 
Burkitt's lymphomas (Manolova et al. 1979); nonetheless 
the determination of the chromosomal region containing 
MEL was important, to ascertain a possible general 
involvement in human neoplasia. As was reported in
111
Chapter 1, frequent alterations in chromosomes 1,6 and 
7 have been noted in human malignant melanoma, but such 
karyotypic abnormalities are common to other 
malignancies. Assignment of a sequence to a specific 
chromosome is relatively simple, utilising human- 
mouse and human-hamster somatic cell hybrids, which 
contain limited numbers of human chromosomes. The 
progeny resulting from the fusion of human and mouse 
cells invariably contain a full complement of rodent 
chromosomes but only a selection of human chromosomes. 
The mechanism for this is not fully understood. By 
screening a panel of such hybrids, each of which 
possess a few human chromosomes, with the gene probe 
of interest, the gene localisation can be elucidated by 
the process of exclusion.
A selection of human-mouse and human-hamster 
somatic cell hybrids were obtained from P. Goodfellow 
and N. Spurr, which together represented the complete 
human karyotype. The DNA was digested with Eco RI,
electrophoresed on 0.8% agarose gels and Southern 
blotted. Hybridisation was carried out at high 
stringency using the 200 bp Sau3A/AvaI probe (figure 
3:15), and representative figures are shown (figure 
3:21). The hybridisation results are summarised in 
Table 3:3. The only chromosome to show a discordancy of 
0% was chromosome 19 (Spurr et al. 1986). Further 
somatic cell hybrids with translocations of chromosome 
19 were obtained from Dr. J.D. Brook (Brook et al.
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Figure 3:21 Mapping of the human MEL gene locus to 
chromosome 19.
DNA samples (15 ug) were digested with EcoRI, and analysed 
by Southern blotting and hybridisation with a MEL specific 
probe pNK2 00. Panel A: mouse-human hybrids; lane a, MOG
2.E.5 hybrid (-) ; lane b, M0G.2.E.ii hybrid ( + ) ; lane c
WILF 1 hybrid (+); lane d NIH 3T3; lane e, NKI4.
Panel B: Sublocalisation of MEL on chromosome 19. Lane a,
G1711B hybrid ( + ) ; lane b, G24B2AMB hybrid ( + ) ; lane c, 
GM98A99c7B hybrid, (-); lane d, NIH 3T3; lane e, NKI4.
DNA marker fragment sizes are indicated in kilobases (Kb).
A
a b o d e Kb
- 9-6
- 6-7
- 4-4
B
a b o d e
Kb
2 3 1  - #
9 -6 - #
6 - 7 - 4)
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2 - 3 - 
2 0 -
Table 3:3 Hybridisation of Human-Mouse and Human-Hamster 
Somatic Cell Hybrids with MEL probe.
Human Chromosome Present Ref
MEL 1 2 3 4 5 6 7 8 9 10 11 12
SIR19 + + + + - + - + + - + + + 1
PotB2/B2 + - - - - - - - - - - - + 2
DUR4R3 + — — + — + — - - - + + + 3
LSR34 + + + + - + + - - - + - - 4
LSR8 + + + + + + + + - - + + - 4
WILF + - - - - - - - - - - - - 5
Mog2,E.ii + - - + + - - + - + + + - 6
Mog2.E .5. - - - 4* + + + + - + + - + 6
DT1.2R - - - + - - - - - - + + - 3
CTP34B4 - + + + - + + + + - - - tr 3
CTP41A2 - - + + - - + + - - - — - 7
3W4CL7 - - - - - - - + - - + + + 3
Dur4.3 - - - + - + - - - - + + + 7
C4A - - - - - - - - + - - — — 7
298-10 + - + + + - 8
FIR5 - - - - - - - + - - - — - 3
F4SC13C112 - + - - - - - - - + - — — 7
CLONE2IE - - - - - - - + - - — — — 9
Horl9D2Rl - - - - - - - - - - — + — 7
SIR74ii - + + tr + - - - - - - — + 7
298-6 — — — — — — — — — + — + - 8
MEL 13 14 15 16 17 18 19 20 21 22 X
SIR19 + + + + - + + + - + tr +
PotB2/B2 + - - - - + - + - - - -
DUR4R3 + + - - + + - + + + + —
LSR34 + + + + + - + + + + - +
LSR8 + + + - + + + + - + — +
WILF + - - - - - - + - - — —
Mog2.E .ii + - + + + - + + - + - +
Mog2.E .5. - + + + + - + - - + + +
DT1.2R - + - + - + + - + + + -
CTP34B4 - - + - + tr + - - — — +
CTP41A2 - - + - - - - - - - — +
3W4CL7 - - + + - + - - - + — +
Dur4.3 - + + + - + + - + + + +
C4A - - - - - - - - - - + —
298-10 - + + - + —
FIR5 - - + - - - + - - — — +
F4SC13C112 - - + — +
CLONE2IE -
Horl9D2Rl - - - - - - - - - - — —
SIR74ii - + + - - + tr - - + tr +
298-6 - + — + — — — — — — _ _
+ = chromosome present, - = chromosome absent, tr = trace 
References
1: Hall et al. 1983, 2: Andrews et al. 1981, 3: Hobart et al.
1981, 4: Sheer et al. 1982, 5: Brook et al. 1986, 6: Whitehead
et al. 1982, 7: Heisterkamp et al. 1982, 8: Carritt and Povey,
1979, 9: Croce and Koprowski, 1974.
1984) to precisely localise the MEL locus. The results 
of this analysis is shown in Table 3:4. Included are a 
number of markers of defined location as controls. From 
these results MEL was localised to 19pl3.2-ql3.2. The 
genes for the LDL receptor (Franke et al. 1984; 
Humphries et al. 1984; Lusis et al. 1986) and the 
insulin receptor (Yang-Feng et al. 1985) have been 
localised to 19pl3.2. Keith Johnson and Elaine Nimmo at 
St. Marys Medical School have now shown close linkage 
between MEL and two flanking markers, the LDL receptor 
(Franke et al. 1984; Humphries et al. 1984; Lusis et 
al. 1986) and pl3-l-25 from the compound polymorphic 
locus D19S11 (Buroker et al. 1987). Because of the 
proximity of MEL and pl3-l-25, the precise order of 
these loci on chromosome 19 has not being determined. 
Nonetheless the two possibilities are: LDL
receptor-MEL-pl3-l-25 or LDL receptor -pl3-l-25-MEL 
(Nimmo et al. 1989).
(xiii) Chromosome 19 involvement in malignant 
melanoma
There have been occasional reports of karyotypic 
abnormalities involving chromosome 19 in human 
malignancies, most notably in AML (Morse et al. 1979;
Prigogina et al. 1979; Hagemeijer et al. 1981; Berger
et al. 1982; Kaneko et al. 1982; Vermaelen et al. 1983;
Prigogina et al. 1986) and ALL (Abe et al. 1983; Morse 
et al. 1983; Knuttila et al. 1985; Kaneko et al. 1986),
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in CML (Morris et al. 1988) and small cell carcinoma 
of the lung (Whang-Peng et al. 1982). In many cases the 
breakpoint on chromosome 19 was at 19pl3. A fragile 
site has been reported at 19ql3.2-13.3 (Sutherland et 
al. 1985; Yunis et al. 1987). The human pre-B ALL cell 
line 697 contains a t(l;19) translocation which is 
correlated with overexpression of a structurally and 
functionally normal insulin receptor (Kaplan et al. 
1989). A human RAS-related gene, RRAS, has been 
localised to chromosome 19 (Lowe et al. 1987), but the 
published restriction map differs from that of MEL. 
Also RRAS encodes a mRNA of lkb, differing in size to 
that observed for MEL. Recently a family of human 
cellular DNA binding proteins implicated in 
transcription and DNA replication were reported to be 
encoded by multiple transcripts from a single gene 
locus (Santoro et al. 1988). This gene (CTF/NF-1) has 
been localised to the same region of chromosome 19 as 
MEL (C.Santoro, personal communication). However no DNA 
or protein sequence homology was detected between MEL 
and CTF/NF-1.
Interestingly, the prototype melanoma unique 
antigen (AU), a glycoprotein of 25,000-40,000 Da (Carey 
et al. 1979) has tentatively been assigned to 
chromosome 19 (Old,1981). Panniter et al. (1986) 
reported three cases of human malignant melanoma with 
t(l;19). The breakpoint on chromosome 1 was ql2, and 
on chromosome 19 was p!3.2, and therefore in the
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vicinity of the MEL locus. A Southern blot of Eco RI 
digested DNA was provided by Dr. Panniter, and 
hybridised successively with the Sau 3A/ Ava I 200bp 
probe (figure 3:22) and the pc7-l EcoRI fragment 
(figure 3:23). There are no discernible rearrangements 
in the restriction patterns, between the cell lines 
WM793 (lane a) and WM39 (lane f) which carry the 1:19 
translocation, and the other melanoma samples. Since 
the genomic boundaries of the MEL gene have still to be 
determined, it is not possible to rule out an 
involvement in these translocations,Long range analysis 
using pulse field gel electrophoresis would be required 
to clarify any alterations in MEL resulting from the 
translocations.
The available melanoma cell lines were also 
analysed for any rearrangements of the MEL locus, by 
hybridisation with the 200 bp probe and the cDNA pc7.1, 
and no differences were detected.
(xiv) Absence of transforming activity in genomic 
clone NK16
Genomic clones of the activated HRAS gene from 
T24/EJ transform rodent fibroblasts at a frequency of 
103-104 foci/ug (Capon et al. 1983? Reddy 1983). Other 
cellular oncogenes detected by the NIH 3T3 assay have a 
lower transforming activity? a cDNA clone of an 
activated RAF can transform NIH 3T3 fibroblasts at a 
frequency of 100-150 foci/ug (Ishikawa et al. 1987). In
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Figure 3:22 Analysis of melanoma cell lines for MEL 
rearrangements. Nitrocellulose filter with EcoRI digested- 
DNA samples were provided by Dr. A. Linnenebach. The filter 
was hybridised with NK 200. Lane a, WM 793: lane b, WM 983A: 
lane c, WM 266-4: lane d, WM 239A: lane e, c.c.mel. 1167:
lane f, WM 39: lane g, WM 278: lane h, WM 115: lane i, WM 9: 
lane j, SW948: lane k, FF 219: lane 1, SKMEL 23: lane m,
SKMEL 37: lane n, WM 1158: lane o, WM 28: lane p, WM 35:
lane q, WM 1294: lane r, 707: lane s, c.c.mel 1193c. DNA
marker fragment sizes are indicated in kilobases (Kb). WM 
793 and WM 39 carry a t(l:19) translocation; there is no 
gross alteration of the MEL locus.
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Figure 3:23 Analysis of melanoma cell lines for MEL 
rearrangements. Nitrocellulose filter with EcoRI digested- 
DNA samples were provided by Dr. A. Linnenebach. The filter 
was hybridised with MEL cDNA clone pC7.1. Lane a, WM 793: 
lane b, WM 983A: lane c, WM 266-4: lane d, WM 239A: lane e,
c.c.mel. 1167: lane f, WM 39: lane g, WM 278: lane h, WM
115: lane i, WM 9: lane j, SW948: lane k, FF 219: lane 1,
SKMEL 23: lane m, SKMEL 37: lane n, WM 1158: lane o, WM 28:
lane p, WM 35: lane q, WM 1294: lane r, 707: lane s, c.c.mel 
1193c. DNA marker fragment sizes are indicated in kilobases 
(Kb). WM 793 and WM 39 carry a t(l:19) translocation; there 
is no gross alteration of the MEL locus.
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contrast, the genomic clone lambda NK16 was unable to 
transform NIH 3T3 cells in a focus forming assay. 
Cotransfection with a neomycin resistance (neo) marker 
pHSG 272 (Brady et al. 1984) and injection into athymic 
nude mice only produced tumours after a long latency 
period, in which no MEL sequences could be detected. 
The absence of transforming activity in the genomic 
clone NK16 was surprising; this clone represented the 
only human sequences in the secondary transfectant as 
defined by the presence of Alu repetitive sequences. 
The organisation of the clone, with mouse regions 
flanking either side of the human sequences, is such 
that it was unlikely that the remainder of the gene was 
absent as a result of the cloning of an EcoRI fragment. 
If the transfection procedure itself had generated a 
chimaeric human/mouse transforming gene then 
conceivably crucial mouse sequences could be absent 
from this clone. Alternatively, the MEL sequences may 
be uninvolved in the process of NIH 3T3 transformation 
as mediated by DNA from the NKI4 cell line.
(xv) Isolation of overlapping clones
To address the possibility of the requirement of 
futher sequences to restore transforming activity to 
NK16, a random genomic library of DNA from the 
secondary focus NKI4 was constructed in the lambda 
vector Jl, and screened with the previously described 
Bam Hl/Sph I probe at high stringency. Out of 400,00
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phage screened 4 positive clones were identified and 
isolated. Each clone was individually assayed for focus 
forming activity and found to be negative. 
Reconstitution of an active gene following 
cotransfection of complementary portions has been shown 
with transforming genes such as NRAS (Padua et al.
1985). Therefore all the clones were cotransfected with 
lambda NK16 to assay for complementation, but none 
resulted in transformation.
(xvi) Absence of MEL sequences in tertiary 
transformants
Tertiary transformants were isolated and tested 
for growth in soft agar. Those that were positive in 
this assay were analysed for the presence of MEL 
sequences by Southern blotting. Twenty transformants 
were so analysed and in no case could MEL sequences be 
detected (figure 3:24). This result reinforced the 
hypothesis that MEL did not contribute to the 
transformation of NIH 3T3's and was therefore not an 
oncogene. In addition, no Alu positive fragments were 
detectable in tertiary transfectants (figure 3:25).
(xvii) Isolation and analysis of additional 
primary transformants.
Two additional primary transformants were 
isolated, in which multiple Alu sequences were present 
(figure 3:26), but no MEL sequences could be detected
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Figure 3:24 Absence of 16 kb EcoRI fragment in tertiary 
transformants. DNA samples (2 0ug) were digested with EcoRI, 
and analysed by Southern blotting and hybridisation with a 
Sphl/BamHI fragment of pNK4.0. Lanes A-J, tertiary NIH 3T3 
transformants of NIK4; lane K, NIH 3T3; lane L, NIK4 
secondary transformant (NKI4-2-4). DNA marker fragment sizes 
are indicated in kilobases (Kb). Only the endogenous mouse 
fragment was observed in tertiary transformants.
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Figure 3:25 Absence of Alu-repetitive sequences in tertiary 
NKI4 transformants. DNA samples (20ug) were digested with 
EcoRI, and analysed by Southern blotting and hybridisation 
with BLUR 8 Lanes a-f, tertiary
NIH 3T3 transformants of NIK4: lane g, NIK4 secondary
transformant: lane h, NIH 3T3: lane i, EJ secondary focus.
DNA marker fragment sizes are indicated in kilobases (Kb). 
No Alu-repetitive sequences could be detected in tertiary 
transformants.
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Figure 3:26 Presence of Alu repetitive sequences in primary 
transformants. DNA samples (20ug) were digested with EcoRI 
and analysed by Southern blotting and hybridisation with 
BLUR 8. Lanes A,B, primary transformants of NKI4; lane C, 
NIH 3T3; lane D, EJ secondary focus. DNA marker fragment 
sizes are indicated in kilobases (Kb).
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with either the pEMBL600 or the BamHI/SphI probes 
(figure 3 :27).
A sensitive modification of the NIH 3T3 
transformation assay has been developed (Blair et al. 
1982; Brown et al. 1984), in which genomic DNA was 
cotransfected with a selectable marker, usually the 
gene encoding resistance (neo) to the aminoglycoside 
antibiotic G418 (Southern and Berg, 1982). Those cells 
which have taken up DNA can be selected for with the 
addition of G418 to the culture medium. Drug resistant 
colonies can be assayed for transformation by injection 
into athymic nude mice to assay for tumorigenicity. HMW 
DNA from NKI4 was cotransfected with the neo containing 
plasmid pHSG 272, and resistant colonies were tested 
for tumorigenicity. Tumours appeared in 8/8 sites of 
injection within 4 weeks? figures 3:28 and 3:29 show 
the result of hybridising Eco RI digested DNA from 
these tumours with BLUR 8 and a Pvu II/Sma I fragment 
contining the neo gene from pHSG272. Multiple copies of 
the human Alu sequence are present in the tumours 
(figure 3:28); these are not as a result of cross 
hybridisation of contaminating plasmid sequences in the 
probe with the multiple integrated copies of pHSG272 
(figure 3:29). Only the endogenous mouse sequences 
could be detected using the 200 bp MEL probe (figure 
3:30), supporting the hypothesis that MEL is not the 
oncogene in NKI4. The presence of multiple Alu 
sequences in these transformants confirms the observed
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Figure 3:27 Lack of MEL sequences in primary transformants. 
DNA samples (20ug) were digested with EcoRI and analysed by 
Southern blotting and hybridisation with Sphl/BamHI fragment 
of pNK4.0. Lanes A,B, primary transformants of NKI4: lane C, 
NIH 3T3: lane D EJ secondary focus. DNA marker fragment
sizes are indicated in kilobases (Kb).
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Figure 3:28 Presence of Alu-repetitive sequences in primary 
nude mice tumours of NKI4 cotransfected with pHSG272. DNA 
samples (2 0ug) were digested with EcoRI, and analysed by 
Southern blotting and hybridisation with BLUR 8. Lanes a-h, 
primary NKI4 nude mouse tumours: lane i, NIH 3T3: lane j, EJ 
secondary focus. DNA marker fragment sizes are indicated in 
kilobases (Kb) . All tumours contained multiple human 
sequences.
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Figure 3:29 Presence of pHSG272 in primary nude mouse 
tumours of NKI4 cotransfected with pHSG272. DNA samples 
(2 0ug) were digested with EcoRI and analysed by Southern 
blotting and hybridisation with pHSG272. Lanes a-h, primary 
NKI4 nude mouse tumours: lane i, NIH 3T3 : lane j, EJ
secondary focus. DNA marker fragment sizes are indicated in 
kilobases (Kb).
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Figure 3:30 Absence of human MEL sequences in primary 
tumours. DNA samples (20ug) were digested with EcoRI, 
electrophoresed on 0.8% agarose, transferred to a nylon 
membrane, and hybridised with the MEL-specific probe pNK 
200. Lane a-h, primary nude mice tumours of NKI4 
cotransfected with pHSG272; lane i NIH 3T3; lane j, EJ 
secondary focus. DNA marker fragment sizes are indicated in 
kilobases (Kb). Only the endogenous mouse MEL sequence was 
observed in primary tumours.
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transforming ability of genomic DNA from the melanoma 
cell line NKI4 (Padua et al. 1984; section I), but 
such transformation is not transmitted via the 
described MEL gene. DNA from one primary tumour was 
transfected onto NIH 3T3's with the addition of 
pHSG272, and drug resistant colonies were 
subcutaneously injected into athymic nude mice. Tumours 
appeared at 2/8 sites of injection. The primary tumours 
were negative for human H, K and NRAS sequences. They 
were also negative for the presence of HST (Sakamoto et 
al. 1987) and MAS (Young et al. 1986).
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Section III: Discussion
Transmissable transforming activity has been 
demonstrated in a variety of tumour types (Krontiris 
and Cooper, 1981; Perucho et al. 1981), and has led to 
the identification of several genes, most notably 
members of the RAS gene family (Bos, 1988). However it 
is apparent that not all tumour DNA's have transforming 
activity; estimates of the number of tumours and cell 
lines containing oncogenes capable of transforming NIH 
3T3 cells vary between 10% to 50% (Cooper, 1982; 
Pulciani et al. 1982). Transformation is frequently due 
to the presence of an activated RAS gene, irrespective 
of tissue type, although the frequency of activation 
varies between different tumour types (Chapter 6 for 
further details). Previous attempts to detect 
transforming activity in human melanomas have 
suggested a low frequency of such genes in cell lines 
(Albino et al. 1984) and tumour samples (Raybaud et al. 
1988); either NRAS (Albino et al. 1984; Padua et al. 
1985; Raybaud et al. 1988) or HRAS( Albino et al. 1984; 
Sekiya et al. 1984). In this study 16 melanoma cell
lines and tumour biopsies have been assayed for focus 
forming activity in NIH 3T3 mouse fibroblasts, and 
transforming activity has been identified in activity 
in 6 cell lines and 2 tumours. The activation of NRAS
in the cell line Mel Swift has been reported previously
(Padua et al. 1985). Transforming activity was also
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detected in the cell line NKI4, but no human RAS 
sequences could be detected in transfectants. In the 
secondary transfectant there was a single Alu positive 
EcoRI fragment which was subsequently cloned. Alu 
sequences are a middle repetitive element thought to 
be contained within or close to many human genes 
(Jelinek et al. 1980? Rubin et al. 1980;). Thus any 
transforming sequences would be expected to retain 
linked Alu sequences upon serial rounds of transfection 
(Murray et al. 1981? Perucho et al. 1981). Many
oncogenes that are active in the NIH 3T3 assay were
originally cloned on the basis of linked Alu
repetitives (Pulciani et al. 1982b? Shih and Weinberg, 
1982; Hall et al. 1983). So the rationale behind such a 
cloning would be that isolation of the Alu sequences 
from a transfectant would also lead to the
identification of the linked transforming gene.
Analysis of the clone NK16 delineated four
distinct regions in a 57 to 3' direction as follows: 5 
kb of repetitive mouse sequences, from which no
specific probes have been isolated. This is followed by 
two possibly unrelated human sequences, the first of 
which contains the only identified coding sequences in 
the clone, and the second is human specific. The 3' end
of the clone is also mouse in origin. The overall
picture is of complex rearrangement occurring during 
transfection to generate this clone. Recombination of 
transfected sequences has enabled the identification of
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several oncogenes. Of the many genes identified by the 
NIH 3T3 assay, excluding the RAS genes, the majority 
have been activated by the process of transfection, by 
recombination with unrelated sequences as in the case 
of RAF (Ishikawa et al. 1986, Ishikawa et al. 1987; 
Chang et al. 1987), BRAF (Ikawa et al. 1988), RET 
(Takahashi et al. 1985; Takahashi and Cooper, 1987), 
ROS-l/mcf-3 (Fasano et al. 1984; Birchmeier et al.
1986), MAS (Young et al. 1986; Janssen et al. 1988), 
DBL/mcf2 (Eva and Aaronson, 1985; Eva et al. 1987; 
Fasano et al. 1984; Noguchi et al. 1987), or the 
removal of regulatory sequences leading to ectopic 
expression, as in HST/KFGF(Sakamoto et al. 1986; Taira 
et al. 1987; Yoshida et al. 1987; Delli-Bovi and 
Basilico, 1987; Delli-Bovi et al. 1987; Delli-Bovi et 
al. 1988). The sequences corresponding to the pEMBL600 
probe display the characteristics of a functionally 
important gene. They are conserved between a variety of 
species, and expression has been demonstrated in human 
melanoma and bladder carcinoma cell lines, and 
transformed and non-transformed NIH 3T3 cells. 
Sequencing of the pEMBL 600 probe revealed a possible 
open reading frame, and further confirmation was 
provided by the subsequent isolation of cDNA clones 
from a normal human fibroblast cDNA library. The 
rearrangement of this gene in transfectants was not 
present in either the original donor DNA from the NKI4 
cell line, nor in any other human melanoma samples as
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demonstrated by Southern blotting. Comparison of the 
restriction maps of the genomic clone NK16 with that of 
the cDNA clones suggested that some of the transcribed 
sequences were absent. No smaller transcripts were 
observed in transfectants.
The MEL gene was localised to human chromosome 
19, to pl3.2 close to the LDL receptor. This region of 
chromosome 19 has been implicated as the breakpoint for 
translocations in a variety of malignancies, notably 
leukaemia (Hayashi et al. 1988) and small cell lung 
carcinoma (Whang-Peng et al. 1982). It has been 
reported that t (14?19)(q32?ql3.1) is a recurring 
translocation in B-cell chronic lymhocytic leukaemia 
(CLL), (Ueshima et al. 1985). The translocation 
juxtaposes the IGH locus on 14q32 with unknown 
sequences on chromosome 19 (McKeithan et al. 1987). 
These sequences have recently been cloned but as yet no 
gene has been identified (McKeithan et al. 1987).
Three cases of a t(1;19)(ql2?pl3.3) chromosome 
translocation have been observed in human malignant 
melanoma (Parmiter et al. 1986). DNA from two of these 
samples was analysed for any rearrangements in the 
coding sequences of the MEL locus, but none were 
observed. This does not conclusively eliminate an 
involvement of MEL in this translocation, as any 
breakpoint may occur in as yet unidentified coding or 
regulatory sequences.
Despite the identification of coding sequences
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in the clone NK16, it was not possible to assign 
transforming activity to this gene. The clone itself 
was unable to transform NIH 3T3 cells. To identify a 
requirement for further sequences, clones overlapping 
the 3' end of the clone were isolated from a random 
library and transfected singly or in combination with 
NK16. Again no transforming activity was detected. 
Further evidence against an involvement of these 
sequences in transformation was provided by the 
analysis of tertiary transformants. Over twenty were 
analysed for the presence of these sequences without 
success. Additional primary transformants were 
generated by conventional focus formation or 
cotransfection with a selectable marker and 
tumorigenicity. Human MEL sequences were undetectable 
in these also. Thus unlike previously identified 
oncogenes, which are conserved in all subsequent 
transfectants (Takahashi et al. 1985), the presence of 
MEL sequences could not be demonstrated in tertiary 
transfectants or indeed further primary transformants 
identified by focus formation or
co-transfection/tumorigenicity assays. The current 
understanding is that only functionally important and 
adjoining sequences will be retained in a second cycle 
of transfection. This is especially true in cases like 
that described here where the human sequences are 
minimal, as determined by the presence of Alu 
repetitive sequences. Indeed the clone NK16 represents
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the only Alu containing sequences in the transformant. 
It is thus difficult to assess the importance, if any, 
of these sequences in the generation and maintenance of 
the transformed phenotype. The human genome is
• Q . . . .estimated to be 5 x 10 bp in size, comprising some 
50,000 genes. Thus if 0.1% of the donor genome is 
stably integrated upon transfection into NIH 3T3 cells, 
then any transformant would be expected to contain 
possibly 50 heterologous genes. A further round of 
transfection, and the transformant would be expected to 
retain only the transforming sequences and those 
physically linked. Thus the probability in retaining 
human sequences in a transformant that are neither 
responsible nor linked to the transformation is very 
low. That those sequences should be expressed and code 
for a polypeptide is more improbable. However as yet no 
function can be ascribed to these sequences.
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Chapter 4: MEL related sequences with low
frequency transforming activity
Chapter 4: MEL-related sequences with low
frequency transforming activity 
Section I: Introduction
In the preceding chapter the identification of 
transforming activity in genomic DNA from the human 
melanoma cell line NKI4, and the subsequent cloning of 
the human sequences presumed to be responsible was 
described. Although this work resulted in the 
identification of a previously undescribed human gene 
(MEL), further data suggested that MEL was unlikely to 
be responsible for the transforming activity of the DNA 
from NKI4. Whilst attempting to isolate MEL sequences 
from the human melanoma cell line NKI4, a MEL-related 
clone was identified which possessed the ability to 
transform NIH 3T3 cells to a tumorigenic phenotype at a 
low but reproducible frequency. This transformation 
arose by a possibly novel mechanism. This sequence also 
defines a polymorphism in human DNA.
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Section II: Results
(i) Preparation and screening of random library of
NKI4 DNA
The clone identified in Chapter 3, lambda NK16, 
was incapable of transforming NIH 3T3 cells in either a 
focus forming or a cotransfection and tumorigenicity 
assay. However a contribution of these sequences to 
transformation could not be completely ruled out. By 
testing the effect of the corresponding sequences from 
the cell line NKI4, it was hoped to assess the 
relevance of these sequences to transformation. A
partial Sau3A random genomic library was prepared in 
the lambda vector Jl. 400,000 phage were screened with 
the 600bp fragment of pEMBL600 and 60 positive plaques 
were identified. This figure was higher than would be
expected for a single copy sequence in a random
library, and could be due either to the Alu-like
sequence in the probe or the presence of MEL related 
sequences in the human genome. No other fragments have 
been observed on hybridisation of the 600 bp probe to 
human DNA, nor has any amplification of the MEL locus 
had been observed in the cell line NKI4. Rather than 
independently isolate and characterise each clone, an 
approach based on the selection of transforming clones 
was used ( • . . - " Goubin et
al. 1983).
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Table 4:1
DNA Transformation Anchorage ^
frecruencv Indeoendance
NIH 3T3 0.015 —
L47 0.37 -
NKI 0.073 +
NKII 3.82 +
NKII-A 0.42 -
NKII B 0.8 ND
NKII C 0.9 +
NKII D 0 -
NKII C4-2 3.33 +
NKII Cl-1 3.0 ND
NKII C6-3 3.0 ND
NKI 6 0.04 -
* The efficiency of plating in soft agar for NIH 3T3 cells j 
was < 0.001% . Transfectants were considered positive for 
anchorage independent growth when the efficiency of plating 
was >2%.
(ii) Isolation of transforming clone by phenotypic 
selection.
The 60 positive phage were picked from the 
library, and divided into 8 groups. Aliquots of the 
resuspended phage were then pooled in two groups (I 
and II) from which DNA was prepared, and 5ug of phage 
DNA was cotransfected with lOOug of NIH 3T3 carrier 
DNA onto NIH 3T3 cells. DNA from group II produced foci 
within 30 days, so DNA was prepared from the four 
subgroups A-D and tested for transformation. The 
results of these transfections are shown in table 4.1. 
The group C lysate was plated out and three phage 
hybridising to the pEMBL 600 probe were identified and 
purified. DNA was prepared and assessed for 
transforming activity. All three displayed the ability 
to transform NIH 3T3 cells at a frequency of around 3 
foci/ug DNA. These transformants were also able to grow 
in soft agar.
(iii) Mapping of the transforming clone.
A preliminary restriction map of the clone
II-C-4 is shown in figure 4:1. The cloned fragment was 
approximately 17 kb in size so the clone was 
designated lambda NK17. Comparison of the restriction 
patterns after Bam HI and Hind III digests of this 
clone and the two other isolates indicated that they 
were homologous. No similarity was observed between the 
restriction maps of NK17 and NK16. Hybridisation with
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BLUR8 and total human DNA probes determined the extent 
of the repetitive sequences as shown in figure 4:1. 
Sequences hybridising to the pEMBL600 probe are located 
in the 5' region of the clone. However no hybridisation 
was seen with the 200 bp MEL probe. The alternative 
300bp Accl/Aval MEL probe hybridised to NK17, but not 
as strongly as to NK16. The relationship between MEL 
and NKI7 was unclear.
(iv) Identification of specific probes
The majority of the human repetitive sequences 
were confined to the periphery of the insert, as
defined by the Hind III sites. The internal 9 kb Hind
III fragment was isolated for use as a probe (figure 
4:1, probe I) and hybridised to human and mouse Eco RI 
digested DNA (figure 4:2). No homologous sequences
were detectable in NIH 3T3 DNA (lane e). Lanes a-d are 
human melanoma cell line DNA samples in which an Eco 
RI polymorphism is discernible. The probe detects 4 
fragments in NKI4 and Mel Swift of 6.6 kb, 4.4 kb, 4.0 
kb and 3.5 kb, but the 3.5 kb band is absent in MeWo 
and RPMI 5966. The presence or absence of this band 
could reflect a true allelic polymorphism, or
alternatively a deletion of important sequences in 
melanomas.
(v) Eco RI polymorphism: comparison of melanoma and 
normal human DNA
The observation that probe I detects a Eco RI
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Figure 4:2 NK17 sequences in human DNA. DNA samples (20ug) 
were digested with EcoRI, electrophoresed in 0.8% agarose, 
transferred to a nylon membrane and hybridised with a 
Hindlll fragment of NK17 (probe I). Lane a, NKI4: lane b,
MeWo: lane c, RPMI 5966: lane d, MEL Swift: lane e, NIH 3T3. 
DNA marker fragment sizes are indicated in kilobases (Kb) . 
No sequences homologous to NK17 are observed in NIH 3T3 DNA. 
Additionally this probe identifies an EcoRI RFLP in human 
DNA.
Kb
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polymorphism in human melanoma DNA prompted the further 
analysis of melanoma samples. Eco RI digested DNA from 
10 melanoma cell lines and 3 tumour samples were 
hybridised with probe I. Also included was DNA from the 
bladder carcinoma cell line EJ. As shown in section IV, 
probe I detected three bands of 6.6, 4.4, and 4.0 kb in 
all samples,but the 3.5 kb band was present in only 2/4 
melanoma cell lines. Of the samples analysed the 3.5 kb 
fragment was present in only 2/10 cell lines and 1/3 
tumours. This fragment was also absent in EJ. From the 
restriction map of NK17, Eco RI fragments of 6.0, 4.4 
and 3.5 kb would be detected by probe I. The 4.0 kb 
fragment observed on hybridisation to human DNA (figure 
4:2) is absent from the clone and must therefore 
represent the corresponding allele of the polymorphism 
to the 3.5 kb Eco RI fragment. A single 9kb band was 
observed on hybridisation to Hind III digested human 
melanoma DNA, arguing against the deletion of specific 
fragments. Several normal individuals were analysed 
for this polymorphism. No individuals have been 
observed to be homozygous for the 3.5 kb allele.
(vi) Detection of heterologous sequences in 
transformants.
Implicit in the observation that these clones 
are able to transform NIH 3T3 fibroblasts is that they 
should be present in the resultant transformants. DNA
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from the transfectants obtained during sib-selection 
was analysed for the presence of NK17 sequences with 
probe I without success. It has been reported that 
following transfection of a selectable marker into 
fibroblasts, tumours were generated in nude mice in 
which the vector sequences are undetectable (Lau et al.
1985). It has also been observed following transfection 
of genomic DNA from samples containing an activated 
HRAS gene that the human HRAS sequences are undete ct ab 1 e/ 
in the resultant foci by conventional Southern analysis 
(Gow et al. 1988). However following cotransfection of 
focus DNA with a selectable marker and injection into 
nude mice, tumours formed in which the human HRAS gene 
was now detectable (Gow et al 1988).
Therefore NK17 was cotransfected with the neo
selectable marker pHSG 272 (Brady et al. 1984) and 
resistant colonies were injected into nude mice. 
Tumours developed within 30 days at 3/6 sites of 
injection. DNA was extracted from the tumours, digested 
with Bam HI, and analysed by Southern blotting. Three 
bands of 6.6, 4.4 and 2.0 kb were detected in each 
tumour when hybridised with the 9kb Hind III fragment 
of NK17 (figure 4:3), and as before no homologous
sequences were found in NIH 3T3 DNA. The probe was
removed and the filter rehybridised with a lambda DNA
probe. No lambda sequences were detectable in the 
tumours, demonstrating that the transformation event is 
a specific property of the sequences present in NK17.
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Table 4:2
DNA NUMBER OF TUMOURS/ LATENCY
SITES OF INJECTION (DAYS)
PHSG272 0/18
L47 + PHSG272 0/8
NKI6 +PHSG272 1/6 42
NK17-N 1/6 56
NK17-M 2/8 30
NK17-MTAGGED 4/10 26
Figure 4:3 Presence of NK17 sequences in nude mouse tumours. 
DNA samples (2 0ug) were digested with BamHI, electrophoresed 
on 0.8% agarose, transferred to a nylon membrane and 
hybridised with a Hindlll fragment of NK17 (probe I) . Lane 
a,b, primary tumours of NIH 3T3 cells transfected with NK17; 
lane c, NIH 3T3. DNA marker fragment sizes are indicated in 
kilobases (Kb).
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The size of NK17 precluded the subcloning into 
a plasmid vector with a selectable marker. Instead NK17 
DNA was digested with Hind III under conditions 
favouring partial digestion, and the fragment 
corresponding to the entire NK17 sequences was isolated 
from LGT agarose. The purified DNA was ligated to Hind 
III digested pHSG272 and transfected onto NIH 3T3 
cells. Drug resistant colonies were injected into nude 
mice producing tumours within 26 days. These tumours 
retained the same NK17 fragments as previous tumours.
A Bam HI/Hind III fragment, lacking human 
repetitive sequences was isolated from NK17, (figure 4: 
1;, probe II) and hybridised to DNA from two tumours 
from nude mice and two human melanoma lines, NKI4 and 
RPMI5966, digested with BamHI (figure 4:4). A single 
fragment of approximately 6.6kb was observed in both 
the tumours and the cell lines. There is a small size 
discrepancy between the fragments observed in the 
tumour and human samples. This may be as a result of 
rearrangement of the transfected DNA following 
integration into the NIH 3T3 genome. Alternatively NK17 
was isolated from a random library, and the size 
difference may reflect the creation of a Bam HI site at 
the cloning junction. Probe II still retains some human 
repetitive sequences as seen from the background 
hybridisation to human DNA.
(vii) Transmission of transformed phenotype
DNA from an NK17 tumour was tested for
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Figure 4:4 Presence of NK17 sequences in human and 
transfectant DNA. DNA samples (2 0ug) were digested with 
BamHI, electrophoresed on 0.8% agarose, transferred to a 
nylon membrane, and hybridised with a BamHI/Hindlll fragment 
of pNK5 (probe II) . Lane a-c, primary NK17 nude mice 
tumours: lane d, NIH 3T3: lane e, NKI4: lane f, MEL Swift. 
DNA marker fragment sizes are indicated in kilobases (Kb). 
A band was observed in lane a after a longer exposure
a b c d
9.4
6.6
4.4
transforming activity, by further transfection into NIH 
3T3 cells. The foci generated were also able to grow in 
soft agar. However NK17 sequences could not be 
detected by analysis with probe I.
(viii) Isolation and mapping of a homologous clone 
from a normal library
To ascertain whether the transforming property 
of NKI7 was a general function of these sequences, or 
was in some way unique to the clone derived from NKI4, 
required the isolation of equivalent sequences from a 
normal genomic library.
A normal human leucocyte lambda library 
(Clontech), was screened with probe II. One positive 
clone was identified in 400,000 phage screened, and 
plaque purified (lambda NK17-N). DNA was prepared, and 
cotransfected with pHSG272 onto NIH 3T3 cells. G418 
resistant colonies were injected into nude mice to 
assay for tumorigenicity. One tumour appeared after a 
long latency period (52 days), but upon analysis of the 
DNA no hybridisation was observed with probe I. As 
tumours can form in mice injected with untransfected 
NIH 3T3 cells with a similar latency period, it is 
probable that this tumour arose due to a spontaneous 
event. Therefore it was concluded that the normal NK17 
clone was not transforming.
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Figure 4:5 Comparison of NK17-M and NK17-N.
NK17-N
NK17-M
B B B
I I I
B B B 
I I I
(ix) Comparison of normal and transforming clones
A restriction map of lambda NK17-N was 
determined and compared with that of lambda NK17 
(figure 4:5). Unlike NK17 in which it is probable that 
the 57 Bam HI site was generated during the cloning, 
the equivalent Bam HI fragment of NK17-N is nearer the 
size observed in Bam HI digested genomic DNA (figure 
4:4). On the basis of the restriction maps and 
hybridisation analysis this Bam HI fragment is the only 
common region between the two clones.
(x) Subcloning and localisation of transforming
sequences
The retention of only a portion of
the NK17 sequences in the transformants suggested that
not all the clone was required for transformation.
Utilising the Bam HI sites to subdivide the clone, 5 
Bam HI fragments were subcloned into either pEMBL 8 (1 
and 2) or pBR322 (3,4 and 5). Plasmid DNA was 
prepared, and each clone wascotransfec ted,with pHSG272 
into NIH 3T3 cells. Drug resistant colonies were 
assayed for growth in soft agar to test for 
transformation. Of the five clones tested, only clone 1 
transfectants were anchorage independant. Colonies were 
picked and transferred to fresh medium, and expanded in 
culture. DNA was extracted from these cells, digested 
with Bam HI and hybridised with probe I from NK17
(figure 4:6). The BamHI clone 1 was not itself suitable
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Figure 4:6 Presence of pNKl sequences in transfectants. DNA 
samples (20ug) were digested with BamHI, electrophoresed in 
0.8% agarose, transferred to a nylon membrane and hybridised 
with NK17 probe I. Lane a, NIH 3T3: lane b,c, primary foci 
of pNK-1. DNA marker fragment sizes are indicated in 
kilobases (Kb).
Kb
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for hybridisation due to the presence of a high 
proportion of human repetitive sequences. A Bam HI 
fragment of 2 kb in size is present in two independant 
agar colonies. ' ~
.. ... ' . The observation of
selective retention of specific sequences argues 
against transformation arising purely as a result of 
the random integration of DNA. Instead the effect must 
be a specific property of the sequences in NK17, in 
particular those within the 2kb Bam HI fragment. 
Sequencing of the pNKl clone has failed to reveal any 
continuous open reading frames, (K.Johnson and E.Nimmo, 
personal communication). The method by which this clone 
transforms NIH 3T3 cells is therefore unlikely to be as 
a consequence of expression of these sequences.
If as suggested the transforming activity of 
this clone is localised in the 2.0 kb Bam HI fragment, 
then this provides an explanation for the lack of 
transforming activity associated with the normal clone, 
from which the 2.0 kb fragment is absent. Therefore a 
preferable control would be the equivalent sequences 
from a normal library. Attempts to isolate homologous 
sequences from a normal human genomic library have been 
unsuccessful.
(xi) Integration of NK17 in transformants
It has been suggested that transformation of NIH 
3T3 cells can arise following integration of
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transfected sequences into critical loci (Cooper 1982), 
and this has supposedly been demonstrated by the 
generation of transformants with sonicated DNA from 
untransformed mouse and avian fibroblasts (Cooper et 
al. 1980). This transformation activity is 
transmissable through serial rounds of transfection. 
This property of normal DNA has been infrequently 
observed with human samples. DNA from normal human 
lymphocytes has been reported to transform NIH 3T3 
cells (Schafer et al. 1984), although this activity 
resulted from the spontaneous mutation of a human HRAS 
gene at codon 12 during the process of transfection 
(Schafer et al. 1985).
If, as suggested, the method of transformation 
by NK17 is by insertional activation, then
transformants would be expected to possess common sites 
of integration for these sequences.High molecular 
weight DNA from the tumours arising after transfection 
of NKI7 were digested with Sst I and hybridised with 
probes I from NK17. A single hybridising fragment was 
detected in these tumours, of 4.4 kb in Tl, 8kb in T2 
and T3, and 12kb in T4 (figure 4:7).
. . . . ' , To
determine whether these tumours contain different 
integrations at the same genetic locus would require 
the isolation and characterisation of the flanking 
sequences, in a manner analogous to the analysis of the 
preferred integration sites of the latent oncogenic
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Figure 4:7 Site of integration in NK17 transfectants.
DNA samples (2 0ug) were digested with SstI and analysed by 
Southern blotting and hybridisation with NK17 probe I. Lane 
a, Tl; lane b, T2; lane c, T3; lane d, T4. DNA marker 
fragment sizes are indicated in kilobases (Kb) .
a b c d
9 .4
6.6
4.4
retroviruses for example, MMTV which preferentially 
integrates into int-1 and int-2 (Nusse and Varmus, 
1982? Dickson et al. 1984). Such sequences could then 
be used to analyse the other transformants for 
integration at the same locus.
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Section III Discussion
A MEL-related clone was identified and isolated 
from a random genomic library of NKI4 on the basis of 
hybridisation to a MEL specific probe and the 
concomitant presence of transforming activity. This 
clone was able to transform NIH 3T3 cells at a 
frequency of approximately 3 foci per ug. When 
cotransfected with a selectable marker these sequences 
can transform NIH 3T3 cells to a tumorigenic phenotype, 
in which the same sequences can be detected by Southern 
blot analysis. The transforming activity was localised 
to a 2kb Bam HI fragment by assaying individual 
subclones. The inability to detect homologous sequences 
in secondary transformants may reflect the requirement 
of only a very small proportion of this 2kb fragment 
for transformation. Given that the lambda clone is 
approximately 47 kb in size, and as suggested the 
transforming activity resides within at most 2 kb, then 
this is equivalent to a focus forming frequency of 
about 75 foci/ug. The transforming activity of a clone 
is more clearly defined in terms of the number of 
copies of the sequence responsible. However this 
frequency is low in comparison to other transforming 
genes; for example HRAS-Val 12 is able to transform at 
frequencies of 103-104 foci/ug (Capon et al. 1983? 
Reddy, 1983). Nonetheless, this transformation to a 
tumorigenic phenotype is reproducible, and specific to 
these sequences. It is unlikely that transformation
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arises as a consequence of the transfection of cloned 
DNA. Other genomic clones have proved to be negative in 
a transformation assay, although they have not been 
identified on the basis of sib-selection for those 
clones which are able to transform NIH 3T3 cells.
Sib-selection based on transformation has been 
used before to identify a transforming gene, the 
chicken B-cell lymphoma oncogene Blym-1 (Goubin et al. 
1983). Transforming activity had been noted in a 
chicken B-cell lymphoma cell line RP9 using the NIH 
3T3 assay (Cooper and Neiman, 1981). A partial library 
of 200,000 recombinants was generated from an NIH 3T3 
transfectant and phage pools were assayed for 
transforming activity until a single active clone was 
isolated. This cloned gene designated Chicken Blym-1 
was sequenced and reported to show homology to 
transferrin and related proteins (Goubin et al. 1983). 
A human B-lym clone (HuBlym-1) was isolated from a 
Burkitt's lymphoma cell line and also found to be 
transforming (Diamond et al. 1983, 1984). However it
was subsequently reported that chicken Blym-1 clone 
displayed 60% homology to TBG41, (Hattori et al. 1985), 
a member of the human long interspersed repetitive 
sequence family (LINES; Singer and Skowronski, 1985). 
Of greater significance though was the observation that 
chicken Blym-1 displayed more than 90% homology to the 
mouse line-1 sequence (Rogers, 1986; Cooper et al. 
1986). Thus this transforming gene is a portion of a
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mouse LINES element which was probably activated 
during either cloning or transfection, and not as 
initially described a chicken transforming gene. This 
gene was redesignated mouse LINES transforming element 
(LINES-TE) in recognition of this report (Cooper et al.
1986). The relationship of cBlym to HuBlym-1 is 
unclear; despite the homology of HuBlym-1 to cBlym, 
HuBlym-1 is unrelated to human LINE-1, although the 
central portion is a human Alu dispersed repetitive 
sequence which substantially overlaps the proposed 
Blym-1 open reading frame (Rogers, 1986). Also further 
isolates of HuBlym-1 from Burkitt's lymphoma cell lines 
have been reported to be non-transforming (Devine, 
1986a), despite sequence identity with the original 
transforming HuBlym-1 isolate. There is some contention 
with regards to these observations (Devine, 1986a, 
1986b; Cooper and Diamond, 1986), and transformation 
may arise as the result of loss of regulatory 
sequences.
Despite the similarities in method between the 
isolation of cBlym and the transforming clone NK17, 
there are important differences. Blym was identified by 
selecting for transforming clones from a library of an 
NIH 3T3 transfectant, hence the origin of the mouse 
sequences. In contrast NK17 was isolated from a genomic 
library of the human melanoma cell line NKI4; thus 
there are no doubts about the origin of these 
sequences. Also the preliminary screen was for
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MEL-related clones, as opposed to sib-selection purely 
on the basis of transforming activity as employed by 
Cooper and colleagues. The transforming clone also 
retained hybridisation to the probe with which the 
clones were originally selected.
The mechanism by which these sequences transform 
is as yet unknown. Like the human Blym-1, the 
transforming pNKl contains abundant Alu repetitive 
sequences; despite the many functions ascribed to and 
hypothesised for these sequences, such as hotspots for 
recombination (Jagadeeswaran et al. 1983; Vanin et al. 
1983; Lehrman et al. 1986), particularly in the 
chromosome translocations observed in malignancies 
(Heisterkamp et al. 1985; Rogers. 1985), and as origins 
of DNA replication (Jelinek et al. 1980; Johnson and 
Jelinek. 1986), a role in transformation has not been 
demonstrated. The inability to detect an open reading 
frame in the sequence of pNKl would argue against the 
presence of a functional gene. Also homologous 
sequences have not been detected in mouse DNA, even at 
low stringency, suggesting that they are not conserved 
across species. Instead it is more likely that these 
sequences transform by integration at a specific locus, 
resulting in inappropriate expression of a normal gene 
product, or normal expression of an abnormal gene 
product. This would explain the low frequency of 
transformation demonstrated for these sequences. This 
would be analogous to the observed integration of
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retroviruses such as MMTV, which lack an activated 
oncogene and transform only after long latency periods. 
They are thought to act by integration at critical 
loci such as int-1 and int-2 (Nusse and Varmus, 1982; 
Dickson et al. 1984)
It is possible that pNKl contains DNA 
elements involved in transcriptional regulation,such as 
an enhancer (Banerji et al. 1983; Gillies et al. 1983; 
Gillies et al. 1984) which can act independantly of 
orientation with respect to the gene. The observation 
that a gene lacking an enhancer can be activated by 
integration into the genome following transfection 
(Hamada. 1986a) led to the development of a method for 
identifying cellular gene activator elements (Hamada. 
1986b). HeLa cells were transfected with an enhancer 
trap, a plasmid containing an enhancerless gpt gene 
transcribed from an SV40 early promoter, and stably 
transformed GPT+ cells were selected. Thus the method I 
have used is possibly analogous, but instead relieson 
the converse effect of the activation of a cellular 
gene by the integration of enhancer or enhancer-like 
elements within a cloned sequence. A similar technique 
has been used to identify potential oncogenes in the 
NIH 3T3 genome (Muller and Muller. 1984). 
Morphologically transformed, tumorigenic cell lines 
were obtained after cotransfection of NIH 3T3 DNA with 
the cloned 3'-LTR of Moloney Leukaemia virus. In one 
case transformation resulted from an activated RAF gene
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(Rapp et al. 1983).
The Alu repetitive sequences present in the 
transforming clone may be of functional importance; 
like tRNA and VAI RNA, Alu sequences are transcribed by 
RNA polymerase III and the promoters of polymerase
III-dependant genes are located within the transcribed 
regions (Ciliberto et al. 1983). The effect of these 
promoter sequences when inserted in front of other 
genes is unknown.
If however pNKl contains as yet unidentified 
coding sequences, then a number of explanations are 
possible. The gene itself could activated in the cell 
line in some way, probably by point mutation as no 
gross rearrangements have been observed in NKI4. 
Alternatively the normal gene product could be 
transforming when introduced into NIH 3T3 cells. This 
is indeed the case with two oncogenes previously 
identified by the NIH 3T3 assay. The fibroblast growth 
factor HST transforms at equal frequency whether it is 
isolated from stomach tumour DNA or normal DNA 
(Yoshida et al. 1987). Also the proto-oncogene DBL 
transforms NIH 3T3 cells, albeit at a lower frequency 
than the activated DBL (Ron et al. 1988).
A restriction fragment length polymorphism was 
recognised by probes specific for these sequences in 
EcoRI digested human genomic DNA. In the small sample 
population of melanomas the smaller allele was detected 
in only 3 out of 13 individuals, all of which were
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heterozygotes. Homozygosity for this allele has not 
been observed. The freguency of this allele in the 
normal population has not been accurately assessed, 
although individuals are found who lack the smaller 
fragment. Thus further study is required to determine 
the importance of these sequences if any in malignancy. 
As yet they have not been assigned to a particular 
chromosomal location.
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Chapter 5sTagging with a selectable marker
as an approach to isolate transforming 
sequences.
Chapter 5: Tagging with a selectable marker as an 
approach to isolate transforming sequences.
Section I: Introduction
Several transforming genes have been identified 
on the basis of focus formation in the NIH 3T3 assay. 
However the variability in focus morphology 
consequently emphasises the subjective nature of the 
assay. Refinements of the assay have been developed, 
which rely instead on the induction of tumours in nude 
mice (Blair et al. 1982). The sensitivity has been 
further increased by cotransfection with the genomic 
DNA of a selectable marker, such as the bacterial neo 
gene (Southern and Berg, 1982), which confers 
resistance to the aminoglycoside antibiotic G418 
(Davies and Jiminez, 1980) in eukaryotic cells (Brown 
et al. 1984? Fasano et al. 1984). Cells that have 
taken up the transfected DNA are then selected by 
plating in medium containing G418, and resistant 
colonies are injected into nude mice to assay for 
transformation. However these developments still rely 
on the retention of flanking human repetitive sequences 
to clone the transforming gene.
In 1985, Robert Brown and coworkers published a 
modification of their previously described 
co-transfection method (Brown et al. 1984? Brady et al.
1985) which facilitated the cloning of transforming
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genes which lacked Alu repetitive sequences or were 
present in a homologous background (for example, NIH 
3T3 cells transformed by murine sequences). It had 
previously been shown that transfected DNA can be 
physically linked to a known cloned DNA sequence 
(tag), before transfer (Perucho et al. 1980b? Goldfarb 
et al. 1982). The subsequent cloning of adjacent donor 
sequences is simplified if the tag contains a gene 
which is selectable in bacteria (Perucho et al, 
1980b? Goldfarb et al. 1982). Brown and colleagues used 
the cosmid vector pHSG272 (Brady et al. 1984) to tag 
transfected DNA for the following reasons. The vector 
contains a eukaryotic drug resistance marker (neo) 
which allows selection for transfected cells. They had 
previously shown that co-transfer of tumour DNA and 
pHSG272 into NIH 3T3 cells resulted in G418 resistant 
colonies which were tumorigenic in nude mice (Brown et 
al., 1984). The neo gene also confers resistance to the 
antibiotic kanamycin (Km) in bacteria. Finally, pHSG272 
contains a cos site, which can be used for cosmid 
cloning of flanking genomic sequences, up to 50kb 
either side of the integrated vector. The strategy 
used was as follows: NIH 3T3 cells were transfected 
with concatamers of alternating vector/genomic DNA, 
selected for G418 resistance, and then injected into 
nude mice to assay for tumorigenicity. Tumour DNA was 
then serially transfected, selecting alternately for 
drug resistance and transformation, until the copy
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number of the vector sequences was reduced to 1-5 
copies per cell. A cosmid rescue strategy was used to 
isolate Kmr clones containing the flanking transforming 
sequences. Using this method an activated NRAS gene was 
identified in and cloned from the mouse Lewis Lung 
carcinoma cell line (Brady et al. 1985). This approach 
seemed particularly applicable to identifying the 
transforming gene in NKI4, as tertiary transformants 
lack any detectable human sequences, making 
identification and cloning of the transforming 
sequences difficult.
Section II: Tagging of transforming sequences.
(i) Tagging of NKI4 DNA
HMW DNA was isolated from the melanoma cell 
line NKI4, partially digested with Sau 3A to an average 
size of around 40 kb, phenol extracted, precipitated 
with ethanol, and resuspended in 1 x TE. pHSG272 was 
linearised with BamHI and added sequentially to the 
ligation mix over a period of two days. The ligation 
mix was transfected onto NIH 3T3 cells, which were 
selected for G418 resistance, and then G418 resistant 
colonies were injected into nude mice. In two separate 
transfection experiments, with 8 sites of injections in 
each case, no tumours were produced. This result is in 
contrast to that observed following co-transfection of 
DNA from NKI4 and pHSG272 [Chapter 3, (xiii)], where 
tumours formed at 8/8 sites of injection. This
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apparent contradiction can be explained if the 
transforming gene in NKI4 is greater than 40 kb in 
size. The procedure of tagging requires the initial 
digestion of high molecular weight DNA to approximately 
40kb, and therefore any genes greater than 40 kb will 
be underrepresented, if present at all, in the final 
ligation mixture which is transfected. However in 
comparison the limitation on size in a cotransfection 
experiment is the quality of the the DNA preparation 
and the possible shearing effects due to transfection. 
Thus undigested NKI4 DNA transformed NIH 3T3 cells 
whereas the partially digested DNA did not, implying a 
size of greater than 40 kb for the transforming gene in 
NKI4.
(ii) Tagging of NKI4 secondary focus DNA
DNA was extracted from an anchorage independant 
clone of NKI4-2-4, and tagged as described previously. 
G418 resistant colonies were injected into nude mice 
and 2/8 sites of injection yielded tumours within 30 
days. DNA was extracted from these tumours and 
transfected back onto NIH 3T3 cells. The transfected 
cells were then selected in medium containing G418, and 
resistant colonies were then assayed for transformation 
by plating in soft agar, as opposed to injection into 
nude mice, enabling the establishment of cell lines. 
Far fewer G418r colonies were produced on the second 
round of transfection, corresponding to the reduced
148
number of copies of pHSG272 in the transfected sample. 
Anchorage i n d e p e n d e n t  colonies were isolated and 
transferred to fresh medium, and expanded to produce 
enough cells for DNA extraction. No human MEL sequences 
could be detected in these transfectants (figure 5:1). 
There are two EcoRI sites in the vector pHSG272, which 
would be expected to yield a 2.9 kb fragment in the 
tagged DNA upon digestion with Eco RI. This corresponds 
to an internal fragment of the vector not disrupted by 
the Bam HI cloning site used for cloning (figure 5:2). 
DNA from the two primary tumours and three secondary 
transformants was probed with either pHSG272 or a 
PvuII/Smal fragment containing the neo gene (figure 
5:3). The primary tumours contain multiple copies of 
the vector sequence? however there was not an intense 
signal at 2.9 kb corresponding to the diagnostic 
internal fragment. The observation that even using a 
probe specific for the neo gene many bands are visible 
implies that rearrangements has occurred during the 
first transfection. The copy number of pHSG272 in the 
secondary transfectants is possibly as low as one copy 
per cell. In three transfectants the neo probe 
preferentially hybridises to a single 18kb EcoRI 
fragment . On the basis of the restriction map of 
pHSG272, one would expect the neo probe to hybridise to 
the internal 2.9 kb Eco RI fragment? however loss of 
one of the Eco RI sites upon transfection and 
integration could result in an altered fragment size.
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Figure 5:1 Absence of MEL sequences in tagged primary nude 
mice tumours. DNA samples (2 0ug) were digested with EcoRI, 
electrophoresed on 0.8% agarose and transferred to a nylon 
membrane. Lane a, primary nude mouse tumour of NKI4-2-4 
tagged with pHSG272 (NKI4-2-4/272-T1): lane b, primary nude
mouse tumour of NKI4-2-4 tagged with pHSG272 (NKI4-2-4/272- 
T2) : lane c, spontaneous nude mouse tumour: lane d, NKI4
secondary focus (NKI4-2-4). Filter hybridised with a: pNK200 
or b: BamHI/SphI fragment of pNK4.0. DNA marker fragment
sizes are indicated in kilobases (Kb).
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Figure 5:2 Maps of vectors: pHSG272 (Brady et al. 1985),
pHSG250 (Brady et al. 1985) and C2XB (Bates and Swift, 
1983).
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Figure 5:3 Presence of pHSG272 sequences in nude mouse 
tumours. DNA samples (20ug) were digested with EcoRI, 
electrophoresed on 0.8% agarose, transferred to a nylon 
membrane and hybridised with pHSG272. Lane a-c, tagged 
secondary transfectants (NKI4-2-4/272-T1-A6, -A7, -A9); lane 
d,e, tagged tertiary transfectants (NKI4-2-4/272-A9-A7,
A8) ; lane g, NIH 3T3; lane h,i, primary tagged tumours 
(NKI4-2-4/272-T1,-T2). DNA marker fragment sizes are 
indicated in kilobases (Kb).
a b o d e  f g h i
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(iii) Cosmid Rescue
The physical linkage between the neo gene and 
the transforming sequences was confirmed by a further 
round of transfection and selection for drug resistance 
and anchorage independant growth. Transfection of DNA 
from the transfectant NKI4-2-4-A9 produced G418r 
colonies which displayed a high frequency of colony 
formation in soft agar. The close linkage between the 
two genes meant that this clone was suitable for cosmid 
rescue of the selectable marker and flanking sequences. 
Two alternative methods for cosmid rescue are possible; 
a cosmid library can be constructed by preparing cos 
arms from the cosmid vector pHSG250 (figure 5:2); or 
directed packaging utilising the cos site in pHSG272 to 
enable cloning of the region flanking one side of the 
vector, with the other cos site provided by the cosmid 
pHSG250, and isolating kanamycin resistant clones.
HMW DNA was prepared from the transfectant
NKI4-2-4-A9, partially digested with Sau3A to
approximately 40kb and ligated to pHSG250 cos arms. The 
ligation was packaged in vitro and added to ED8767 
cells. The cells were then plated onto agar containing 
30ug/ml kanamycin and incubated overnight at 37°C. 
Constructing a library from lug of genomic DNA would be 
expected to yield 5 Kmr recombinants. However no Kmr 
colonies were obtained from this experiment. The
inability to rescue the neo gene and flanking sequences 
by this method could be due to the genomic DNA not
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;* Efficiency of plating in soft agar > 10%. I
Figure 5:4 Analysis of Km1- cosmids. Cosmid DNA samples (lug) 
were digested with Nrul, electrophoresed on 0.8% agarose, 
transferred to a nylon membrane and hybridised with P 
labeled C2XB DNA. Lanes a and 1 contain Nrul-digested C2XB, 
with two fragments of 1.6 and 5.2 kb. Panel A, lanes b-k, 
Cosmids 25-34; Panel B, lanes b-k, Cosmids 35-44; Panel C, 
lanes a-h, Cosmids 45-51. The majority of recombinants 
possess the 1.6kb fragment corresponding to the Kmr of C2XB.
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being of sufficiently high molecular weight; 
alternatively the flanking region could contain 
"unclonable" or "poison" sequences (Brookes et al.
1986). Because the rescue strategy uses a drug 
sensitive cosmid pHSG250, it is not possible to assess 
the efficiency of the library construction, and 
therefore the quality of the genomic DNA used. This can 
only be determined by preparing a library in a vector 
which contains an alternative selectable marker.
(iv) Construction of a cosmid library in the vector 
C2XB
The cosmid vector C2XB (Bates and Swift, 1983) 
has several useful features to simplify the procedure 
of cosmid cloning (figure 5:2)? the vector contains two 
cos sites, eliminating the need to separately prepare 
the left and right cos arms. Also two drug resistance 
markers are present (Ampr and Kmr), of which the Kmr is 
lost following successful cloning; aberrant 
recombinants can be identified by the retention of Kmr .
HMW genomic DNA was prepared as described, 
partially digested to an average fragment size of 40-50 
kb with Sau3A and centrifuged on a sucrose gradient to 
obtain DNA fragments of 40-50kb. C2XB cos arms were 
prepared as described. Cosmid libraries were prepared 
and titrated by plating on L-agar containing lOOug/ml 
Ampicillin. The estimated number of recombinants was
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600,000 from a series of independant ligations. 
Aliquots of the packaged library were added to 1046 
plating cells and plated onto sterile nylon filters on 
L-agar containing lOOug/ml Ampicillin. The whole 
library was thus plated and incubated overnight. 
Replica filters were prepared and incubated overnight 
on L-agar plates containing 15 ug/ml Kanamycin. 51 Km 
resistant colonies were identified, picked and replated 
on L-agar containing 15ug/ml Km. Not all colonies 
replated on Km (10/51). DNA was prepared from 
resistant clones by a mini-prep protocol and digested 
with Nrul. Nrul is diagnostic for recombinants 
retaining the Kmr of C2XB. The majority of recombinants 
displayed a conserved Nrul fragment, of the same size 
as the fragment of C2XB corresponding to the neo gene 
(figure 5:4), and so were assumed to have arisen by 
retention of the Kmr gene from C2XB. Clones 34, 35, 40, 
49 and 51 however displayed differing patterns with 
Nrul and were investigated further.
(v) Assaying recombinants for G418r
The neo gene of pHSG272 by virtue of two 
promoters, pi and pTk, is able to confer resistance to 
kanamycin in prokaryotic cells and G418 in eukaryotic 
cells. Although the neo gene in C2XB is structurally 
the same as that of pHSG272, the promoter is only 
functional in prokaryotic cells and does not confer 
resistance to G418 in mammalian cells. NIH 3T3 mouse
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fibroblasts were transfected with both pHSG272 and 
C2XB, and selected for resistance to G418. As predicted 
lug of pHSG272 resulted in approximately 106 resistant 
colonies (figure 5:5). A small number of resistant 
colonies were observed with C2XB transfectants, perhaps 
reflecting integration in regions of the genome capable 
of providing a suitable promoter for the neo gene 
(figure 5:5). The recombinant clones 19,49,51 were 
assayed for transformation of NIH 3T3 mouse fibroblasts 
to G418r. The clones 49 and 51 resulted in numbers of 
colonies intermediate in frequency between C2XB and 
pHSG272. The number of copies of the neo gene in lug of 
cosmid DNA is approximately l/10th of that in lug of 
pHSG272, given the increased size of a typical cosmid 
(40-50kb) compared to the 3.4 kb of pHSG272. Thus 
transfection of cosmid with a single functional neo 
gene would be expected to result in a reduction of the 
number of G418r resistant colonies compared to pHSG272.
Linkage between G418r and transformation was 
demonstrated by the co-segregation of these two 
phenotypes in another round of transfection. As the 
tagging strategy initially links each neo gene with 40 
kb of genomic DNA, then in transfectants with a single 
copy of the neo gene the transforming sequence should 
be within 40 kb of either side. To determine whether 
these cosmids were capable of morphological 
transformation, the G418r colonies were assayed for 
growth in soft agar. However no anchorage independent
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Figure 5:5 G418 resistant colony forming ability of pHSG272, 
C2XB and recombinant cosmids. NIH 3T3 cells were transfected 
with either pHSG272, C2XB or recombinant cosmids 37 and 49 
and assayed for resistance to G418. pHSG272 results in many 
G418r colonies and C2XB in only a few. Both recobinants gave 
an intermediate number of resistant colonies.
growth was observed in transfectants of either cosmid.
(vi) Further characterisation of recombinants
Recombinants obtained from a C2XB library would 
be expected to have a similar structure; the genomic 
DNA insert would be 35-50 kb in size, bounded by the 
BamHI site of C2XB on either side, and the vector 
sequences containing the Ampr would be 5.1 kb. The 
position of the integrated neo gene could be anywhere 
within the cloned fragment.
To investigate the relative positions of the 
Ampr and Kmr genes in the cosmid clones, a subcloning 
proceedure was used to isolate those sequences flanking 
C2XB. Cosmid DNA was digested with BamHI or EcoRI, then 
ligated under conditions favouring circularisation. 
Equivalent amounts of transformed LE392 cells were then 
plated out on either L-agar/Ampicillin or 
L-agar/Kanamycin, and incubated at 37°C overnight. A 
higher frequency of transformation was observed when 
plated out on L-agar/Ampicillin compared with 
L-agar/Kanamycin. This probably reflects the reported 
greater instability of Km transformants. Ampicillin 
resistant colonies were then replated on both 
ampicillin and kanamycin plates.
All Bam HI subclones were both Ampr and 
Kmr, placing the two drug resistance genes in proximity 
to each other in all the cosmid clones. By comparison 
of the restriction maps of the subclones, it was
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possible to determine a simple restriction map of the 
the vector sequences and flanking regions (figure 
5:6). All the cosmid subclones displayed similar
restriction patterns.
(vii) Hybridisation with flanking probes
If the rescued cosmid represented the
integrated neo gene and flanking sequences, then a
probe adjacent to the neo gene would be expected to 
hybridise to the same restriction fragments as the neo 
gene in the transfectants. Hindlll fragments flanking 
the vector sequences (figure 5:6, probe A and B) were 
isolated from the subclone of cosmid 51, and hybridised 
to Sstl-digested transfectant DNA (figure 5:7). Probe I 
and the neo gene from pHSG272 detected different 
fragments. The conclusion was that these clones 
represented a group of cosmid in which a more complex 
set of recombinations had resulted in the retention of 
the Kmr gene from C2XB.
(viii) Plasmid Rescue
An attempt was made to plasmid rescue (Hanahan 
et al., 1980, Perucho et al. 1980, Anderson et al. 
1982) the integrated pHSG72 and flanking seuences. The 
integrated pHSG272 is contained within an 8kb SstI 
fragment in the secondary transfectants (figure 5:7; 
pHSG272 contains no recognition sites for SstI). 50ug 
of genomic DNA was digested with SstI, precipitated and
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Figure 5:6 Restriction map of cosmid 49/51.
Subclones of cosmid 49/51 (BamHI or EcoRI) were generated 
which relied on the ori sequence present in the C2XB vector 
sequences for replication, and then tested for resistance to 
ampicillin (Ampr) and kanamycin (Kmr). The sequences 
encoding Ampr and Kmr were found to reside on the same BamHI 
and adjacent EcoRI fragments respectively. This suggests 
that this clone was generated as a consequence of retention 
of the Kmr sequence from C2XB.
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Figure 5:7 Comparison of hybridisation profiles of 
recombinant derived probe and pHSG272 in transfectants. DNA 
samples (20ug) were digested with SstI and analysed by 
Southern hybridisation with a probe (probe A) from the 
recombinant cosmid 49 (panel A) and pHSG272 (panel B). Lane 
a-c, tagged secondary transfectants (NKI4-2-4/272-T1-A6, -
A7, -A9) ; lane d, NIH 3T3. DNA marker fragment sizes are
indicated in kilobases (Kb). The recombinant specific probe 
is not linked to the integrated pHSG272 in the tagged 
transfectants.
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resuspended, then ligated under conditions favouring 
circularisation. Competent HB101 cells were then 
transformed with the ligation mixture and plated on 
L-agar/Km, but no resistant colonies were found after 
overnight incubation.
(ix) Construction of a cosmid library in the vector 
pJB8
As described previously, the background 
frequency of Kmr clones in a C2XB cosmid library was 
too high to successfully identify a recombinant with 
the genomically integrated pHSG272 sequences. Therefore 
a vector was required which would not produce a 
background of Kmr clones, a property of the cosmid 
pJB8 (Ish-Horowicz and Burke, 1981). This cosmid has 
the advantage over more recently developed vectors such 
as loristB and C2XB, in that the only resistance marker 
was that for Ampr. This was advantageous, in that the 
efficiency of cloning could be estimated by plating on 
L-agar/Ampicillin; also if expression of Kmr was 
delayed following transformation, then the whole 
library could initially be plated on L-agar/Ampicillin. 
Kmr recombinants could be detected by replating on to 
L-agar/Kanamycin.
A library was thus constructed in pJB8, 
(materials and methods) with insert DNA prepared 
previously. A total of 4 x 105 recombinants were 
generated, plated on L-agar /Amp and incubated
156
overnight at 37°C. L-broth with 15% glycerol was added 
to each plate and resistant colonies were scraped off. 
Aliquots were plated onto L-agar/Km and incubated 
overnight at 37°C, but no Kmr colonies were found.
The observed neo positive EcoRI fragment in the 
three transfectants (figure 5:3) was larger than 
expected, as a result of the loss of one of the EcoRI 
sites in pHSG272. One of the EcoRI sites is close to 
the pi promoter responsible for expression of Km 
resistance in bacterial cells. It is conceivable that 
both the promoter and the EcoRI site were lost 
together, providing an explanation for the inability to 
rescue functional Kmr. The pJB8 cosmid library was 
replated on nylon membranes and replica filters were 
produced. These were then hybridised with the neo probe 
from pHSG272 at high stringency. 6 x 105 colonies were 
screened with this probe without success.
(x) Rearrangement of the integrated pHSG272 in 
transfectants
Rearrangement of the transfected pHSG272 is 
observed in the primary tumours, as demonstrated by the 
multiple hybridising bands (figure 5:3), a phenomenon 
reported for pHSG272 (Brady et al. 1985), and other 
transfected sequences (Perucho et al. 1980). Secondary 
transformants contained one major neo positive EcoRI 
fragment in addition to a number of minor bands (figure
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5:3); this 18 kb fragment is conserved in two of three 
tertiary transformants. The expected size of the neo 
positive EcoRI fragment is 2.9kb (figure 5:2); the size 
discrepancy could be due to the loss of one of the 
EcoRI sites in the integrated pHSG272. The seeming loss 
of a functional Kmr in bacteria, without a 
corresponding loss of G418r suggested deletion of the 
region of pHSG272 containing the pi promoter and 
adjacent EcoRI site. To determine the extent of the 
rearrangement, HMW DNA from the secondary and tertiary 
transfectants was digested with Bglll/EcoRI and 
Hindlll/EcoRI, and analysed by Southern blotting for 
the neo gene (figures 5:8 and 5:9). From the comparison 
of the expected fragments with the observed fragments, 
it could only be concluded that substantial 
rearrangement of the vector sequences had occurred in 
the transfectants, thus reducing the feasibility of 
successfully isolating the neo gene and flanking 
transforming sequences by the strategy of cosmid 
rescue.
(xi) Lambda cloning of integrated neo gene
Despite the inability to clone the integrated 
pHSG272 and flanking regions by cosmid rescue, cloning 
was still possible by conventional lambda cloning 
techniques. A random Sau 3A partial library of the 
transfectant NKI4-2-4-T1/272-A9 was hybridised with the
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Figure 5:8 Rearrangement of pHSG272 in transfectants. DNA 
samples (20ug) were digested with Bglll/Hindlll, and 
analysed by Southern blotting and hybridisation with
pHSG272 . Lane a,i lkb DNA ladder (BRL) ; lane b-d,
secondary tagged transfectants (NKI4-2-4/272-T1-A6, -Al, -
A9) ; lane e-g, tertiary tagged transfectants (NKI4-2-4/272- 
T1-A9-A7, -A8, -A9) ; lane h, NIH 3T3; lane j, pHSG272. DNA
marker fragment sizes are indicated in kilobases (Kb).
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Figure 5:9 Rearrangement of pHSG272 in transfectants. DNA 
samples (20ug) were digested with Hindlll/EcoRI, and 
analysed by Southern blotting and hybridisation with 
pHSG272 . Lane a,i, lkb DNA ladder (BRL) ; lane b-d, 
secondary tagged transfectants (NKI4-2-4/272-T1-A6, -A7, -
A9) ; lane e-g, tertiary tagged transfectants (NKI4-2-4/272- 
T1-A9-A7, —A8, -A9) ; lane h, NIH 3T3; lane j, pHSG272. DNA 
marker fragment sizes are indicated in kilobases (Kb).
b c d e f g h i J
12
8
6
5
2
1.5 a
neo gene from pHSG272. 600,000 phage were screened, but 
no positive signals were observed. Given the difficulty 
in cloning the integrated neo gene and flanking 
sequences by a random cloning procedure;, the 
alternative approach was to enrich for DNA restriction 
fragments containing the sequence of interest, prior to 
generating a genomic library. The neo positive EcoRI 
fragment observed in the transfectants was suitable for 
lambda cloning (figure 5:3).
HMW DNA from the two transfectants 
NKI4-2-4-T1-A6 and A9 was digested with EcoRI, and size 
fractionated by sucrose; gradient centrifugation. 
Aliquots of individual fractions were electrophoresed 
on 0.8% agarose gels, Southern blotted and hybridised 
with the neo probe from pHSG272. Positive fractions 
were pooled and two libraries, corresponding to either 
transfectant were constructed in the lambda vector 
EMBL4. 200,000 recombinants from each library were 
plated, utilising as a host cell NM538 and screened 
with the neo containing PvuII/Smal fragment of pHSG272. 
No positives were observed so more clones were 
screened. A total of 6 x 105 recombinants of each 
library were screened without success. The presence of 
the sequence of interest in the digested genomic 
fractions used had been confirmed by hybridisation, and 
the library was non-random, with a bias to EcoRI 
fragments of approximately 18 kb. In such a library, a 
single copy gene would usually be represented 1-5
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copies per 105 recombinants. The lambda vector EMBL4 
offers the facility to select for recombinants by 
plating in a non-permissive strain. The growth of 
vector molecules is restricted in NM539 due to the 
presence of the prophage P2, hence Spi+ (sensitive to 
P2 interference). Recombinants however lack two genes 
involved in recombination (red and gam) and are able to 
grow in NM539 (Spi-), (Maniatis et al. 1982). The titre 
of recombinants was estimated by serial dilution and 
plating, and 200,000 recombinants from each library 
were plated out on NM539. Duplicate filters were 
screened with the neo probe at high stringency; two 
positive signals were detected in the library from 
NKI4-2-4-T1-A6, but none in the NKI4-2-4-T1-A9 library. 
The two positive clones were picked and the one with 
the stronger hybridisation signal was plaque purified.
(xii) Characterisation of neo positive clone
DNA was prepared from the purified clone, and 
digested with EcoRI. The EcoRI fragment was 
approximately 18 kb, as predicted from hybridisation to 
genomic DNA, and hybridised to the neo probe. The clone 
was digested with a number of restriction enzymes, and 
Southern blots were hybridised with neo, NIH 3T3 and 
human placental DNA probes. The neo positive region of 
the clone was localised to the 3' end of the insert 
and a preliminary map was determined of this region
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(figure 5:10). The clone was positive for the presence 
of mouse sequences, but no hybridisation was observed 
with human placental DNA. The clone would not be 
expected to contain Alu repetitive sequences, (ii); 
nonetheless if a human gene was present it would be 
expected to contain at least a small amount of lower 
frequency repetitive sequences, detectable with total 
human DNA. Therefore the lack of hybridisation argued 
against a human gene present in the clone.
(xiii) Derivation of specific probes
As no human sequences could be detected, the 
possibility arose that a mouse gene had been activated 
at some point in the transfection procedure- If this 
were the case then rearrangements of the locus would be 
expected in previous transfectants. Attempts to detect 
specific sequences with the whole EcoRI fragment were 
unsuccessful due to the proportion of repetitive 
sequences in the clone. Specific probes free of 
repetitive sequences were required to address this 
question, as well as confirming that the correct 
sequence had been cloned. Three candidate probes were 
suggested from the results of digestion with SstI and 
hybridisation with NIH 3T3 DNA. Probes I,II and III 
were 1.8 kb, 1.6 kb and 1.4 kb respectively, and were 
hybridised in turn to EcoRI and SstI digested DNA from 
the tagged transfectants and NIH 3T3 cells. Also 
included were Sst I digests of one of the tumours
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Figure 5:10 Restriction map of lambda NK/272
Three SstI fragments were isolated from this clone for use as 
hybridisation probes (Probes I, II and III).
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Figure 5:11 Hybridisation of probes derived from lambda 
NK/2 72 onto tagged transfectants. DNA samples (2 0ug) were 
digested with SstI, and analysed by Southern blotting and 
hybridisation with probes I, II and III from lambda NK/272. 
Lane a-c, secondary tagged transfectants (NKI4-2-4/272-T1- 
A6, -A7, -A9) ; lane d, NIH 3T3. DNA marker fragment sizes
are indicated in kilobases (Kb).
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generated by cotransfection of NKI4 and pHSG272 DNA 
(Chapter 3, section xvii), the secondary transfectant 
NKI4-2-4 and equivalent anchorage independant clone 
NKI4-2-4-4A. All three probes hybridised to the neo 
positive EcoRI fragment in the transfectants (figures 
5:12, 5:13 and 5:14), and an Sst I fragment of expected 
size in all transfectants and NIH 3T3 cells. These 
probes should also hybridise to an additional 
endogenous mouse Eco RI fragment, given that one of the 
Eco RI restriction sites defining the fragment cloned 
would be contributed by the integrated vector 
sequences. Unexpectedly each of the three probes 
hybridised to different endogenous mouse Eco RI 
fragments (figures 5:12, 5:13 and 5:14). The probes 
respectively identify Eco RI fragments in both the 
transfectants and NIH 3T3 cells as follows; I: 7.0 kb, 
II: 20 kb, and III: three fragments of 10 kb, 4.0 kb,
and 2.2 kb. Thus during the process of serial 
transfection and integration, at least three unrelated 
genomic regions have been juxtaposed and retained 
flanking the selectable marker. Because of this it is 
unlikely that any of these fragments correspond to the 
transforming gene. That this is not an artifact of the 
cloning proceedure is demonstrated by the observation 
that all three probes detect the same neo positive 
EcoRI fragment in the tagged transfectants.
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Figure 5:12 Hybridisation of NK/272 probe I. DNA samples 
(2 0ug) were digested with SstI (lanes a-h) or EcoRI (lanes 
i-k), electrophoresed in 0.8% agarose, transfered to a nylon 
membrane, and hybridised with NK/272 probe I. Lane a, NKI4 
primary nude mice tumour: Lane b, NKI4 secondary focus
(NKI4-2-4): lane c, secondary tagged NKI4-2-4 transfectant
(NKI4-2-4/272-T1-A9): lane d, secondary tagged NKI4-2-4
transfectant (NKI4-2-4/272-T1-A6): lane e, tertiary NKI4
transfectant (NKI4-2-4-9A-7): lane f, tertiary NKI4
transfectant (NKI4-2-4-9A-8): lane g, anchorage independent 
clone of NKI4 secondary transfectant (NKI4-2-4-4A): lane h, 
NIH 3T3: lane i, secondary tagged NKI4-2-4 transfectant
(NKI4-2-4/272-T1-A9): lane j, secondary tagged NKI4-2-4
transfectant (NKI4-2-4/272-T1-A6): lane k, NIH 3T3. DNA
marker fragment sizes are indicated in kilobases (Kb).
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Figure 5:13 Hybridisation of NK/272 probe II. DNA samples 
(2 0ug) were digested with SstI (lanes a-h) or EcoRI (lanes 
i-k), electrophoresed in 0.8% agarose, transfered to a nylon 
membrane, and hybridised with NK/272 probe II. Lane a, NKI4 
primary nude mice tumour: Lane b, NKI4 secondary focus
(NKI4-2-4): lane c, secondary tagged NKI4-2-4 transfectant
(NKI4-2-4/272-T1-A9): lane d, secondary tagged NKI4-2-4
transfectant (NKI4-2-4/272-T1-A6): lane e, tertiary NKI4
transfectant (NKI4-2-4-9A-7): lane f, tertiary NKI4
transfectant (NKI4-2-4-9A-8): lane g, anchorage independent 
clone of NKI4 secondary transfectant (NKI4-2-4-4A): lane h, 
NIH 3T3: lane i, secondary tagged NKI4-2-4 transfectant
(NKI4-2-4/272-T1-A9): lane j, secondary tagged NKI4-2-4
transfectant (NKI4-2-4/272-T1-A6): lane k, NIH 3T3. DNA
marker fragment sizes are indicated in kilobases (Kb).
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Figure 5:14 Hybridisation of NK/272 probe III. DNA samples 
(2 0ug) were digested with SstI (lanes a-h) or EcoRI (lanes 
i-k), electrophoresed in 0.8% agarose, transfered to a nylon 
membrane, and hybridised with NK/272 probe III. Lane a, 
NKI4 primary nude mice tumour: Lane b, NKI4 secondary focus 
(NKI4-2-4): lane c, secondary tagged NKI4-2-4 transfectant
(NKI4-2-4/272-T1-A9): lane d, secondary tagged NKI4-2-4
transfectant (NKI4-2-4/272-T1-A6): lane e, tertiary NKI4
transfectant (NKI4-2-4-9A-7): lane f, tertiary NKI4
transfectant (NKI4-2-4-9A-8): lane g, anchorage independent 
clone of NKI4 secondary transfectant (NKI4-2-4-4A): lane h, 
NIH 3T3: lane i, secondary tagged NKI4-2-4 transfectant
(NKI4-2-4/272-T1-A9): lane j, secondary tagged NKI4-2-4
transfectant (NKI4-2-4/272-T1-A6): lane k, NIH 3T3. DNA
marker fragment sizes are indicated in kilobases (Kb).
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(xiv) Transfection of recombinant
NIH 3T3 cells were transfected with the clone 
and assessed for transformation in a focus forming 
assay and resistance to G418. The clone scored negative 
in the transformation assay, but was able to produce 
G418r colonies. This was unexpected on the basis of the 
preliminary restriction map which suggested that the tk 
promoter was absent. Drug resistant colonies were 
assessed for tumorigenicity in nude mice. Tumours arose 
after a long latency period equivalent to the 
background frequency of NIH 3T3 cells.
(xv) Analysis of recombinant
It was evident that rearrangement had occurred 
during the passage of these sequences through 
transfection. The genomic sequences present seemed to 
derive from at least three different genomic regions. 
As evident from hybridisation to Eco RI digested DNA 
from the tagged transfectants, there was some 
rearrangement of the integrated pHSG272. From analysis 
of the cloned fragment it was probable that both Eco RI 
sites of pHSG272 were absent from the integrated 
vector. This is because of the presence of an Sst I 
restriction site between the vector sequences and the 
Eco RI site with which this fragment was cloned 
(pHSG272 does not possess an Sst I site). To precisely 
assess the extent of the pHSG272 rearrangement, the 
clone was analysed further. The neo gene of pHSG272 is
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bounded by a Pvu II and a Sma I site (figure 5:2), loss 
of either would in all probability impair the neo 
activity. The clone was digested with PvuII and Sma I, 
either singly or in combination, Southern blotted and 
hybridised with the neo probe of pHSG272. The Pvu 
II/Sma I neo positive fragment was the same size as the 
equivalent fragment in pHSG272 (figure 5:15). This 
confirmed that the neo gene itself was unaffected. To
assess the extent of the rearrangement use was made of
the restriction enzyme Hae II. There are five 
recognition sites for the restriction enzyme Hae II in 
pHSG272, producing fragments ranging in size from 
1600bp to 450bp (figure 5:15). The recombinant clone
was digested with Hae II and the hybridisation profiles 
obtained with either the whole vector or the neo probe 
were compared with Haell digested pHSG272 (figure 
5:15). Only the neo containing Hae II fragment is
retained in the clone, the other four having been lost 
at some point during the transfection. Thus only 1.2 
kb of the vector sequences have been retained during 
the process of transfection.
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Figure 5:15 Analysis of NK/272. pHSG272 and NK/272 were 
digested with PvuII, Smal and PvuII/Smal, electrophoresed on 
2% agarose, transferred to a nylon membrane, and hybridised 
with pHSG272. Lane a, pHSG272 PvuII; lane b, NK/272 PvuII; 
lane c, pHSG272 PvuII/Smal; lane d, NK/272 PvuII/Smal; lane 
e, pHSG272 Smal; lane f, NK/272 Smal. DNA marker fragment 
sizes are indicated in kilobases (Kb). The recombinant 
NK/272 contains the Kmr gene of pHSG272, which is 
unrearranged with respect to the flanking PvuII and Smal 
sites.
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Figure 5:16 Analysis of NK/272. pHSG272 and NK/272 were 
digested with various restriction enzymes, electrophoresed 
on 2% agarose, transferred to a nylon membrane, and 
hybridised with pHSG272. Lane a, pHSG272 Haell; lane b,c, 
NK/272 Haell; lane d, NK/272 Haell/EcoRI; lane e, pHSG272 
BamHI/EcoRI/Haell; lane f, NK/272 BamHI/EcoRI/Haell. DNA 
marker fragment sizes are indicated in kilobases (Kb). Only 
one pHSG272-positive Haell fragment was detected in the 
clone NK/272.
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Section III: Discussion
Transforming activity had been detected in 
genomic DNA from the melanoma cell line NKI4; however 
the loss of linked Alu sequences prevented the 
isolation of the transforming gene by conventional 
cloning techniques (Shimizu et al. 1985: Sakamoto et
al.1986; Young et al. 1986). Thus another means of 
identification was required to clone this gene. 
Transfected sequences can become linked prior to 
integration (Perucho et al. 1980b)? but the association 
between sequences is not precise enough to enable the 
subsequent cloning of the transforming gene. Instead 
the donor DNA can be specifically linked to a 
selectable marker (tag) prior to transfection (Perucho 
et al. 1980a, Goldfarb et al. 1982). The presence of a 
gene selectable in bacteria facilitates the cloning of 
adjacent genomic regions (Perucho et al. 1980; Goldfarb 
et al. 1982). A similar technique was described by 
Robert Brown and colleagues, in which donor DNA was
tagged by a cosmid vector containing a dually
selectable neo gene, pHSG272, and transfected cells 
were assayed for G418 resistance and tumorigenicity in 
nude mice. The presence of a cos site facilitated the 
cloning of linked sequences by a strategy of cosmid
rescue (Brown et al. 1985).
Thus genomic DNA from the cell line NKI4 was 
tagged with pHSG272, and transfected onto NIH 3T3
cells. The G418 resistant colonies were not tumorigenic
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in nude mice, in contrast to the previously observed 
transforming activity of DNA from this cell line 
[Chapter 3, (i) and (x)]. This can be explained if the 
transforming gene in NKI4 is of significant size? the 
larger the gene in question the greater the liklihood 
that the partial digestion disrupts the genomic 
sequences. Thus as the gene increases in size it 
becomes proportionally underepresented in the 
transfected ligation mix. In contrast, the transforming 
activity of the secondary transfectant NKI4-2-4 was 
successfully tagged with the selectable marker. If the 
gene responsible for transformation in both the 
original sample and the transfectant is identical, then 
this result is somewhat surprising. However it is 
possible that the transforming gene may be amplified in 
the transfectant, compensating for the effect of the 
size of the gene; also tumours only formed in 2/8 sites 
of injection unlike the frequency of 100% with EJ or 
following cotransfection of NKI4 DNA.
The linkage between the two phenotypes of 
transformation and G418r was sufficiently tight to 
enable their concomitant transfer through three rounds 
of serial transfection. Although initially selecting 
for transformation by tumour induction in nude mice, 
the low copy number of the neo gene in the primary 
mouse tumours enabled subsequent selection for growth 
in soft agar. It has not been demonstrated before that 
the G418r colonies from either a cotransfection or
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tagging procedure can be assessed for transformation 
by selecting for anchorage independent growth? previous 
studies have only assessed for tumorigenicity in nude 
mice (Fasano et al. 1984? Brown et al. 1984). Although 
lacking in sensitivity for the first round of 
transfection following tagging, once transforming 
activity has been demonstrated for a sample by the 
tumourigenicity assay, growth in soft agar provides a 
viable alternative for subsequent rounds of selection.
The cosmid vector pHSG272 was chosen as the 
"tag" because of the reported ease of isolation of the 
integrated sequences and flanking regions (Brown et 
al.1984). In the previous use of this vector a 
transforming NRAS gene was identified by means of a 
cosmid rescue strategy. Five out of five rescuants 
obtained following directed packaging were able to 
induce transformation of NIH3T3 cells (Brown et al. 
1984) . Attempts to rescue the Kmr from NKI4 
transfectants either by directed packaging or 
conventional cosmid rescue were unsucessful. The 
quality of the genomic DNA is critical in the 
generation of cosmid libraries; broken molecules 
compete in the ligation reaction making a successful 
library impossible (P. Little, personal communication). 
The disadvantage of the use of a vector lacking a 
selectable marker, such as pHSG250, is the inability to 
assess the efficiency of the generation of packageable 
molecules in the ligation. Thus the lack of rescuants
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could reflect the quality of the DNA or alternatively 
disruption of the vector sequences by rearrangement 
such that cosmid rescue was not possible. By analysis 
of transfectant DNA it was noted that rearrangement of 
the vector sequences had occurred, involving at least 
the deletion of one of the Eco RI sites.
A library was successfully constructed in the 
cosmid vector C2XB, which contained two selectable 
markers, Ampr and Kmr, of which the latter is 
eliminated during the packaging reaction (Bates and 
Swift, 1983). A total of 41 Kmr cosmids were 
identified, the majority of which represented 
recombinants that had retained the intact vector. No 
Kmr resistant cosmids have been detected in libraries 
constructed in this vector as described previously 
(Bates and Swift, 1983). Those Kmr cosmids which 
differed in the organisation of their vector sequences 
were analysed further. None of these clones was able 
to transform NIH 3T3 cells as judged by the focus 
formation assay. Also in all these clones, the Kmr gene 
was in close proximity to the Ampr gene and other 
vector sequences. A detailed map of two identical 
cosmids in the vicinity of the vector sequences enabled 
the isolation of two probes specific for either side of 
the vector. However neither probe hybridised to the neo 
positive fragment in transfectants, and these cosmids 
were considered to have arisen by recombination events 
involving the Kmr gene of C2XB. Confirmation of this
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was provided by the analysis of library constructed in 
the cosmid vector pJB8 (Ish-Horowitz and Burke,1981) 
which lacks the gene for Kmr . No functionally Kmr 
cosmids were identified, nor could any neo containing 
clones be detected by hybridisation. The difficulty in 
cloning the integrated neo gene was further 
demonstrated by the inability to identify a positive 
clone in a partial lambda library of the transfectant.
The integrated neo gene and flanking genomic 
sequences was eventually isolated by constructing a 
lambda library from size fractionated EcoRI digested 
DNA, and then only when recombinants were preselected 
by growth in the appropriate host strain (NM539). The 
difficulty in cloning this fragment is surprising: 
there have been suggestions that some sequences may be 
relatively ~unclonable~ , however there is little 
direct evidence for this.
Analysis of the clone localised the pHSG272 
sequences to the 3' of the Eco RI fragment; however 
these sequences were heavily rearranged in comparison 
to the intact vector. Both Eco RI sites were absent; 
indeed the only portion of the vector retained in the 
clone was the neo gene itself, as defined by the 1.6 kb 
Hae II fragment. This includes the promoter pTK which 
is required for the generation of functional resistance 
to G418. Nonetheless the clone was capable of 
conferring G418r upon transfection of NIH 3T3 
fibroblasts, suggesting that endogenous promoter
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sequences may be in the vicinity of the neo gene. 
Further support for this hypothesis is provided by the 
observed G418r of the transfectants and the 
transmission of this phenotype in subsequent rounds of 
transfection. Several methods of identifying mammalian 
promoters (Featherstone et al. 1984) and enhancers 
(Weber et al. 1984; Hamada. 1986b) have been described, 
of which the data of Hamada bears the closest 
similarity to my own. This study described the 
activation of an enhancerless gene (gpt) by integration 
into suitable sites in the genome, the enhancer trap. 
Thus in the example reported here it is probable that 
pHSG272 has acted as a "promoter trap".
In addition to the rearrangment of the pHSG272 
sequences, the flanking genomic region was also 
substantially altered. Three probes free of repetitive 
sequences detected the expected neo positive fragment 
in tagged transfectants but hybridised to differing 
endogenous murine fragments. Thus the clone obtained is 
the result of the juxtaposition of at least three 
genomic regions, all of which are murine in origin. No 
human repetitive sequences were detected in the EcoRI 
fragment, nor was this clone capable of transforming
NIH 3T3 cells to a tumorigenic phenotype. Thus it is 
unlikely that any of these sequences are involved in
the observed transforming activity of the DNA from the 
transfectants. The tagging strategy is designed to link 
the neo gene and the transforming gene within
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approximately 40 kb of each other. Isolation of the 
transforming gene is therefore achieved by virtue of 
the tag. However the location of this gene can be 
either 5' or 3' of the tag, requiring the cloning of 
possibly 80kb of genomic DNA to obtain transforming 
sequences. Given the number of rearrangements in the 
clone isolated it is probable that the transforming 
gene resides on the other side of the integrated 
pHSG272. Furthermore the presence of at least three 
different genomic regions in this clone, suggests that 
this defines the boundary of the transforming unit. 
Each region represents the site of integration of the 
transforming unit upon transfection. This is 
illustrated in figure 5: 17. An Sst I site defines the 
3' extent of the integrated neo gene, and from analysis 
of the restriction map it is possible that an Sst I/Eco 
RI fragment may be of use in the isolation of those 
sequences 3' to the neo gene, and thus ultimately the 
transforming gene by "walking" procedures.
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Figure 5:17 The acquisition of multiple flanking sequences 
during tagging and transfection.
Partially digested genomic DNA was ligated to pHSG272, prior 
to transfection, linking the G418 resistance (NEO) to the 
transforming sequence (ONC) and mouse genomic sequences 
(MI) . This then integrated in the mouse genome (Mil) . DNA 
from the resulting nude mouse tumour was transfected, and 
the linked NEO and' ONC sequences integrated in the mouse 
genome (Mill) . As a consequence the cloned NEO gene was 
flanked by three independant sections of mouse DNA.
GENOMIC DNA pHSG272
NEO
ONC LIGATION
CONCATAMER
Ml . NEO ONC NEO
*
TRANSFECTION/INTEGRATION
Mil Ml
NEO ONC
TRANSFECTION/INTEGRATION
Mill
Mil Ml
NEO
CLONING
LAMBDA NK/272
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Chapter z_ RAS activation in human malignant 
melanoma
Chapter 6s RAS activation in human malignant melanoma 
Section I: Introduction.
(i) RAS genes
Activation of members of the RAS oncogene family 
is the most frequent genetic lesion in human 
malignancies (Bos, 1988), although RAS mutations have 
only been occasionally described in human melanoma. It 
was therefore of interest to assess the frequency of 
RAS mutations in human melanoma cell lines and tumour 
biopsies.
The first reports of RAS gene activation in a 
human tumour was HRAS codon 12 mutations in human 
bladder carcinoma cell lines (Krontiris and Cooper, 
1981? Perucho et al. 1981; Shih et al. 1981; Der et al.
1982) . However, further investigations indicated that 
these three cell lines and some other bladder cell 
lines were identical, and probably derived from T24 by 
cross contamination (O'Toole et al. 1983). The 
transforming activity in the cell lines Calu-1 and 
SK-N-SH was shown to be due to an activated cellular 
homologue of the KRAS gene of K-MSV, and the previously 
unidentified NRAS gene respectively. Thus the RAS gene 
constitute a multigene family of which their are five 
members in the human genome (Ellis et al. 1981). In 
addition to the three mentioned, two members related to
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HRAS and KRAS respectively have been identified, but 
are thought to be pseudogenes lacking open reading 
frames, and therefore unable to code for functional 
proteins (McGrath et al. 1983? Miyoshi et al. 1984). 
RAS genes have been highly conserved during evolution 
and are found not only in mammalian genomes (DeFeo et 
al. 1981? Ellis et al. 1981? Parada et al. 1982? Santos 
et al. 1982? Der et al. 1982? Shimizu et al. 1983? Hall 
et al. 1983), but also in other eukaryotes (Barbacid, 
1987), including yeasts (DeFeo-Jones et al. 1983? 
Powers et al. 1984? Fukui and Kaziro, 1985). The degree 
of similarity between these RAS genes is such that 
mammalian RAS genes, under appropriate conditions can 
function in yeast cells, complementing non-viable 
rasl-, ras2- mutants (DeFeo-Jones et al. 1985? Kataoka 
et al. 1985).
Molecular clones of both the activated HRAS from 
a human bladder carcinoma (Santos et al. 1982? Chang et 
al. 1982) and the corresponding normal gene have been 
isolated (Goldfarb et al. 1982? Shih and Weinberg, 
1982? Pulciani et al. 1982) and the nucleotide sequence 
determined (Capon et al. 1983? Reddy, 1983). Plasmid 
constructs of the normal and activated HRAS under the 
control of the SV40 promoter were assayed for 
transformation of Rat-1 fibroblasts? only the T24 HRAS 
clone exhibited transforming activity (Capon et al. 
1983). Thus the oncogenic property of T24 HRAS is due 
to a qualititative not quantitive difference.
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Comparison of the sequences of the oncogene and the 
normal homologue revealed several nucleotide 
differences in the first exon, and first and third 
introns (Capon et al. 1983? Reddy, 1983). By 
constructing hybrids of the normal and T24 HRAS, the 
functional difference was localised to the first coding 
exon and hence the G-T transversion at codon 12 (Capon 
et al. 1983). This mutation results in the substitution 
of valine for glycine (the normal amino acid at 
position 12); the viral HRAS gene of Ha-MSV contains 
\ a mutation at the same codon
Early transfection studies utilised tumour cell 
lines to assay for transformation with the caveat that 
such cells had been maintained in culture for many 
years. As such it was necessary to exclude the 
possibility of the generation of artifacts during 
tissue culture. Transforming activity has now been 
demonstrated in DNA prepared from patient biopsies 
(McCoy et al. 1983; Murray et al. 1983; Feig et al. 
1984? Santos et al. 1984). The activated HRAS in the 
lung carcinoma cell line HS242 was analysed by 
constructing chimaeric molecules (Yuasa et al. 1983)? 
here the alteration was not at codon 12 but instead at 
codon 61. There are scattered reports of activating 
mutations at positions 59 (Dhar et al. 1982? Tsuchida 
et al. 1982), 63 (Fasano et al. 1984), 116 (Walter et 
al. 1986), 117 (Reynolds et al. 1987) and 119 (Sigal et 
al. 1986a) . A systematic analysis of all possible
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amino acid changes at position 12 of HRAS has indicated 
that replacement of the normal glycine by any amino 
acid apart from proline results in a transforming 
protein (Seeburg et al. 1984). Furthermore, an inframe 
deletion of the amino acid at position 12 has the same 
effect (Der et al. 1986). Analogous results have been 
obtained for position 61 (Chipperfield et al. 1985).
(ii) RAS gene mutations in human malignancies.
RAS genes have been identified as the 
transforming agent in the majority of reports of human 
tumours and tumour cell lines registering in the NIH 
3T3 transfection assay. The frequency of RAS activation 
in human malignancies ranges from 5-40% (Bos, 1988), 
with many tumours possessing a complement of RAS 
mutations. A full list is given in table 6:1. Only in 
primary oesphageal cancers have RAS mutations been 
undetected (Hollstein et al. 1988). Despite the initial 
detection of a mutated HRAS gene in bladder carcinoma 
cell lines, subsequent studies have suggested that HRAS 
codon 12 mutations are infrequent in human cancers 
(Feinberg et al. 1983), except for bladder carcinomas 
(Fujita et al. 1985). KRAS activation predominates in 
the majority of solid tumours, notably colon (McCoy et 
al. 1984) and lung carcinomas (Pulciani et al. 1982; 
Yuasa et al. 1983) whereas in haemopoietic neoplasms, 
NRAS is preferentially activated, paricularly in AML
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(Bos et al. 1985; Bos et al. 1987; Needleman et al. 
1986) and MDS (Padua et al. 1988). Early studies relied 
on DNA-mediated gene transfer assays to detect 
activated RAS genes; the limitations of transfection 
are the requirement for significant quantities of DNA, 
thus eliminating many small malignant lesions from 
study. Both the isolation of genomic DNA and the 
process of transfection induce shearing. This is not a 
problem with genes such as HRAS which are contained 
within 4 kb of genomic DNA (Santos et al. 1982; 
Taparowsky et al. 1982); however as the genomic size of 
a gene increases it is less likely to be transfected 
intact. For example the KRAS locus is thought to 
encompass greater than 40 kb of genomic DNA (Shimizu et 
al. 1983b,c). Increasingly sophisticated methods have 
been devised to detect RAS gene mutations in tumour 
DNA, since the localisation of the vast majority of 
activating mutations in and around codons 12 and 61. 
Within codon 12 of human HRAS is the recognition site 
for the restriction enzymes Mspl/Hpall (Feinberg et al.
1983) ; digestion of normal DNA yields fragments of 
355bp and 57bp, whereas mutations at codon 12 abolish 
this site, resulting in a 412bp fragment. Feinberg et 
al. (1983) failed to detect HRAS 12 mutations in a 
number of human cancers with this method; but mutations 
have been demonstrated in a human bladder cancer 
(Fujita et al. 1985) and in the mammary carcinoma cells 
and not normal mammary cells of a patient (Kraus et al.
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Table 6:1
RAS GENE ACTIVATION IN HUMAN MALIGNANCIES
SOLID TUMOURS
RAS Source No of +ves/ References Detection
Gene No of samples Method
Basal icell carcinoma
HRAS B 1/1 Ananthaswamy et al. 
1988
FI, NMT
Breast
HRAS B 2/24 Spandidos 1987 SSO
C SK-BR-3 Knayev et al. 1986 Al
H12/13 C HS578T Kraus et al. 1984 FI
KRAS B 1/8 Yanez et al. 1987 SSO
K12/13 C MDA-MB2 31 Kozma et al. 1987 NMT 
Rochlitz et al. 1989
,PCR/SSO 
PCR/SSO
C H-466B Prosperi et al.1987 FI
C PE600I Rochlitz et al. 1989 PCR/SSO
B 2/61 Rochlitz et al. 1989 PCR/SSO
Cervix
H12/13 B 8/76 Riou et al. 1988 MspI
/Hpall
Colon
H12/13 C CC20 Greenhalgh and
Kinsella, 1985
KRAS C A2233 Pulciani et al. 1982b FI
C Duke-2 McCoy et al. 1983
B 2/2 Pulciani et al. 1982b FI
B 5/30 Forrester et al. 1987 FI
B 4/16 Yanez et al. 1987 SSO
B 38/92 Vogelstein et al. 1988 PCR/SSO
K12/13 C SW480 McCoy et al. 1983. FI
C SK-CO-1 Shimizu et al. 1983b FI
C SW620 Bos et al. 1986 FI,SSO
C SW1116 Bos et al. 1986 FI,SSO
C SW1398 Bos et al. 1986 FI,SSO
C PC/JW Farr et al. 1988b PCR/SSO
B KMS-4 Yuasa et al. 1986b FI
B 10/27 Bos et al. 1987b PCR/SSO
B 26/66 Forrester et al. 1987 RNAseMM
NRAS B 1/1 Murray et al. 1983 FI
N12/13 B 1/27 Bos et al. 1987b PCR/SSO
N61 C 7060 Yuasa et al. 1986a FI
Primary adenomas
KRAS B 24/80 Vogelstein et al. 1988 PCR/SSO
K12/13 C PC/AA Farr et al.1988b PCR/SSO
C S/AN Farr et al.1988b PCR/SSO
B 3/29 Farr et al. 1988b PCR/SSO
concurrent K12 mutations in 1 patient
Fibrosarcoma
N61 C HT1080 Hall et al.1983 FI
C SHAC
Notario et al. 1984 
Andeol et al. 1988
FI
FI,SEQ
Gall bladder
KRAS C A1069 Pulciani et al. 1982b FI
Keratoacanthoma 
H61 B 1/1 Leon et al.1988 NMT,SSO
Liver
NRAS C 7402 Gu et al. 1986
B 3/10 Gu et al. 1986
B 1 Notario et al. 1984 FI
N61 B 1/1 Takada & Koike, 1989 FI,SSO
Lung
HRAS C KNS 62 Zhan et al. 1987 DMTA
H12/13 C HS242 Yuasa et al.1983 FI
B 1/36 Rodenhuis et al. 1987 PCR/SSO
KRAS C LX-1
1988
Der et al. 1982 FI
C LC-12-JCK Fukui et al. 1985 FI
C Calu-4 Zhan et al. 1987 DMTA
B 1/5 Pulciani et al. 1982b FI
B 2/19 Stanton & Cooper, 1987 FI
B 2/27 Yanez et al. 1987 SSO
K12/13 C A2182 Pulciani et al. 1982b FI
C A427 Pulciani et al. 1982b FI
C Calu-1 Shimizu et al. 1983 FI
C SK-LU-1 Shimizu et al.1983b FI
C PR371 Nakano et al.1984 FI
C Lu-65 # Taya et al.1984 FI
C A549 Valenzuela & SSO
C A427 Groffen, 1986 SSO
C Lu-65 Taya et al. 1984 FI
B 1/1 Santos et al. 1984 FI
B 9/36 Rodenhuis et al. 1987 FI
K61 C PR310
1988
Nakano et al.1984 FI
C QG56 Kagimoto et al. 1986 ??
NRAS B 1 Notario et al. 1984 FI
B 1/30 Forrester et al. 1987 FI
B 5/92 Vogelstein et al. 1988 PCR/SSO
N61 C SW1271 Yuasa et al. 1986a FI
Primary adenomas
B 1/80 Vogelstein et al. 1988 PCR/SSO
Melanoma
HRAS C SK-MEL-146 Albino et al. 1984 FI
H61 C SK2 Sekiya et al. 1984 FI
NRAS C SK-MEL-93 Albino et al. 1984 FI
C SK-MEL-119 Albino et al. 1984 FI
C SK-MEL-147 Albino et al. 1984 FI
N61 C MEL SWIFT Padua et al. 1985 FI
B 1/13 Raybaud et al.1988 NMT
B 1/1 Keijzer et al.1989* NMT,SSO
* tumour isolated from XP patient
Neuroblastoma
HRAS C LA-N-1
N61 C SK-N-SH
Oesophageal
B 0/25
Osteosarcoma 
KRAS C OHA
Knayev et al. 1986 Al
Shimizu et al. 1983a,b FI
Hollstein PCR/SSO
et al.1988
Nardeux et al. 1987 FI
Ovarian
KRAS
K12/13
B
C
B
1/5
OVCA1
0/37
Feig et al. 1984 FI
Bos et al. 1986b
van't Veer et al. 1988 PCR/SSO
Pancreas
KRAS
K12/13
K61
B
C
C
B
B
C
1/2
Panel
A1165
21/22
28/30
T3M-4
Pulciani et al. 1982b FI
Malone et al. 1985 NMT
Valenzuela & Groffen SSO
1986
Almoguerra et al. 1988 PCR,RNA
Smit et al. 1988 PCR/SSO
Hirai et al. 1985a FI
Prostate
KRAS B 1/8
Renal carcinomas 
H12/13 B 1/16
H61 B 1/16
Rhabdomyosarcoma 
KRAS B 1/2
N61 C RD301
Seminoma
KRAS B 1/1 case
Squamous cell carcinoma 
HRAS B 3/7
H12/13
N61
B
B
2/2
(Oral SCC) 
2/7
Peehl et al. 1987 FI
Fujita et al. 1988 FI
Fujita et al. 1988 FI
Pulciani et al. 1982b FI
Hall et al. 1983 FI
Chardin et al. 1985
Stanton & Cooper, 1987 FI
Ananthaswamy et al. 
1988
Tadokaro et al.1989 
Suarez et al.1989*
FI,NMT 
NMT 
FI,PCR/SSO
* N61 mutation in two independant SCC's from a single XP p
Stomach
H12/13 C BGC-823 Deng et al. 1987
C PACM-82 Deng, 1988
FI
PCR/RFL
C MGC80-3 Deng, 1988 PCR/RFL
B 5/18 Deng, 1988 PCR/RFL
K12/13 B 1/1 Bos et al. 1986 FI,SSO
NRAS B 1/1 Nishida et al. 1987a NMT,SSO
N61 B 1/1 O'Hara et al. 1986 NMT
Teratocarcinoma
N12/13 C PA-1 Tainsky et al. 1984 FI
Thyroid
HRAS B 1/1
B 1/6
inc
KRAS B 2/6
(inc
NRAS B 1/6
(inc
Follicular
H12/13 B 1/15
H61 B 4/15
K12/13 B 1/15
N61 B 2/15
Suarez et al. 1987 
Suarez et al. 1988 
.lary cancers 
Suarez et al. 1988 
.icular ca, 1/1 ana] 
Suarez et al. 1988
FI
FI
FI 
.c < 
FI
Lemoine et al.1988,1989 NMT,PCR 
Lemoine et al.1988,1989 /SSO 
Lemoine et al.1988,1989 
Lemoine et al.1988,1989
Undifferentiated carcinomas 
H12/13 B 2/10
H61 B 1/10
K12/13 B 2/19
N12/13 B 1/10
Lemoine et al.1988,1989 NMT,PCR 
Lemoine et al.1988,1989 /SSO 
Lemoine et al.1988,1989 
Lemoine et al.1988,1989
Primary adenomas 
Microfollicular
H12/13 B 1/16 Lemoine et al.1988,1989 NMT,PCR
H61 B 2/16 Lemoine et al.1988,1989 /SSO
K12/13 B 1/16 Lemoine et al.1988,1989
N12/13 B 1/16 Lemoine et al.1988,1989
N61 B 3/16 Lemoine et al.1988,1989
Macrofollicular
B 0/8 Lemoine et al.1988,1989 NMT,PCR
\SSO
Urinary tract
HRAS C WEB Marshall, 1985
B 1/15 Malone et al. 1985
H12/13 C EJ/T24 Krontiris and Cooper, 1981 FI
Shih et al. 1981 FI
Perucho et al. 1981 FI
Pulciani et al. 1982a FI
Der et al. 1982 FI
Parada et al. 1982 FI
Santos et al. 1982 FI
B 4/23 Visvanath and
Summerhayes 1986 FI
B 1/38 Fujita et al. 1985 FI/RFL]
B 1/7 Fujita et al. 1987 WB
H12/13 B 4/24 Visvanathan NMT,PCR
et al. 1988
H61 B 2/38 Fujita et al. 1985 FI/RFLP
KRAS C 639 V Zhan et al. 1987. DMTA
K12/13 C A1698 Pulciani et al. 1982b FI
K12/13 C A1663 Valenzuelas Groffen,1986, SSO
N61 C HT1197 Bos et al. 1986 FI,SSO
HAEMOPOIETIC TUMOURS
ALL
NRAS C RPMI 8402 Souyri & Fleissner 1983 FI
C T-ALL-1 Souyri & Fleissner 1983 FI
C p-12 Souyri & Fleissner 1983 FI
C MOLT-3 Eva et al. 1983 FI
N12/13 C MOLT-4 Eva et al. 1983 FI
B 2/19 Rodenhuis et al.1986 FI
B 1/8 Hirai et al. 1986 FI
(inc T-ALL 1/3 cases)
N12/13 B 6/33 Neri et al.1988 PCR/SSO
T-ALL 2 Nishida et al.1987b NMT ,SS0
Null-ALL 2 Nishida et al.1987b NMT. SSO
KRAS C CCRF-CEM Eva et al. 1983 FI
AML
H12/13 B 1/9 Janssen et al. 1987b NMT,SSO
K12/13 C Rc2a # Janssen et al.1987a NMT ,PCR/SSO
B 2/45 Bos et al. 1985, 1987a PCR/SSO
K61 B 1/2 * Janssen et al. 1987a NMT,PCR/S
# concurrent N12 & K12 mutations
* concurrent N61 & K61 mutations
NRAS C PAC Murray et al.1983 FI
C 31-26-146 Eva et al.1983 FI
N12/13 C Rc2a # Janssen et al.1987a NMT ,PCR/SSO
C KG-1 Janssen et al. 1985 FI
Janssen et al. 1987b NMT,SSO
C THP-1 Janssen et al.1987b NMT,SSO
B 1/1 Gambke et al. 1984 FI
B 8/45 Bos et al.1985,1987aNMT ,PCR/SSO
B 1/3 Janssen et al. 1985 FI
B 3/6 Needleman et al.1986 FI
1988
B 1/9 Janssen et al.1987b NMT ,SSO
B 2/2 Hirai et al. 1987b NMT
B 3 $ Nishida et al. 1987b NMT,SSO
B 14/52 Farr et al. 1988 PCR/SSO
N61
B 5/18 
B 4/45
Senn et al.1988 SSO
Bos et al.1985,1987aNMT,PCR/SSO
B 3/9 Janssen et al.1987b NMT,SSO
B 1/2 * Janssen et al.1987a NMT,PCR/SSO
B 2/52 £ Farr et al. 1988 PCR/SSO
# concurrent N12 + K12 mutations
* concurrent N61 + K61 mutations
$ includes cases of Hirai et al 1987 
£ cases showed concurrent NRAS mutations (2x N12/13 
2x N12/61)
AML, Ph+.
N61 B 1/2 Rovera et al. 1989.
Secondary AML , therapy related
N12/13 B 1/9 Pedersen-Bj ergaard PCR/SSO
et al. 1988
Acute myelomonocytic leukaemia
KRAS B 1/1 Hirai et al. 1987b NMT
Acute monocytic leukaemia
NRAS B 2/3 Hirai et al.1987b NMT
Acute promyelocytic leukaemia
N61 C HL60 Murray et al.1983 FI
Burkitts lymphoma
NRAS C AW Ramos Murray et al. 1983 FI
CLL
B 0/51 Neri et al. 1988 PCR/SSO
CML
Chronic phase
H12/13 B 1/6 Liu et al. 1988 NMT
B 0/29 LeMaistre et al. PCR/SSO
1989 *
B 0/23 Collins et al. PCR/SEQ
1989
N61 B 4/4 Rovera et al. 1989 PCR/SEQ
Blast crisis
HRAS B 1/2 Janssen et al. 1985 FI
H12/13 B 2/6 Liu et al.1988 NMT
B 1/2 Gow et al.1988 NMT,PCR
NRAS C 1M9 Eva et al. 1983 FI
B 1/10 Hirai et al.1986 FI
N12/13 B 1/6 Liu et al.1988 NMT/SSO
K12/13 B 2/22 LeMaistre et al. PCR/SSO
1989.*
B 0/21 Collins et al. 1989 PCR/SEQ
B 0/26 Janssen et al. 1987k> PCR/SSO
* samples available from chronic phase and blast crisis
patients
Hairy cell leukaemia 
B 0/6 Neri et al.1988 PCR/SSO
Hodgkin's lymphoma
K12/13 C Co Steenvoorden PCR/SSO
et al•1988•
NRAS B 2/3 Sklar and FI
Kitchingman, 1985
B 0/25 Steenvoorden FI
et al. 1988
Non-Hodgkins lymphoma
NRAS B 1/1 Wodnar-Flipowitz NMT/SSO
et al. 1987
B 0/88 Neri et al. 1988 PCR/SSO
MDS
H12/13 B 1/50 Padua et al.19881 NMT', PCR/SSO
H61 B 1/50 Padua et al.1988-1- NMT,PCR/SSO
KRAS B 1/1 Liu et al. 1987 NMT, PCR/SSO
K12/13 B 5/50 Padua et al.1988 NMT,PCR/S
N12/13 B 3/8 Hirai et al.1987a NMT
B 1/19 Janssen et al.1987b PCR/SSO
B 11/50 Padua et al.1988-1- NMT,PCR/SSO
B 5/21 Bar-Eli et al. 1989 PCR/SEQ
N61 B 4/50 Padua et al.1988 NMT, PCR/SSO
1: concurrent mutations -N12/H61 & H12/K12 in two paitents
MPS
N12/13 B 1/19 Janssen et al.1987b PCR/SSO
Abbreviations:
B, biopsy; C, Cell line; FI, focus induction; 
NMT, nude mouse tumorigenicity assay; PCR, 
polymerase chain reaction; SSO, single strand 
oligonucleotide hybridisation; SEQ, sequencing,
1984) by virtue of this polymorphism. Similar RFLP's 
have been utilised to assess for HRAS codon 61 (Fujita 
et al. 1984) and KRAS codon 12 (Santos et al. 1984) 
mutations. Such methods are of limited use? only 2/6 
K12 mutations are informative for polymorphic analysis 
(Santos et al. 1984), Southern blot analysis is 
relatively insensitive, and the presence of a 
polymorphism only localises the activating mutation.
These problems were overcome by Bos and 
colleagues, who developed a highly specific assay for 
the detection of RAS mutations, based on 
oligonucleotide hybridisation (Bos et al. 1984), and 
have used this technique to assess the prevalence and 
identity of RAS activation in AML (Bos et al. 1987) and 
ALL (Rodenhuis et al. 1986). In this method 
mutation-specific oligonucleotides were hybridised to 
membrane bound DNA; the specificity of the technique is 
reliant on the observation that incomplete matches are 
thermodynamically less stable than complete matches. 
Thus RAS mutations can be identified in samples where 
lack of material precludes the option of transfection. 
However this technique is relatively insensitive and 
requires sizeable amounts of DNA.
The major advance in the analysis of tumour 
samples for RAS mutations has been the development of 
the polymerase chain reaction (PCR), wherein defined 
sequences can be enzymatically amplified using specific 
oligonucleotide primers flanking the region of interest
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(Saiki et al. 1985,1986,1988) This technique has many 
uses, from the detection of point mutations in such 
genes as B-globin and Factor VIII, and minimal 
residual disease in CML patients, to the detection of 
viral sequences such as HIV in AIDS patients 
(Macintyre, 1989). Of particular interest is the 
coupling of PCR to oligonucleotide hybridisation 
techniques to detect RAS mutations in many tumour 
types. The sensitivity of the technique is such that a 
RAS mutation can be detected at the level of 10% (Farr 
et al. 1988); in addition, many samples can be 
analysed simultaneously, enabling large patient cohorts 
to be studied. The frequency of RAS mutations in 
several human malignancies has been assessed including 
AML (Farr et al. 1988), myelodysplastic syndromes (MDS) 
(Padua et al. 1988), lung cancer (Rodenhuis et al.
1987), and thyroid carcinomas (Lemoine et al. 1988). 
Estimates of the frequency of RAS activation in these 
malignancies are of 30-50%. Significantly >90% of 
adenocarcinomas of the exocrine pancreas have been 
shown to possess KRAS 12 mutations (Almoguerra et al. 
1988; Smit et al. 1988).
(iii) RAS activation in animal model systems
A bias towards activation of one RAS gene at a 
particular position has been noted for some 
malignancies.These observations may reflect either the
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specific functions of the protooncogene in a particular 
tissue, or the specificity of the carcinogenic agent. A 
number of animal models for human neoplasms exist, 
wherein specific malignancies can be induced by 
carcinogenic agents, either chemical or UV and X-ray 
irradiation. Those chosen frequently display good 
correlation between mutagenic activity and potency as 
carcinogens. RAS oncogenes have been found to be 
reproducibly activated in several carcinogen -induced 
animal model systems (Barbacid. 1987). Induction of 
mammary carcinomas in female rats by a single dose of 
NMU prior to sexual development, leads to the 
activation of HRAS in 86% of tumours (Sukumar et al. 
1983; Zarbl et al. 1985). If DMBA is substituted for 
NMU, then HRAS activation is still observed, but in 
only 25% of tumours (Zarbl et al. 1985). In thyroid 
carcinogensis RAS activation is agent specific; HRAS is 
activated in 87% of NMU-induced tumours, whereas KRAS 
is activated in 60% of radiation-induced tumours 
(Lemoine et al. 1989). RAS activation has been 
investigated in rodent skin carcinogenesis models, 
wherein malignant development is initiated by DMBA or 
DBACR treatment, followed by promotion with TPA. In 
these cases HRAS activation has been demonstrated in 
90% of skin papillomas and carcinomas (Balmain and 
Pragnell, 1983; Quintanilla et al. 1986; Bizub et al.
1986). The presence of RAS mutations in benign, 
precursor lesions is considered evidence that this is
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an initiating event. Similarly, HRAS activation has 
been observed in keratoacanthomas, a benign self 
regressing skin lesion, that can be induced on rabbit 
ears by repeated applications of DMBA (Leon et al. 
1988).
Although there may be preferential activation of 
a particular RAS gene in a single histologically 
defined neoplasm induced by an agent such as NMU, the 
specificity may vary between different neoplasms or 
different species (Sukumar et al. 1983? Zarbl et al. 
1983; Guerrero et al. 1984? Lemoine et al. 1988). It is 
probable that the patterns of RAS activation observed 
in human malignancies may reflect the combined effects 
of different carcinogenic agents and the site of 
action.
(iv) RAS protein properties
The three functional RAS genes code for highly 
related proteins of 21 kD (p21), (Shih et al. 1979). 
p21 binds the guanine nucleotides GDP and GTP (Scolnick 
et al. 1979?' Shih et al. 1980? Tamanoi et al. 1984? 
Temeles et al. 1985) and has an intrinsic GTPase 
activity (Gibbs et al. 1984; McGrath et al. 1984? Sweet 
et al. 1984; Manne et al. 1985? Temeles et al. 1985). 
That these properties are crucial to the transforming 
activity and normal function of p21 has been 
demonstrated in several ways? microinjection of
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anti-RAS antibodies that inhibit guanine nucleotide 
binding (Clarke et al. 1985) reverses the malignant 
phenotype of RAS transformed NIH 3T3 cells (Feramisco 
et al. 1985)? mutant RAS oncogenes that have lost 
their ability to bind guanine nucleotides do not 
transform NIH 3T3 cells (Willumsen et al. 1986; Lacal 
et al. 1986)? the GTPase activity is severely impaired 
in the transforming proteins (Gibbs et al. 1984? 
McGrath et al. 1984? Sweet et al. 1984? Manne et al. 
1985? Temeles et al. 1985).
Another class of cellular proteins have been 
identified that bind guanine nucleotides and possess 
GTPase activty. G proteins are membrane-bound 
molecules which transduce a diverse series of 
extracellular signals (Gilman,1984? Neer and Clapham,
1988). They bind and hydrolyse GTP in response to 
stimulation by a specific signal detector element, such 
as a hormone receptor? GTP binding is essential for 
transduction of the signal. For example the G protein, 
Gs, activates adenylate cyclase in response to B 
adrenergic stimuli, whereas G^ inhibits this activity 
and perhaps activates phospolipase C. Sequence 
homology has been noted between the RAS genes and G 
proteins (Hurley et al. 1984? Medyinski et al. 1985), 
although unlike p21, G proteins are composed of three 
subunits. Similar homology has been observed with 
another nucleotide binding protein, the bacterial 
elongation factor EF-Tu (Leberman and Enger, 1984),for
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which extensive structural data was available (la Cour 
et al. 1985), and on the basis of which a model for 
the tertiary structure of p21 was suggested (McCormick 
et al. 1985). The predicted guanine nucleotide binding 
site included the regions of p21 corresponding to amino 
acid sequences 10 to 16 and 57 to 63 (McCormick et al. 
1985), both of which contain the target codons for 
activating mutations.
Comparison of the deduced amino acid sequences 
of the three RAS proteins has enabled the
identification of four domains, within which are 
regions critical for normal RAS functions (Barbacid,
1987). The first domain encompasses the amino-terminal
third of p21, which is highly conserved between all
three RAS genes and across species. The next 80 amino 
acids define a second domain, where slight amino acid 
sequence divergence is noted. A highly variable region 
comprises the carboxy terminus of the molecule, except 
for the last four amino acids (Cys186-A-A-X-COOH, 
where A is any aliphatic amino acid) which are always 
conserved. The Cys at position 186 is necessary for
membrane attachment, without which mutant p21 fails to 
transform (Willumsen et al. 1984).
A single amino acid substitution is sufficient 
to convert p21 to a transforming protein, but only at 
certain critical residues. Positions 12, 13 and 61
correspond to regions of the RAS molecule that interact 
with the guanine nucleotides (de Vos et al. 1988?)
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suggesting that nucleotide binding and hydrolysis are 
the critical biochemical functions of p21. RAS proteins 
are indeed controlled by GTP and GDP? GTP-bound forms 
are active, and GDP-bound forms are inactive (Trahey 
and McCormick, 1987? Field et al. 1987), and the GTPase 
activity is reduced by 10-1000 fold in various 
oncogenic proteins (Temeles et al. 1985? Gibbs et al. 
1985? McGrath et al. 1984? Sweet et al. 1984? Manne et 
al. 1985). The effect of reduced hydrolysis would be 
the accumulation of the active GTP-bound p21 complex. 
However reduced GTPase activity does not correlate 
quantitatively with the transforming activity of RAS 
mutants at codon 12 and 61 (Der et al. 1986? Trahey et 
al. 1987? Feig and Cooper, 1988). Similarly, mutations 
which increase nucleotide exchange activate 
transforming potential (Sigal et al. 1986b). 
Transformation is elicited by stabilisation of the 
active GTP-p21 complex and continuous flow of signal. 
Mammalian RAS proteins expressed in yeast were 
unexpectedly found to exist mostly complexed to GTP 
rather than GDP. By microinjecting mammalian RAS 
proteins complexed with GTP into xenopus oocytes, Frank 
McCormick and colleagues identified a cytosolic GTPase 
activating factor (GAP), which stimulates the GTPase 
activity of normal RAS by 100-fold but has no effect on 
the GTPase of oncogenic RAS (Trahey and McCormick,
1987). GAP activity has been detected in mammalian 
cells, but not yeast. The differential effect of GAP on
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normal and oncogenic p21 renders the variation in 
GTPase activity between mutant proteins less 
significant, when compared to normal p21.
If RAS proteins function as G proteins in 
signaling pathways, there must be interaction with 
upstream regulator and downstream effector molecules 
respectively. Amino acid substitutions in the region of 
residues of 30 to 40 reduce the biological activity of 
RAS proteins in both mammalian transformation and yeast 
complementation assays (Sigal et al. 1984), however no 
biochemical activites have been ascribed to this 
region. Instead this is a good candidate for the 
effector binding region. H, K and NRAS are identical 
between residues 32 and 40, suggesting they share a 
common effector. It has been shown that RAS proteins 
(RAS 1 and RAS 2) control adenylate cyclase activity 
in S. Cerevisae (Toda et al. 1985). In addition, RAS 1 
and RAS 2 must interact with other systems, as 
simultaneous disruption of both genes is lethal, 
whereas disruption of adenylate cyclase is not. 
Mammalian p21 does not however function as a regulator 
of adenylate cyclase in mammalian cells (Beckner et al.
1985). The site of interaction with GAP on p21 was 
found to coincide with the putative effector region, 
residues 32-40, and the failure of GAP to stimulate the 
GTPase of several effector mutants was due to the 
inability to interact physically with p21-GTP (Cales et 
al. 1988; Vogel et al. 1988). GAP is a 120 kD protein
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and has been purified and cloned from bovine brain and 
human placenta (Gibbs et al. 1988? Vogel et al. 1988? 
Trahey et al. 1988). The presence of an extremely 
hydrophobic N-terminus suggests a role in membrane 
association, whereas in contrast, most GAP activity in 
mammalian cells appears to be cytosolic (Trahey and 
McCormick 1987? Trahey et al. 1988). An alternative GAP 
mRNA has been identified in human placenta, lacking the 
sequences coding for this hydrophobic terminus (Trahey 
et al. 1988), the product of which is likely to be 
located in the cytoplasm. Statistically significant 
homology to the non-catalytic region of S. Cerevisiae 
adenylate cyclase has been noted in the carboxy 
terminus of the molecule, (Vogel et al. 1988), although 
more striking homology has been noted between two 
regions of GAP and SH2 sequences (Vogel et al. 1988), 
which have been identified in nonreceptor tyrosine 
kinases (Sadowski et al. 1986). There is evidence that 
cellular factors interact at these sites and regulate 
kinase activity, providing a possible link between 
tyrosine kinase oncogenes and RAS proteins.
Given the existence of three highly related 
proteins which display similar patterns of expression, 
then each must differ in function. Since all three RAS 
proteins bind GAP, the putative effector molecule 
(McCormick, 1989), then it is likely they receive 
signals from different sources. Residues 166-185 have 
been postulated as a candidate detector binding site,
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given the variability between the RAS proteins in this 
region. It has been reported that RAS-transformed NIH 
3T3 cells have an increased basal rate of inositol 
phosphate production, implicating a chronic stimulation 
of phospholipase C-dependent phosphatidyl inositol 
bisphosphate turnover (Berridge and Irvine,1984? 
Nishizuka, 1984? Fleischman et al. 1986? Hancock et al.
1988), while others have reported increased levels of 
diacylglycerol but no changes in inositol phosphates 
(Lacal et al. 1987? Wolfman and Macara, 1987). Wakelam 
et al. (1986) presented evidence that p21-NRAS may 
stimulate phospholipase C activity in response to 
bombesin in NIH 3T3 cells. Similarly, HRAS p21 was 
reported to increase the phospholipase C response to 
PDGF in NIH 3T3 cells (Marshall, 1987), although others 
have reported that mutant HRAS inhibits the stimulation 
of phospholipase C-mediated phosphoinositide hydrolysis 
in response to PDGF (Benjamin et al. 1987? Parries et 
al. 1987). RAS-transformed NIH 3T3 cells however 
display an increased sensitivity to the stimulation of 
phospholipase C by bradykinin (Parries et al. 1987), as 
a result of increase in receptor number (Downward et 
al. 1988). The various effects of PDGF including 
stimulation of phospholipase C and an increase in Ca2+ 
fluxes in mouse fibroblasts (Berridge, 1984) have been 
linked to induction of the nuclear oncogenes FOS and 
MYC and the subsequent stimulation of mitogenesis 
(Kruiper et al. 1984? Armelin et al. 1984? Deuel and
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Huang, 1981? Ross et al. 1974). In mutant 
HRAS-transformed fibroblasts, PDGF-stimulated Ca2+ 
mobilisation is diminished (Benjamin et al. 1988), as 
is the induction of MYC and FOS (Lin et al. 1988? Zullo 
and Faller. 1988), although PDGF still stimulates 
mitogenesis. Thus transforming p21 may deregulate 
growth by uncoupling growth factor binding and 
phospholipase C activity (Fleischman et al. 1986? 
Marshall, 1987). Recently it has been shown in rodent 
fibroblasts that p21 does not regulate phospholipase C 
(Alonso et al. 1988? Seuwen et al. 1988) and in C3H 
10T1/2 mouse fibroblasts mutated HRAS actually 
down-regulates Protein Kinase C (Weyman et al. 1988). 
p21 can be phosphorylated in vitro by protein kinase C, 
predominantly at serine residues, and a p21-PKC complex 
can be immunoprecipitated with antibodies to either 
molecule from such in vitro mixtures (Jeng et al.
1987). The precise nature of the interaction between 
p21 and molecules such as protein kinase C and 
phospholipase C, still requires clarification. 
Furthermore, It has been speculated that many different 
G ' proteins couple phospholipase C to different 
receptors (Ashkenazi et al. 1989).
(v) Mechanism of Transformation by mutated p21
Expression of the normal p21 is critical for 
cell proliferation? NIH 3T3 fibroblasts are rendered
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quiescent by the microinjection of the RAS specific 
antibody Y13-259 (Smith et al. 1986), However normal 
p21 is itself capable of eliciting morphological 
transformation of NIH 3T3 cells, if present at high 
enough concentration, either by overexpression of 
transfected RAS genes (Chang et al. 1982; Pulciani et 
al. 1985) or microinjection of purified protein
(Feramisco et al. 1984? Stacey and Kung, 1984).
RAS proteins probably transform due to increased 
stability of the p21-GTP complex and sustained
transmission of signal. However a multiplicity of 
changes constitute the RAS-transformed phenotype and 
attempts to dissect this process have identified 
several steps. Microinjection of mutant HRAS into rat 
embryo fibroblasts transiently induces a transformed 
phenotype. Early events induced by the RAS protein 
include cytoplasmic alkalinisation (Hagag et al. 1987), 
membrane ruffling and pinocytosis (Bar-Sagi and 
Feramisco, 1986) within 30 minutes to one hour of
injection; the stimulatory effect of mutant p21 is
maintained for over 15 hours, in contrast to normal p21 
where the effects are no longer apparent 5 hours 
post-injection (Bar-Sagi and Feramisco, 1986). The 
introduction of oncogenic p21 into mouse fibroblasts by 
the technique of scrape loading is more efficient than 
micro-injection? approximately 90% of the cells appear 
morphologically transformed within 15 hours of 
scrape-loading (Morris et al. 1989). Oncogenic p21
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rapidly induces phosphorylation of the 80 kD protein 
kinase C substrate? demonstrating that activation of 
protein kinase C is a direct consequence of p21 action 
in the absence of changes in phosphatidyl inositol 
breakdown (Morris et al. 1989). Unless protein kinase C 
is being activated by a novel route, p21 must stimulate 
the formation of diacylglycerol from a source other 
than inositol phospholipids.
NIH 3T3 cells transformed by mutant RAS genes 
release growth factors, includng a PDGF-like activity 
(Bowen-Pope et al. 1984), and transforming growth 
factors (TGF'S) alpha and beta (Anzano et al. 1983, 
1985? De Larco and Todaro, 1978? Devouge et al. 1982? 
Ozanne et al. 1980? Shih et al. 1979), and it is 
suspected that this may contribute to the transformed 
phenotype (Carpenter et al. 1983? Kaplan et al. 1982? 
Kaplan and Ozanne, 1983? Sporn and Roberts, 1985? Sporn 
and Todaro, 1980). TGF-alpha is a polypeptide of 50 
amino acids (Derynk et al. 1984) which competes with 
epidermal growth factor (EGF) for the EGF receptor 
(Derynk et al. 1984? Marquardt et al. 1983? Todaro et 
al. 1976). However NIH 3T3 cells which lack an EGF 
receptor (NR6) are still susceptible to malignant 
transformation by a human HRAS oncogene (McKay et al. 
1986a), demonstrating that the production of TGF-alpha 
is not neccesary for transformation.
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(vi) RAS genes and multistep carcinogenesis
RAS oncogenes are capable of transforming 
established rodent fibroblasts to a fully malignant 
phenotype (Marshall, 1985? Barbacid, 1987)? under 
conditions of increased expression RAS protooncogenes 
are capable of fully transforming NIH 3T3 fibroblasts 
(Defeo et al. 1981? Chang et al. 1982? McKay et al. 
1986b), but not Rat-1 cells (Rickets and Levinson,
1988). Primary rat embryo cells seem to be refractory 
to transformation by RAS oncogenes (Land et al. 1983? 
Ruley, 1983? Newbold and Overell, 1983), although 
Wilkie and Spandidos (1984) have reported the complete 
tansformation of early passage rodent cells by a mutant 
HRAS gene linked to transcriptional enhancers. Complete 
transformation of primary rodent fibroblasts has been 
achieved by the cotransfection of a "nuclear" oncogene 
with a mutant RAS gene (167), such as the myc family of 
genes, MYC (Land et al. 1983, 1986), MYCN (Yancopoulos 
et al. 1985) and MYCL (Birrer et al. 1988), and the 
mutant p53 gene (Eliyahu et al. 1984? Jenkins et al. 
1984? Parada et al. 1984). Similarly, viral oncogenes 
can cooperate with RAS in transformation of primary 
cells, including polyoma large T (Land et al. 1983), 
adenovirus E1A (Ruley, 1983) and human papillomavirus 
(HPV) early genes (Matlashewski et al. 1987? Storey et 
al. 1988). This phenomenon is not restricted to 
fibroblast cells? activated RAS and MYC can cooperate 
in the transformation of a variety of primary cell
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types including rat adrenocortical cells (MaCauley and 
Pawson, 1988) and murine lymphoid cells (Schwartz et 
al. 1986), but not human lymphocytes (Stevenson and 
Volsky, 1986). These results are consisitent with the 
idea of transformation arising due to the accumulation 
of several genetic lesions. The concurrent activation 
of two cellular oncogenes has been demonstrated in a 
number of human tumours (Cooper and Lane, 1984? Taya et 
al. 1984? Peters et al. 1986? Suarez et al. 1987). In 
the human leukaemic cell lines, HL60 and AW Ramos, 
(Murray et al. 1983) and the human stomach fibrosarcoma 
cell line SHAC (Andeol et al. 1988) an activated NRAS 
oncogene coexists with altered versions of the MYC 
oncogene. Additionally in HL60 both p53 alleles are 
deleted (Wolf and Rotter, 1985) and in the bladder 
carcinoma cell line J82, an activated HRAS gene is 
coexistent with an abnormal RB-1 gene (Horowitz et al.
1989).
(vii) Timing of RAS activation
Given that RAS activation is a frequent event in 
human malignancies (20%-40%? Bos, 1988), the question 
arises at what stage in carcinogenesis does RAS 
activation occur? Initial evidence that RAS mutations 
occurred late in tumour development was provided by 
Albino et al. (1984), who reported that of 5 melanoma 
cell lines originating from separate metastatic tumours 
of a single patient, only one contained an activated
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HRAS gene. Similarly, a mouse T-lymphoma cell line 
acquired a metastatic phenotype concurrent with a 
mutation in a KRAS gene (Vousden and Marshall, 1984). 
In contrast, RAS activation has been demonstrated to be 
an early event in the generation of mammary tumours by 
NMU (Zarbl et al. 1985) and of skin carcinomas induced 
by treatment of mouse skin with DMBA and TPA 
(Quintanilla et al. 1986). HRAS activation has been 
observed in keratoacanthomas, a benign self-regressing 
skin lesion, in both a human sample and a 
carcinogen-induced rabbit ear model (Leon et al. 1988). 
Cancer development in the colorectum is a well 
characterised multistage process,in which the majority 
of cancers develop from benign adenomatous polyps. KRAS 
codon 12 mutations have been observed in up to 40% of 
colorectal cancers (Bos et al. 1987? Forrester et al.
1987), in some cases in adjacent residual adenomas. 
KRAS 12 mutations have also been detected in colonic 
adenomas from familial polyposis coli patients (Farr et 
al. 1988). Similarly RAS mutations are present at all 
stages of thyroid carcinoma development (Lemoine et al. 
1987,1988). RAS mutations have also been demonstrated 
in patients with MDS (Hirai et al. 1987? Liu et al. 
1987? Padua et al. 1988). However, in human mammary 
carcinoma it has been suggested that RAS activation may 
be a late event, associated with disease progression 
(Liu et al. 1988a), although more comprehensive 
investigations have detected RAS mutations at all
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stages of development (Rochlitz et al. 1989). The stage 
of tumour development where RAS activation occurs seems 
to vary between different neoplasms, although not 
neccessarily due to differences in the target cell 
type.
The presence of activated RAS genes in benign 
lesions suggests that this is not sufficient for full 
expression of the malignant phenotype. This is 
consistent with in vitro observations that the 
supposedly equivalent bladder carcinoma cell lines EJ 
and T24 differ in the transformation characteristics? 
EJ are tumorigenic in nude mice, whereas T24 have been 
reported to be both tumorigenic and nontumorigenic 
despite the presence of an activated HRAS gene (O'Toole 
et al. 1983? Flatow et al. 1987? Senger et al. 1988). 
Nontumorigenic T24 cells are susceptible to malignant 
transformation following carcinogen treatment (Senger 
et al. 1988). In addition, the tumorigenic phenotype 
of RAS-transformed cells can be suppressed following 
fusion with normal fibroblasts (Geiser et al. 1986) or 
transfection of human DNA (Schaefer et al. 1988? Noda 
et al. 1989) . Nonetheless it is clear that RAS 
activation contributes to the malignant phenotype of 
both RAS and other viral oncogene transformed 
fibroblasts (Smith et al. 1986), and tumour cell lines 
which possess mutated RAS genes (Stacey et al. 1987).
(viii) RAS-related genes
It is now clear that the RAS genes are part of a
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much larger superfamily of genes. At least 15 related 
genes encoding guanine nucleotide binding proteins of 
approximately 21 kDa have been identified; five of 
which (RAL, RRAS, RAPla, RAPlb, and RAP2) display 50% 
amino acid homology to the classical RAS genes (Chardin 
and Tavitian, 1986? Lowe et al. 1987? Pizon et al.
1988). The RHO (Madaule and Axel, 1985? Chardin et al.
1988) and RAB (Touchot et al. 1987) families have 
around 30% amino acid homology with RAS. Attempts to 
convert RAS-related genes to oncogenic forms have been 
unsuccessful (Lowe and Goeddel, 1987). Recently Garrett 
et al. (1989) have demonstrated that p23RRAS interacts 
with the same 125 kDa GAP protein as p21RAS, whereas
"RTTO • . . .p2n^nv interacts with a distinct 29 kDA protein, 
RHO-GAP.
(ix) RAS gene activation in human melanoma.
In common with most malignancies, activated RAS 
genes have been demonstrated in human malignant 
melanoma by the application of transfection techniques. 
Mutations at codon 61 of NRAS (Albino et al. 1984?
Padua et al. 1985? Raybaud et al. 1988) and HRAS 
(Sekiya et al. 1984) have been observed, although it 
has been suggested that the frequency of such 
activation is lower than in other neoplasms (Albino et
al. 1984? Raybaud et al. 1988). However as stated in
chapter 3, transforming activity has been detected in 
the melanoma cell lines SKMEL-28, SKMEL-64 and MeWo,
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which had previously been reported to be negative in 
transfection assays (Albino et al. 1984). Albino et al. 
(1984) also questioned the significance ofRAS 
mutations in melanoma development, finding activation 
of NRAS in only one of five cell lines derived from 
separate metastatic foci of a patient (Albino et al.
1984).
In an effort to assess the frequency and 
relavance of RAS mutations in human melanoma, melanoma 
cell lines and melanoma biopsies corresponding to 
different stages in malignant development have been 
analysed for activated RAS genes. A number of 
biological and biochemical techniques have been used, 
which have been found to be in close agreement with 
each other.
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Section II: Results
(i) Transfection analysis
As reported in Chapter 3, transforming activity 
was detected in a number of human melanoma cell lines, 
of which one (Mel Swift) contained an activated NRAS 
(Padua et al. 1985), and another (NKI4) a putative 
novel oncogene (Padua et al. 1984). Primary 
transformants obtained with SK-MEL-64 and SK-6005 were 
subjected to Southern analysis and hybridised with a 
HRAS specific probe BS-9. Sequences in addition to the 
expected endogenous NIH 3T3 HRAS gene were observed in 
both cases (figure 6:1).
(ii) Tagging of DNA from the cell line RPMI 5966
Variations on the NIH 3T3 assay have been 
described, which display greater sensitivity, and 
possibly allow the detection of transforming genes 
incapable of inducing focus formation. Transformation 
can be assessed by assaying for tumour induction in 
nude mice (Blair et al. 1982; Fasano et al. 1984). A 
further modification of this assay involves "tagging" 
genomic DNA with a selectable marker, prior to 
transfection (Brown et al. 1984a). To assess whether 
this method was indeed more sensitive than the standard 
NIH 3T3 focus-forming assay, high molecular weight
196
Figure 6:1 Detection of human HRAS sequences in NIH 3T3 
transfectant DNA samples. DNA samples (2 0ug) were digested 
with BamHI and analysed by Southern blotting and 
hybridisation with a v-Ha-ras probe BS-9. Lane a, SK 6005 
transfectant; lane b-d, SKMEL 28 transfectants; lane e, 
SKMEL 64 transfectant; lane f, MeWo transfectant; lane g, 
NIH 3T3; lane h, EJ secondary focus. DNA marker fragment 
sizes are indicated in kilobases (Kb). HRAS sequences in 
addition to the endogenous mouse gene where observed in 
transfectants of EJ, SK 6005 and SKMEL 64.
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genomic DNA from the melanoma cell line RPMI 5966, 
which was consistently negative for transforming 
activity in a focus-forming assay (Chapter 3, Table 
3:1), was tagged with the selectable marker pHSG272 
(Brady et al. 1984? Brown et al. 1984a) and transfected 
as described. Tumours arose at 3/8 sites of injection 
within 15 days. DNA was extracted and analysed by
Southern blotting and hybridisation for the presence of 
human RAS sequences. All three tumours contained a
human HRAS SstI fragment of 5kb (figure 6:2), which was 
greatly amplified in two of these tumours. DNA from 
one tumour (Tl) was transfected, selected as before
for G418r and assayed for tumorigenicity. Genomic DNA
from the resultant tumour also contained amplified 
human HRAS sequences (figure 6:2).
(iii) Determination of mutation in transfectants
Genomic DNA from the nude mice tumours was 
digested with Sst I, electrophoresed in an agarose gel, 
and hybridised with oligonucleotides corresponding to 
HRAS codon 12 glycine (normal) and codon 12 valine 
(mutant). Included as controls were DNA samples from 
the human bladder carcinoma cell line EJ, previously 
reported to be hemizygous for a HRAS codon 12 mutation 
(Val). Under these conditions the RPMI 5966 tumours 
hybridised to H12 Val (figure 6:3).
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Figure 6:2 Detection of human HRAS sequences in nude mouse 
tumour DNA samples. DNA samples (20ug) were digested with 
SstI and analysed by Southern blotting and hybridisation 
with a Smal fragment of pEJ which specifically detects human 
HRAS sequences. Lane a, EJ; lane b, EJ secondary focus; lane 
c, NIH 3T3; lane d, human leucocyte; lane e, primary nude 
mouse tumours RPMI-T1; lane f, RPMI-T3; lane g, secondary 
nude mouse tumour RPMI-T1-T1. DNA marker fragment sizes are 
indicated in kilobases (Kb).
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Figure 6:3 Identification of HRAS mutation in nude mouse 
tumours. DNA samples were digested with SstI and 
electrophoresed in 0.8% agarose. The gel was dried down and 
hybridised with oligonucleotide probes corresponding to the 
normal (Gly) or mutant (Val) HRAS codon 12 sequences. Lane 
a-f CMML and CGL transfectants; lane g-i, RPMI 5966 nude 
mouse tumours; lane j, NIH 3T3; lane k, RPMI 5966; lane 1, 
EJ. The CMML and CGL transfectants possess HRAS 12 Val 
mutations (Gow et al. 1988), as does E J . Under these 
conditions the RPMI 5966 tumours hybridise with H12 Val but 
not H12 Gly. DNA from the cell line RPMI 5966 fails to 
hybridise with H12 Val but hybridises with H12 Gly. The 
signal obtained with H12 Gly is not strong, and the 
inability to detect H12 Val in this sample may reflect the 
low copy number of the mutated sequence.
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(iv) HRAS mutations in human melanomas
Although the first case of a RAS mutation in a 
human tumour was a HRAS 12 mutation, attempts to detect 
similar activations both in bladder carcinomas and 
other human malignancies have been largely unsuccessful 
(Feinberg et al. 1983? Pulciani et al. 1984). More 
frequently, mutations have been observed in either 
KRAS or NRAS (Bos, 1988).
The observation of HRAS activation, as detected 
by NIH 3T3 transformation, in 3/9 melanoma cell lines 
was significant. Indeed since the sampled group 
included the cell line Mel Swift, previously reported 
to possess an NRAS codon 61 mutation (Padua et al.
1985), the frequency of RAS mutations in this 
admittedly small sample was greater than 40%.
Mutations at codon 12 of HRAS can be detected by 
the abolition of the recognition site for the 
restriction enzymes Msp I and Hpa II (Feinberg et al.
1983). The normal HRAS protein contains a glycine at 
amino acid position 12, the codon for which is GCC 
(Capon et al. 1983? Reddy, 1983). As a consequence of 
the redundancy of the genetic code, only changes in the 
first or second bases alter the encoded amino acid and 
thus produce a transforming protein (Seeburg et al.
1984). Codon 12 is preceded by the dinucleotide CC; 
thus mutations at codon 12 disrupt the tetranucleotide 
CCGG, which corresponds to the recognition site for the
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restriction enzymes Msp I and Hpa II (Tabin et al. 
1983? Reddy et al. 1983). The normal HRAS codon 12 is 
flanked by two Mspl/Hpa II sites at 57 bp 5' and 355 bp 
3'. Digestion with Msp I results in two fragments of 
355 bp and 57 bp in the absence of a mutation and a 
single 412 bp fragment in the presence of a codon 12 
mutation. In practice, this polymorphism is detected by 
the digestion of genomic DNA with an excess of Msp I 
and Hpa II, and Southern blotting and hybridisation 
with a 600 bp Sma I fragment from a genomic clone of 
HRAS. This approach has been used to analyse genomic 
DNA from a number of human tumours including carcinomas 
of the lung, colon, bladder and breast (Feinberg et al. 
1983? Fujita et al. 1984? Kraus et al. 1984).
Genomic DNA samples from ten melanoma cell lines 
and a melanoma metastasis biopsy were digested to 
completion with excess Msp I and Hpa I, fractionated by 
agarose gel electrophoresis, and Southern blotted. DNA 
from the human bladder carcinoma cell line EJ, which 
is hemizygous for a HRAS codon 12 mutation (Santos et 
al. 1984) was included as a positive control. Filters 
were hybridised with a Sma I fragment from pEJ, a human 
HRAS genomic clone, the result of which is shown in 
figure 6:4. The majority of samples demonstrated a 
fragment of 355 bp corresponding to the normal 
sequence, and a single fragment of 412 bp was observed 
in EJ DNA (lane b). Mutation-specific 412 bp fragments 
were present in the cell lines SK-MEL-64 (lane a, lane
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Figure 6:4 Detection of HRAS codon 12 mutations in human 
melanoma samples. 4 0ug of DNA samples were digested with 
MspI and Hpall, electrophoresed on 3% agarose, and 
transferred to a nylon membrane. Hybridisation was carried 
out with a 32P labelled 600 bp Smal fragment of pEJ, 
containing exon 1. The lanes contained (a) SKMEL 64, (b) EJ,
(c) MEL Swift, (d) MeWo, (e) RPMI5966, (f) SKMEL 64, (g) SK
6005, (h) SKMEL 13, (i) SKMEL 19, (j) NKI4, (k) MeWo, (1)
MELT7, (m) MEL2a. DNA marker fragment sizes are indicated in
base pairs (bp).
f) and SK-MEL-6005 (lane g), confirming the 
transfection results, and also SK-MEL-13 (lane h), all 
of which were heterozygous for the mutant allele. The 
tumour sample MEL T7 (lane 1) appeared to be hemizygous 
for a HRAS codon 12 mutation, as no normal fragment was 
detectable. DNA from MEL T7 had previously been tested
for transformation in the NIH 3T3 assay, and had failed
\\to produce foci, (Chapter 3, Table 3:1). However,
\ \attempts to cotransfect ^EL T7 DNA with pHSG272 had
(\
resulted in very few c\418 resistant colonies. This
\
. .decrease in the efficiencyy^f transfection could be due 
to the significant melanUn contamination of the DNA 
sample. Although the melanom^\ cell line RPMI 5966 has 
previously been shown to possess an HRAS codon 12 
mutation (iii), a mutant-specific fragment was not 
observed by this technique, ^ i s  could mean that the 
HRAS mutation is present in a \ minor population of 
cells.
(v) Determination of mutations by in vitro 
amplification and oligonucle \tide analysis
v\
DNA from 12 melanoma cell lines 'and 5 melanoma 
tumours was amplified with\Vimers specific
for HRAS codon 12. Equal volumes of each
amplified sample were applied to nylon m mbranes via a 
slot blot apparatus. Filters were hybrids ed with a 
32P labelled oligonucleotide correspond \ig to the
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Table 6:2 HRAS codon 12 primers and probes
Oligomer
H12 primers:
H12 probes:
PI
PI
PI
P2
P2
P2
Sequence Amino Acid
Substitution
CTGAGGAGCGATGACGGAAT RS 51 
AGTGGGGTCGTATTCGTCCA RS 5 2
GTGGGCGCCGGCGGTGTGGG WT
-AGC
-CGC
-TGC
-GTC
-GCC
-GAC
Ser
Arg
Cys
Val
Ala
Asp
Strand
s
s
s
s
s
s
s
normal HRAS 12 sequence (H12-Gly) to determine the 
extent of amplification of the HRAS 12 sequences. The 
sample volume was adjusted to ensure the loading of 
equivalent amounts of amplified DNA on subsequent 
filters, on the basis of the intensity of 
hybridisation with H12 Gly. Duplicate filters were 
prepared and hybridised successively with 
oligonucleotides corresponding to all the possible 
transforming base substitutions (table 6:2). Included 
on each filter was amplified DNA from EJ (H12 Val). 
Filters were washed in 2 x SSPE, 0.1% SDS at the 
predicted temperature for the dissociation of single 
base mismatches (Tm) and then autoradiographed. The 
presence of a mutation was based on the hybridisation 
to both the controls and surrounding samples. As shown 
in figure 6:5 only the H12 Val mutation in EJ was 
detected. No H12 mutations were detected in any of the 
melanoma cell lines, including those shown to possess 
HRAS 12 mutations by alternative techniques.
No mutations were detected at codon 61 of HRAS 
in these cell lines.
(vi) RAS mutations in melanoma tumours (in 
collaboration with Dr. V.K. Shukla, Department 
of Surgery, UWCM.)
To determine if RAS mutations were a common 
event in vivo. a larger number of melanoma samples 
were analysed. Forty patient biopsies were obtained
201
J? lC^lliCG b  • O  /^Ild-LytS-Lia U i  lilt; J. ctiioiuct u c i i  x  x n c o  j.u j . i n \ n u  u u u w i  i _i_
mutations. Amplified DNA from melanoma cell lines and EJ 
bladder carcinoma cell line was slot blotted onto nylon 
membranes and hybridised with 32P-labelled synthetic 
oligonucleotide probes, corresponding to either the normal 
HRAS codon 12 sequence (H12 Gly) or point mutations (only 
H12 Arg and H12 Val are shown) . Filters were washed at low 
stringency, autoradiographed, washed at high stringency and 
autoradiographed again. Lane a, SKMEL 64; lane b, Sk6005; 
lane c, NKI4; lane d, EJ; lane e, RPMI 59 66; lane f, MEL 2a; 
lane g, MEL Swift; lane h, MeWo. Only the H12 Val mutation 
in EJ was detected.
H 12 Gly Arg Va I
L O W  a _  m
9 —
h
h i g h  a
b
c
d
e
I
9
h
)
including benign naevi, superficial spreading melanoma, 
nodular melanoma and metastatic melanoma (patient 
details in table 6:3) and in 28 cases constitutional 
DNA was obtained from either peripheral blood or 
adjacent normal skin. Genomic DNA was extracted and 
subjected to amplification for codons 12 and 61 or 
HRAS. Amplified samples were treated as described 
previously.
Samples were analysed for mutations at codons 
12, 13 and 61 of HRAS by hybridisation with sequence
specific oligonucleotide probes. A HRAS mutation was 
detected in only one sample. The H12 Val probe 
hybridised strongly to the melanoma sample from patient 
JC but not to the adjacent normal skin sample (figure 
6:6). No mutations were detected at codons 13 or 61 of 
HRAS.
This patient cohort have also been analysed for 
mutations at codons 12,13 and 61 of KRAS and NRAS 
(Shukla et al. 1989, in press), the results of which 
are shown in table 6:3. A high frequency (23%) of KRAS 
codon 12 mutations was noted, in both primary and 
secondary tumours, and significantly 2/4 naevi. In 
addition two samples possessed NRAS 61 mutations. In 
all cases where analysis was possible, corresponding 
normal tissue lacked detectable RAS mutations.
Two patients demonstrated concurrent activation 
of two RAS genes; H12 and K12 in a primary melanoma 
(JC), and K12 and N61 in a secondary melanoma (MW).
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Figure 6:6 Amplified DNA from melanoma tissue and 
corresponding normal skin samples, slot blotted and 
hybridised with 32P labelled oligonucleotides, either the 
normal H12 Gly or the mutant H12 Val, and washed at 
stringent temperature. One primary melanoma sample (row 1) 
contained a H12 Val mutation which was not observed in the 
corresponding normal skin.
H12 Gly H12 Val
1 2 3 4 1 2 3
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(vii) Distribution of RAS Mutations
As shown in table 6:3, RAS mutations were 
detected in 10/40 patients (25, corresponding to all 
stages of melanoma development, (2/4 naevi, 4/22 
primary tumours and 4/12 metastases), although no 
mutations were observed in systemic metastases, 
probably as consequence of the small number of samples 
analysed. Mutations were equally distributed between 
male and female patients. The frequency of RAS 
mutation was 18% and 33% in primary and secondary 
melanomas respectively. There was no association 
between the presence of a RAS mutation and either the 
site or the thickness of the lesion. Where a RAS 
mutation was shown in the melanoma sample, in all 
cases the corresponding normal tissue lacked the 
mutation, consistent with the hypothesis of RAS gene 
mutation as a somatic event.
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Section III: Discussion
In this study, melanoma cell lines and patient 
biopsies have been analysed for the presence of RAS 
mutations by a combination of biological (transfection) 
and biochemical (Msp I/Hpa II polymorphism, PCR and 
oligonucleotide hybridisation) assays. There are 
discrepancies when comparing the results of different 
techniques. Despite the identification of HRAS 12 
mutations by transfection and/or Mspl/Hpall analysis in 
melanoma cell lines, the amino acid substitution could 
not be determined by PCR and oligonucleotide 
hybridisation. Digestion with Hpall is sensitive to 
methylation? however the additional use of MspI and 
digesting the DNA in a vast excess of restriction 
enzyme would be expected to give complete digestion. In 
the case of RPMI 5966 the HRAS mutation may be present 
in less than 10% of the cell population, on the basis 
of the Mspl/Hpall analysis. Such a mutation would be 
undetectable by the technique of specific 
oligonucleotide hybridisation. Another explanation for 
the failure to detect specific hybridisation would be 
the presence of two or more base changes, resulting in 
a sequence differing from all of the oligos used. Two 
adjacent point mutations have been demonstrated at 
codon 12 of the KRAS gene in a human mammary carcinoma 
cell line (Prosperi et al. 1987); such mutations would 
not be detected by the technique of specific
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oligonucleotide hybridisation used here. Alternatively 
a polymorphism might be present within the 20 
nucleotide span of the probes used? Janssen and Bartram 
(1989) have reported a silent mutation at codon 15 in a 
codon 12 mutated NRAS allele from transfectants of 
KG-1, and have suggested that similar silent mutations 
may hamper the detection of activating RAS mutations 
when using synthetic oligonucleotide probes.
Contrary to previous reports (Albino et al. 
1984, Raybaud et al. 1988), the frequency of RAS 
activation in CMM (25%) is comparable to that for other 
human tumours (Bos, 1988). The frequency of KRAS 12 
mutations is significant (20%). This is the first 
report of either KRAS codon 12 or HRAS codon 12 
mutations in CMM? only HRAS 61 (Sekiya et al. 1984) 
and NRAS 61 (Albino et al. 1984? Padua et al. 1985? 
Raybaud et al. 1988? Keijzer et al. 1989) mutations 
have been reported previously.
In the majority of human solid tumours, 
mutations are biased to a particular position of a 
single RAS gene, for example KRAS 12 in lung (Rodenhuis 
et al. 1987) and colorectal carcinomas (Bos et al. 
1987a? Forrester et al. 1987? Vogelstein et al. 1988) 
and HRAS 12 in bladder carcinomas (Fujita et al. 1985? 
Visvanathan et al. 1988). In haematological 
malignancies, although activation of all three RAS 
genes has been demonstrated (Padua et al. 1988), 
mutations are predominantly localised to NRAS codons 12
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and 13 (Farr et al. 1988a? Padua et al. 1988). CMM, in 
common with thyroid cancer (Lemoine et al. 1988, 1989b) 
displays activation of all three RAS genes in vivo, a 
phenomenon not demonstrated in other human solid tumour 
biopsies (as opposed to cell lines).
The presence of KRAS 12 mutations in 2/4 naevi 
is interesting? naevi represent a focal growth of 
benign normal melanocytes, and can be classified into 
one of several groups, with differing associated risks 
of transformation to melanoma. Naevi have been 
considered as precursors for melanoma development? 
Clark et al. (1984) reported histological evidence of 
precursor lesions in the form of melanotic dysplasia in 
both superficial spreading and nodular melanoma. The 
presence of dysplastic naevi, either in a familial or 
sporadic form,is considered a risk factor for melanoma 
development (Elder et al. 1980? Greene et al. 1985? 
Titus-Ernstoff et al. 1988? Rigel et al. 1989). Common 
acquired naevi (common moles) are found on the skin of 
most white adults, and first appear in the early years 
of childhood. They undergo a predictable evolution over 
a period of time. Naevus cells are derived from 
melanocytes in the basal epidermal domain and they 
proliferate there for a time as junctional naevi. 
Later, some cells descend into the dermis and the 
lesion becomes a compound naevus. When junctional 
hyperplasia is no longer seen, the lesion is termed an 
intradermal naevus (Clark et al. 1984). Histologically,
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only junction or compound naevi can undergo malignant 
transformation, whereas the intradermal naevus, for 
practical purposes, never does. Congenital naevi are 
indistinguishable from compound naevi histologically, 
except they are larger, sometimes considerably so. 
However there is a significant incidence of the 
subsequent development of malignant melanomas from 
these lesions. Both samples with KRAS 12 mutations were 
congenital naevi where surgical excis ion was 
considered necessary; it is not possible to predict 
whether they would have transformed to malignant 
melanoma if they had not been excised. Nonetheless it 
is significant that similar mutations are present in 
primary melanomas.
The presence of a RAS mutation in benign lesions 
is not unique to this study. It is well known that an 
activated RAS gene is insufficient to fully transform 
primary cells in culture (Land et al. 1983? Ruley, 
1983; Newbold and Overell, 1983). KRAS 12 mutations 
have been demonstrated in both colorectal carcinomas 
and adjacent non-malignant adenoma tissue (Bos et al. 
1987? Forrester et al. 1987), and Farr et al. (1988b) 
have identified RAS mutations in adenomatous polyps 
from a Familial polyposis coli (FPC) patient. A HRAS 
61 mutation was detected in a human keratocanthoma 
biopsy (Leon et al.1987), a benign self-regressing skin 
lesion. A high frequency of RAS activation has been 
reported in the preleukaemic condition, MDS (Padua et
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al. 1988) and benign thyroid adenoma (Lenmoine et al. 
1989). Similarly, RAS mutations have been demonstrated 
in papillomas generated by carcinogen treatment of 
mouse skin, prior to the development of skin carcinomas 
(Quintanilla et al. 1986). In this system the HRAS 
mutation is considered to be an early, or even an 
initiating event, as demonstrated by the presence of 
HRAS mutations in premalignant papillomas; however 
hemizygosity for the mutation was observed upon 
progression to carcinomas (Quintanilla et al. 1986). 
Similarly RAS activation seems to be an early event in 
human melanoma development.
Concurrent RAS mutations were observed in two 
samples; one primary and one secondary melanoma. KRAS 
12 mutations were common to each sample, in conjunction 
with either HRAS 12 or NRAS 61 mutations. It is not 
possible to determine whether these mutations are 
present in the same or different cells, or whether they 
arose simultaneously or consecutively. The coexistence 
of two mutant RAS genes in a single sample has been 
reported in MDS (Padua et al. 1988), AML (Farr et al. 
1988a) and colorectal adenomas (Forrester et al. 1987? 
Farr et al. 1988b) . In both AML and colorectal 
carcinomas it has been has been suggested that 
mutational activation of at least one of these RAS 
genes was not the initiating event, but more likely an 
event in neoplastic progression. Whilst melanomas may 
display some functional heterogeneity, they are still
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considered monoclonal. It is most likely that in these 
two patient samples multiple RAS mutations co-exist in 
the same cell, particularly the secondary tumour which 
would be assumed to have developed from dissemination 
of a single metastatic clone. The observation that KRAS 
12 mutation is common to these samples, and that KRAS 
12 mutations are present in precursor lesions suggests 
that KRAS activation may be an early or even 
initiating event and the acquisition of a second RAS 
mutation may give a selective growth advantage to a 
particular clone.
The result of Mspl/Hpall analysis of one 
melanoma tumour (MELT7) was consistent with the
concurrent loss of one HRAS allele and mutation at 
codon 12 of the remaining allele. However it has not 
been possible to identify the mutation by PCR and 
oligonucleotide analysis. This would be the first
report of HRAS allele loss in CMM? this was only 
detected when in conjunction with a HRAS 12 mutation, 
and so may be an underestimate. Loss of one normal
allele may be occurring in samples in the absence of 
HRAS 12 mutations. Yokota et al. (1986) analysed a 
selection of human tumours, and observed HRAS allele 
loss in 18% of samples, and more frequently in 
metastases than in primary tumours. Loss of
heterozygosisty at the HRAS locus has also been 
reported in many tumours including carcinomas of the 
bladder (Capon et al. 1983a? Feinberg et al. 1983?
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Fearon et al. 1985? Deng, 1988), breast (Theillet et 
al. 1986? Liu et al. 1988? Mackay et al. 1988), cervix 
(Riou et al. 1988), and ovary (Yokota et al. 1984? 
Krontiris et al. 1985? Lee et al. 1989). The frequency 
of allele loss is significant in some neoplasms? 27% of 
breast carcinomas (Theillet et al. 1986), 36% of
cervical carcinomas (Riou et al. 1988), and 50% of 
ovarian carcinomas (Lee et al. 1989), and can occur in 
conjunction with either a mutation at HRAS 12 (Capon et 
al. 1983? Feinberg et al. 1983? Riou et al. 1988? Deng, 
1988) or activation of another RAS gene (Liu et al. 
1988). HRAS allele loss is associated with disease 
progression and poor prognosis in breast (Theillet et 
al. 1986? Liu et al. 1988) and ovarian carcinomas (Lee 
et al. 1989). Loss of a HRAS allele could be a marker 
for the loss of the proposed suppressor gene on 
chromosome 11 (Saxon et al. 1986), possibly the locus 
involved in Wilms' tumorigenesis (Riccardi et al. 
1978) .
RAS mutations were not detected in 
constitutional DNA from either normal skin or 
peripheral blood, particularly in those patients whose 
melanomas displayed RAS activation. This study 
supports the involvement of RAS gene mutations in 
human malignancy, and the activation of RAS genes as a 
consequence of somatic mutation rather than germline 
transmision (Kraus et al. 1984? Santos et al. 1984).
The frequency of RAS gene mutations did not
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differ significantly between primary and metastatic 
melanoma, or between SSM and NM. This correlates with 
reports of no major aetiological differences between 
SSM and NMM (Holman and Armstrong, 1984b? Elwood et al.
1987) .
No correlation was observed between the presence 
of a RAS mutation and prognostic indices such as tumour 
thickness or histological subtype. A correlation has 
been noted in skin cancers (SCC and BCC) between RAS 
mutations and location of the tumour in sun-exposed 
areas (Ananthaswamy et al. 1988). No such correlation 
was observed in this study, probably reflecting the 
different aetiology of CMM. Whether RAS mutations are 
of prognostic significance in CMM awaits more extensive 
studies.
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Chapter 7: General Discussion
Chapter 7: General Discussion and Summary.
Section I: MEL, transformation and chromosome 19.
The aim of this work has been to try and 
identify some of the genetic changes that contribute to 
the development of Cutaneous Malignant Melanoma (CMM).
A novel human gene, MEL, was identified following 
transfection of DNA from a human melanoma cell line 
NKI4, and as such was initially proposed as a novel 
oncogene (Padua et al. 1984). However as the work 
presented in this thesis demonstrates, there is no 
evidence that MEL is itself a transforming oncogene or 
that it is responsible for the transforming activity 
observed in DNA from the NKI4 cell line. In particular 
the inability of the genomic clone isolated from the 
secondary transformant to transform NIH 3T3 fibroblasts 
and the loss of MEL sequences in subsequent rounds of 
transfection. There is also no evidence that the MEL- 
related clone NK17 is responsible for the transforming 
activity of DNA from NKI4.
MEL is a previously undescribed human 
gene, which does not display significant homology to 
any known gene sequences. This gene is conserved in the 
mouse genome and is expressed in human melanoma cell 
lines, the EJ bladder carcinoma cell line and NIH 3T3 
mouse fibroblasts. Identification of the function of the 
MEL gene product awaits sequencing and expression of 
full length cDNA.
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MEL localises to a critical region of chromosome 
19 (19pl3.2), which has been identified as the
breakpoint in several human malignancies, particularly 
in three cases of CMM (Parmiter et al. 1986). Two of 
these cases were analysed for abnormalities of the MEL 
gene by conventional southern blotting, but no gross 
alterations were detected. Long range involvement of 
the MEL locus in the breakpoint on chromosome 19 is 
currently being investigated using pulse field gel 
electrophoresis (E. Nimmo and K. Johnson, personal 
communication). Similar analysis is planned for any 
haemopoietic malignancies with breakpoints at 19pl3.2.
It is unclear why these sequences were retained 
in a secondary transfectant, while not themselves 
transforming unless perhaps they were linked to the 
actual transforming gene in the primary transfectant, 
or in some way conferred a growth advantage to 
transformed cells. Alternatively the retention of these 
sequences in a secondary transfectant may be fortuitous.
Section II: Low frequency transforming events.
Screening of a genomic library of NKI4 DNA with 
a MEL specific probe resulted in the isolation of 
sequences capable of transforming NIH 3T3's. The exact 
relationship of the NK17 sequences to MEL is unclear; 
cross hybridisation is between Alu-containing 
regions,but the very method of isolation precludes an
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involvement of the major Alu repeat.
The exact mechanism of transformation is 
unclear; the seemingly monoclonal nature of the tumours 
suggests that the NK17 sequence is itself not 
sufficient for transformation, but that additional 
events are required to induce tumorigenicity. One 
possibility is the integration at a critical locus, 
analogous to latent oncogenic viruses. Retroviral LTR's 
have ben used as insertional mutagens to identify 
potential oncogenes (Muller and Muller, 1984) and 
similar mechanisms are believed to operate when 
transformation is elicited following transfection of 
sheared genomic DNA (Cooper, 1982). Integration of HRAS 
at a specific site may even contribute to 
transformation of primary rat embryo fibroblasts in 
cooperation with MYC (McKenna et al. 1988). NK17 
sequences may act thus, considering transforming 
activity has been localised to at most 2kb of DNA, 
which does not seem to be expressed nor display any 
obvious open reading frames. Cloning and analysis of 
sequences flanking the site of integration in 
independant transfectants may identify a critical gene 
locus. The low transforming activity of the NK17 
sequence would render such activity undetectable in the 
context of transfection of genomic DNA.
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Section III: RAS activation in melanoma
Previous attempts to detect activated RAS genes 
in melanoma cell lines (Albino et al. 1984) or biopsies 
(Raybaud et al. 1988) have used transfection assays, 
and as a result have suggested RAS mutations are 
infrequent in CMM. However activated RAS genes are 
capable of inducing some phenotypic characteristics of 
melanoma in normal melanocytes (Albino et al. 1986). 
The combination of transfection and PCR/oligonucleotide 
analysis in this study has shown that RAS mutations are 
present in 25% of melanoma samples. KRAS codon 12 
mutations are frequent in melanoma; failure to detect 
such mutations in melanoma by transfection assays are 
probably due to the genomic size of the KRAS gene 
(>40kb- Shimizu et al. 1983b,c) which renders it 
susceptible to damage during the process of DNA 
extraction and transfection.
The presence of KRAS 12 mutations in congenital 
naevi supports the activation of RAS genes as an early 
event in melanoma development. There is considerable 
evidence that naevi represent melanoma precursors; the 
presence of histological remnants of naevi adjacent to 
primary lesions, and the association of melanoma risk 
and multiple atypical naevi. Congenital naevi have a 
increased risk of malignant progression, compared to 
common acquired naevi. If RAS activation occurs early 
in melanoma progression, and is relavant to the
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malignant phenotype then the same mutations would be 
expected in primary and secondary lesions, and this is 
indeed borne out in this study.
Similar results have been reported in other 
neoplasms where precursor lesions are observed. 
Specifically, the presence of KRAS 12 mutations in both 
colorectal adenomas and carcinomas (Forrester et al. 
1987; Bos et al. 1987; Farr et al.1988b), and a high 
frequency of NRAS mutations in MDS (Padua et al.1988) 
and AML (Farr et al. 1988a).
The value of RAS mutations as a prognostic 
indicator requires further studies. As yet no 
correlation has been observed between the presence of a 
mutation and depth of tumour, which is a well 
recognised indicator of prognosis. Subsequent follow up 
of the patients in this study may clarify the 
contribution of RAS mutations to prognosis in human 
melanoma. Albino et al. (1984) reported that of 5 
melanoma cell lines originating from separate 
metastatic tumours of a single patient, only one 
contained an activated RAS gene, suggesting that 
mutation had occurred at the stage of metastasis. HRAS 
activation is correlated with disease progression and 
poor prognosis in human cervical cancer (Riou et al.
1988). MDS patients with RAS mutations reportedly 
evolve to AML more frequently than those without (Hirai 
et al. 1987; Liu et al. 1987; Padua et al. 1988), and
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in CML RAS mutations have been detected upon 
progression to blast crisis (Le Maistre et al. 1989) .
In contrast, Rodenhuis et al. (1988) observed an 
inverse correlation between presence of a RAS mutation 
and tumour size in lung carcinoma and probability of 
metastases at diagnosis.
Section IV: The contribution of UV irradiation to CMM
Exposure to sunlight, in particular the UV 
wavelength, has been implicated as a major aetiological 
factor in development of CMM as well as other forms of 
skin cancer. The major component of sunlight is UV-A, 
which is known to damage cell membranes (Kelland et al. 
1983; Peak et al. 1985), although the carcinogenic 
effect of sunlight is generally attributed to UV-C, 
which induces mutations via two forms of DNA damage; 
the cyclobutane pyrimidine dimer (Setlow and Carrier, 
1966; Gordon and Haseltine, 1982) and the (6-4) 
pyrimidine-pyrimidone photoproduct (Lippke et al. 1981; 
Brash and Haseltine, 1982). There is some controversy 
over the relative importance of both types of lesions 
for cell killing and mutagenesis (Protic -Sablijic et 
al. 1986; Brash et al. 1987; Drobetsky et al. 1987; 
Mitchell et al. 1988). The autosomal disease Xeroderma 
Pigmentosum is marked by extreme sensitivity of the 
skin to UV exposure and is though to involve defects 
in the repair of UV-induced DNA damage. This is
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manifested by increased susceptibility to skin cancer 
(SCC, BCC and CMM). Recently activation of the NRAS 
gene at codon 61 has been demonstrated in melanoma 
(Keijzer et al. 1989), and SCC's (Suarez et al. 1989) 
from XP patients. Interestingly, Suarez et al. (1989) 
identified the same N61 mutation in two independant 
SCC's from an XP patient, suggesting a specific
mutagenic effect of UV and/or defect in DNA repair. UV 
irradiation in vitro can activate NRAS genes,
predominantly at codon 61 (van der Lubbe et al. 1988)
via the formation of cyclobutane dimers.
In addition to mutagenic activity, it has 
recently been suggested that UV-irradiation may have 
other effects that contribute to the transformed 
phenotype. Romerdahl et al. (1988) have shown that the 
in vivo growth of murine melanoma cells can be 
stimulated by UV irradiation, presumably by the 
induction of expression of proliferation genes.
Expression of the MYC and HRAS proto-oncogenes can be 
induced by UV-C irradiation in rodent fibroblasts and 
human keratinocytes (Ronai et al. 1988). The HRAS 
oncogene may induce the expression of other genes, 
including probable transcription factors, JUN and JUNB 
(Sistonen et al. 1989), MYC (Lloyd et al. 1989) and 
transformation-associated genes such as ornithine 
decarboxylase (Holtta et al. 1988), MDR-1 and 
glutathione-S-transferase (Burt et al. 1988) glucose
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transorter protein (Flier et al. 1987) and the 
oestrogen-responsive gene pS2 (Nunez et al. 1989). It 
is conceivable that continual UV exposure may propel 
normal melanocytes along the path of malignant 
progression by inducing activating mutations in 
endogenous RAS genes, and subsequently stimulating 
expression of such mutant genes, initiating a cascade 
of events
Section V: The validity of the NIH 3T3 assay in
identifying transforming genes.
Since the initial reports of transforming 
activity in DNA from chemically transformed mouse cell 
lines (Shih et al. 1979) and human tumour cell lines 
(Krontiris and Cooper, 1981? Shih et al. 1981; Cooper, 
1982) , genomic DNA from many human tumour cell lines 
and biopsies has been assessed for morphological 
transformation of NIH 3T3 cells. In the majority of 
cases, those transforming genes detected have been 
members of the RAS gene family (Bos, 1988). Non-RAS 
genes have been identified occasionally, and in a 
diverse set of neoplasms. Transforming activity has 
been reported in normal human DNA, but as a 
consequence of spontaneous RAS gene activation (Schafer 
et al. 1985? Viel et al. 1988).
In all but a few cases of non-RAS transforming 
genes, the activating lesion was undetectable in the
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original tumour sample. The MET (Cooper et al. 
1984,a,b) and TRK (Martin-Zanca et al. 1986) oncogenes, 
both activated by fusion to unrelated sequences 
(Tempest et al. 1986? Martin-Zanca et al. 1986), have 
only been observed in a single tumour sample in each 
case. TRK can be activated during transfection of 
genomic DNA (Kozma et al. 1988), or of cDNA clones 
encoding the normal sequence (Kozma et al. 1988; Oskam 
et al. 1988). Other genes have probably been activated 
during transfection, by fusion with unrelated sequences 
as with RAF (Stanton and Cooper, 1987; Tahira et al. 
1987) and RET (Takahashi and Cooper, 1987) or deletion 
of amino-terminal coding sequences as with DBL/mcf-2 
(Noguchi et al. 1988), although the normal gene can 
transform NIH 3T3 cells, albeit at a lower frequency 
(Ron et al. 1988). The mechanism of activation of the 
HST/K-FGF gene is unclear? Rearrangements have been 
noted in transfectants, but the normal coding sequence 
is sufficient to transform NIH 3T3's (Yoshida et al.
1987), so it is unlikely that HST/K-FGF is activated in 
the original sample. In the process of DNA 
transfection, unlinked DNA fragments are transferred 
into the same cell (Wigler et al. 1979), and evidence 
suggests that cotransferred DNA's become linked to each 
other (Perucho et al. 1980? Anderson et al. 1982). Thus 
there is ample oppurtunity for the activation of 
proto-oncogene sequences during the process of
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transfection, to which some genes such as RAF are 
particularly sensitive.
It has been suggested that NIH 3T3 cells are 
particularly attuned to detecting RAS mutations, which 
is confirmed by the infrequent detection of other 
transforming genes. The majority of human neoplasms 
lack the cpability to transform NIH 3T3's, Some display 
a paucity of RAS activation, such as CML (Collins et 
al. 1989; Le Maistre et al. 1989), where instead the 
major genetic lesion is the fusion of the ABL 
proto-oncogene with the BCR gene. The hybrid BCR-ABL 
gene, whilst unable to transform NIH 3T3 cells, induces 
morphological transformation and tumorigenicity in 
Rat-1 fibroblasts (Daley et al. 1987; Lugo and Witte,
1989), and weakly transforms haemopoietic cells 
(McLaughin et al. 1987). The bcl-2 gene, implicated in 
follicular lymphoma, will induce tumours but not foci 
following transfection into NIH 3T3's (Reed et al.
1988) ; the oligoclonal nature of such tumours 
demonstrated the requirement of additional changes for 
expression of the full tumorigenic phenotype.
In common with bcl-2, a number of other cloned 
genes have been demonstrated to fully or partially 
transform NIH 3T3's (Table 7:1). The normal homologues 
of some oncogenes can transform purely by over 
expression (FOS and DBL) whereas others require point 
mutations (SRC and FMS). Genes not neccesarily 
considered oncogenic, such as protein kinase C, can
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also induce partial transformation in rodent
fibroblasts when overexpressed. However transfection 
assays will not pick up those instances of gene 
activation due to increased expression, except 
perhaps when negative regulatory sequences are 
deleted.
Despite the range of genes capable of 
transforming NIH 3T3's, the majority of human tumour 
DNA's fail to register in an NIH 3T3 assay. Genes such 
as SRC and FMS,which can be activated by a single point 
mutation (analogous to that required for RAS 
activation) have not been observed in transfection 
experiments; similarly, rearrangements in the RAF and 
MAS genes, which are capable of activating these genes 
during transfection,have not being observed in vivo. 
Thus with the exception of the RAS genes, the NIH 3T3 
assay has failed to identify conclusively any genes 
that significantly contribute to human malignancy in 
vivo. There have been attempts to identify other cell 
lines as recipients for transfection assays. Lugo and 
Witte (1989) have suggested use of Rat-1 fibroblasts to 
identify genetic changes in CML, such as BCR-ABL and 
genes capable of cooperation in a manner analogous to 
v-myc. As most human tumours are epithelial in origin, 
a non-tumorigenic clone of the human osteosarcoma cell 
line HOS (TE-85 clone F5) has been proposed as a 
recipient for transfection, and transformation has been
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demonstrated following introduction of cloned mutant 
HRAS and NRAS, and genomic DNA from the cell line 
HT1080, which contains an activated NRAS (Tainsky et 
al. 1987). Whilst the NIH 3T3 assay has been useful 
indentifying possible oncogenes, future assays will 
require the use of other complimentary cell types.
Section VI: Conclusions
In this work melanoma cell lines and biopsies 
have been systematically analysed for transforming 
genes using both biological and biochemical assays. As 
a result a novel human gene sequence, MEL, was 
identified and partially characterised. The function of 
this gene is undetermined as yet? it cannot be termed 
an oncogene as there is no evidence for any such 
activity. MEL is localised to the vicinity of 
translocation breakpoints on chromosome 19, which have 
been observed in melanomas and leukaemias. A MEL- 
related sequence with low level transforming activity 
has been isolated, but the mechanism of
transformation is unknown. The transforming 
activity originally observed in NKI4 seems to be due 
to sequences in addition to those above, and as such 
constitute a novel oncogene, which will be 
confirmed by isolation of genomic clones.
As this study has shown, RAS gene activation is
223
a frequent event in human melanoma, and can occur at a 
relatively early stage in melanoma development. The 
prognostic value of RAS mutations awaits a more 
detailed study, including follow up of this cohort of 
patients. Nonetheless, it is probable that RAS 
activation participates in the transformation of 
melanocytes and the subsequent development of 
malignant melanoma.
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Appendix I Solutions
Appendix I; Solutions
Acrylamide (40% stock solution): 38g Acrylamide, 2g
bis-Acrylamide, H20 to lOOmls.
Denaturing Acrylamide gel mix (10%): 12.5mls
40% acrylamide, 21g Urea, 5 mis 10 x TBE, H20 to 50mls. 
BBL: 10g/l BBL, 5g/l NaCl,- Agar 10g/l, Top
agar/agarose 6.5g/l
Bromophenol blue dye: 50% glycerol (sterile), 2%
ficoll, 0.25% bromophenol blue, 20mM EDTA.
CsCl, saturated: 65g CsCl in 35 g H20.
Cy Medium: lOg casamino acids, 5g yeast extract, 3g 
NaCl, 2g KC1, lOmM MgCl2, 25mM Tris HC1 pH 7.5, H20 to 
11; CY agar: 14g/l; CY top agar: 6.5g/l.
Denaturing Solution. (nitrocellulose/Hybond-N): 0.5M 
NaOH, 1.5M NaCl.
Denhardts Solution (1 x) 0.02% BSA, 0.02% Ficoll 400, 
0.02% polyvinyl pyrolidone
Formamide: Deionise with 50g of Dowex MR-3/1, stirring 
for at least 1/2 hour. Filter and store at -20°C.
2 x HBS: 280 mM NaCl,50 mM Hepes,1.5 mM Na2HP04.2H20. 
Adjust pH to 7.1 with 0.5N NaOH, filter sterilize and 
store at at 4°C 
Hybridisation Solutions.
Nitrocellulose:
Prehybridisation: 50% formamide (deionised), 5 x 
SSC, 5 x Denhardts solution, 1% glycine, 50mM Sodium
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Phosphate pH 6.5, 250ug/ml carrier DNA.
Hybridisation: 50% formamide (deionised), 5 x SSC, 1 x 
Denhardts', 20mM Sodium Phosphate pH 6.5, 10% Dextran 
Sulphate, lOOug/ml carrier DNA.
Probe Wash: 50% formamide (deionised), ImM EDTA, 1 x 
SSC.
Hybond-N:
6 x SSC, 5 x Denhardt's, 0.5% SDS, lOOug/ml carrier 
DNA.
L-Broth: Bactotrypsin lOOg, Bacto-yeast extract
50g, NaCl lOOg, pH 7.5, H20 to 10 1 and autoclave. 
L-Agar: 7.5g of agar/500mls of L-broth.
Ligation buffer (10 x) : 0.5M Tris-HCl pH7.4,
0.1M MgCl2, 0.1M dithiothreitol (DTT), lOmM 
spermidine, lOmM ATP, lmg/ml BSA. Store at -70°C.
M13 Dye: 0.25% bromophenol blue, 0.25% xylene cyanol, 
20mM EDTA in deionised formamide
Neutralising Solution (Hybond/Nitrocellulose): 1.5M 
NaCl, 0.5M Tris-HCl, pH 7.2, 0.001M Na2EDTA.
Neutralising solution (Pall filter): 3M Na Acetate pH 
5.5.
Northern gel electrophoresis buffer: 20mM sodium
MOPS pH 7.0, 5mM NaOAc, ImM EDTA.
OLB buffer: solutions A,B and C in the ratio
10:25:15
Solution A: lOOOul solution O, 18ul of 2-
mercaptoethanol, 5ul each of dATP, dGTP, dTTP (0.1M) 
Solution B: 2M Hepes pH 6.8 (pH with 4M Na OH).
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Solution C: dNTP(6) 50u
Solution 0: 1.25M Tris HC1 pH 8.0, 0.125M MgCl.
Phage Buffer: 6mM Tris-HCl pH 7.5, 0.5mM MgS04, 68.4 mM 
NaCl, 0.005% gelatin. Heat to dissolve gelatin, 
then autoclave.
Plasmid Preparation Solutions
Solution I: 25mM Tris HC1 pH 8.0, lOmM EDTA, 50mM 
glucose.
Solution II: 0.2 M Na OH, 1% SDS.
Solution III: 3M K+ 5M Acetate- pH 4.8.
Pronase Buffer: 20mM Tris HC1 pH 8.0., ImM EDTA, 0.1M 
NaCl, 0.01% Triton X100.
RNA sample buffer: 50% formamide, 2.2M formaldehyde, 1 
x northern gel buffer.
SSC, 20 X: 3.0M NaCl, 0.3M Na Citrate.
SSPE, 20 X: 3.6M NaCl, 0.2M Na Phosphate, pH 7.7,
0.02M Na2EDTA.
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Abstract— The human malignant melanoma cell line NKI4 contains a novel transforming gene 
which was identified using DNA transfection into NIH 3T3 cells (1). This gene has been 
assigned to chromosome 19pl3.2-ql3.2 using human-mouse and human-hamster somatic 
cell hybrids.
INTRODUCTION MATERIALS AND METHODS
Human protooncogenes have been de­
fined both by homology to the oncogenic 
sequences present in acute transforming retro­
viruses (2) and in their activated form by 
direct transformation of target cells in vitro 
(3). Specific chromosomal translocations are 
a feature of several human tumors (4). In 
several cases these chromosomal rearrange­
ments occur next to known protooncogenes. 
The chromosomal location of a protooncogene 
may therefore have implications for carcino­
genesis.
A recent report described the isolation 
and cloning of a novel transforming gene 
found in the human malignant melanoma cell 
line NKI4 (1). This gene has been named 
according to convention, M EL  (5, 6). Using 
somatic cell hybrids we have mapped the 
M EL  gene to chromosome 19.
5Author to whom reprint requests should be addressed.
Cells. All cell lines were maintained in 
RPM1-1640 medium With 10% fetal calf 
serum, penicillin, and streptomycin at 37°C 
with a 5% C 0 2 atmosphere. To retain human 
chromosomes X or 17, where appropriate, 
media were supplemented with HAT medium 
(hypoxanthine 10-4 M, methotrexate 10-5 M, 
thymidine 1.6 x 10~5 M).
All hybrids were checked for the pres­
ence of human chromosomes by isoenzyme 
(7) and karyotype analysis (8, 9) at the same 
passage as that used to prepare high-molecu- 
lar-weight genomic DNA. All the hybrids 
used in the work have been described previ­
ously and are referenced in the text and Ta­
ble 1.
M EL Probe. The probe used was a 200- 
base pair genomic DNA fragment (pNK 200) 
subcloned from the lambda clone ANK/16 
(1). Sequence data shows this probe is poten­
tially coding in one reading frame and cDNA
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Table 1. Hybridization of H um an-M ouse and Human-Hamster Somatic Cell Hybrids with MEL  Probe
MEL
Chromosome'
Ref.1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X
S1R19A + + + + _ + _ + + _ + + + + + + _ + + + _ + tr + 13
PotB2/B2 + - - - - - - - - - - - + - - - + - + - - - - 18
DUR4R3 + - + - + - - - + + + + - - • + - + + + + - 17
LSR34 + ■ + + - + • - + - - + + + + - + + + + - + 19
LSR8 + + + + + + + • - + + - + + + + + + - + - + 19
WILF + + 11
Mog2.E.ii + - - + + - + - • + + - - + ■ + + + - + - + 25
Mog2.E.5 - - + + - + + - + + + + + + + + - - + + + 25
DT1.2R - + - - - + • - + - + ■ + - + + + - 17
CTP34B4 - ■ ■ + - - + ■ ■ - - - tr - + ■ tr + - - - - + 17
CTP41A2 - - + + - - + + - - - - - - + - - - - - - - + 16
3W4CL7 - - - - - + - - + + + ■- + ■ - + - - - + + 17
DUR4.3 - - ■ - • - - - + + + + + + - + + - + + • + 16
C4A ■ + 16
298-10 + - + + + - + + - + - - - - - 20
FIR5 — — — — — — + — — — — — — + — — — + — — — — ■ 17
F4Scl3C112 - ■ - - - - + - - + - - - - - - + 16
CLONE21E ■ 21
Horl9D2Rl + 16
SIR74ii + + tr + - + + - + tr - - + tr + 16
298-6 - - - - - + ~b - - + - ■ - - - - - 20
Discordancy (%) 50 50 45 50 57 40 30 33 20 50 40 38 44 29 43 50 44 40 100 50 50 20 33
a+ = chromosome present; —= chromosome absent; and tr = trace.
clones have been isolated by using this frag­
ment to screen a normal human fibroblast 
cDNA library. The weak homology originally 
observed to members of the R A S  gene family 
was due to CG richness (Padua and Hughes, 
unpublished results).
Southern Blot and Hybridization. Stan­
dard procedures were used for the isolation of 
genomic DNA, restriction enzyme digestion, 
Southern blot transfer, radiolabeling of 
probes, and hybridization (10).
RESULTS
Ten to fifteen micrograms of human, 
mouse, and somatic cell hybrids DNAs were 
cleaved with the enzyme EcoRI; this DNA 
was separated by electrophoresis and immo­
bilized on a nitrocellulose filter. The filter was 
probed with the 200-base pair M EL  specific 
probe which hybridizes to 5.5-kb human, 6.6- 
kb mouse, and 3.9-kb hamster bands in Eco- 
Rl-cleaved DNA. This differs from the 
restriction pattern observed in the NIH3T3 
transformants from NKI4 (1) where 16-kb
and 6.6-kb EcoRI fragments hybridized to the 
probe. This suggests that these sequences have 
been rearranged in the transformants. Activa­
tion of the R E T  protooncogenes as a result of 
rearrangements has been reported (22).
A panel of 21 hum an-m ouse and 
human-hamster somatic cell hybrids was 
screened using this M EL  specific probe. Seven 
of these were positive (Table 1), including the 
hybrid WILF-1 which contains fragments of 
human chromosome X and 19 and little other 
detectable human material (11). The only 
chromosome to show complete concordance 
with the presence of the human c-M EL  gene is 
chromosome 19. An example of hybridization 
to human, cleaved mouse, and hybrid DNAs 
with EcoRI using the M EL  probe can be seen 
in Fig. 1.
To further localize the position of the 
M EL  gene within chromosome 19, we used 
DNA from three different hybrids containing 
chromosome 19 translocations. The first, 
G1711B (12), contains t(19,X )19ql3.2-> 
1 9 p te r::X q te r—>Xq23-25; th e  second, 
G 24B 2A M B  (1 2 ), co n ta in s  t(1 9 ,X )
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Fig. 1. M apping of c-M E L  to chromosome 19. Fifteen m icrogram s of EcoRI-digested D N A  was electrophoresed, 
transferred to nitrocellulose filters, and hybridized (10) to 106 cpm /m l of 32P-labeled pN K 200 (specific activity =  108 
cpm //ig ). Panel A, m ouse-hum an hybrids: lane a, M O G  2.E.5 hybrid ( - ) ;  b, M O G 2.E.ii hybrid ( +  ); c, W IL F  1 
hybrid ( +  ); d, N IH 3T 3 mouse; e, N K I4  hum an. Panel B, ham ste r-hum an  hybrids: lane f, C4A hybrid ( —); g, 298-10 
hybrid ( —); h, 298-6 hybrid ( —). +  =  c-M E L  present, — =  c-M E L  absent. H ind lll-d igested  XC1857 D N A  served as 
m olecular weight m arker.
19p 13.2—>►19qter::Xqter—*Xcen-ql3; and the 
th ird , G M 9 8 A 9 9 c7 B  (1 2 ) ,  con ta in s  
1 9q 1 3 .3—► 1 9qter::X pter-X q22. Hybrids 
G24B2AMB and G 171 IB both hybridized 
with the M E L  probe and GM 89A99c7B was 
negative (Fig. 2). These results localize the 
M E L  gene to 19 p l3 .2 -q l3.2 as shown in 
Fig. 3.
DISCUSSION
The M E L  gene is assigned to human 
chromosome 19 and localized to 19p 13.2- 
ql 3.2. Several transforming genes have been 
shown to be active in the NIH3T3 assay. 
Members of the R A S  gene family have regis­
tered most frequently in this assay. R A S -  
related genes or pseudogenes have been iden­
tified in the human genome on five different 
chromosomes. N R A S  has been assigned to 
chromosome 1 (3), H R A S 1  and -2 have been 
assigned to chromosomes 11 and X (14), 
K R A S  I and -2 have been assigned to chromo­
somes 6 and 12, respectively (14). Other novel 
oncogenes identified using this assay, such as 
M E T , have been assigned to chromosome 7 
(23); the ERB-Wkt N E U  gene has been 
assigned to chromosome 17 (24). Therefore,
a b c d e
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Fig. 2. Sublocalization of c-M E L  on chromosome 19. 
Ten m icrogram s of EcoRl-digcstcd D N A  was electropho­
resed, transferred to nitrocellulose filters, and hybrid­
ized (10) to 106 cpm /m l of ,2P-labeled pN K 200 (specific 
activity = 10s cpm /jug). Lane a, G 171 IB hybrid ( +  ); b, 
G 24B2A M B hybrid ( +  ); c, G M 98A 99c7B  hybrid ( - ) ;  
d, N IH 3T3 mouse; and e, N K I4  hum an. H indlM - 
digested AC1857 DN A  served as m olecular weight m ark ­
er.
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Fig. 3. Schematic localization of MEL  on chromosome
19. (A) GM98A99c7B; (B) G24B2AMB; (C) G1711B.
the M EL  gene does not seem to map where a 
previously described oncogene has been 
assigned.
Specific human tumors have been shown 
to be associated with chromosomal transloca­
tion, and these chromosomal rearrangements 
may occur adjacent to known protooncogenes. 
On chromosome 19 a number of specific 
translocations have been reported, in preB 
acute lymphocytic leukemia (ALL) t(l;19) 
(q23;pl3.3), in an acute nonlymphocytic leu­
kemia (ANLL) and ALL t(ll;1 9 ) (q23;pl3), 
and in B-chronic lymphocytic leukemia (B- 
CLL) t(14;19) (q32;ql3). In malignant mela­
noma, translocations and deletions have been 
reported involving chromosomes 1 and 6. No 
gross chromosome abnormalities have been 
reported involving chromosome 19.
A more precise regional localization for 
the M EL  oncogene will be required before it is 
possible to speculate on the relationship 
between M EL  and any specific transloca­
tions.
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A c-DNA probe for the oncogene c-MEL (pC7-l) recognises a polymorphism with Ncol
Elaine R.Nimmo, Rose Ann Padua12, David Hughes1-2, Robert Williamson and Keith Johnson
Department of Biochemistry, St. Mary’s Hospital Medical School, Norfolk Place, London W2 IPG and 1Marie 
Curie Memorial Foundation, Research Institute, The Chart, Oxted, Surrey RH8 OTL, UK
SOURCE AND DESCRIPTION. A 2kb EcoRI fragment of the human MEL 
oncogene c-DNA inserted into pEMBL8 .
POLYMORPHISM. Ncol (C/CATGG1 identifies two alleles with bands
at 4 . Okb and 3.8k b . Constant bands of 8kb, 4.3 k b , 2.h 5 k b ,
2 .1kb and 1.95kb are seen.
FREQUENCIES. Studied in 32 unrelated individuals.
4.Okb allele 73.4?
3 -8kb allele 26.65
NOT POLYMORPHIC FOR. AccI , Alul, Aval, Avail, BamHI, Bell, 
Bgll, Bglll, Clal, EcoRI, Haelll, HincII, Hindlll, Hlnfl, H p a l , 
Hpall, K p n l , MspI, PstI, Pvul, PvuII, Rsal, Sail, Sau3A, Smal, 
T a q I , T t h l l l , Xbal, Xhol.
CHROMOSOMAL LOCATION. Localized to chromosome 19 using a panel 
of human-hamster and human-mouse hybrids.
MENDELIAN INHERITANCE. Co-dominant segregation demonstrated in 
4 families.
PROBE AVAILABILITY. Available for collaborators, contact 
D.Hughes or R.A.Padua.
o
OTHER COMMENTS. Wash at 65 C, 0.1 X SSC.
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B S T R A C T
Human thyroid epithelial (follicular) cells give rise to two malignant 
imors— “follicular” carcinomas, which metastasize almost exclusively 
ia the bloodstream, and “papillary” carcinomas, which metastasize 
redominantly via lymphatics (Williams, E. D. In: W. Duncan (ed.), 
lecent Results in Cancer Research: Thyroid Cancer, pp. 47-55. Berlin: 
ipringer-Verlag, 1980). We have investigated whether this contrast in 
iological behavior might be associated with different patterns of onco- 
ene activation. DNA transfection analysis of five follicular and ten 
apillary cancers indeed showed a statistically significant difference in 
he pattern of genes responsible, activated m s  oncogenes being found in 
0% of follicular tumors but only 20% of papillary tumors. In addition, 
i  follicular cancers we have found activation of all three ras oncogenes 
H-ras, K-ras, and N-ras), the first time that this has been demonstrated 
n a primary human tumor type (as opposed to cell lines). We suggest 
herefore that ras activation may be an important determinant of met- 
static capability in these epithelial cancers.
INTRODUCTION
Activated oncogenes of the ras family have been identified in 
a wide range of solid and hematological malignancies, but 
usually in only about 10 to 15% of cases of randomly selected 
tumors (1). There is some evidence to suggest a specificity of 
activation of one oncogene in a particular tumor type (notably 
H-ras in urinary tract tumors, K-ras in colon and lung cancers, 
and N-ras in hematological neoplasms; see Ref. 1 for review), 
and in some experimental model systems there are definite 
associations of certain ras oncogene mutations with individual 
etiological agents, including chemical carcinogens and ionizing 
radiation (1).
Although thyroid carcinoma is a relatively uncommon clini­
cal malignancy, it has special interest for two reasons, (a) A 
single epithelial cell type (the thyroid follicular cell) may give 
rise to two malignant differentiated tumor types (follicular 
carcinoma and papillary carcinoma) with very different patho­
logical features and clinical behavior. (b) Papillary thyroid 
cancer has a well-known association with previous accidental 
or therapeutic radiation exposure. We therefore investigated 
the possibility that the marked contrast in tumor characteristics 
might be associated with differences in oncogene activation, 
using the focus-induction and nude mouse tumorigenicity as­
says to search for dominant transforming genes, including those 
of the ras family. [We previously published a brief preliminary 
report of transforming activity due to activated H-ras in 2 cases 
of follicular thyroid cancer (2).]
MATERIALS AND METHODS
Tumor Material. The human tumor tissue analyzed in this study was 
mostly obtained from surgical specimens removed at the University
Received 1/27/88; revised 5/16/88; accepted 5/20/88.
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Hospital cV Wales in Cardiff, but cases were also kindly provided by 
Dr. P. A. Hall o f  St. Bartholomew’s Hospital in London, United 
Kingdom, and C. A. Pegg o f City Hospital in Nottingham, United 
Kingdom. One patient contributed both a follicular cancer (HFC4) and 
a papillary cancer (HPC9) which had been surgically removed on 
different occasions. Brief details are provided in Table 1.
Transfection Assays. The focus induction assay was performed by 
the protocol which we have previously described (3). The tumorigenicity 
assay, which depends upon in vivo selection o f transformed cells (4), 
was performed essentially as described by Fasano et al. (5) using 
cotransfection o f the dominant drug-resistant selectable marker 
pSV2neo (6) followed by G4is selection. Nude mice given s.c. injections 
of pooled cells were observed for 3 mo.
Southern Blot Analysis. This was performed as previously described 
(7), using nylon filters (Hybond; Amersham International). Human 
repetitive sequences were detected with the 0.3-kilobase insert o f  
BLUR8 plasmid (8), labeled by a random primer method (or nick- 
translated genomic D N A  previously sonicated to average size 4 kilo- 
bases, in which case the filter was prehybridized with 50 Mg/ml o f NIH  
3T3 DN A, and the hybridization mixture also included 25 p g /m \ o f  
NIH  3T3 DNA). Human H-ras was detected using the 6.6-kilobase 
insert of pEJ (9). Human N -ras was detected using the insert o f pN R800  
(a 0.8-kilobase E coR l/Sstl  fragment derived from pAT8.8; Ref. 10) 
kindly provided by Dr. C. J. Marshall, Institute o f Cancer Research, 
London, United Kingdom. Human K-ras was detected using the insert 
o f the Amprobe K-ras, intron probe (obtained from Amersham Inter­
national) which is equivalent to the insert o f p640 (11).
Polymerase Chain Reaction Amplification and Oligonucleotide Prob­
ing. Selective amplification o f 60- to 130-base pair D N A  fragments 
surrounding the coding region o f interest in each o f the transfected ras 
genes in first round nude mouse tumors was achieved using the polym­
erase chain reaction, and oligonucleotide probing performed essentially 
as these techniques are described in Ref. 12.
RESULTS
DNAs prepared from the 5 follicular carcinomas (HFC1-5) 
and 10 papillary cancers (HPC1-10) were examined for their 
abilities to transform NIH3T3 cells, using both the focus in­
duction assay (3) as well as the cotransfection/nude mouse 
tumorigenicity assay (4, 5). The results are shown in Table 1.
DNA from only one tumor (HFC2) was capable of inducing 
foci of morphologically transformed cells in first round trans­
fection, with an efficiency of 0.01 focus//ig of genomic DNA. 
In second and third rounds of transfection all DNAs tested 
were capable of inducing foci at higher efficiencies (0.05 to 1.2 
foci/Vg of DNA).
DNAs from 5 of 5 follicular tumors and 9 of 10 papillary 
tumors registered in the nude mouse tumorigenicity assay in 
the first round of transfection, with tumors appearing within 6 
wk of injection of 107 pooled cells. In the second and third 
rounds of transfection, the latent interval to tumor appearance 
was reduced. DNA prepared from normal human leukocytes 
and tested in parallel control assays registered only a very low 
incidence of tumors (1 of 20) which appeared more than 10 wk 
after injection.
Southern blot analysis of first round nude mouse tumors with 
specific probes for oncogenes of the ras family showed that the
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Table 1 Transfection analysis o f  malignant human thyroid tumors
Transforming activity
Specimen
code DNA source
1st round 2nd round 3rd round
FA“ NMTA FA NMTA FA NMTA
HFC 1 Primary follicular Ca 0/10 6/8 10/10 3/8 4/8
HFC 2 Primary follicular Ca 2/10 3/4 20/10 6/8 6/8
HFC 3 Primary follicular Ca 0/10 4/4 240/10 5/8 4/4
HFC 4 Primary follicular Ca 0/10 4/4 186/10 4/4
HFC 5 Primary follicular Ca 0/10 3/4 3/4
HPC 1 Primary papillary Ca 0/10 2/4 3/8 4/8
HPC 2 Primary papillary Ca 0/10 0/4
HPC 3 Lymph-nodal metastasis 0/10 1/4 1/4
of papillary Ca
HPC 4 Lymph-nodal metastasis 0/10 2/4 2/8
of papillary Ca
HPC 5 Lymph-nodal metastasis 0/10 3/4 6/8
of papillary Ca
HPC 6 Primary papillary Ca 0/10 4/4 1/4
HPC 7 Lymph-nodal metastasis 0/10 2/4 4/4
of papillary Ca
HPC 8 Primary papillary Ca 0/10 1/4 3/4
HPC 9 Primary papillary Ca 0/10 3/4 3/4
HPC 10 Primary papillary Ca 0/10 3/4 3/4
“ FA, focus induction assay, results expressed as (number of foci)/(number of 
dishes of 1.5 x  105 NIH3T3 cells transfected); NMTA, nude mouse tumorigenicity 
assay, results expressed as (number of tumors)/(number of sites injected with 
pooled geneticin-resistant colonies from 2 or 3 dishes, approximately 5 x 106 
cells); Ca, carcinoma.
NIH FC FC 
wbc 3T3 1 3
23.1
9.4 
6.6
4.4
2.3
2.0
Fig. 1. Detection of human Ha-ras sequences in first round transfectants. Ten 
Mg of each DNA were digested with BamHl, electrophoresed in 0.7% agarose, 
and transferred to a nylon filter. Hybridization was carried out with the insert of 
pEJ (7) which is specific for human Ha-ras. wbc, normal human leukocyte DNA; 
NIH , NIH3T3 DNA; FC1, FC3, first round transfectant DNAs obtained after 
transfection of genomic DNA from these follicular cancers (Table 1).
transforming activity was due to human K-ras in 2 cases (HFC2, 
HPC4), human N-ras in 2 cases (HFC4, HPC10), and human 
H-ras in 2 cases (HFC1, HFC3) (Figs. 1 to 3). These results 
indicate that 80% of follicular cancers analyzed possessed an 
activated ras oncogene, in contrast to only 20% of papillary 
cancers (Table 2).
No signal was detected with ras oncogene probes in the DNA 
of nude mouse tumors derived from transfection of DNA from 
the other 9 cases. Hybridizations of the DNA from second and 
third round nude mouse tumors from these cases with the
NIH FC PC 
wbc 3T3 4 10
-
— 23.1
— 9.4
—  6.6
-  4.4
-  2.3
-  2.0
Fig. 2. Detection of human N-ras sequences in first round transfectants. Ten 
Mg of each DNA were digested with EcoRI, electrophoresed in 0.7% agarose, and 
transferred to a nylon filter. Hybridization was carried out with the insert of 
pNR800 (8) which is specific for human N-ras. wbc, normal human leukocyte 
DNA; NIH, NIH3T3 DNA; FC4, PC10, first round transfectant DNAs obtained 
after transfection of genomic DNA from a follicular cancer (FC4) and a papillary 
cancer (PC 10); see Table 1.
NIH
wbc 3T3
FC PC 
2 4
_  4.4
-
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Fig. 3. Detection of human Ki-ras sequences in first round transfectants. Ten 
Mg of each DNA were digested with EcoRI, electrophoresed in 0.7% agarose, and 
transferred to a nylon filter. Hybridization was carried out with a human Ki-ras 
intron probe (9). wbc, normal human leukocyte DNA; NIH, NIH3T3 DNA; FC2, 
PC4, first round transfectant DNAs obtained after transfection of genomic DNA 
from a follicular cancer (FC2) and a papillary cancer (PC4); see Table 1.
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Table 2 Transforming genes in human thyroid cancer
Follicular
carcinoma
Papillary
carcinoma
j Transforming activity 5/5 9/10
Activated ras genes, total 4/5 2/10
H-ras mutants H-ras 61 arg
H-ras 61 arg
N-ras mutants N-ras 61 arg N-ras 61 arg
K-ras mutants K-ras 12 ser K-ras 13 asp
CON FC1 FC3
NIH
3T3
FC1
Nu1
FC3 
Nu 1
CON FC4 P C 10
NIH FC4 PC10
3T3 i' Nu1 ir NU1
N12wt
N61 wt
H12wt
N61 arg
H61 wt
H61arg
Fig. 4. Slot-blot analysis for mutations of human H-ras at codons 12 and 61. 
Only the filters that showed specific hybridization at the discriminating temper­
ature are illustrated. In addition to the normal H-ras allele present in each of the 
primary tumors HFC1 and HFC3, there is also an abnormal H-ras allele with 
mutation at codon 61 substituting arginine in place of glutamine. The activated 
human H-ras oncogenes present in NIH3T3 transfectants (HFC1 N u l and HFC3 
N ul)  derived from these cases possess an identical mutation to that present in 
the primary tumor. CON, normal leucocyte DNA. H12 primers, CTGAG- 
GAGCGATGACGGAAT and AGTGGGGTCGTATTCGTCCA; H61 primers, 
GTCATTGATGGGGAGACGTG and ACACACACAGGAAGCCCTCC; H I2 
glycine (wild type), TACTCCTCTTGACCTGCTGT (sense); H61 glutamine 
(wild type), TACTCCTCCTGGCCGGCGGT (antisense); H61 arginine, 
TACTCCTCCCGGCCGGCGGT (antisense).
BLUR8 probe (9), and similarly with labeled genomic DNA, 
show the presence of human repetitive sequences (data not 
shown), but the genes responsible have not yet been identified.
In order to identify the mutation responsible for the trans­
forming activity in the cases where human ras oncogenes were 
detected in transfection assays, we used a panel of oligonucle­
otide probes specific for all possible mutations at codons 12 
and 61 of the human H-ras, K-ras, and N-ras genes, and also 
at codon 13 of human K-ras and N-ras. In each case the presence 
of the activating mutation of the relevant ras oncogene was 
confirmed in the original primary thyroid tumor DNA and the 
nude mouse tumors derived by transfection (Table 2).
As shown in Figs. 4 and 5, mutation at codon 61 was detected 
in the H-ras genes transfected from both HFC1 and HFC3 and 
in the N-ras genes transfected from HFC4 and HPC 10. In all 
these cases the mutation was an A to G transition in the second 
nucleotide of the codon, resulting in arginine at position 61 
instead of the normal glutamine. In the two cases involving K- 
ras, different mutations were identified (see Fig. 6): the K-ras 
allele derived from HFC2 possessed a codon 12 mutation (G 
to A transition in the first nucleotide) resulting in serine instead 
of glycine at this position, while the K-ras allele derived from
Fig. 5. Slot-blot analysis for mutations of human N-ras at codons 12 and 61. 
In addition to the normal N-ras allele present in each of the primary tumors 
HFC4 and HPC 10, there is also an abnormal N-ras allele with mutation at codon 
61 substituting arginine in place of glutamine. The activated human N-ras 
oncogenes present in NIH3T3 transfectants (HFC4 N u l  and HPC10 N u l)  derived 
from these cases possess an identical mutation to that present in the primary 
tumor. CON, normal leucocyte DNA. N12/13 primers, CTGGTGTGAAAT- 
GACTGAGT and GGTGGG AT CAT ATT CAT CTA; N61 primers, GTTATA- 
GATGGTGAAACCTG and ATACACAGAGGAAGCCTTCG; N12 glycine 
(wild type), GGAGCAGGTGGTGTTGGGAA (sense); N61 glutamine (wild 
type), ACAGCTGGACAAGAAGAGTA (sense); N61 arginine, 
ACAGCTGGACGAGAAGAGTA (sense).
HPC4 had a codon 13 mutation (G to A transition in the 
second nucleotide) that substitutes aspartic acid for glycine at 
this position.
DISCUSSION
The detection of serially transmissible transforming activity 
in 100% of the follicular cancer DNAs and 90% of the papillary 
cancer DNAs studied was an unexpected finding, since previous 
studies have shown only 10 to 20% of randomly selected human 
tumors to contain transforming genes detectable by transfection 
assays (13,14). The only previous report of oncogene activation 
in human thyroid cancer (15) analyzed solely papillary cancers 
and found a lower frequency of transforming activity (25%) 
than that shown in our study of these tumors (90%). Those 
authors conclude that the transforming activity could be as­
cribed to a putative novel oncogene in human papillary cancer. 
Our finding of a higher rate of transforming activity is most 
likely explained by the greater sensitivity of the tumorigenesis 
assay, as reported previously (5). Indeed, only one of the trans­
forming genes in our tumors (the mutant K-ras allele of HFC2) 
was detectable by the focus induction assay.
In most transfection studies of human tumor material, trans­
forming activity has been found to be due to a member of the 
ras oncogene family (for review see Ref. 1). Activated K-ras 
oncogenes have been found in tumor tissue from a wide range 
of neoplasms (but especially carcinomas of lung and colon) and 
activated N-ras oncogenes most often in hematological malig­
nancies; in contrast, activated H-ras can be found in only a 
relatively small number of carcinomas (notably bladder cancer 
(16)) and melanoma cell lines (17). It is possible, however, that 
the true frequency of ras oncogene activation (particularly K- 
ras activation) is underestimated by transfection studies, since
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CON FC2 PC4
NIH FC2 PC4
, 3T3 r Nu 1 ■, Nu1
K61 wt
K21 wt
K12ser
K13asp
Fig. 6. Slot-blot analysis for mutations of human K-ras at codons 12, 13, and 
61. In addition to the normal K-ras allele present in each of the primary tumors 
HFC2 and HPC4, there is also an abnormal K-ras allele: in HFC2 there is a 
mutation at codon 12 substituting serine for the normal glycine; and in HPC4 
there is mutation at codon 13 substituting aspartic acid for the normal glycine. 
The activated human K-ras oncogenes present in NIH3T3 transfectants (HFC2 
N ul and HPC4 N ul)  derived from these cases possess an identical mutation 
to that present in the primary tumor. CON, normal leucocyte DNA. K12/13 
primers,CCTGCTGAAAATGACTGAATandTGTTGGATCATATTCGTCCA; 
K61 primers, GT AATTGATGGAGAAACCTG and AAATACACAAA- 
GAAAGCCCT; K12/K13 glycine (wild type), CCTACGCCACCAGCTCCAAC 
(antisense); K12 serine, GTTGGAGCTAGTGGCGTAGG (sense); K13 aspartic 
acid, GTTGGAGCTGGTGACGTAGG (sense); K61 wild type, TACTCCTCTT- 
GACCTGCTGT (antisense).
in a parallel analysis of colonic cancers RNase A mismatch 
cleavage demonstrated mutant K-ras genes in 39% (26 of 66), 
while transforming activity was detected in only 20% (6 of 30) 
by the focus induction assay (18).
Our finding of a high frequency of ras oncogene activation in 
follicular cancers (80%) is made more intriguing by two other 
observations, (a) Activated alleles of all three ras oncogenes (li­
ras, K-ras, and N-ras) were found in this tumor type, which we 
believe is a novel finding since to our knowledge, activation of 
all three members of the ras oncogene family has never been 
reported in tissue samples (as opposed to derived cell lines) 
from a single tumor type. (b) There appears to be a preferential 
mechanism of activation, namely, replacement of glutamine by 
arginine at position 61 in all of our H-ras or N-ras samples. 
Previously this mutation has been reported sporadically, for 
instance, in two urinary tract tumors (16, 19) and in a propor­
tion of cases of acute myeloid leukemia (20-22). Mutation of 
K-ras to give serine at position 12 has been reported in carci­
nomas of the stomach and colon (19, 23). Mutation of K-ras to 
give aspartic acid at position 13 had recently been described in 
bone marrow cells of a patient with myelodysplastic syndrome 
(24) and in the breast cancer line MDA-MB231 (25).
The relative strength of signal detected after hybridization of 
replicate filters with wild-type and mutant specific probes sug­
gests that, in most of our cases, there are fewer copies of the 
mutant ras oncogene than of the normal ras allele in the DNA
of the primary tumors. Of course, a normal allele is present i 
all tumor cells that are heterozygous for the mutant gene, an 
uninvolved stromal cells will have two copies of the norm 
gene. However, in one case (HFC 3) the signal with mutai 
probe is stronger than that with wild-type probe, suggestin 
that the activated oncogene is present in slightly greater cop 
number than the normal allele. In this study it was not possibl 
to assess the proportion of tumor cells which possess th 
activated gene, since DNA was extracted from homogenize 
tumor tissue, but we are carrying out a more detailed investi 
gation of other tumors (using DNA extracted from tissue sec 
tions) to correlate histopathological features with ras muta 
tions.
Our finding of a marked difference in the frequency of acti 
vated ras oncogenes detectable by transfection assays in papil 
lary cancers (20%) compared with follicular cancers (80% 
suggests a connection between this pattern of oncogene activa 
tion and the marked difference in biological behavior of thesi 
tumor types, both derived from the follicular epithelial cell 
Papillary carcinoma is typically multifocal and not encapsu 
lated, invades the lymphatics, and metastasizes to the loca 
lymph nodes. Follicular carcinoma is typically solitary anc 
encapsulated, invades veins, and when it metastasizes ofter 
involves bones and lungs (26).
Transfection experiments have shown that the metastatic 
potential of tumor cells may be modified by introduction of an 
activated ras oncogene, and it has been suggested that ras gene 
product may trigger a program of metastasis that is specific for 
the particular cell type (27, 28). Transfection of an activated 
H-ras oncogene enhanced the spontaneous metastasis of 
MTIC1.5/7 mouse mammary carcinoma cells (29) and also 
induced the spontaneous metastasis of SP1 mouse mammary 
carcinoma cells (30), after s.c. inoculation in nude mice (the 
predominant target for metastasis in both these studies was the 
lungs). This preferential hematogenous metastasis after intro­
duction of the activated ras oncogene into carcinoma cells has 
much in common with the almost exclusively hematogenous 
metastasis of follicular thyroid cancers in which we have iden­
tified a very high frequency of ras oncogene activation.
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ACTIVATION OF Ha-ras IN HUMAN CHRONIC GRANULOCYTIC 
AND CHRONIC MYELOMONOCYTIC LEUKAEMIA
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Abstract—DNAs from chronic granulocytic leukaemia (CGL) and chronic myelomonocytic leukaemia 
(CMML) were assayed for transforming genes by transfection into NIH 3T3 cells. Foci DNA was 
tagged with a geneticin-resistance cosmid, then followed through a drug selection and tumorigenicity 
assay. Activated Ha-ras genes, with point mutations at codon 12 (glycine to valine) were subsequently 
detected. The mutation was detected in the original samples by either Mspl/Hpall digestion or 
polymerase chain reaction (PCR). Although mutations in the ras gene family may occur frequently 
in leukaemias, these are the first examples of Ha-ras mutations in CGL (blast crisis) and CMML.
Key words: Chronic granulocytic leukaemia, chronic myelomonocytic leukaemia, Ha-ras oncogene.
chromosomal translocation was present. DNA from per­
ipheral blood was obtained on 12.11.82 and frozen for 
future study.
Patient MB presented in February 1983 with pleural and 
pericardial effusions. The white blood count was 46 x 109/1 
with 94% monocytes and promonocytes. Her bone marrow 
showed trilineage dysplasia and a diagnosis of chronic 
myelomonocytic leukaemia was made. Her disease was 
controlled by low dose etoposide for 18 months before she 
transformed to AML (M5). This responded to intensive 
chemotherapy but she relapsed one year later and died 
from CNS disease. DNA was obtained from peripheral 
blood in February 1983. Both samples of DNA were used 
in transfection experiments in June 1985.
Methods
Human DNA samples (20 pg) were transfected into 
3 x 10s NIH3T3 cells which had been seeded into 25 cm2 
flasks 24 h earlier. Focus formation was scored after 3 
weeks [6]. Anchorage independent assays were carried out 
in 0.3% noble agar and scored 2-3 weeks after plating [7].
High molecular weight DNA (>100 kb) was partially 
digested with Sau 3A to a size range of 30-40 kb and ligated 
to the BamHI site of pHSG272. Transfection and G418 
selection was essentially as described by Brady et al. [8]. 
Female, 3-week old, athymic nude mice (OLAC) were 
injected subcutaneously with 1 x 106 G418-resistant cells 
(representing around 5000 colonies) and resultant tumours 
harvested after 19 days. Tumour DNA was either analysed 
directly or used in further rounds of transfection.
For DNA analysis, 20 pg of high molecular weight 
transformant DNA was digested with BamHI and elec­
trophoresed on 0.8% agarose gels. DNA was transferred 
to Hybond N (Amersham) and hybridised to the v-Ha-ros 
probe BS9 [9]. Transformed DNA (40 pg) was digested 
with SStl and electrophoresed on 0.5% agarose gels. The 
gels were dried and hybridised to 32P-labelled oligomer
INTRODUCTION
DNA  m e d ia te d  gene transfer techniques have 
enabled the detection of activated transforming genes 
in many animal and human neoplasia [1]. A ltered N- 
and Ki-ras genes have been detected in cell lines and 
tumours from leukaemic samples [2,3]. Recently two 
examples of H a-ras activation in acute myeloid leu­
kaemia (AML) and acute lymphocytic leukaemia 
(ALL) were reported [4,5]. We present here two 
examples of c-Ha-ras with a point mutation at codon 
12 which were identified in chronic myelomonocytic 
leukaemia (CMML) and chronic granulocytic leu­
kaemia (CGL) in blast crisis.
PATIENTS AND M ETHODS
Patients
Eight patients were studied; two with the myelo- 
dysplastic syndrome and six with chronic granulocytic syn­
drome (four in chronic phase and two in blast crisis). 
Details of the index cases are as follows: Patient AS 
presented in December 1982 with a white blood count of 
120 x 109/l with 70% blasts. The blasts were positive for 
MHC class II antigens and for CD33 but negative for 
lymphoid, erythroid and platelet antigens. The 9;22
Abbreviations: CGL, chronic granulocytic leukaemia; 
CMML, chronic myelomonocytic leukaemia; PCR, 
polymerase chain reaction.
Correspondence to: Dr J. Gow, Leukaemia Research 
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probes at 60°C in 5 x SSPE (20 x SSPE = 3.6 M NaCl, 
200 mM NaH2P 0 4, pH 7.4, 20 mM EDTA), 0.1% SDS, 
200 pg/ml tRNA, 100 pg/ml calf thymus DNA. The gels 
were washed to remove mismatched hybrids at 75°C in 
5 x SSPE. Hindlll digested C1857 DNA was used for 
molecular weight markers. The polymerase chain reaction 
(PCR) was carried out as described in Saiki et al. [10]. 
The PCR primers for Ha-ras were 20-mer oligo­
nucleotides; CTGAGGAGCGATG ACGG AAT and 
AGTGGGGTCGTATTCGTCCA.
RESULTS
DNAs isolated from eight patients, including two 
patients with myelodysplasia (one R A , one CMML) 
and six patients with Ph positive CGL (four in chronic 
phase, two in blast crisis), were transfected into 
NIH3T3 cells [6] and produced low transformation 
frequencies. Only those transformants which demon­
strated both human repetitive sequences and anchor­
age independent growth [7] were assayed in further 
rounds of transfection. The CMML and the CGL 
blast crisis samples produced secondary and tertiary 
foci and were investigated further (Table 1). The 
other samples will be discussed elsewhere (Padua et 
al., in prep.).
Hybridisation of D N A  from transformants to H a­
ras, Ki-ras, N-ras, abl, myc, sis, fm s, erb ,fos  and rel 
clones showed no homology to expected human-sized 
fragments and hybridised only to the mouse bands 
(data not shown).
High molecular weight DN A (>100 kb) was iso­
lated from a first cycle transformant from the CMML 
patient and a third cycle transformant from the CGL 
blast crisis patient. The DNAs were partially digested 
with Sau 3 A  to yield 35-45 kb fragments and sequen­
tially ligated [8] to BamHI-digested cosmid pHSG272 
containing the neomycin-resistance selectable 
marker. Using a modification of the calcium phos­
phate precipitation technique the DNAs were 
transfected into NIH3T3 cells, selected for G418-
resistance and the colonies injected into athymic 
nude mice (106 cells/site of injection).
Tumours (0.5 cm diameter) were harvested on day 
19 (no tumours in control animals after 50 days). 
DN A was then extracted and analysed by Southern 
blotting for the presence of both cosmid and human 
repetitive sequences. These sequences were readily 
detectable in DNA derived from tumours produced 
by transformants of both the CMML and the CGL 
blast crisis samples (data not shown). The focus form­
ing frequency of the DNA from these tumours 
increased from 0.04 to 8.0 and 6.0 foci/pg, 
respectively. A t this stage, the morphology of the 
third round “tagged” transformants appeared “ras- 
like” and isolated DNA was therefore hybridised to 
members of the ras gene family. Ha-ras sequences 
were detected (Fig. 1).
Using 20-mer synthetic oligonucleotides [11] the 
m utation in both CMML and CGL G418R-tagged 
transformants was shown to occur in the 2nd base of 
codon 12 G—>T (glycine to valine), a similar mutation 
to that detected in bladder carcinoma (EJ) [12] (Fig. 
2).
Point mutations around amino acid positions 12, 
13 and 61 have been shown to result in the activation 
of ras genes (see [1,2]). The normal ras sequence 
at amino acid position 12 encodes a M spl/H pall 
restriction site. W hen c-Ha-ras is digested with MspI 
and H p a ll and probed with a 600 bp Smal fragment 
containing the first exon of c-Ha-ras [13], a fragment 
355 bp in size is detected. A  mutation in amino acid 
position 12 abolishes the restriction site resulting in 
a larger 412 bp fragment. To determine whether the 
mutation was present in the original CGL sample, 
DNA  was extensively digested with M spl/H pall. 
The 412 bp fragment was detected (in addition to the 
normal allele at 355 bp), indicating a mutation in the 
amino acid at position 12 (Fig. 3a, lane b).
Very little CMML relapse DNA was available 
(approx. 5 pg), representing very few blast cells
T a b l e  1. T r a n s f o r m i n g  a c t i v i t y  o f  DNA f r o m  CMML a n d  GCL b l a s t  c r i s i s
Transformation frequency 
(Foci/pg of DNA)
1st round 2nd round 3rd round
Anchorage
independence Blur 8
Controls
3T3 0.03 ND ND - -
Human blood leukocytes 0.05 ND ND - -
EJ bladder carcinoma 0.13 >1.2 >1.6 + -1-
Patients
CMML 0.04 0.08 0.03 + +
Blast crisis 0.12 0.09 0.04 + +
Blur 8: human Alu repeat sequence probe (Amersham).
Kb a b c d e f g h i j
23.1-
9.4- 
6.6-
4.4-
2.3
F ig . 1. Detection of Ha-ras sequences. Lane a: First round 
CMML transformant DNA; b,c,d: DNA from three inde­
pendently picked third round G418R-tagged CMML 
transformants; e: third round CGL transformant DNA; 
f,g,h: three independently picked fifth round G418R-tagged 
CGL transformants; i: NIH3T3 DNA; j: EJ second round *
transformant DNA. Blots were hybridised to 32P-labelled 
v-Ha-ras probe BS9 [9]. Human BamHI band arrowed, 
lower band represents the endogenous mouse sequence.
B
d e f g h i Kb
23.1
a b c d e f g h i
9.4 m 
6.6
4-4 !#;
2.3
2.0
F ig . 2. Identification of the Ha-ras mutation by synthetic 
oligonucleotide hybridisation. Lane a,b,c: DNA from inde­
pendently isolated third round G418R-tagged CMML 
transformants; d,e,f: DNA from fifth round G418R-tagged 
CGL blast crisis transformants; g: NIH3T3 DNA; h: RPMI 
5966 DNA (melanoma cell line with normal Ha-ras alleles); 
i: EJ secondary transformant (bladder carcinoma cell line) 
DNA. 2.9 kb human SStI band arrowed. Dried gels were 
hybridised to 32P-labelled oligomer probe H12WT (Panel 
A) or H12Val (Panel B). H12WT sequence: 5'- 
GTGGGCGCCGGCGGTGTGGG-3'. H12Vai;
sequence: 5'-GTGGGCGCCGTCGGTGTGGG-3'.
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F ig . 3a. Detection of the Ha-ras mutation in human CGL 
DNA by Mspl/Hpall digestion. Lane a: DNA from third 
round G418R-tagged CML blast crisis transformant; b: 
DNA from CGL blast crisis patient; c: DNA from EJ 
secondary transformant. 40 pg DNA were analysed on a 
3% agarose gel. Note lane b shows both a normal and a 
mutated allele.
F ig . 3b. Detection of the Ha-ras mutation in human 
CMML DNA by PCR amplification and oligonucleotide 
hybridisation. 0.1 pg EJ transformant and CMML genomic 
DNA slot-blotted onto nitrocellulose and hybridised to 
H12WT (GLY) and H12Val oligo probes. 10 ng each pEC 
(normal Ha-ras) and pCT 24 (mutant Ha-ras) controls. 
Filters washed at 76°C {Tm = 74°C).
pCT 2 4
r — -""t
4
II
III
Activation of Ha-ras in CGL and CMML
(compared with 70% blast cells in the CGL sample). 
To investigate further the presence of the mutation, 
the polymerase chain reaction technique [10] was 
employed. Aliquots of the amplified DNA were slot 
blotted onto nitrocellulose after 25 cycles of PCR and 
probed with 32P-labelled synthetic oligonucleotides, 
Figure 3b indicates that the m utation in codon 
12 Cr-»T is also present in the CMML sample.
The initial transfection experiments took place in 
June 1985. The Ha-ras mutation was detected in the 
NIH 3T3 transformants on 6.5.86 and subsequently 
in the CGL (18.8.86) and CMML (23.10.86) DNAs.
DISCUSSION
We describe the first example, as far as we are 
aware, of Ha-ras activation in a CMML sample and 
in a CGL blast crisis sample. In both cases the 
mutation was in codon 12 GLY-»VAL, a mutation 
similar to that found in AM L [5].
Southern blot technology did not detect the 
mutation in the first round NIH3T3 transformants 
and the decreasing transformation frequencies 
(Table 1) suggested that the transformants were 
unstable. Also a decreasing number of cells grew in 
soft agar as the cells were passaged. This may suggest 
that only a small population of the NIH3T3 cells 
contained the m utated ras gene, i.e. the ras mutation 
was present at less than one copy per cell. In addition, 
transformed cells in culture are known to lose the 
transforming gene. However, after tagging with a 
selectable m arker, the transforming gene can be 
maintained at a high enough copy number to be 
readily detected by hybridisation (see Fig. 1). Growth 
in G418-medium exerts a selective pressure on the 
cells to retain the integrated DNA and eliminates 
cells which have not taken up DNA, thereby reducing 
the number of normal NIH3T3 cells.
It is possible that the ras transformed NIH3T3 cells 
may recruit adjacent cells by paracrine stimulation. 
Colonies of ras transformants would then contain 
only a low percentage of ras transformed cells and a 
high percentage of untransformed but growth-stimu­
lated cells. These “normal” stimulated cells are 
removed by the G418 drug selection and allow mol­
ecular detection of the ras transformants.
Land et al. [14] have shown that under conditions 
of neomycin selection, constructs containing c-Ha- 
ras can fully transform primary rat embryo 
fibroblasts. This suggests that in the presence of 
adjacent normal tissue culture cells the ras transfor­
mants may be repressed and unable to expand into 
tumorigenic clones. However, when the normal cells 
are removed by drug selection, the ras transformed 
population can expand and progress to tumorigenic
809
clones. Toksoz et al. [5] could not detect ras mutants 
in five out of six AM L samples by direct hybridisation 
but subsequently detected ras mutations in transfec­
tants after G418-selection followed by a nude mouse 
tum our assay. The authors suggested that even in 
AM L with a high percentage of blast cells, cells 
containing m utant ras may comprise only a small 
proportion of the m ajor leukaemic clone.
Shen et al. [4] have dem onstrated the presence of 
a m utant Ha-ras protein in an ALL sample. Again, 
however, m utant protein was less abundant than 
normal p21 ras proteins, implying that only a portion 
of leukaemic cells in an individual patient carried the 
m utant ras oncogene. These findings indicate that 
Ha-ras m utation may be a late event associated with 
clonal progression.
The advent of the polymerase chain reaction has 
facilitated the detection of such mutations. However 
transfection assays are still required to test the 
mutations for transforming ability. In this study, the 
CMML sample was obtained prior to chemotherapy 
and the CGL blast crisis was in relapse of disease 
initially diagnosed several years earlier. Therefore 
the transforming ras m utation m ay.persist in a 
population of cells throughout the course of disease. 
Many groups have now described N- and Ki-ras acti­
vation in various forms of hum an leukaemia, and ras- 
gene activation may occur in as many as 40% of 
cases. Ha-ras activation appears to be a less frequent 
event. We have now looked at over fifty different 
patient samples using the PCR assay; but only these 
two samples carried a transforming Ha-ras m utation 
(J. Gow and R. Padua, unpublished observation).
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Confirmation and refinement of the localisation of the c-MEL locus 
on chromosome 19 by physical and genetic mapping
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Summary. The human gene locus c-MEL was identified follow­
ing transfection of genomic DNA from the human melanoma 
cell line NK14; it has previously been assigned to chromosome 
19 (pl3.2-ql3.2) by analysis of somatic cell hybrids. We have 
further refined the position of this gene to the proximal region 
of 19p (cen-pl3.2), using cell hybrids containing only frag­
ments of human chromosome 19. We have confirmed this 
physical localisation by linkage analysis with a recently de­
scribed restriction fragment length polymorphism for the c- 
MEL gene, and mapped the locus within the region of the low 
density lipoprotein receptor gene (LDLR) (Lod 4.43, 0 =
0.10) and the anonymous marker D19S11 (13.1.25) (Lod 9.33, 
0 = 0). This gene thus maps to a region of chromosome 19 in­
volved in karyotvpic abnormalities in a variety of malignancies 
including melanomas and leukaemias.
Introduction
Karyotypic abnormalities are characteristic of human malig­
nancies (for review see Croce 1986), particular markers being 
associated with specific diseases. Several proto-oncogenes 
have been mapped to the regions of the breakpoints of these 
abnormalities, such as c-abl in Philadelphia positive CMML 
(Groffen et al. 1984), and c-myc in Burkitts lymphoma (Dalla- 
Favera et al. 1983).
Transformation of NIH 3T3 mouse fibroblasts with DNA 
from the human melanoma cell line NK14 led to the identifica­
tion of a previously unknown human gene (Padua et al. 1984), 
designated c-MEL. This gene was subsequently localised to 
chromosome 19 (pl3.2-ql3.2) using a panel of somatic cell 
hybrids containing a defined set of human chromosomes or 
translocations in rodent backgrounds (Spurr et al. 1986). A 
diallelic restriction fragment length polymorphism (RFLP) 
with the enzyme Ncol has been described previously (Nimmo 
et al. 1987). Further physical mapping of this locus has utilised 
cell lines that carry defined breakpoints of chromosome 19 
and indicates that c-MEL is localised on the proximal short 
arm of this autosome, co-segregating with LDLR and D19S11. 
This region has previously been reported as the breakpoint for 
a number of translocations of chromosome 19 in both human 
leukaemias (Garry and Grindlev 1984; Havashi et al. 1988) 
and malignant melanoma (Parmiter et al. 1986). Large sibship
Offprint requests to: K .J. Johnson
families from Centre Etudes de Polymorphisme Humane 
(CEPH) have been genotyped with c-MEL, LDLR, D19S11 
and other markers on chromosome 19.
Materials and methods
Probes
The c-MEL probe (pC7.1) has been described by Nimmo et 
al. (1987). The LDLR and D19S11 probes were made avail­
able by Drs. Goldstein and Brown (Dallas) and By Dr. 
Michael Litt (Portland) respectively. D19S7 (p4.1), D19S9 
(plJ2) and D19S8 (pl7.1) were provided by Dr. Duncan Shaw 
(Cardiff). CYP2A was provided by Dr. Ian Phillips (London). 
D19S19 (LDR152) was provided by Dr. Richard Bartlett 
(Duke University). Protein kinase C gamma-gene (PKCG) 
was provided by Dr. Axel Ullrich (Genentech, Calif). Details 
of these probes are described in Human Gene Mapping 9, 
1987).
DNA techniques
DNA samples were isolated from peripheral blood lympho­
cytes or cell lines using standard techniques, or were obtained 
from CEPH (Paris). Restriction digests were performed on 2 - 
3 pg human DNA using standard conditions as detailed by the 
manufacturers. Electrophoresis, blotting and hybridisation 
were all performed using routine methods (Maniatis et al. 
1982).
Cell lines
Cell lines WILF M4 and WILF M6 have been reported previ­
ously (Brook et al. 1986). Cell lines WILF M6 CMB3 and 
WILF M6(TH)J3 are derivatives of WILF M6. The G175- 
derived cell lines have been described recently with respect to 
several chromosome 19-specific DNA markers (Brook et al. 
1987).
Results
Hybrid cell line DNAs were digested with several restriction 
enzymes and scored for the presence or absence of the differ­
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ent probes after Southern blotting and hybridisation. These 
data are presented in Table 1. They show that c-MEL segre­
gates with D19S11 in all the hybrid cell lines tested. The four 
Gl75-derived lines contain the markers D19S8 and D19S7, on 
the proximal long arm, and D19S11, which is on the proximal 
short arm. of chromosome 19 (Human Gene Mapping 9, 
1987). They also contain c-MEL, but not the more distal short 
arm markers LDLR and C3. The WILF cell lines, with the ex­
ception of WILF M6 CMB3, which contains only the cen- 
tromeric marker D19S7, contain D19S7 and the short arm 
markers D19S11 and LDLR, but not the more distal marker 
C3 or any of the long arm markers. c-MEL is present in the 
WILF cell lines with the exception of WILF M6 CMB3. These 
data support the localisation of c-MEL on the short arm of 
chromosome 19 proximal to LDLR.
As further support for these data, the CEPH families, 
which were informative for both the LDLR probe and c- 
MEL, were subsequently typed with D19S11. Our results 
show that more recombination occurs in females than in 
males; this agrees with previous reports (Donis-Keller et 
al. 1987). The resultant lods for these data, computed with 
the LINKAGE program (Lathrop et al. 1984), are shown in 
Table 2. c-MEL has a maximum pairwise lod with LDLR of 
4.43 at 0 = 0.10. Graphic interpolation has shown that c-MEL
Table 1. Characterisation of cell lines with chromosome 19-specific 
probes and c-MEL
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WILF M6(TH)J3 - + + + - +
WILFM4 - + + + - +
G175B3 + + + - - +
G175B5 + 4- + - - +
G175C4 + T + - - +
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is 12 cM from LDLR (95% confidence interval 5-24 cM) 
(Human Gene Mapping 8, 1985; Report of the Committee on 
Methods of Linkage Analysis and Reporting). c-MEL and 
D19S11 appear to be very tightly linked with a pairwise lod of 
9.33 at 0 = 0.0, but because no recombinants have been found 
between these two loci, it is not possible to deduce their order 
on chromosome 19 relative to the other markers. In order to 
gain further information regarding probe order, multi-point 
analysis of the data was performed, but no significantly prefer­
red order could be demonstrated.
Discussion
The human c-MEL locus has previously been assigned to 
chromosome 19 pl3.2-ql3.2 (Spurr et al. 1986). We have fur­
ther defined the position of this gene to the proximal region of 
19p, in the vicinity of the markers LDLR and D19S11. In­
deed, the linkage between c-MEL and the marker D19S11 is 
such that the correct determination of the order of these loci 
has not yet been achieved.
Although c-MEL was identified in NIH 3T3 transformants 
following transfection of DNA from the human melanoma cell 
line NK14 (Padua et al. 1984), these sequences are unlikely 
to be the activated gene, as detected by the assay. To date, 
genomic clones of c-MEL have no transforming activity. More­
over, c-MEL sequences are not retained in subsequent rounds 
of transfection, nor are they present in other first-round trans­
formants that have been shown to have human repetitive se­
quences (D.Hughes, unpublished work). Nonetheless, the 
human c-MEL'gene is localised to a region of chromosome 19 
involved in translocations in a variety of malignancies. There 
have been reports of 11;19 translocations in acute myeloid 
leukaemia (Prigogina et al. 1979; Morse et al. 1979; Hayashi 
et al. 1988) and the blast crisis of chronic myeloid leukaemia 
(Morris et al. 1988). Other translocations involving 19pl3 
have been reported in myeloid preleukaemia (Wilmoth et al. 
1985), small cell carcinoma of the lung (Whang-Peng et al. 
1982) and non-Hodgkins lymphoma (Kaneko et al. 1984). Of 
particular interest, a t(l;19) chromosome translocation was 
recently reported in three separate cases of human melanoma, 
with a breakpoint at 19pl3 (Parmiter et al. 1986). No rear­
rangements of the c-MEL coding sequences have been ob­
Table 2. Pairwise lod scores for c-MEL, LDLR and D19S11
Recombination fraction
0.00 0.001 0.01 0.05 0.10 0.15 0.20 0.25 0.30 0.40
LDLR vs c-MEL
Female — CC -3 .8 9 -0 .9 5 0.86 1.39 1.52 1.47 1.31 1.07 0.44
Male —  CC -0 .5 9 1.34 2.42 2.60 2.50 2.28 1.98 1.62 0.77
Combined — CO -7 .1 8 -0 .3 9 3.55 4.43 4.41 4.03 3.45 2.77 1.21
D19S11 vs c-MEL
Female 4.21 4.21 4.14 3.84 3.44 3.02 2.58 2.11 1.64 0.69
Male 3.01 3.01 2.96 2.74 2.46 2.17 1.86 1.53 1.20 0.54
Combined 9.33 9.31 9.15 8.38 7.40 6.39 5.35 4.30 3.24 1.30
LDLR vsD 19Sll
Female — CO -1 .8 0 -0 .8 1 -0 .1 9 0.02 0.10 0.12 0.12 0.10 0.03
Male 3.61 3.61 3.55 3.30 2.97 2.63 2.26 1.87 1.46 0.64
Combined — 00 -1 .7 9 1.09 2.66 2.88 2.72 2.40 2.01 1.57 0.67
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served in preliminary analysis of two of these cases (D. Hughes 
and R.A.Padua, unpublished work), although disruption could 
occur in flanking regulatory regions. Direct involvement of 
the c-MEL gene has not yet been determined, as such studies 
await the elucidation of the genomic organisation of this locus.
We have thus localised a human gene of unknown function 
to a region of chromosome 19 that is disrupted in a number of 
human malignancies.
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RAS Mutations in Myelodysplasia Detected by Amplification, Oligonucleotide
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Members of the RAS gene family have been implicated in many 
neoplasms with activating mutations around amino acid posi­
tions 12 and 61. We have assessed the mutational activation of 
H, K, and NRAS in myelodysplasia (MDS) by polymerase chain 
reaction and hybridization with synthetic oligonucleotide probes. 
Using this method, point mutations in codons 12/13 and 61 of 
these RAS genes were detected in 20 of 50 patients including 
two with refractory anemia with ringed sideroblasts (RARS). Ten 
normal individuals had no detectable RAS mutations. In 11 in­
stances, DNA from patients with detectable RAS mutations were 
shown to register in either NIH3T3 focus-forming or nude mouse 
tumorigenicity assays. In addition, one patient (RARS) was shown 
to have an activated NRAS gene detected by a tumorigenicity 
assay and Southern blot analyses. Two MDS patients had mu­
tations detected in two different RAS genes. DNA from one of 
these patients was observed to give rise to transformants with 
activated N and HRAS. Two patients with detectable NRAS mu­
tations in the MDS stage progressed to AML and DNA from the 
AML stage registered positively in a transformation assay with 
NRAS activation. These results show that RAS mutations can 
occur at early, as well as late, stages of leukemic progression. 
The incidence of RAS mutations appears to be significantly 
higher in CMML than in the other subgroups (p = 0.02).
INTRODUCTION
PRELEUKEMIA and leukemia are characterized by the expansion of undifferentiated self-perpetuating stem cells with poorly differentiated progeny. The mechanisms control­
ling the balance between stem cell renewal and maturation are 
complex. A precise model to describe the human preleukemic 
process would be difficult to define as the different groups are 
heterogeneous and probably follow different pathways of pro­
gression. However, preleukemia still provides us with a model 
of human leukemogenesis which is consistent with current hy­
potheses of the multistage development of malignancy (1) and 
in which it is possible to investigate the sequential stages.
The myelodysplastic syndromes (MDSs) represent a preleu­
kemic state. Five groups of patients have been described based 
on the morphological appearance of blood and bone marrow 
cells observed by the French-American-British (FAB) group 
(2, 3). An increasing number of blast cells correlates with a
Received April 24, 1988. Accepted May 16, 1988.
Abbreviations: MDS, myelodysplastic syndrome: PCR, polymerase chain 
reaction; RARS, refractory anemia with ringed sideroblasts; CMML, chronic 
myelomonocytic leukemia; AML, acute myelogenous leukemia.
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poor prognosis and disease progression. RARS and RA with 
5% or less blast cells in the bone marrow have a good prognosis 
with a median survival of about 4 years. Ten to 15% of these 
patients progress to AML. RAEB has between 5 and 20% blast 
cells in the marrow with a median survival of about 1 year and 
a progression frequency to AML of 30-40%. RAEB in trans­
formation has between 20 and 30% blast cells and usually less 
than a year’s survival, up to 50% progressing to AML. CMML 
has up to 20% bone marrow blast cells, a median survival of 
about a year, and a progression rate to AML of 30-40%. AML 
patients have more than 30% blast cells in the marrow.
Oncogenes and their products are thought to play a role in 
leukemogenesis as well as in other malignancies. NRAS, a 
member of the RAS gene family (4, 5), has particularly been 
implicated in AML, chronic myelogenous leukemia (6-9), and 
ALL (10, 11). Substitutions in codons 12/13 and 61 in RAS 
have been observed to result in the activation of these genes 
(12-16). Recently, NRAS activation has been described in 
three MDS patients with position 13 mutations (17) and KRAS 
activation has been seen in two MDS patients (18). Presumably, 
RAS activation plays a part in malignant progression by con­
ferring a selective growth advantage on the cells in which the 
mutations occur and, possibly, by interfering with their dif­
ferentiation program. In this investigation we have assessed 
the mutational status of members of the RAS gene family in 
different groups of MDSs by the PCR (19) and hybridization 
with synthetic oligonucleotide probes containing different point 
mutations around codons 12,13, and 61. This approach allowed 
the analysis of a large number of patients and the identification 
of a number of mutants. In all of the mutants detected which 
have been further investigated, we have confirmed activation 
of the RAS genes by using either NIH3T3 focus-forming or 
nude mouse transformation assays. Only in CMML is the in­
cidence of mutations higher than would be expected from the 
overall incidence.
MATERIALS A N D  M E T H O D S
Patients. Blood or bone marrow samples were obtained from 50 
patients with MDS, 13 with RARS, 13 with RA, 8 with RAEB, and 
16 with CMML. The details of the patients are shown in Table 1. 
Samples were also obtained from two patients with AML who were 
previously myelodysplastic and 10 hematologically normal subjects 
undergoing cardiac or hip replacement surgery and were matched for 
age with the MDS patients. Fully informed consent was obtained from 
all individuals and the investigation was approved by the South Gla­
morgan Joint Ethics Committee.
High molecular weight DNA was extracted from cells obtained from 
either peripheral blood or bone marrow as described by Maniatis et al. 
(20).
PCR and Hybridizations. Sequences of around 100 bp were am­
plified by PCR (19, 21) using primers flanking codons 12/13 and 61 
of H, K, and NRAS (Table 2). One p.g of genomic DNA was amplified
LEUKEMIA, Vol 2, No 8 (August), 1988: pp 503 -510 503
Table 1. Details of Patients
P a t i e n t A g e  ( y r ) / (S e x )
T y p e  o f  
S a m p l e 3
%  B la s t6
F o llo w -u p
P e r io d
(m o )c
L e u k e m ic
T r a n s f o r m a t io n
A m in o  A c id  „  , 
S u b s t i tu t io n  83
RARS
H.P. 74(M) BM 5 20 - K12Asp ' +
C.N. 27(F) BM 2 19 - N12 Val -
G.D. 52(M) BM 2 18 _
H61 Arg 
NRAS
D.W. 66(M) BM 5 4 - - +
A.W. 82(M) BM 3 8 - - +
D.L. 71(F) BM 1 30 - - -
A.G. 60(M) BM 4 21 - - -
B.M. 80(M) BM 5 19 - - -
D.M. 83(M) BM 2 19 - - -
P.W. 59(M) BM 1 30 - - -
Z.G. 64(M) PB 1 13 - - -
H.J. 55(M) BM 4 23 - - -
F.S. 81 (M) BM 5 13 - - -
RA
W.B. 72(M) BM 2 3 - N12 Val +
O.O. 82(F) BM 3 1 N12 Asp +
G.D. 64(F) BM 1 30 - K12 Asp -
G.B. 80(F) BM 4 21 - N61 Leu -
S.E. 80(M) BM 3 6 - - +
D.R. 56(M) BM 3 <1 - - -
T.T. 64(M) BM 4 32 - - -
M.W. 35(F) BM 2 20 - - -
E.V. 83(M) BM 1 31 - - -
G.S. 64(F) ( BM 3 15 - - -
D.J. 62(M) BM 1 19 - - -
M.H. 20(M) BM 1 8 - - -
S.H. 47(F) BM 1 8 - - -
RAEB
J.S. 66(M) BM 9 7 + K12 Arg +
T.B. 76(M) BM 11 6 + N12 Asp +
K.S. 61 (M) BM 5 6 + N12 Ala +
J.O. 79(M) BM 8 10 + - +
S.M. 74(M) BM 19 15 - - +
M.D. 68(F) BM 8 30 - - +
D.D. 65(M) BM 6 22 - - -
M.M. 48(F) BM 8 30 - - -
CMML
G.B. 73(M) BM 11 2 + N12 Ala +
W.S. 71(F) PB 7 20 + N61 His +
R.P. 64(M) PB 5 5 + NI3 Ala . . +
H.M. 83(F) PB 5 6 - NI3 Ala +
R.G. 86(M) PB - 11 + N61 His +
M.B. 61(F) PB 3 40 + H12 Val +
H.E. 78(M) BM 6 4 _
K12 Asp 
K12 AspJ +
F.B. 85(F) PB < 3 0 4 - N12 Asp +
A.T. 71(F) PM 3 + - +
J.N. 35(F) PB 18 9 + - +
H.W. 88(F) PB 7 36 + - +
C.B. 84(M) PB 3 24 - - +
S.L. 79(M) PB 1 <1 - - +
L.H. 85(M) PB 5 14 - K12 Asp -
T.L. 84(M) PB 3 14 - N13 Ala -
D.P. 81(F) PB 4 13 - N61 His -
aBM, bone marrow; PB, peripheral blood.
^Percentage of blast cells in bone marrow either at the time of sampling or at diagnosis. 
cFollow-up period, interval between date of sampling and death or to end of December 1987.
in a reaction mixture with a 1 |xm concentration of each of the primers. 
The 20-mer primers were annealed to opposite strands of the genomic 
DNA and extended using Klenow (large fragment polymerase I) or 
the heat-stable Taq polymerase (Cetus). In this way, the extension 
product o f one primer served as a template strand for the other in a 
second cycle o f extension. At least 25 repeated cycles of denaturation, 
annealing, and extension were performed. This should result in ap­
proximately a 105-fold amplification. Amplified DNA was applied to 
Hybond-N filters, using a slot blot manifold, and was hybridized (19, 21) 
with 32P 5' end-labeled 20-mer oligonucleotide probes (kindly provided 
by C. Farr or synthesized by us using an Applied Biosystems DNA 
synthesizer). Labeling was obtained using [32P-y]ATP (Amersham; 
specific activity, >5000 Ci/mmol; 1 Ci =  37 GBq) and T4 polynu­
cleotide kinase (Amersham). The labeled probes were separated from
unincorporated [32P-y]ATP by purifying on 10% acrylamide denatur­
ing gels and eluting in 1 m M  EDTA (22). The specific activities of 
the probes were =  4 |xCi/pmol. A list of the probes used is shown in 
Table 2. Duplicate filters were prehybridized and hybridized in the 
presence of 3 m  tetramethylammonium chloride (19, 23) at 55°C. Fil­
ters were rinsed twice in 2 x  SSPE (1 x  SSPE =  10 m M  sodium 
phosphate, pH 7.0, 0.18 m  NaCl, 1 m M  EDTA), 0.1% NaD odS04 
for 10 min at room temperature, followed by a high stringency wash 
at 60°C for 30 min in the prehybridization solution without carrier 
DNA and a final wash in 5 x  SSPE, 0.1% NaDodS04 for 5 -3 0  min 
at 60°C for N, K at codons 12/13 and 61 and HRAS at codon 61 and 
76-80°C for 15-30 min for HRAS at codon 12. Filters were autora­
diographed using XAR-5 film for at least 4 hr at — 70°C with inten­
sifying screens (Du Pont Lightning Plus). The washing conditions were
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Table 2. Sequence of the PCR Primers and Probes for H, K, and NRAS
Oligomer Sequence Strand
N12/13 primers: 
N12 probes:
CTGGTGTGAAATGACTGAGT 
GGTGGGATCAT ATT C ATCTA 
GGAGCAGGTGGTGTTGGGAA WT S
P1 ------------- nGT.................................. n = A, C, T S
P2 ------------- G nT................................. . n = A, C, T S
N13 probes: P1 -------------- ------nGT........................ n = A, C, T S
P2 -------------- ------GnT------------------ n = A, C, T S
N61 primers: 
N61 probes:
GTTATAGATGGTGAAACCTG
ATACACAGAGGAAGCCTTCG
ACAGCTGGACAAGAAGAGTA WT S
P1 ...........................nA A ----------------- n = A, G S
P2 ...........................C nA ----------------- n = C, G, T S
P3 --------------------C A n----------------- n = C, T S
K12/13 primers: 
K12 probes:
CCTGCTGAAAATGACTGAAT
TGTTGGATCATATTCGTCCA
CCTACGCCACCAGCTCCAAC WT A
P1 GTTGGAGCTnGTGGCGTAGG n = A, C, T S
P2 -------------------GnT------------------- n = A, C, T S
K13 probes: P1 GTTGGAGCTGGTAGCGTAGG S
P2
P1
-------------------------- g a c -----------
CCTACGCnACCAGCTCCAAC n = A, G
S
A
P2 — ........GnC.................................... n = A, G A
K61 primers 
K61 probes:
GTAATTGATGGAGAAACCTG 
AAAT ACACAAAGAAAGCCCT 
TACTCCTCTTGACCTGCTGT WT A
P1 ...................... T Tn------------------- n = C, T A
P2 -----------------TnG ------------------- n = A, C, G A
P3 ACAGCAGGTCAnGAGGAGTA n = C, T S
H12 primers: 
H12 probes:
CTGAGGAGCGATGACGGAAT
AGTGGGGTCGTATTCGTCCA
GTGGGCGCCGGCGGTGTGGG WT S
P1 ............................ nG C ------------------ n = A, C, T s
P2 ----------- --------- G nC ------------------ n = A, C, T s
H61 primers: 
H61 probes:
GTCATTGATGGGGAGACGTG 
ACACACACAG GAAG CCCTCC 
TACTCCTCCTGGCCGGCGGT WT A
P1 -----------------CTn--------------------- n =  C, T A
P2 -----------------CnG--------------------- n = A, C, G A
P3 -----------------nTG---------------------- n = A, G A
The primers and probes are 20 bases long. Hyphens represent wild-type sequences. P = position of substitution; WT = wild type; n =  base substitution; S  
sen se; A = antisense. Unique probes were used with the base substitutions as shown. For example, an N12 Arg probe has C at position 1.
critical because the different probes, which only differed by a single 
base change, appeared to have subtly different melting off tempera­
tures. These conditions were often determined empirically. Due to 
these constraints, the use of mixed base oligonucleotide probes was 
inadequate for this analysis.
Transformation Assays. High molecular weight DNA was trans­
fected into NIH3T3 cells by a modification of the calcium phosphate 
precipitation method (24, 25). Flasks (25 cm2) were seeded 24 hr pre­
viously with 3 x  105 cells maintained in Dulbecco’s modification of 
Eagle’s medium with 10% fetal bovine serum (Hyclone). Twenty p-g 
DNA were transfected onto each flask. In experiments which were 
assayed for focus formation, foci were scored 3 -4  weeks after trans­
fection, picked, and expanded, and their DNA were extracted for 
further analysis. Tumorigenicity assays (26) were performed by co­
transfection of NIH3T3 cells (3 x  105/25-cm2 flask) with 20 pg ge­
nomic DNA and 1-2  pg of cosmid pHSG272 (27) containing a dom­
inant neomycin resistance-selectable marker, followed by G418 selection 
(800 pg/ml) (Gibco). The G418-resistant colonies were harvested and 
106 cells were injected into each of the hind flanks of 6-week-old 
athymic nude mice. At least 3000 G418-resistant colonies were injected 
per sample. Tumors which appeared with latency periods of 3 -6  weeks 
were analyzed further.
Southern Blot Analysis. Genomic DNA (20 pg) was digested with 
restriction endonucleases EcoRI (for NRAS or KRAS) and BamWl 
(for HRAS). Electrophoresis was carried out in 0.8% agarose gels 
(20) and DNA was transferred onto Hybond N membranes (Amer­
sham). Filters were prehybridized and hybridized as recommended by
the manufacturer. The probes used were pBRN 1.0 (a 1 -kb Pvull 
fragment of human NRAS containing exom l) (28), HiHi-3 (a 1-kb 
EcoRI fragment of v-Ki-ras) (29), and BS9 (a 460-bp EcoRI fragment 
of v-Ha-ras) (30). Probes were labeled by primer extension (Boeh- 
ringer).
RESULTS
RAS Mutation in MDS. Representative filters of some of the 
patient samples after hybridization and autoradiography are 
shown in Figures 1 and 2. Most samples hybridized to the wild- 
type probe. In some instances no signal was obtained with 
either normal or abnormal probes, and it must be assumed that 
there was a failure of amplification in these cases; therefore, 
these cases were eliminated from the analysis. Differential hy­
bridizations were observed in those samples which contained 
the appropriate mutations. Cross-hybridizations between mu­
tant samples and different probes were observed, but differ­
ential hybridizations were obtained by increasing washing times 
and temperatures where necessary. Some of the probes were 
sequenced by end labeling with T4 kinase (Amersham) and 
using the sequencing methods described by Maxam and Gilbert 
(31). The heterogeneity of the signals obtained with the wild- 
type probes may be due to the quality of the initial DNA; 
however, qualitatively, the mutants can be readily identified. 
Table 3 summarizes the results obtained. Mutations in codons
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1 2  3 — — - — ___
4 5 6 — - — — -----
7 8 9 — — — — ___
10 11 12 — — — — -----
13 14 15 — — — —  — — ---- ------
16 17 18 — — — — -----
19 20 21 ~ — — ■ — ------- -----
22 23 24 — — rnrnm - — • ----
25 26 2 7 - mm — - — -----
28 29 30 — mm - — <a» —  • * -----
31 32 33 — — — — -----
34 35 36 — — — - — -----
37 38 39 — *  ■ — — — -----
40 41 42 — m mm — — _ _  — * -----
43 44  45  — < • > m  - — * *  - ■ —  ‘
46  47 48 — mm • --  ; —
—  r *49  50 51 — mm mm mm .— — P # 5
52 53 54 — m mm — —
N 12G ly-W T N12 Asp N12Val N12Ala N13 Ala I
Figure 1. D etection of NRAS mutation by hybridization of oligon ucleotide probes to amplified DNAs. Twenty pi of amplified DNA (approxim ately  
130 ng) were s lo t blotted. Filters were hybridized (106 cpm/m l) to  the appropriate probe as show n. S lo ts  where no signal with the wild-type or any 
mutant probe w as obtained were d iscounted  from the an alyses. All m utants were observed at least tw ice on different filters and in m ost c a s e s  were 
amplified and analyzed tw ice. The panels have been aligned s o  that each  slot is numbered. No sam p les were applied on s lo ts  18, 21, 24, 33, and 54. 
S am ples on s lo ts  31, 32, 36, and 37 were d iscounted  a s  failed PCRs. S lo ts  19, 20, 22, and 23 (100 ng each) are cloned  NRAS DNAs of pAT 7.8 Fe and 
pAT 8.8 HT (16) which have normal seq u en ces  around c o d o n s  12/13. S lots 48 and 49 are DNAs from normal individuals. S lo ts 1, 4, 5, 13, 14, 16, 43, 
and 46 are sam p les from patients with other hem atological d isorders apart from MDS. The remaining s lo ts  represent MDS patient sam ples. Mutants 
can be observed  in the N12 Asp panel s lo ts  9 (CMML F.B.), 39 (RA O.O.), and 41. N12 Val m utants can be observed in s lo ts  29 and 44 (RARS C.N.). The 
faint hybridizations see n  in s lo ts  8 and 40 w ash off at higher str ingencies. T hese s lo ts  hybridize to N13 Ala (CMML H.M.) and N12 Ala probes, respectively, 
as show n on the appropriate panels.
1 2 3 
4 5 6 
7 8 9 
10 11 12 
13 14 15
16 17 18 
19 20 21 
22  23 24  
25  26 27  
28  29 30 
31 32 33 
34  35 36 
37  38 39  
4 0  41 42  
43  44  45  
4 6  47  48  
4 9  50 51 
52  53 54  
55 56 57  
58 59 60  
61 62 63 
6 4  65 66  
6 7  68 69  
7 0  71 72
—
_
... •
-
—
"
;
,  ^  j
, *
—
!
—
—
—
-
—
• . —
* —
! ■
e  ■
'".s
#
• -
,A: II —
K12 Gly -WT K12 Asp K12 Arg K 12 Arg 
H igh str in gen cy
Figure 2. Detection of KRAS m utations. Filters were prepared and hybridized a s  described  in the legend to Figure 1. No sam p les were applied on  
s lo ts  10, 14, and 48. Sam ples in s lo ts  23, 27, 31, 32, 48, 50, and 71 w ere d iscounted  as failed PCRs. Sam ples on s lo ts  31, 32, and 48 were reslotted with 
50 pi o f the PCR and analyzed further a s  the wild-type sign a ls from th ese  sam p les were com parable to the others. S lo ts 48 and 49 are sam p les from 
normal individuals. S lots 3 (E.J. bladder carcinom a) and 4 (M.S. a m elanom a) (28) are solid  tumor cell lines. S lots 2, 7, 8, 16, 17, 19, 43, 62, 66, and 68 
are sa m p les  from patients with other hem atological d isorders apart from MDS. Mutants can be observed in the K12 Arg panel in s lo ts  1 (CMML M.B.), 
s lo ts  8, 13, 25, and 33, and slo t 70 (CMML H.E.). A s in g le  K12 Arg mutation can be observed in slot 28, where differential hybridization can be observed. 
The n on sp ecific  hybridizations w ash  off at a higher stringency w ash for a further 30 m inutes at 60°C.
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Table 3. RAS Mutations in MDS
N o . R A S  M u ta n t s /  
N o . S a m p l e s
S u b s t i tu t io n
Controls 0/10
MDSs
RARS 2/13 1 X H61 Arg ( A - G )
1 X N12 Val (G -»  T)
1 X K12 Asp (G —> A)
RA 4/13 1 X N12 Asp (G —*■ A)
1 X N12 Val (G —* T)
1 X N61 Leu (A -»  T)
1 X K12 Asp (G A)
RAEB 3/8 1 X N12 Ala ( G - C )
1 X N12 Asp (G -»  A)
1 X K12 Arg ( G - C )
CMML 11/16 1 X N12 Ala (G —» C)
1 X N12 Asp (G -»  A)
3 X N13 Ala (G -> CL
3 X K12 Asp (G -»  A)
1 X H12 Val (G -»  T)
3 X N61 His (A —> C)
Total 20/50 (40%)
Square brackets indicate mutations of the two patients with double muta­
tions.
12/13 of H, K, and NRAS were detected. Mutations in codon 
61 of N and HRAS were also observed.
A total of 22 mutations were detected in samples from 50 
patients. Two patients had mutations in two different RAS 
genes. A RARS patient (C.N.) had both N 12 Val and H61 Arg 
substitutions. Both genes segregated in transformation assays 
(see below). A CMML patient (M.B.) showed hybridization 
to both H12 Val (32) and K12 Asp (Fig. 2, slot 1) probes. A 
total of 14 NRAS mutations were identified, 10 in codons 12/ 
13 and 4 in codon 61. In addition, 6 KRAS mutations in codon 
12, 1 H-12, and 1 H-61 mutation have been detected to date 
by PCR and oligonucleotide hybridization.
Presence o f Mutation is Related to Transforma­
tion. Independent confirmation of the results obtained by PCR 
and hybridization was obtained by using transformation assays. 
DNA from 11 MDS patients with detectable mutations were 
positive when tested (Table 4). Representative transformants 
from a CMML DNA sample are shown in Figure 3. In 8 of 
11 cases tested to date, the transformants derived from patients’ 
DNA were shown by PCR and hybridization to have the same 
mutation as the original DNA.
A CMML patient (R.G.) with a detectable N61 His mutation 
progressed to AML, and DNA from this AML phase (R.G.) 
registered in a transformation assay. Another CMML patient 
(R.P.) with an N13Ala mutation progressed to AML, and DNA 
from both stages of this patient were positive in a transformation 
assay (Table 4). The two patients with double mutations also 
registered in transformation assays. The RARS patient (C.N.) 
developed tumors which showed hybridization to HRAS and 
NRAS probes (data not shown). Only HRAS activation has 
been detected in tumors derived from the second of the double 
mutants hybridizing to both H12 Val and K12 Asp probes 
(CMML patient M.B.) (32). Because HRAS has a smaller 
transforming unit (<6.6 kb) than the KRAS gene (>40 kb), 
it is expected to register more frequently in a transfection assay.
In addition to the transformation experiments with detectable 
mutant RAS genes, five other DNA samples from MDS patients 
were tested in which no mutants were found after hybridization: 
three with RARS (G.D., P.W., Z.G.), one with RAEB (J.O.), 
and one with CMML (H.W.). The RARS patient (G.D.) reg­
istered in a nude mouse tumorigenicity assay with a short la-
Table 4. Transformation Assays
T u m o r ig e n ic i ty  A s s a y
S lo t  n o .
N o . T u m o r s /  
N o . S i t e s  
I n je c te d
L a te n c y
T ra n s f o r m in g  
G e n e  a n d  
S u b s t i tu t io n
Controls
NIH3T 2/30 33
EJ focus 16/16 21 H12 Val
MDS
RARS
CN 44 8/8 38 N12 Val + HRAS
GD 6/8 19 NRAS
PW 0/8
ZG 0/8
RA
OB 39 8/8 21 NRAS
GB 6/6 10 N61 Leu
RAEB
KS 5/8 22 N12 Ala
TB 3/8 22 N12 Ala
JO 0/8
CMML
HM 8 3/8 36 N13 Ala
RP 3/8 24 N13 Ala
DP 5/8 27 NRAS
HE 70 4/8 26 KRAS
HW 4/8 23 Non RAS
AML
RP 6/8 24 NRAS
RG 5/8 27 NRAS
F o c u s  F o r m a t io n
T r a n s f o r m a t io n  F r e q u e n c y :  T r a n s f o r m in g
S lo t  N o . F o c i / j ig  D N A  
(n o .  f o c i /n o .  f la s k s )
G e n e  a n d  
S u b s t i tu t io n
Controls 
NIH3T3 
EJ focus
0
0.2
(0/5)
(20/5) H12 Val
MDS
CMML
FB 9 0.06 (6/5) N12 Asp
MB 0.04 (8/10) H12 Val
Twenty p.g DNA were transfected onto N1H3T3 cells which were plated at 
a density of 3 x 10 5, 24 hr earlier. Precipates were left overnight and media 
were changed the next day. For tumorigenicity a ssays 1 -2  p.g of PHSG272, 
a neomycin resistance-containing cosmid, was co-transfected with genomic 
DNAs. Three days after transfection, cells were split into G418-containing 
media (800 |xg/ml) and resistant colonies were selected. A total of 10® cells/ 
site were injected in both of the hind flanks of athymic nude mice. Tumors 
with latency periods of less than 6 weeks were scored and analyzed. For focus 
formation assays media were changed every 3 days in 5% serum. Foci were 
scored 3 w eeks after transfection. For each sample, 100 p.g DNA was used 
per experiment and three to four mice were injected. Slot number refers to the 
slots shown in Figure 1 for NRAS activations and Figure 2 for KRAS activa­
tions.
tency period (19 days), and the remaining RARS (P.W., Z.G.) 
and the RAEB patient (J.O.) gave negative results. The tumors 
from the RARS patient (G.D.) were shown to have an activated 
NRAS gene by Southern blot analysis (data not shown). It is 
possible that the proportion of cells with mutated RAS was 
below the level of detection by PCR analysis, thus illustrating 
that the biological assay may be more sensitive than the bio­
chemical analysis, although it has the disadvantage of requiring 
at least 100 fig of DNA and a greater length of time for analysis. 
The CMML patient (H.W.) formed tumors with latency periods 
of 23 days. Hybridization of DNA from these tumors showed 
no evidence of human RAS activation (data not shown).
Although the NIH3T3 control DNA gave rise to 2 tumors 
out of 30 injections, these tumors arose on different occasions, 
33 days after injection. Most of the tumors obtained from the 
other samples either had shorter latency periods or had more 
than one tumor appearing in a single experiment. Southern blot
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FB FOCUS-1
FB FOCUS-2 
NIH 3T3
MEL SWIFT FOCUS 
EJ FOCUS 
FB CMML
Figure 3. NRAS mutational activation in transform ants. EcoRI-digested DNA w as electrophoresed , blotted, and hybridized to an exon 1 NRAS probe 
(28). The 8.8-kb human EcoRI fragm ent hybridized to the probe. The m ou se  en d o g en o u s band of 7 kb w as a lso  detected.
analysis confirmed the presence of human-activated RAS genes 
in the tumors derived from patient DNAs.
Prognosis o f Patients with RAS Mutations. There seems to 
be little difference in the incidence of mutations in the different 
FAB diagnostic groups, except for an apparently higher fre­
quency in CMML (p = 0.02) (Table 5). The precise criterion 
used for the diagnosis of leukemic transformation in the FAB 
classification is somewhat arbitrary (>30% blasts in the bone 
marrow). All the eases in which we have made this diagnosis 
had greater than 40% blast cells in the marrow, although their 
other biological features were variable. Of the 21 patients with 
RAS mutations detected by PCRs and oligonucleotide hybrid­
ization or RAS activations detected by a transformation assay, 
S progressed to AML. Of the 29 patients without detectable 
RAS mutations, 4 progressed to AML. Two of these patients 
failed to transform NIH3T3 cells and one registered in a trans­
formation assay (CMML H.W.) with transformants with an 
unknown transforming gene. Seven patients with activated RAS 
and 18 patients without evidence of RAS activation are still 
alive.
DISCUSSION
The basis for preferential activation of a particular RAS gene 
is not clearly understood. In hemopoietic cells NRAS and KRAS 
p21 proteins arc expressed at higher levels than HRAS p21 
(33). There is a relatively high frequency of activated NRAS, 
and a somewhat lower frequency of activated KRAS, in hemo­
poietic malignancies. This might suggest a specific role for the 
NRAS and KRAS proteins in the growth control of these tissues
with its consequent disruption by the production of an abnormal 
protein. The present data support and extend recent work on 
the involvement of RAS genes in MDS and leuekmia. Muta­
tions of NRAS are found in 20-30% of patients with AML 
(6-9), and Hirai et al. (17) have demonstrated similar muta­
tions in three patients with MDS. Liu et al. (18) have found 
KRAS activation in two MDS patients. These and other data 
suggest that specific RAS genes are likely to be activated in a 
particular malignancy. Preferential activation of HRAS is found 
in urinary tract cancer (12, 13, 34-36) and KRAS activation 
is commonly found in lung and colon cancer (37-40). In ro­
dents, not only are HRAS mutations found with a high fre­
quency in chemically induced epithelial tumors (41-43) but 
normal mouse skin epithelium shows a high expression of the 
normal HRAS p21 (44).
Our present findings show that RAS mutations occur in about 
40% of patients with MDS and may be found at all stages of 
hemopoietic neoplastic progression. If the amount of the RAS
Table 5. Frequency of Normal and Mutant G enes in RARS, RA, RAEB, 
and CMML
RARS RA RAEB CMML TOTAL
Normal 10 (7.5) 9 (7.5) 5 (4.6) 5 (9.3) 29
Abnormal 3 (5 .5 ) 4 (5 .5 ) 3 (3.4) 11 (6.7) 21
13 13 8 16 50
Numbers in parentheses are the frequencies that would be expected if the 
prevalence of mutant genes was the same in each group, and equal to the 
overall rate of 21/50 = 42%. A comparison of these expected frequencies 
with those actually observed by the exact test indicates that there are more 
CMML patients with mutant genes than would be expected (x2 = 5.39, p  = 
0 .02).
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proteins produced in hematopoietic cells reflects the importance 
of each of the RAS genes in these cell types (33), then it might 
be predicted that more mutations in N and KRAS would be 
detected than in HR AS in hematopoietic malignancies. Our 
results to date would tend to support this hypothesis for MDS, 
with a total of 14 NR AS mutations compared to 6 in KRAS 
and 2 in HR AS. Furthermore, 17 mutations at codons 12/13 
were observed compared to 5 at codon 61, suggesting a par­
ticular susceptibility at this site.
Evidence from chemically induced skin tumors in mice sug­
gests that HRAS mutation is an early event in the malignant 
process and may be found in premalignant papillomas before 
they undergo carcinomatous transformation (42). Similar ex­
periments in chemically induced rat mammary tumors suggest 
an early occurrence of HRAS mutations (41). We have detected 
mutations in three patients with RARS, the most benign form 
of MDS and possibly an early stage in the preleukemic process 
(45). In our experience, mutations may be found in all clinical 
subgroups of MDS, although there are more cases of CMML 
showing a mutation than in other groups. Similarly, in AML, 
NRAS mutations are not related to any particular morphological 
subtype (46, 47).
Our observations indicate that patients with mutations may 
evolve to AML more frequently than those without mutations. 
This agrees with previous reports. Hirai et al. (17) noted that 
three MDS patients with N13 mutations progressed to AML 
within a year while five patients without the lesion did not. 
Liu et al. (18) reported similar findings with two MDS patients 
with KRAS activations which progressed to AML, whereas 
two others without RAS mutations remained in an MDS state. 
They also found a KRAS mutation in an AML patient with a 
previous history of MDS. It is too early to attempt to define 
the significance of these mutations, but the incidence in MDS 
appears to be similar to that found in AML and suggests a role 
at an early stage of leukemogenesis. The fact that four of our 
MDS patients without detectable RAS mutations progressed to 
AML prior to death would tend to suggest that there are other 
factors apart from RAS mutations which may be important in 
progression. Clearly, more patients should be assayed both 
biochemically and biologically for the presence of transforming 
genes in order to understand the importance of such genes in 
the etiology of the disease. It seems likely that further evidence 
of specific biological abnormalities will emerge and that this 
will necessitate a reevaluation of our methods for the clinical 
investigation of MDS.
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